ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERSIONASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

Inventors: Simon Mark Jackson, San Carlos, CA (US); Nigel Pelham Clinton Walker, Burlington, CA (US); Derek Evan Piper, Santa Clara, CA (US); Wenyen Shen, Palo Alto, CA (US); Chadwick Terence King, North Vancouver (CA); Randal Robert Ketchum, Snohomish, WA (US); Christopher Mehlin, Seattle, WA (US); Teresa Arazas Carabco, New York, NY (US)

Assignee: Amgen Inc., Thousand Oaks, CA (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Filed: Apr. 24, 2014

Prior Publication Data

Related U.S. Application Data
Continuation of application No. 13/251,909, filed on Oct. 3, 2011, which is a division of application No. 12/197,093, filed on Aug. 22, 2008, now Pat. No. 8,030,457.

Provisional application No. 61/086,135, filed on Aug. 4, 2008, provisional application No. 60/957,688, filed on Aug. 23, 2007, provisional application No. 61/008,965, filed on Dec. 21, 2007, provisional application No. 61/010,630, filed on Jan. 9, 2008.

US 11/396,682 A1 April 24, 2014

Field of Classification Search
See application file for complete search history.

References Cited
U.S. PATENT DOCUMENTS
5,545,807 A 8/1996 Surani et al.
5,809,619 A 2/1999 Studnicka
7,368,531 B2 5/2008 Rosen et al.
7,482,147 B2 1/2009 Glucksman et al.
8,030,457 B2 10/2011 Jackson et al.
8,168,762 B2 5/2012 Jackson et al.
8,188,233 B2 5/2012 Condra et al.
8,188,234 B2 5/2012 Condra et al.
8,344,114 B2 1/2013 Sparrow et al.
8,357,371 B2 1/2013 Sleeman et al.
8,399,646 B2 3/2013 Liang et al.
8,501,184 B2 8/2013 Sleeman et al.
8,563,698 B2 10/2013 Jackson et al.
8,598,320 B2 12/2013 Hedrick et al.
(Continued)

FOREIGN PATENT DOCUMENTS
EP 2481758 8/2012
EP 2650016 10/2013
(Continued)

OTHER PUBLICATIONS
(Continued)

Primary Examiner — Sharon Wen
Attorney, Agent, or Firm — Knobbe, Martens, Olson & Bear, LLP

ABSTRACT
Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.

24 Claims, 152 Drawing Sheets
<table>
<thead>
<tr>
<th>U.S. PATENT DOCUMENTS</th>
<th>FOREIGN PATENT DOCUMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP 2703009</td>
<td>3/2014</td>
</tr>
<tr>
<td>EP 2706070</td>
<td>3/2014</td>
</tr>
<tr>
<td>WO 00/12227</td>
<td>6/1993</td>
</tr>
<tr>
<td>WO 2003/75310</td>
<td>12/2003</td>
</tr>
<tr>
<td>WO 01/31007</td>
<td>5/2001</td>
</tr>
<tr>
<td>WO 01/57081</td>
<td>8/2001</td>
</tr>
<tr>
<td>WO 01/98468</td>
<td>12/2001</td>
</tr>
<tr>
<td>WO 02/45358</td>
<td>2/2002</td>
</tr>
<tr>
<td>WO 03/46383</td>
<td>6/2002</td>
</tr>
<tr>
<td>WO 03/090526</td>
<td>11/2002</td>
</tr>
<tr>
<td>WO 02/102993</td>
<td>12/2002</td>
</tr>
<tr>
<td>WO 02/102994</td>
<td>12/2002</td>
</tr>
<tr>
<td>WO 04/018649</td>
<td>3/2004</td>
</tr>
<tr>
<td>WO 04/097047</td>
<td>11/2004</td>
</tr>
<tr>
<td>WO 08/057457</td>
<td>5/2008</td>
</tr>
<tr>
<td>WO 2008/057457 A2</td>
<td>5/2008</td>
</tr>
<tr>
<td>WO 2008/057459</td>
<td>5/2008</td>
</tr>
<tr>
<td>WO 2008/086395</td>
<td>5/2008</td>
</tr>
<tr>
<td>WO 2008/125623 A2</td>
<td>10/2008</td>
</tr>
<tr>
<td>WO 2010/068526</td>
<td>6/2010</td>
</tr>
<tr>
<td>WO 2010/029513 A3</td>
<td>7/2010</td>
</tr>
<tr>
<td>WO 2010/077854</td>
<td>7/2010</td>
</tr>
<tr>
<td>WO 2011/072263 A2</td>
<td>5/2011</td>
</tr>
<tr>
<td>WO 2012/054438</td>
<td>4/2012</td>
</tr>
<tr>
<td>WO 2012/088313</td>
<td>6/2012</td>
</tr>
<tr>
<td>WO 2012/101251</td>
<td>8/2012</td>
</tr>
<tr>
<td>WO 2012/101252</td>
<td>8/2012</td>
</tr>
<tr>
<td>WO 2012/101253</td>
<td>8/2012</td>
</tr>
<tr>
<td>WO 2012/109530</td>
<td>8/2012</td>
</tr>
<tr>
<td>WO 2012/154999</td>
<td>11/2012</td>
</tr>
<tr>
<td>WO 2012/168491</td>
<td>12/2012</td>
</tr>
<tr>
<td>WO 2012/170607</td>
<td>12/2012</td>
</tr>
<tr>
<td>WO 2012/177741</td>
<td>12/2012</td>
</tr>
<tr>
<td>WO 2013/008185</td>
<td>1/2013</td>
</tr>
<tr>
<td>WO 2013/016648</td>
<td>1/2013</td>
</tr>
<tr>
<td>WO 2013/039958</td>
<td>3/2013</td>
</tr>
<tr>
<td>WO 2013/039969</td>
<td>3/2013</td>
</tr>
<tr>
<td>WO 2013/148284</td>
<td>10/2013</td>
</tr>
<tr>
<td>WO 2013/169886</td>
<td>11/2013</td>
</tr>
<tr>
<td>WO 2013/188855</td>
<td>12/2013</td>
</tr>
</tbody>
</table>

**OTHER PUBLICATIONS**


References Cited

“PCSK9 (mouse) Polyclonal Antibody Cayman Chemical”, Quartzy PCSK9 (mouse) Polyclonal Antibody; Website: https://www.quartzy.com/reagent-detail/1464130/1/PCSK9--mouse--Polyclonal-antibody-cayman-ch.jpg
Chamov et al., TIBTECH 14: 52-60, 1996 (entitled “Antibody Engineering at the Millennium”).
Ex Parte Quaye action received in U.S. Appl. No. 13/095,234, dated Jul. 3, 2012 (Regeneneron).
File History of European Appl. No. 09808999.8, filed Sep. 11, 2009.
(WO 2010/029513).
References Cited

OTHER PUBLICATIONS


GenomeNet Database: PIR, Entry T1824D, Barrett et al., Nov. 1998.


Human/Mouse Proprotein Convertase 9/PCSK9 Antibody, Monoclonal Rat IgG, Clone # 407119, Catalog No. MAB3888. R &
References Cited

OTHER PUBLICATIONS


Office Action dated Jan. 5, 2011, received in European Application No. 08798550.3.


References Cited

OTHER PUBLICATIONS


Parhofer et al., “What we have learned about VLDL and IDL metabolism from human genetics studies,” Journal of Lipid Research, 47(8), pp. 1620-1630, 2006.
Polesiecki et al., “Genetic variation a the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population,” Atherosclerosis, 201(1): 95-101, (2008).
Response to Office Action dated Jan. 5, 2011 received in European Application No. 08798550.3.
Response to Office Action filed on Dec. 21, 2012 in European Application No. 08798550.3.
References Cited

OTHER PUBLICATIONS

“Sanofi and Regeneron Report Positive Preliminary Phase 2 Program
positive-preliminary-phase-2-program-results-for-anti-pcsk9-antib-
ody-in-hypercholesterolemia-133590188.html, PR Newswire, Nov.
10, 2011, pp. 1.

Schmidt et al., “A Novel Splicing Variant of Proprotein Convertase
Schmidt et al., “A 15-ketosterol is a liver X receptor ligand that
suppresses sterol-responsive element binding protein-2 activity,”

Schmidt et al., “Secreto protein convertase subtilisin/kexin type 9
reduces both hepatic and extrahepatic low-density lipoprotein
receptors in vivo,” Biochem Biophys Res Commun., 370(4): 634-

Search Report dated May 16, 2012 received in Chinese Patent Appli-
cation No. 200880113475.4 (with English Translation).

Search Report dated Sep. 9, 2013 received in Korean Patent Appli-
cation No. 10-2010-7006252 (with English Translation).

Search Report and Written Opinion received in Singaporean Patent

Seidah et al., “Mammalian subtilisin/kexin isozyme SKI-1: a widely
expressed proprotein convertase with a unique cleavage specificity
and cellular localization,” Proc Natl Acad Sci USA 96: 1321-1326,
1999.

Seidah et al., “The proprotein convertases and their implication in
sterol and/or lipid metabolism,” Biological Chemistry, 387(7): 871-
877, 2006.

Seidah et al., “The proprotein convertases in health and disease,”

Seidah et al., “The secretory proprotein convertase neural apoptosis-
regulated convertase 1 (NARC-1): Liver regeneration and neuronal

Seidah et al., “The proprotein convertases are potential targets in
2007.

Shan et al., “PCSK9 binds to multiple receptors and can be func-

Shen et al., “The molecular genetics of coronary artery disease and
myocardial infarction,” Acute Coronary Syndromes, 6(4), pp. 129-

Shibata et al., “No genetic association between PCSK9 polymor-
phisms and Alzheimer’s disease and plasma cholesterol level
2005.

Shioji et al., “Genetic variants in PCSK9 affect the cholesterol level
Stahl, “Regeneron: Investor Day Early Clinical Development #1
Sun et al., “Evidence for effect of mutant PCSK9 on apolipoprotein B
secretion as the cause of unusually severe dominant hypercholesterolemia, Human Molecular Genetics 14: 1161-1169,
2005.

Tall, “Protein variants, LDL, and coronary heart disease,” New
England Journal of Medicine, 354(12), pp. 1310-1312, Mar. 23,
2006.

Tangrea et al., “Solution structure of the pro-hormone convertase 1
Third Party Observations for Application No. EP20080798550 dated
Third Party Observations for Application No. EP20080798550 dated
Jan. 2013 by Carpmaels & Ransford.
Third Party Observations for Application No. EP20080798550 sub-
mited Dec. 22, 2012 by third party.
Timms et al., “A mutation in PCSK9 causing autosomal-dominant
hypercholesterolemia in a Utah pedigree,” Hum Genet., 114(4): 349-

Topol, “Cholesterol, racial variation and targeted medicines,” Nature
Topol et al., “Genetic susceptibility to myocardial infarction and
coronary artery disease,” Human Molecular Genetics, 15 (Rev. Issue
Transmittal Date from Information Disclosure Statement dated May
Tukkili-Wosornu et al., “Genetic deficiency of proprotein convertase
Subtilisin Kexin 9: identification of a compound heterozygote with
Vajdos et al., “Comprehensive Functional Maps of the Antigen Bind-
ing Site of an Anti Erib2 Antibody Obtained with Shotgun Scanning
Van Regenmortel et al., “Mapping Epitope Structure and Activity:
From One-Dimensional Prediction to Four-Dimensional Description
of Antigenic Specificity,” Methods: A Companion to Methods in
Varell et al., “A Third Major Locus for Autosomal Dominant
Hypercholesterolemia Maps to 1p. 34.1-34.2,” American Journal of
Varell et al., “ARH and HCHOL3: Two different genes at 1p both
implicated in familial hypercholesterolemia,” American Journal of

Varell et al., “Familial autosomal dominant hypercholesterolemia:
Highly skewed contribution of mutations in the LDLR, APOB, FH3
Villegger et al., “Familial hypercholesterolemia: 30 years after Brown
and Goldstein,” Recent Research Developments in Human Genetics,

Wells, “Additivity of mutational effects in proteins,” Biochemistry
Wu et al., “Humanization of a Murine Monoclonal Antibody by
Simultaneous Optimization of Framework and CDR Residues,” J.

Yende et al., “Genetic polymorphisms that predict outcome and need
for treatment in cardiovascular disease,” Current Opinion in Critical
Yue et al., “The c.43_44insCTG variation in PCSK9 is associated
with low plasma LDL-cholesterol in a Caucasian population,”
Zaid et al., “Proprotein convertase subtilisin/kexin type 9 (PCSK9):
hepatocyte-specific low-density lipoprotein receptor degradation and
critical role in mouse liver regeneration,” Hepatology, 48(2): 646-

Zhang et al., “Binding of PCSK9 to EGF-A Repeat of LDL Receptor
Decreases Receptor Recycling and Increases Degradation,” Journal
Zhang et al., “Structural requirements for PCSK9-mediated degra-
dation of the low-density lipoprotein receptor,” PNAS, Sep. 2, 2008,
105(35): 13045-13050.

Zhang et al., “Binding of Proprotein Convertase Subtilisin/Kexin
Type 9 to Epidermal Growth Factor-like Repeat A of Low Density
Lipoprotein Receptor Decreases Receptor Recycling and Increases
Degradation,” Journal of Biological Chemistry, 282(25), pp. 18602-
Zhang et al., “Molecular characterization of loss-of-function muta-
tions in PCSK9 and identification of a compound heterozygote,”
Zhang et al., “Functional characterization of sequence variations in

14/260,975.
14/261,063.
14/261,065.
14/260,985.
References Cited

OTHER PUBLICATIONS

SEQ ID NO:1

FIG. 1A
FIG. 1B
100 1110 1120 1130 1140 1150
----------|----------|----------|----------|----------|----------|
Query : catcattggtgtcctccccagactgcagcactgcctgttttgtctcagaggtg
Frame 1: I I G A S S D C S T C F V S Q S G

150 1160 1170 1180 1190 1200
----------|----------|----------|----------|----------|----------|
Query : ggacatccacagctgtcgtgcccaacggttgctgctcattgcctacgcaagtcatgtgcag
Frame 1: T S Q A A A H V A G I A A M M L

200 1210 1220 1230 1240 1250
----------|----------|----------|----------|----------|----------|
Query : tctgccccagcggagcgtcactacccttgcccagatggctgagtcagagactgtcattcc
Frame 1: S A E F E L T L A E L R Q R L I H

250 1260 1270 1280 1290 1300
----------|----------|----------|----------|----------|----------|
Query : cttctctgcacaagagcatcactcaatgagcctgttcctcgagaccaacgc
Frame 1: F S A K D V I N E A W F P E D Q R

300 1310 1320 1330 1340 1350
----------|----------|----------|----------|----------|----------|
Query : ggtgactgaccccaacctggttcgccccgctgcagccccagcagcctagg
Frame 1: V L T P N L V A A L P P S T H G

350 1360 1370 1380 1390 1400
----------|----------|----------|----------|----------|----------|
Query : gcaggtgccagctgttttgcagaggactgtgtggtgcaacactcggggcc
Frame 1: A G W Q L F C R T V W S A H S G P

400 1410 1420 1430 1440 1450
----------|----------|----------|----------|----------|----------|
Query : tacacggatgcccccaacgctcgccctgcccccaagagcagcgagacgcctgc
Frame 1: T R M A T A I A R C A P D E E L L

450 1460 1470 1480 1490 1500
----------|----------|----------|----------|----------|----------|
Query : tgagctctccagctttttccagggttggagacgggagcggccagcagcgagcctg
Frame 1: S C S S F S R S G K R R G E R M

500 1510 1520 1530 1540 1550
----------|----------|----------|----------|----------|----------|
Query : ggggccccaggggcaagcgctggctgctggtgcccccaacgctttttgcccccc
Frame 1: E A Q G G K L V C R A H N A F G G

550 1560 1570 1580 1590 1600
----------|----------|----------|----------|----------|----------|
Query : tgagcttttgcagccatggtggtgtggccctgctgctgctccccagcccagcact
Frame 1: E G V Y I A R C C L L P Q A N C

600 1610 1620 1630 1640 1650
----------|----------|----------|----------|----------|----------|
Query : gacaggtgctgcacacagctccacagcagcttgccagccagcatgagcccccttgctg
Frame 1: S V H T A P P A E A S M G T R V

FIG. 1B3
FIG. 1B4
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Germline</td>
<td>DIVM</td>
<td>TQSP</td>
<td>LSVPT</td>
<td>PGEPASISC RQQSSLHSNGYNYLD WYLQKPGSPS</td>
<td>QLLIY</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>30A4</td>
<td>A3</td>
<td>JK3</td>
<td></td>
<td>S---P--- F-N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Germline</td>
<td>DIQMTQSFSSLSAVGDRVTICT</td>
<td></td>
<td>RASQSISSYN</td>
<td>WYQQPGKAPKLLIY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>3C4</td>
<td>Q2</td>
<td>JK4</td>
<td></td>
<td>-----R--N--S      --L--I-----</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Germline</td>
<td>DIQMTQSFSSLSAVGDRVTICT</td>
<td></td>
<td>RASQSISSYN</td>
<td>WYQQPGKAPKLLIY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>23B5</td>
<td>Q2</td>
<td>JK5</td>
<td></td>
<td>--L--              ---------              V--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>25G4</td>
<td>Q2</td>
<td>JK5</td>
<td></td>
<td>---------I---       ---------            Y---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Germline</td>
<td>QSVLTTQPPSVGAPGQRVTISC</td>
<td></td>
<td>TGSNSNIGAGVDHV</td>
<td>WYQQPGKAPKLLIY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>31H4</td>
<td>V1-13</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>27B2</td>
<td>V1-13</td>
<td>JL2</td>
<td></td>
<td>H---           ---------            V---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Germline</td>
<td>QSAALTQPASVSGSPGQSITISC</td>
<td></td>
<td>TGTSSDVGGNYVVS</td>
<td>WYQQPGKAPKLMY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>25A7</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              R--S--              H---V---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>27H5</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              R--S--            P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>26H5</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S---           P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>31D1</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S---           P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>20D10</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S--Y--P--K--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>27E7</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S--Y--P--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>30B9</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S--           P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>19H9</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              --N--S--              P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>26E10</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S---           P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>21B12</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              S--           P---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>17C2</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>---------              ---------              --A--S--              R---</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIG. 2A**
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>Germline</td>
<td>V1-4</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGNYVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>26</td>
<td>23G1</td>
<td>V1-4</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGNYVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>27</td>
<td>Germline</td>
<td>V1-7</td>
<td>JL3</td>
<td>L</td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>28</td>
<td>13H1</td>
<td>V1-7</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>29</td>
<td>Germline</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>30</td>
<td>9C9</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>31</td>
<td>9H6</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>32</td>
<td>31A4</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>33</td>
<td>1A12</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>34</td>
<td>Germline</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>35</td>
<td>16F12</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>36</td>
<td>22E2</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>37</td>
<td>27A6</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>38</td>
<td>28B12</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>39</td>
<td>28D6</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>40</td>
<td>31G11</td>
<td>V1-19</td>
<td>JL1</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>41</td>
<td>Germline</td>
<td>V1-19</td>
<td>JL2</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>42</td>
<td>13B5</td>
<td>V1-19</td>
<td>JL2</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>43</td>
<td>Germline</td>
<td>V2-1</td>
<td>JL2</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>44</td>
<td>31B12</td>
<td>V2-1</td>
<td>JL2</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>45</td>
<td>Germline</td>
<td>V5-2</td>
<td>JL2</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
<tr>
<td>46</td>
<td>3B6</td>
<td>V5-2</td>
<td>JL2</td>
<td></td>
<td>QSLTQPASVASPGQSITSC</td>
<td>TGTSSDVGGSYNLVS</td>
<td>WYQQHPGKAPKLMY</td>
</tr>
</tbody>
</table>

FIG. 2B
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>CDR2</th>
<th>FR3</th>
<th>CDR3</th>
<th>FR4</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>EVSNRPS</td>
<td>GVS NRFSGSKSGNTA SLTISGLQAEDADYYC</td>
<td>SSYTTSSS V</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>23G1</td>
<td>--T----</td>
<td>-----------------</td>
<td>N-----T-K-</td>
<td>--- --------</td>
</tr>
<tr>
<td>27</td>
<td>EGSKRPS</td>
<td>GVS NRFSGSKSGNTA SLTISGLQAEDADYYC</td>
<td>CSYAGSST</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>13H1</td>
<td>--V----</td>
<td>-----------------</td>
<td>--------</td>
<td>LV</td>
</tr>
<tr>
<td>29</td>
<td>SNNQRPS</td>
<td>GVPD RFSGSKSGTASLA IGLQ SDEADYYC</td>
<td>AANDDSLNV</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>9C9</td>
<td>R------L</td>
<td>-----------------</td>
<td>--------</td>
<td>W-</td>
</tr>
<tr>
<td>31</td>
<td>9H6</td>
<td>--R----</td>
<td>-----------------</td>
<td>--------</td>
<td>N-</td>
</tr>
<tr>
<td>32</td>
<td>31A4</td>
<td>-------</td>
<td>-----------------</td>
<td>------V-</td>
<td>GNV</td>
</tr>
<tr>
<td>33</td>
<td>1A12</td>
<td>--R----</td>
<td>-----------------</td>
<td>--------</td>
<td>A-</td>
</tr>
<tr>
<td>34</td>
<td>DNKRPNS</td>
<td>GIPDFRSGSKSGTASLGLTGGLQTGDADYYC</td>
<td>GTWDSSLAYV</td>
<td>FGGGTKVTVL</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>16F12</td>
<td>--Y-----</td>
<td>-----------------</td>
<td>--------</td>
<td>R-</td>
</tr>
<tr>
<td>36</td>
<td>22E2</td>
<td>--Y-----</td>
<td>-----------------</td>
<td>--------</td>
<td>G-</td>
</tr>
<tr>
<td>37</td>
<td>27A6</td>
<td>--Y-----</td>
<td>-----------------</td>
<td>--------</td>
<td>S-</td>
</tr>
<tr>
<td>38</td>
<td>28B12</td>
<td>--Y-----</td>
<td>-----------------</td>
<td>--------</td>
<td>G-</td>
</tr>
<tr>
<td>39</td>
<td>28D6</td>
<td>--Y-----</td>
<td>-----------------</td>
<td>--------</td>
<td>R-</td>
</tr>
<tr>
<td>40</td>
<td>31G11</td>
<td>--S----</td>
<td>-----------------</td>
<td>--------</td>
<td>D-</td>
</tr>
<tr>
<td>41</td>
<td>DNNKRPNS</td>
<td>GIPDFRSGSKSGTASLGLTGGLQTGDADYYC</td>
<td>GTWDSSLAVV</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>13B5</td>
<td>-------</td>
<td>-----------------</td>
<td>--------</td>
<td>N-</td>
</tr>
<tr>
<td>43</td>
<td>QDSKRPS</td>
<td>GIPERFSGSNSCMTATLTTISG TQAMDEADYYC</td>
<td>QAWDSSAVV</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>31B12</td>
<td>--N-T-W-L</td>
<td>-----------------</td>
<td>--V--</td>
<td>V-</td>
</tr>
<tr>
<td>45</td>
<td>VGTGFIVGSKGD</td>
<td>GIPDFR SVLGSGLNLRTIKNIQEEDSYHC</td>
<td>GADHGSGSNFVVV</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>3B6</td>
<td>--D-----</td>
<td>-----------------</td>
<td>--------</td>
<td>T-</td>
</tr>
<tr>
<td>45</td>
<td>VGTGGIVV</td>
<td>GSGKDGGIPDFRSVLGSGLNLRTIKNIQEED</td>
<td>SDYKCGADHSGSGSNFVVV</td>
<td>FGGGTKLTVL</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>3B6v1</td>
<td>--D-----</td>
<td>-----------------</td>
<td>--------</td>
<td>T-</td>
</tr>
</tbody>
</table>

**FIG. 2D**
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>Germline</td>
<td>VH1-18</td>
<td>JH6B</td>
<td>-I-----</td>
<td>QVQLVQSGAEGVKKPGASVKVSCAS</td>
<td>GYFTFSYGIS</td>
<td>WVRQAPGQQGLEWMA</td>
</tr>
<tr>
<td>48</td>
<td>20D10</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--PL--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>49</td>
<td>26E10</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>49</td>
<td>21B12</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>50</td>
<td>23G1</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>51</td>
<td>26H5</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>52</td>
<td>27H5</td>
<td>VH1-18</td>
<td>JH6B</td>
<td>-R------</td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>53</td>
<td>31D1</td>
<td>VH1-18</td>
<td>JH6B</td>
<td>-L------</td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>54</td>
<td>27E7</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>55</td>
<td>30B9</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>56</td>
<td>19H9</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>57</td>
<td>17C2</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>58</td>
<td>25A7</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>59</td>
<td>Germline</td>
<td>VH1-18</td>
<td>JH4B</td>
<td></td>
<td>QVQLVQSGAEGVKKPGASVKVSCAS</td>
<td>GYFTFSYGIS</td>
<td>WVRQAPGQQGLEWMA</td>
</tr>
<tr>
<td>60</td>
<td>3B6</td>
<td>VH1-18</td>
<td>JH4B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>61</td>
<td>Germline</td>
<td>EVQLVESGGGLVQPGGLRLSCAAS</td>
<td>GFFYSSYNSM</td>
<td>WVRQAPGKGLEWVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>9H6</td>
<td>VH3-7</td>
<td>D7-27</td>
<td>JH3A</td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>63</td>
<td>Germline</td>
<td>EVQLVESGGGLVQPGGLRLSCAAS</td>
<td>GFFYSSYNSM</td>
<td>WVRQAPGKGLEWVA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>9C9</td>
<td>VH3-7</td>
<td>D7-27</td>
<td>JH3B</td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>65</td>
<td>1A12</td>
<td>VH3-7</td>
<td>D7-27</td>
<td>JH3B</td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>66</td>
<td>Germline</td>
<td>EVQLVESGGGLVQPGGLRLSCAAS</td>
<td>GFFYSSYNSM</td>
<td>WVRQAPGKGLEWVS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>31H4</td>
<td>VH3-21</td>
<td>D3-3</td>
<td>JH3A</td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
<tr>
<td>68</td>
<td>Germline</td>
<td>EVQLVESGGGLVQPGGLRLSCAAS</td>
<td>GFFYSSYNSM</td>
<td>WVRQAPGKGLEWVS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>13B5</td>
<td>VH3-23</td>
<td>JH4B</td>
<td></td>
<td>-L------</td>
<td>--L--------</td>
<td>--L--------</td>
</tr>
</tbody>
</table>

**FIG. 3A**
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>70</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>EVQLLESGGGLVQPGGSLRLSCAAS</td>
<td>GFTFSSYAMS</td>
<td>WVRQAPGKGLEWVS</td>
</tr>
<tr>
<td>71</td>
<td>23B5</td>
<td>VH3-23</td>
<td>D2-8</td>
<td>JH4B</td>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>72</td>
<td>25G4</td>
<td>VH3-23</td>
<td>D2-8</td>
<td>JH4B</td>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>73</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLVESGGGVQPGGRSLRLSCAAS</td>
<td>GFTFSSYGMH</td>
<td>WVRQAPGKGLEWVA</td>
</tr>
<tr>
<td>74</td>
<td>30A4</td>
<td>VH3-33</td>
<td></td>
<td>JH6B</td>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>75</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLVESGGGVQPGGRSLRLSCAAS</td>
<td>GFTFSSYGMH</td>
<td>WVRQAPGKGLEWVA</td>
</tr>
<tr>
<td>76</td>
<td>27A6</td>
<td>VH3-33</td>
<td>D6-6</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>N-F--</td>
</tr>
<tr>
<td>77</td>
<td>28B12</td>
<td>VH3-33</td>
<td>D6-6</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>F--</td>
</tr>
<tr>
<td>78</td>
<td>28D6</td>
<td>VH3-33</td>
<td>D6-6</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>F--</td>
</tr>
<tr>
<td>79</td>
<td>16F12</td>
<td>VH3-33</td>
<td>D6-6</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>N-F--</td>
</tr>
<tr>
<td>80</td>
<td>22E2</td>
<td>VH3-33</td>
<td>D6-6</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>F--</td>
</tr>
<tr>
<td>81</td>
<td>31B12</td>
<td>VH3-33</td>
<td>D6-6</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>F--</td>
</tr>
<tr>
<td>82</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLVESGGGVQPGGRSLRLSCAAS</td>
<td>GFTFSSYGMH</td>
<td>WVRQAPGKGLEWVA</td>
</tr>
<tr>
<td>83</td>
<td>31G11</td>
<td>VH3-33</td>
<td>D6-19</td>
<td>JH6B</td>
<td>--H--</td>
<td>------------</td>
<td>R--</td>
</tr>
<tr>
<td>84</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLQESGPGLVKPSQTLSLCTVS</td>
<td>GGSISSGGYYWS</td>
<td>WIRQHPGKGLEWIG</td>
</tr>
<tr>
<td>85</td>
<td>3C4</td>
<td>VH4-31</td>
<td></td>
<td>JH6B</td>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>86</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLQESGPGLVKPSQTLSLCTVS</td>
<td>GGSISSGGYYWS</td>
<td>WIRQHPGKGLEWIG</td>
</tr>
<tr>
<td>87</td>
<td>27B2</td>
<td>VH4-31</td>
<td>D5-5</td>
<td>JH4B</td>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>88</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLQQWAGLLKPSLETSLTCAY</td>
<td>GGSFSGYWS</td>
<td>WIRQPPGKGLEWIG</td>
</tr>
<tr>
<td>89</td>
<td>31A4</td>
<td>VH4-34</td>
<td>D6-6</td>
<td>JH4B</td>
<td>------------------------</td>
<td>A--N</td>
<td>------------</td>
</tr>
<tr>
<td>90</td>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLQQSGPGLVKPSQTLSLTCAINS</td>
<td>GDSVSSNSAAWN</td>
<td>WIRQSPSGLEWLG</td>
</tr>
<tr>
<td>91</td>
<td>13H1</td>
<td>VH6-1</td>
<td></td>
<td>JH4B</td>
<td>------------------------</td>
<td>------------</td>
<td>------------</td>
</tr>
</tbody>
</table>

**FIG. 3B**
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>CDR2</th>
<th>FR3</th>
<th>CDR3</th>
<th>FR4</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>20D10</td>
<td>WISAYNGNTNYAQKLQG</td>
<td>RVTMTTDSTSTAYMELRSRLSDDTAVYYCAR</td>
<td>YGMDV</td>
<td>WGGQTTVTVSS</td>
</tr>
<tr>
<td>48</td>
<td>26E10</td>
<td>-V-F---------</td>
<td>-S- ---------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>49</td>
<td>21B12</td>
<td>-V-F---------</td>
<td>-G- ---------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>50</td>
<td>23G1</td>
<td>-V-F---------</td>
<td>-G- ---------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>51</td>
<td>26H5</td>
<td>--F-----------</td>
<td>---V-------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>52</td>
<td>27H5</td>
<td>--V-----------</td>
<td>---V-------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>53</td>
<td>31D1</td>
<td>--F-----------</td>
<td>---V-------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>54</td>
<td>27E7</td>
<td>--V-----------</td>
<td>---V-------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>55</td>
<td>30B9</td>
<td>--V-----------</td>
<td>---V-------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>56</td>
<td>19H9</td>
<td>--V-----------</td>
<td>---V-------------------------</td>
<td>G-----</td>
<td>------------</td>
</tr>
<tr>
<td>57</td>
<td>17C2</td>
<td>--V-----------</td>
<td>---V-------------------------</td>
<td>G-V---</td>
<td>------------</td>
</tr>
<tr>
<td>58</td>
<td>25A7</td>
<td>--E-----------</td>
<td>---V-------------------------</td>
<td>G-V---</td>
<td>------------</td>
</tr>
<tr>
<td>59</td>
<td>3B6</td>
<td>WISAYNGNTNYAQKLQG</td>
<td>RVTMTTDSTSTAYMELRSRLSDDTAVYYCAR</td>
<td>GY DY</td>
<td>WGGQTLVTVSS</td>
</tr>
<tr>
<td>60</td>
<td>9H6</td>
<td>--H-----------</td>
<td>---H-------------------------</td>
<td>--FR--</td>
<td>--H---------</td>
</tr>
<tr>
<td>61</td>
<td>9C9</td>
<td>NIKQDGSEKYYVDSVKG</td>
<td>RFTISRDNAKNSLYQLMNSLRAEDTAVYYCAR</td>
<td>NWG AF4V</td>
<td>WGGQTMVTVSS</td>
</tr>
<tr>
<td>62</td>
<td>1A12</td>
<td>--S-----------</td>
<td>---S-------------------------</td>
<td>ES-F--</td>
<td>--H---------</td>
</tr>
<tr>
<td>63</td>
<td>31H4</td>
<td>NIKQDGSEKYYVDSVKG</td>
<td>RFTISRDNAKNSLYQLMNSLRAEDTAVYYCAR</td>
<td>NWG AF4V</td>
<td>WGGQTMVTVSS</td>
</tr>
<tr>
<td>64</td>
<td>31H4</td>
<td>SISSSSYIYYADSVKG</td>
<td>RFTISRDNAKNSLYQLMNSLRAEDTAVYYCAR</td>
<td>DYSFWSGYHTAFDV</td>
<td>WGGQTMVTVSS</td>
</tr>
<tr>
<td>65</td>
<td>31H4</td>
<td>AIGSQQGDTYYADSVKG</td>
<td>RFTISRDNSKNTLYQLMNSLRAEDTAVYYCACAK</td>
<td>FDY</td>
<td>WGGQTLVTVSS</td>
</tr>
<tr>
<td>66</td>
<td>31B5</td>
<td>T-------R------</td>
<td>---E-------------------------</td>
<td>EVGSP---</td>
<td>------------</td>
</tr>
</tbody>
</table>

**FIG. 3C**
<table>
<thead>
<tr>
<th>Seq ID No.</th>
<th>LINE</th>
<th>CDR2</th>
<th>FR3</th>
<th>CDR3</th>
<th>FR4</th>
</tr>
</thead>
<tbody>
<tr>
<td>70</td>
<td>23B5</td>
<td>ALGSGGCTYYADSVKG</td>
<td>RFTISRFDNSKNTLYLQMSLRAEDTAVYYCAK</td>
<td>VLMVYA DY</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>71</td>
<td>25G4</td>
<td>T-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>72</td>
<td>30A4</td>
<td>T-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>73</td>
<td>27A6</td>
<td>VIYDSKYYADSVKG</td>
<td>RFTISRFDNSKNTLYLQMSLRAEDTAVYYCAR</td>
<td>YYYGMVD</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>74</td>
<td>28B12</td>
<td>L-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>75</td>
<td>28D6</td>
<td>L-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>76</td>
<td>16F12</td>
<td>L-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>77</td>
<td>22E2</td>
<td>L-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>78</td>
<td>22E2v1</td>
<td>L-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>79</td>
<td>31B12</td>
<td>I-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>80</td>
<td>31B12v1</td>
<td>I-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>81</td>
<td>31G11</td>
<td>L-E-</td>
<td>T-V-</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>82</td>
<td>31G11</td>
<td>L-E-</td>
<td>T-V-</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td>83</td>
<td>3C4</td>
<td>YYYGCTYYNPSLKS</td>
<td>RVTISVTSDKQFSLKLSSVTAADTAVYYCAR</td>
<td>YYYGMVD</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>84</td>
<td>27B2</td>
<td>YYYGCTYYNPSLKS</td>
<td>RVTISVTSDKQFSLKLSSVTAADTAVYYCAR</td>
<td>GCGVTT-A-</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>85</td>
<td>27B2</td>
<td>YYYGCTYYNPSLKS</td>
<td>RVTISVTSDKQFSLKLSSVTAADTAVYYCAR</td>
<td>EDDMV YFDY</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>86</td>
<td>31A4</td>
<td>RYYRSKYNNDAYAVSVKS</td>
<td>RVTISVTSDKQFSLKLSSVTAADTAVYYCAR</td>
<td>GQLV FDY</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>87</td>
<td>31A4</td>
<td>RYYRSKYNNDAYAVSVKS</td>
<td>RVTISVTSDKQFSLKLSSVTAADTAVYYCAR</td>
<td>GQLV FDY</td>
<td>WCGTTLVTSS</td>
</tr>
<tr>
<td>88</td>
<td>13H1</td>
<td>K-N-</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
</tbody>
</table>
31H4

Nucleotide sequence of heavy chain variable region:
5'GAGGTGCAGCTGGTGGAGTCTGGGCTGGGTGCACCGTGCTGGAAGCTGGGCTGGTCCCTGA
GACTCTCCTGAGACGCTGGTCTGGATTCACCTTACGAAGCATGAACTGGGCTGCC
GCCAGGCTCCAGGAGGAGGGCTGGATGGTTGCTCTACATTAGTAGTAGTAAGTGAT
TACATTTCTCAGCATGACCTAGAAGGGCCATTACCAATCCCAGAGACACACGCGC
AAGAATCACTGTATCTGCAAATGAAACACCTGAGACCGGAGACACCGCTGTA
TTCTGTGCGAGAGATTACGATTGTTTGAGGTGCTTACTATGATGCTTTTGATGCTGG
GGCCAAAGGACAAATGGCTACCCGCTTCTTCA3' (SEQ ID NO: 152)

Amino acid sequence of heavy chain variable region:
EVQLVESGGGLVQPGSGSLRLSCAASGFTLYFQSVGPLEWSSLISSSSSYISY
ADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYFCARDYDFWSAYYDADFVWGQGT
MVTVSS (SEQ ID NO: 67)

Nucleotide sequence of light chain variable region:
5'CAGTCTGTGCAGCGAGCGCAGCCCTCAGTGTTTCGCTGGCCCTCGAGGCTGA
CCATCTCTCTGACTGGGAGCGATCAGACCGAGGTACATGATGTAACACTGCT
ACCAGCAGCTTTCCAGAACGCCCACACTCCAGCTCTGTTAAGCAATCCAGGC
CTCCGAGAGGTCTCCAGCTGCTGGTACAGCTCAAGGCTCCCTCCCTGAGCTGG
CCATCAGCCTGGGCTCCAGCTGAGATGAGGCTGATTACGACTGCGATCTCTAGACA
GCGAGCCTGAGTGGTTCGCTATCGGAGCGAGCAAGCTGACCGCTCTCA3' (SEQ
ID NO: 153)

Amino acid sequence of light chain variable region:
Q5VLTPSPSVGAPGVRVTISCTGSSSNIGAGYDHYWYQQLPTAPKLLISGNSRPSGV
PDRFSGKSGTSASLALTGLQAEDDEADYYCQSYDSSLGSGVFGGGTKLTVL (SEQ ID
NO: 12)

FIG. 3E
Nucleotide sequence of heavy chain variable region:
5’CAGATTCAGCTGGTGCAGTCTGGAGCTGAGAAGAGCTGGGGCTCACGATG
AGGTCTCTGAGAGGCTTTCTGTTACCCTCTGACCAGCTATGATCATGCTGGTGC
GACAGGGCCCTGGCACAAGGGCTTGAGTGGATGATATGGATAGCATAGGCCCTTTAG
AACACAAACTATGCACAGAAGGTCCAGGCCAGCTCACCAGACCAGACACATC
CACGAGCAACTCTACAGTGGAGAGACCCTGAGATCTGACAGACACGGCCCTG
ATTACTGTGCAGAGGGCTACGGTATGGACGTCTGGGCGCAAGGGACAGCAGGTCA
CCGCTCTCTCT³ (SEQ ID NO: 92)

Amino acid sequence of heavy chain variable region:
QIQLVQSGAEVKKPGASVKSCKASGYPLTSYGISVWVRQAPGQGLEWMGWISAYNGN
TNYAQKVQGVTMTTDTSTSTVYMELRSLRSDDTAVYTCARGYGMVWGQTTVT
SS (SEQ ID NO: 48)

Nucleotide sequence of light chain variable region:
5’CAGTCTGCCCCTGACTCACGCTGGCTGGCTCTGGAGCACGTGATCAC
CATCTCTGCACCTGGAAACGAGCTAGCTTTGGTATATACTTCTGTCCTGGTA
CCAAACAGGACCCAGGCAAAACCCCAACTCAAGATTATAGGCTGATAGATTAGC
CCCTAGGGTTTTCTAATCGTTTCTGGTCAAGTCAAGCTGGCAACACGCGCCCTGTA
CCATCTCTGGGCTCCAGCTGGAGACAGGGCTGATATTCTGCCAGCTCATAACAA
GCACCCAGCATGTCTCTCCGGAGGGACACAGCTGACGCTCTA³ (SEQ ID NO: 93)

Amino acid sequence of light chain variable region:
QSLTQPASVSGSGQISITSCGTSVDSVGYNSVSWYQYPGKPRLKJVEVSNRPSVG
SNRFSGKSKSNTASLTISGLQAEDADYFCSSTSTSMVFGGKLTVL (SEQ ID NO: 19)

FIG. 3F
FIG. 3G
Nucleotide sequence of heavy chain variable region:
5’CAGGTTCAGCTGGTGACAGCAGCTGAGTGAAGAGCTCGCTGGAACGGCCAAGCTCTAGTGA
AGTCTCTGCAAGGCTCTCCGGTATGGGATGAAAGTGCAGTATCAGCTGGGTGC
GACAGGCGCTGGACAAAGGGCTGGATGGGATGGGATGGGATGCTGCTAATTTACAAATGTT
AACACAAACTATGCACAGGAAGATCCAGGGCAGAATCACCATGAACACGACGACACATC
CACGAGCAGTCTATGGAGAGAGGGGCTGAGAGATCTGAGACAGACGGCGGTGT
ATTACTGTGCGAGAGGGCTACGGTATGGAGCAGTCTGGGCCAAAGGACCGACAGGC
CTCCTCTT3’ (SEQ ID NO: 96)

Amino acid sequence of heavy chain variable region:
QVQLVQSGAEVKPGASVQLVKSRASGYTLTSYGISWVRQAPGQGLEWEMGWISFYNGN
TNYAQKVQGRVTMTTDSTSTVYMELRSLRSDDTAVYVYCARFYGMDVWGGGTVTV
SS (SEQ ID NO: 51)

Nucleotide sequence of light chain variable region:
5’CAGTCTGCCCCCTGACTACAGCCTCGCTCCCGTCTGGGTCTCTCCTTGAGAGTCAGACAC
CATCCTCTGCAAGAGAGAGAGGTGGTTGTAATAACTCTGCTCCTCCTGTA
CCAAGGCAAGGGCCAGAGCAGAGCACAGGCTGAGATAGTGTGGTCAAGTCTGAATCAGGC
CCTCAGGGGTCTATTCGCCATCTCTGCTGCTCAGAAGCAGCCGGCCTCCCTGAC
CATCCTCTGGGCTCAGGCTGAGAGGGAGGCTGAGATAGTGTGGTCAAGTCTGAATCAGGC
CACAGGCTAGTCTCCGCGAGAGGACAAAGCTCTGGACCGTCTCTT3’ (SEQ ID NO: 97)

Amino acid sequence of light chain variable region:
QSALTQPASVSQPQSLTSITSTGTSSDVGGYNSVSVWYQHQPGKPKLMIYEVSNRPGS
SIRFGSGKSQNTASLTISGLQAEDAEYFCSSYTYSTSMVFFGGTITL (SEQ ID NO:
17)

FIG. 3H
Nucleotide sequence of heavy chain variable region:
5' CAGATTCAGCTGGTGCAGTCTGGAGCTGAGAGTGAAGAAGCCCTGGGACGTCAAGTGA
AGGTCTCTGCAAGGCTTCTGGTATACGCCTTGACAGCTATGATACGCTGGTGC
GACAGGCCCCTGGACAAAGGGCTTTAGGATGGATGGATCATCAAGTTTTAACATGT
AACACAAACTATGCACAGAGGTCCAGGACAGTCACCATGACACCAGACACATC
CACGAGCACAGTCTCACATGGAGCTGAGAGCTGAGATCTGACGACACGGCCGTTGT
ATTCTCTGCGAGAGGTTACGCTATAGACGTCTGGGCAAGGAAGACACAGTGCTACC
GTCTCTCAA3' (SEQ ID NO: 98)

Amino acid sequence of heavy chain variable region:
YQQLVQSGAVKPGAVSKVCKAGTYLTSYGISWVRQPQGGLEWGMWGYSFUNGNT
NYAQKVQRVMTMTDTSTVTYMERLRSRSDTAVYFCARGYYGMDVWQGTTTVS
S (SEQ ID NO: 53)

Nucleotide sequence of light chain variable region:
5' CAGTCTGCTCCTGACTCAGCCCTGCTCCGGTCTCTGGACTGAGCTGAGTGGTGT
ACTCTCTGCAACTGGAACCCAGCAGTGTGGTGTATACCTTGCTGCTCGTGA
CCAACAGACACCAGGCAAACCCCCACAAACTCATGATTTATAGGAGTCAGTAATCGGC
CCTCAAGGCGTTTTATACGGTCTCTGTCAGGACACAGCTCCCTCTGA
CCATCTCTGGTGGCTCGGAGGACAGAGGCTGATTATTCTGACGCTCATATACAA
GCACCAACATGCTTCTGGCGGAGAGGACCAAGCTGGCGCCGTCCTA3' (SEQ ID NO: 99)

Amino acid sequence of light chain variable region:
QSAQLQPASVSQPSGQSITISCTGTSSDVGYNSWYSWYQQHGPKPKLMIYEVSNRPSGV
SNRFSGKSGNTASLTISGLQAEDAEDEYFCSSYTSMTVMFVGGTMLAVL (SEQ ID NO: 18)

FIG. 3I
23G1

**Nucleotide sequence of heavy chain variable region:**
5'CAGGTTTCAGCTGGTCAGTCGGGAGCTGGTAAAGAAGCCTGGGGCTCTCAGTGA AGGTCTCTGCAAGGCTCTGTTACACTTAAACCAGCTATGATTCAGCTGGGTGC GACAGGCCCGCTGACAGGGCGTTGAGTGATGGGATGGGTGTCTGATTTTATATGT AACACAAACTATGCACAGAAGCTCCAGGGCCAGAGGCCACTGACCAGACCCACCTC CAGGACGACACGCTATGAGCAGTAAGAGGCCTGAGATCTCAGCACACAGGCCTGT GTATACTCTGCGAGAGGCTACGGTCTGGATGGACGTCTGGGCGCAAAGGAGACAGGTCACC GTCTCCTCA3' (SEQ ID NO: 100)

**Amino acid sequence of heavy chain variable region:**
QVQLVQSGAEVKPGASVQLVSCKASGYTLTSYGISWVRQAPGQGLEWMGWVSFYNG NTNYAQKLQGRMTIFMSPSTAYMELELRSLRSDTAVYYCARYGMDVWQGGGTVT VSS (SEQ ID NO: 50)

**Nucleotide sequence of light chain variable region:**
5'CAGTCTGCGCTGACTCAGCCTGGCAGTCTGCTGGGTCTCCTGGACAGTCATCAC CATCTCTGCACTGGAAACAGCACTAGGTTGGTGCTAATCTCTGCTCTGGGA TCAAAACCACAGAGCCAGCCACTATGAGTAAGAGGCCTGAGATCTCAGCACACAGGCCTGT GACGAGCTGCTGGGCGCGGTGGACGTCTGGGCGCAAAGGAGACAGGTCACC GTCTCCTCA3' (SEQ ID NO: 101)

**Amino acid sequence of light chain variable region:**
QSALTQPASVSGPSQSVSTISCTCTGGGYYNSVWSWYQQHGPKAPKLMYIVETNRPNSGV SNRFSGSKSGNTASLTISGLQAEDEADVYCNYSYTSSTSMVFGGTKTVL (SEQ ID NO: 26)

**FIG. 3J**
Nucleotide sequence of heavy chain variable region:
5’CAGGTGCAGCTGCGAGAGTCGGGCGCCAGGACTGGTGAAAGCCTCACAGACCCCGCTCCCTACCTGCACTGGTCGGGCATGCACTGGGTTACTACCTGAGGTAGGATCGGCGCCAGACGGGAGCTGGGAGAATTGGAATGTCATATATAACAGTGCGAGCACTACTACCAACCCCTCCCTCAAGAGTCGAATTACCATATGTCAGAGCACGTCATAAGAACCAGTTCCTCCCTAGAAGCTGACGCTGACTGACGCCGGAGACACGGCGCT GTATTACGTGCGAGAGGATACAGCTATGTTTCTTACTTGTACTGACTGGGGCA GGGAAACCTGGTGACCCGGTCTCCTCAAA (SEQ ID NO: 102)

Amino acid sequence of heavy chain variable region:
QVQLQESGPGLVKPSQTLSLTCTVGGSIISSGGYWSWIRQHPGKLEWIGYIYNSGTY YNPSLKSRTVTISVDSNQFSKLSSVTAADTAVVYCAREDTSAMYPYFDYWGQGTLVT VSS (SEQ ID NO: 87)

Nucleotide sequence of light chain variable region:
5’CAGTCTGTACTGACGCACGGCCGCTCACTGCTGGGGCCAGGGCAAGGCTTACA CACATCTCTGCTGAGCAGCTCCACACATCGGGGACATATTGATGTGCACGTGTA CACAGCAAGTTCAGCTGGCCCCAAAACCTCTCATCTGATAGACACATCCATCGGC CCTCGGGTCCTGCACTGGACAGTCTCTGCTGCTCAAGCTGACCTCGCCCTGCC CGAACACTGCCAGCTGAGGATAGGCTGATTAGACTGCGAGTCCAGTCTCATAGA CAGCCTGAGTTGGTGTTGATTCGCGGAGGAGAGCAGTACGACCCGTCA (SEQ ID NO: 103)

Amino acid sequence of light chain variable region:
QSVLTQPPVSAGPQVRVTISCTGSSNIGAYDVHYQVQVPGTKLIIYGMNTYRPG VPDRTSAGSKSTASLTALTGLQAEDEYYCQSYDNSLSGVVFVGGTTLVL (SEQ ID NO: 13)

FIG. 3K
16F12

**Nucleotide sequence of heavy chain variable region:**
5′CAGGGTCACCTGTTGGAGTCAGTCTGCTTGCCAGCTGGGAGGAGGTCCCTGA
GACTTCCTGTCACGGTCTGGAATTACCCTCAACAAGCTTTGGCATGCACTGGGTCC
GCCAGGCTCCAGCAGGAGGCTGGAGGTGCTGCCACTACTCTCTGATGGAGAT
GATGAACTACTATCGAGACTGCCGTGAAGGGCCGATTCACGCTCAGAGACATCTCC
AAGAACACGCTGTAATCTGCAAAATGAAACGCTGGAAGCGGACACGGCCTGTGTA
TTACTGTGGAGAGCCATAGCACGCCCCCTACTACTAGCTAGTTATGGACGTCTGG
CCAAGGGACACCAGCTCACCCTCCTCCTCA3′ (SEQ ID NO: 104)

**Amino acid sequence of heavy chain variable region:**
QVHLVESGGVVQPGRSRLSCLAASGFTFN5FSGMHWVRQAPGKGLWVAVLIWSGD
EYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAIAALYYYGMWDWGQ
GTTVTSS  (SEQ ID NO: 79)

**Nucleotide sequence of light chain variable region:**
5′CAGTCTCTTGGACGCAGCCCGCCCTCAGTCTCTGCGCGGACCAGACAGGTCA
CCATCTCTCTGCTCGGAACCTGACCTCAACATGGGAATATTGTATCTGGTACC
AGCAGCTCCAGAAGCCCGCAAACTCCTCATTATAGCTATAATAAGCGACCCCT
CAGGGATTCTGACCAGTTCTCTGCTGACGGACTAGCCACCTTGGCA
TCACCGGAATCGAGCTGGGACAGGCAGGCGATTATTACCTCAGGAAACATGGGATAGC
AGGCTAGTCTGTTATGTCTCGGAACTGCGGACCAGGCTACGTCCTCA3′ (SEQ ID NO: 105)

**Amino acid sequence of light chain variable region:**
QSVLTQPPSVAAPGQKVTSCSGSSSNIGNNFFSVWQQQLPGTTAKLLYIDYNYKRPSSGIPD
RFSGSKSGTATLGTGQTGDADYYCGTWDSSELSAYVFGTGTRTVTL (SEQ ID NO: 35)

**FIG. 3L**
22E2

Nucleotide sequence of heavy chain variable region:

5’CAGGTGCAGCTGTGGAGTCTGGGAGGAGGCTGTCGTCAGCAGCTGGAGGGGCTGAAGCTCTCTCTCAAGTCTGGAGGAAGGCTGTCAGGCTGTCGTCAGCAGCTGGAGGGGCTGAAGCTCTCTCTCAAGTCTGGAGGAAGGCTGTCAGGCTG

Amino acid sequence of heavy chain variable region:

QVQLVESGGGLVQPSRLSLCVASGGFTSSFGMSWVRQPAGKLEGWVALIWNQSNKYYADSVGTKISRDNSKNTFLYQMNSLRAEDTAANTYVYCARAIAYLYLGGMDVWGQGTTVTVSS (SEQ ID NO: 80)

Nucleotide sequence of light chain variable region:

5’CAGTCCTGAGTTGACGCAGCCGCCCTCAGTGTCGCGGCCCAGGAAGCTGATCCGCATGCAGCTGTGGGAAGGACACCGCTCAGTGTCGCGGCCCAGGAAGCTGATCCGCATGCAGCTGTGGGAAGGACACCGCT

Amino acid sequence of light chain variable region:

QSVTQPSVSAAPGGQTVSICSGSSSNIGNFFVSWYQQLPTAQKLLYIDYKNKRPSTGIPDRTSGSKTSATLGITGLQTGDEADYNYCGTWDSLSGYVFTGTRVTVL (SEQ ID NO: 36)
Nucleotide sequence of heavy chain variable region:
5'CAGGTGCACCTGGTGAGTCGGCGGGAGGCGTGGTCCAGGCTGGGGAGGCTCGGA
GACCTCTCTTGACAGCTGGAGATCTACCTCAAACAGCTTTGGAATGACTGGTCC
GCCAGGTCCAGGCGACGAGGCGCTGGTGCCACTGATGTCGATGGAAGT
GATAAAATATATGCAAGCAGCTCGTCGGAAGGGCGGATCTACCATACCCAGAGAATTCC
AAGAAGACAGCTGTATCTGCAAATAGAAGACAGCTGAGAGCCGAGACACCGGCTGTA
TTACGTCGCGAGAGCCATAGCAGCCCTCTATAGTCATCAGTGATGCGGAGCTCGGGG
CCAAGGGGACCAGGGTCACCAGCTCCTCTCA3'  (SEQ ID NO: 108)

Amino acid sequence of heavy chain variable region:
QVHLVESGGOVQPGSLRLCAGASFGTFSFGMHWVRQAPGBKGLEWVALIWSDGSD
KYVADSVKGRFTISRDNSKNLTLQGEMLRAEDTAVYYCARAIAYALEYGGMDVWQ
GTTVTVSS  (SEQ ID NO: 76)

Nucleotide sequence of light chain variable region:
5'CATCTCTGTGGACGCAGCCGCCCCTCAGTGCTGGCGCCAGAGAGAAGGTC
CCATCTCTGTGGACGCAGGCCTCAGTGCTGGCGCCCAGAGAGAAGGTC
AGCAGTTCCAGGCAACAGCCCAATCCCTCTATTATGATATATAGCGACCT
CAGGGATTCCCTGGACCAGTCTCTGCTCAGAGTCTGGGACGTCAGCGACCAGCTC
TCACCAGCTCCAGACTGGGACAGAGGCCGATTAATCTGGCAACATGGGATAGC
AGCCTAGTTCTATGTCCTGGGAACTGGGACAGGGGCAGGGTCACCAGCTCCTCA3'  (SEQ ID NO: 109)

Amino acid sequence of light chain variable region:
QSVLTPPSVSAAPGKVT1SCGSSSNNIGNNFSWYQFQPGTAPKLLIYDYNKRPSEGIPD
RFSGSGTSATLGIITGLQTGEADYCYCGTWGWSSLSSYYFVGTGRVTVL  (SEQ ID NO: 37)

FIG. 3N
Nucleotide sequence of heavy chain variable region:
5' CAGGTCAGCTGTTGGAGGCGTGTCAGCCCTGGGAGGTACCCTGA
GACTCTCTGTGAGCAGTCTGGATTTCCACCTTAGCTGGATGAGCTCC
GCCAGGGCTCAGGACAGCAGGGCTGGAGTGGGGTGAAGCTATAAT
AATAAATATATGCAAGACTCTCTGGAAGGTCAGAGCTACACACTCAGAGCC
AAAGAACACGGTCTTTTCAATAGAAACAGCGTTGAGACCCGAGGACACGCTG
TTACTTGCGGAGAGCGTACCGCTACGCTACTACGCGTATGGGACGTCGGG
CCACGGGACCACGGTCACCGTCTCCATA3' (SEQ ID NO: 110)

Amino acid sequence of heavy chain variable region:
QVQLVESGGGVVQVRPLSLQPEKQUERYKQRGFRDSQNLWVGRILWALGISNG
KYNTVDSDTSKNSQNLNYALAYYGMNGMVGGATGVTVSS (SEQ ID NO: 77)

Nucleotide sequence of light chain variable region:
5' CAGTCTGTGTTGGACGACGGCCTGACGATCTTGCGGGGGACAGAAGGTCA
CCATCTCTGTGCTGGAGAAGGACTCCCCACACATGGGAAATTGTCTCTGTACC
AGCAGCTCCAGGAAAGGCCCCCAACACTCTCATTTATGACTATTAAACTACCGACC
TCAGGGATTCTGACCGATTCTCTGCTTCAAGTCTGGACGTCAGGACCCCTCGGCA
TCACGGGACTCCAGATGGGCAAGCGGACGGATTATTACTGGGAAACTGGGATAGC
AGCTGAGTTATGTCTGGAAGCAGGACGGTCACCGTCTCCTATA3' (SEQ ID NO: 111)

Amino acid sequence of light chain variable region:
QSVLTQPPSVAAPQKVTISGSSSSINNQFVSYQQLPETAPKLIYDYNKPRSGIPD
RFSGSKSGTSATLGITQLQTGDADYYCGTWDSLSGYVFGTGRVTVL (SEQ ID NO: 38)

FIG. 30
**Nucleotide sequence of heavy chain variable region:**

5' CAGGTGACGTGGAGTCTCTGCGAGTGCTGGTCAACCTGCGAGGGAGTCCCTGA
GACCTCTGCTGACGTGCCGTTGGAGTTACCCGAGCTGCTTTGCGATGCATCGACTGGTCC
GCCAGGCTCAGGAAGGGAGGCTGAGTGGGTTGGCAGCTATATGGATAATGGAAAGT
AAATAAATCTATGGACAGCTCCGTTGAGGCGGATTCACCACCCTCCAGAGCAGAACATCC
AAGAACACGCCTGTATCCTGCAAATGAAACAGCCCTGAGAGCGAGGAACACGGACTGTGTA
TTACTGTGCGAGAGCCATAGCCAGCCTCCTACTACTACTACGCTATGGAAGCTTGGG
CCAAGGGACCCACGGTCACCCTCCTCTCA3' (SEQ ID NO: 112)

**Amino acid sequence of heavy chain variable region:**

QVQLVESGGVQPSRLRLSCASGFTSFSGMHWVRQAPKGLEWVVALIWDNPSN
KYYADSVKGRFTISRDNSKNTLYQMLNLRAEDTAVYYCARAIAYLYFYGMDVWGWQ
GTTVTVSS (SEQ ID NO: 78)

**Nucleotide sequence of light chain variable region:**

5' CAGTCTGTGTTGACGACAGCAGCCTCCTGGGCTCCACAGTGCTGCTGGCCAGGAGAGGTCAC
CCATCTCCTGCTCTGGAAACAGCTCCAAACATTGGGAATAATTGTATATCCCTGGAACC
AGCAGCTCCGAGAGCAGCAGCCTCAATTGCAGCTATAAATAAGCAGCCCT
CCAGGATCTCTGCAACGGATCTCCTGCTCCCAGTCTGGACGACTCAGCAGCCCATGGGCA
TCACCGGAAGTGCCAGATGGGACAGAGCCGATTACTGTGGAGAACATGGGATAGC
AGCCTGAGTGGTTATGCTTGGGAAAACTGGGACCAGGGTACCCCTCCTCA3' (SEQ ID NO: 113)

**Amino acid sequence of light chain variable region:**

QSLVTQPPTVSAAPGQKVTSCGSSNIGNIFVSKWYQQLPGTAPKLIYDYNKRPSGPDP
RFSGSKGTATLVLITGLQTVGDEADYYCCTWSSLSGYVFGTGVTRVTVL (SEQ ID NO: 39)

**FIG. 3P**
Nucleotide sequence of heavy chain variable region:
5’CAGGTGCAGCTGGTGAGTCTCTGGGGAGGCGTGTCCAGCCTGGAGGCTCCTAG
GAATCTCCTTGTGACAGCCTGGTACCTACCTGAAGCGCTAGATGGCATGCACTTG
GCCAGGGCTCAAGGCAAAGGGCTAGGAGGGTTGGTGCACCTATATGACATGGATGGAAGT
AATACATACATGTGACACCCGTAAGGGCCGATTCCACACTTCAGGACAGACAAATCC
AAGAACACGTGTATCTGCAAATGACAGGCTAGAGGCCAGAGCAACGGCTGTGTA
TTACTGTGCGAGAGGTATAGCACTGGGCTTAATGACTACTACTACGGTGACGTCTGGG
CCAAGGGACCCAGGTTCACCGTCTCCTCA3’ (SEQ ID NO: 114)

Amino acid sequence of heavy chain variable region:
QVQLVESGGGVPGVRSLRLSCAASGVFTFRSGSVMHYWQAPGKGLEWVALIWHGDNS
TYYVDSVKGFRFSRDNSKNLTLQVMNSLRAEDTAVYCYCARGLIVAVYWMVWQG
GTTTVSS (SEQ ID NO: 83)

Nucleotide sequence of light chain variable region:
5’CAGTCTGTGTTGACGCGCCCTAGTTGCTGCGGCCCCAGGACAGAGTCAT
CCATCTCCTTGTGGAAAGCACTCCAACATTGGGATAATTCTTTGCTAGCTGTA
ACGATCCGACGAAAGCCCAACTTGCAATTTATGACACAGAATACGGACCCCT
CAAGGATTCCTGACAGGATCTCTGGCTCAAGTCTGGCACGGACCACCTGTGCA
TCAGCGACTCCAGACTGGGACAGACGCGATATTATACCGGAACATGCCATAGC
AGCCTGAGTGGCTTATGTGTTCCGGAACAGGTAACCGTCTCCTCA3’ (SEQ ID
NO: 115)

Amino acid sequence of light chain variable region:
QSLVTQPPSVAAPGKVTVICSGSNSMGNNFVSVQQLPGTAPKLLYDSNKRPGIPD
RFSGSKGTSATLTDITGLQTGDEADYCYCTGTDSSLSAYVFGGTKVTVL (SEQ ID NO:
40)

FIG. 3Q
Nucleotide sequence of heavy chain variable region:
5’GAGGTGCAGCTTTGAGTGGCTGAGCCTGGGAGCTGGTACAGCCTGAGGCTGGGTCCCTGA
GACTCTCTGTGAGGCCTGGATTCCCTTTAGCAAGACTATGCCCATTGACACTGGGATC
GCCAGGCTCCAGGAGAGGGCTCAGTGCTCCTCAACTATTAGTGATGTTAGGTAT
AACACATACTACGAGACTCGTCAAGGGCCGCTTACCAATCTCAGAGACAAATTC
CAAGAACAAGCTGTATTCTGCAAATGAAAGACGCTGAGAGCAGAGACACGCGCCGTAT
ATTACTGTCGAAAGAAAGTTTCTGTTACTAAATGCTGATGCTATGCTATGCTATGACTACTGGGCGCC
AGGGAACCCCTGGTACCCCTCCCTCA3’ (SEQ ID NO: 116)

Amino acid sequence of heavy chain variable region:
EVQLLESGGGLVQPGSGSRSLCALASGGFTSSYAMNWVRQAPGKGLEWVSTISGSGDNSDNT
YYADSVKGRFTISGRDNSKNTLYLQMNSLRAEDTAHYYCAKKFVLMVYAMLDFWQG
TLVTVS (SEQ ID NO: 71)

Nucleotide sequence of light chain variable region:
5’GACATCTGATGACCAGCTCCATCCATCCATCCATCTGACTCTCCTGATCAGTCTAATTT
CAGCCCTACTGCGCCGAAAGATCAGAACTAGATTATATTATTATGTAATGAGCA
GAAACAGAGAAAAGCCCTAAAGCTGCTCTATGCTGCTGATCCGATTTGAAGGAGG
GGTTACATACAGGTTAGGCAGGGTCTGAGATCTACACTTCAATCAATTACGTCTGCA
ACCITCGAAATCTTGACTACTGTCACAGTACAGTACAGTACATTTCAAGGTCCCAT
CATCCCTCGGCAAGGGGACACCGACTGGAGATTAAA3’ (SEQ ID NO: 117)

Amino acid sequence of light chain variable region:
DILMTQPSSSLASVQDRVLTICRASQSISSYLNWYQQKPQPKVLYAASSLQSGVPSR
FSGGSGETDFTLTINQLPFDATYYIQCQSYSSPIFGQQGTRLEIK (SEQ ID NO: 9)

FIG. 3R
25G4

Nucleotide sequence of heavy chain variable region:
5’GAGGTGCAGCTGTGGAGTCTGGGAGGTGTCGATACAGCGGCGGTTGCCCTGAGACTCTCCTGTGCACGCTCTTGAGTTACACCTTACGACGCTATGCACTGAACCTGGCTCCAAGGCTCAGGAAAGGGCGCTGAGGCTGCTCAACTATTAGTGTAAGTGCTGATTACACATACGACGACTCCGTAAGGGCCGTTACCATCTCCAGAGAACACTTCAAGAACAGCTGTAATCTGCAAAATGAAACAGCCTGAAGCCAGAGACACGGCCGCTATATTCTGTGCGGAAAAAGTTTGTACTAATAGTGTAAGTGATATGCTATTGACTACTGCGGCCAGGAAACCTGGTCAACCGCTTCCTCA3’ (SEQ ID NO: 118)

Amino acid sequence of heavy chain variable region:
EVQLLESGGGLVQPGGLSRLSCAASGVFTSSYAMNWRQRQPGRWKLEGWVSTISSGSGNTYYADSVKGRFTISRDNSKNTLYQLMNSRAEDTAAYVCQAKFVMVYAMDLYWQGTLVTVSS (SEQ ID NO: 72)

Nucleotide sequence of light chain variable region:
5’GACATCCAGATGACACCCAGCTCCTCTCCCTATCTGACTCTGTAGGAGACAGAGACTCAATCCTGGCAGGCAAGAGCTAGCATCTATGTTAATTAGTTGATAGACGAGACCAGAAGCTCTCCTCTGTGACTAGTTAGCTGGGACAGATTTATAGCTACTCCTACCATCACTGCTGAACTGAGATTTGCACACTACTAGCTGCAACAGAGATTTACAGTCAACAGACTGTCAGCCCCCATCACCCTTGGCAGGAAACAGCAGACTGGAAGATTAAA3’ (SEQ ID NO: 119)

Amino acid sequence of light chain variable region:
DIQMhqSPPSSLASVAMDRVITTCRASQSIYLNWYQQKPGKAPYLLIIYAAASLQSGVPSRFSGSGSTDTFTLTISSLQYPDFAVTYYCQQYSHAPITFGQGTRLEIK (SEQ ID NO: 10)

FIG. 3S
Nucleotide sequence of heavy chain variable region:
5'CAGGTTCAGCTGGTGCAGTCTGGGAGTGAGTGAAGAAGCCTGGCGCTCAGCTGA
AGGCTCCTGCAAGGCTCCTGGTTACAGTTGGACAGCTATGTTATCACTGGCGCTGC
GACAGGGGCCCTGGACAGGGCTGGATGGATGAGATGACGGTACGGCCTTACATG
AACACAAACTATGCAAGAAGTCCAGGCGAGAGTCACCATGACCACAGACACATCC
CACGAGCAGCAGTCTCAGATGGAAGGAGGAGATCTGAGATCTGACGACACGGCCGT
ATTACAGTGCGAGAGGCTACGGTATGGAGCCTGCTGGGCGCAAAGGGACACCAGGC
GTCTCCTCA3' (SEQ ID NO: 120)

Amino acid sequence of heavy chain variable region:
QVQLVQSAGAEVKKPGASLKVSCKASQYSLTYSQWVRQAPGQGLEWMGWISAYNGN
TNYAQKTVQRVTMTTDSTSTTVYMEVRSLRSDTAVVLYCARGYGMDSVWQGTTVTV
SS (SEQ ID NO: 54)

Nucleotide sequence of light chain variable region:
5'CAGTCTGGACTGACTGCTGCTGCTCCCTGGCTGCTCTGGACAGTCGATCAC
CATTGCCTGACTGACAGCGAGCTGACCCTGCTTACTGGTATCTATCACTGCTGGT
GCCAACGACGCCCAGCCCAAACCCCCAACCTCATGATTATGAGGTACGATATCGGC
CTCAGGGTGTTCTAATCGGTTCTCTGGCTCAAAGTCGGAATACGGCCCTCTG
CCATCTGCTGGCTCAGGTGGAGGAGGCTGATTATTCCTGCGACCTCATATAAC
AGCACCAGCATGGTCTCGCGAGGAGGACACAGCTGGCGCTCTCA3' (SEQ ID NO:
121)

Amino acid sequence of light chain variable region:
QSALTQPASVSGSPQGSITISCTGTSSTDVGYYNSWYQQHPGKPKLMIIYEVSNRPSGV
SNRSFGSKSGNTASLTISGLQAEDEAFCCSYTSTSMVFGGGTKLTVL (SEQ ID NO:
20)
271H5

Nucleotide sequence of heavy chain variable region:
5'CAGGTTCAAGCTGGTGCAGTGGAGTTGAAGAACGCTGGGGGCCCTCAGTGA
AGTCTCTCCTGGCAGGGCTTCTGTTACACCTTGACCAGCTATGGATCAGCTGGTCG
GACAGGCCCCTGGGACAGGACATTGGAGGGATGGATGACCGCTTTTACAATGGT
AACACAAACTATGCAAGAAGGTCAGGCCAGAGTACCCATGACCCAGACACATC
CACGAGCAGCATTGACTGACGGCTAGCTGACGACGGCTCAGTACGACGCCGCTGT
ATTACTGTGCCGAGGCTACGGTGATGGACGTCTGGGCGAAGGACCACAGGTCACC
GTCTCCTCA3' (SEQ ID NO: 122)

Amino acid sequence of heavy chain variable region:
QVQLVQSGAEWVRKPGASVKVSCKASGYTLTIYLISWVRQAPGQGLEWWMGWISVYNGN
TNKAVKQVRVTMTTDTSTSTLVYMELELRSSSDTAVYYCARGYGMVWGQGTTVTV
SS (SEQ ID NO: 52)

Nucleotide sequence of light chain variable region:
5'CAGTCTGCCCAGTACCAAGCCTTCCGCTGGTCTGGTCTCTGGACAGTCAGACAC
CATCTCCTGGACTGGAACACAGTGACGTGGTATATTACTCTGCTCTGGTACA
CCAACAGCACCAGCAGCCCAAGCTATGGATTTATGAGGTCAGTAATCGGC
CCTCAGGGTTCTATTGCTTCTGGGCTCAAGTCCTGGCAGACGACGGCTTATTATTTCTGACGTCATATACAAAG
CACCCAGCATGGTCTGCGGGAGGACCAGCAGCTGACGCTCTCA3' (SEQ ID NO: 123)

Amino acid sequence of light chain variable region:
QSLATQPSVSWSGPQGSSITISTCSTGDSVGGYNYSVSWYQQHPGKPPKLMYEVSNRPSGV
SIRFSGSKSGNTASLTISGLQAEADAYFCSSYTSTSMVFGGGLKLTVL (SEQ ID NO: 16)

FIG. 3U
30B9

Nucleotide sequence of heavy chain variable region:
5'CAGGTTCCAGCTGGTGGAGCAGTGGTCTTCTGGACAGTGGTGAAGACTGGTCGCTGAGGCTACGGTGAC
GACAGGCGCCCTGGACAGGATGGTAGGGAGTCGATCGGGCCCTCAGTGGATGAGGCTACGGTGAC
ATTACTGGCAGAGCTAGGTATGGACGCTTCGGGGCAAGGACCACGGCCTCACT

Amino acid sequence of heavy chain variable region:
QQQTVVQGRVMTTDTSTTVYEMRSLRSDTAVYYCARQYGMMDVWGGQGTVTV

Nucleotide sequence of light chain variable region:
5'CATCTCTGCACTGCAGTGGAGGACAGCTGGACAGCTGGTCTTCTGGACAGTGGTGC
CTGCTTCTGGACAGTGGTCTTCTGGACAGTGGTGC

Alternative Nucleotide sequence of light chain variable region:
5'CAGGTTCCAGCTGGTGGAGCAGTGGTCTTCTGGACAGTGGTGAAGACTGGTCGCTGAGGCTACGGTGAC
GACAGGCGCCCTGGACAGGATGGTAGGGAGTCGATCGGGCCCTCAGTGGATGAGGCTACGGTGAC
ATTACTGGCAGAGCTAGGTATGGACGCTTCGGGGCAAGGACCACGGCCTCACT

Amino acid sequence of light chain variable region:
QQQTVVQGRVMTTDTSTTVYEMRSLRSDTAVYYCARQYGMMDVWGGQGTVTV

(SEQ ID NO: 124)
19H9

Nucleotide sequence of heavy chain variable region:
5’CAGGTTCAGTTGGTGCAGTCGGAGGTGAAGAGGCTTGGGCTCAGTGA
AGTGTTCCCTGAGCCCCCCTGATGGTCCGCTTCACCATGGAAGCAGCGTTA
CCTCTCTCTTGGGCTTGGGTGGTGAGAAGCAGCGTTA

Amino acid sequence of heavy chain variable region:
QVQLIYFDGGWVKPGASVTKVSCKASGYALTSGSWSWVRQAPGQGLEWMGWISAYNGN

Nucleotide sequence of light chain variable region:
5’CAGTCTGCCCCCTGGACTCACCTGCGCTCCCTTGCTGGTCTCCCTTGGACAGTCGATCA
CATCTCTGACACTGGAACCAAGCTGAGGGTGGTGTATAAATCTGTCTCTCTGGTA
CCACACGACAGCAGCGAACAAAAACAAGCTGAGGTCAGTAATCATGCC
CCTCAGGGATTTCTAATCAGACTCTGTCTGGCTCAAGTCTGCAACACCGCTCCCTGTA
CCATCTCTGCTCGCCGAGCGAGCTGAGATATTCTCTGACGTCTATAACAA
GCACACGACATGGCTCTCGGCAGGGGACACAAGCAGTGAAGCCTCCTGA3’ (SEQ ID NO: 127)

Amino acid sequence of light chain variable region:
QSALTQPASVSQSGQVISITICTGTNQGNYNSVWSYQQHPGKPPKMIYEVSNRPSGI
SNRFSGSKSGNTASLTISGLQAEDDEADYFCSSYTSTSMVFVGSTKLTVL (SEQ ID NO: 22)

FIG. 3W
17C2

Nucleotide sequence of heavy chain variable region:
5' CAGTCTCAGCTGGTGAGTCTGAGGTGAAAGCGCTGGGCTCTCAGTGA
AGGTCTCTGCAAGGGTCTGTTACACGTTACAGCTATGATACGCTGGTGCA
GACAGGCCCTGAGCAGGGCTGAGTGATGGGATGGTCAGCGTCTTCAATGGT
AACAACAATATCGACAGAAGTTCCAGGGGACAGTCAACATGACAGACAGACATC
CAGAGCAGACGGCTACATGGAACCTAGAGGAGCCTGAGATCTGACGACACGCGCCGTGT
ATTACCTGTGCGAGAGGCTACGTATGAGCTGTCTGGGGCAAGAGGACACGCTACC
GTCTCCTCA3' (SEQ ID NO: 128)

Amino acid sequence of heavy chain variable region:
QVQLVQSGAEVKPGASVVKVSCKASGYSFISEWGWVATMTYQKSPEQSPGQLVQGGGGDLMNSQPDVTSQAYNGNTNYAQKFKQRVTMTTDSTSTAYMEILRSLRSDDTAGFVYYCARGYVMDVWGQGTTVTVSS (SEQ ID NO: 57)

Nucleotide sequence of light chain variable region:
5' CAGTCTCGCGCTTCAACTACAGGCTGGCTGCTCTGACAGTGATCAC
CATCTCGTGCAAGGGAGAGGCTCAGTTAGGCTTTGCTTCGTCTCTCCTGGTA
CCAGACAGACGGCTACATGGAACCTAGAGGAGCCTGAGATCTGACGACACGCGCCGTGT
ATTACCTGTGCGAGAGGCTACGTATGAGCTGTCTGGGGCAAGAGGACACGCTACC
GTCTCCTCA3' (SEQ ID NO: 129)

Amino acid sequence of light chain variable region:
QSLATQPASVSGSPGQSITISCTGTSSDVGAYNSVSWYQQHPKAPKRMIEVSNRPSGVSNRFSGSKSNNTASLTSGQAEDEADYYCSSYTSTNMVFGGGTKLTVL (SEQ ID NO: 24)

FIG. 3X
13H1

**Nucleotide sequence of heavy chain variable region:**
5' CAGGTACAGTTGCAAGCAGTCAGTCAGTCAGCTGGGTGAAAGCCCTCGACAGCCCTCTCT
CCTCATCGTGGCCATCTCCGGGAGAGTGTCTAGACAGTGCTGGCTTGGGAACT
GGATCGGACCTCCCATCGAGAGGCTTGAAGTGGCTGGGAAGGACATACAGGG
TCAAGTGGTATAAATAATTZAGATATCTTAGAAAAGTCGAATAACCATCAACCA
GACACTCAGAAGGACGTCTCTCTGCAAACTGAACTCTGTAGCTCCGGGACAGC
GCTGTATTACTGTGCAAGAGGGGGGGCAACTGCTGCTTTTTGACTACTGGGGCCAG
GGAACCCCTGGTCCACCGTCTCTCCTCA3' (SEQ ID NO: 130)

**Amino acid sequence of heavy chain variable region:**
QVQLVQPSGPGGLVKPSQTLSTCAISGDSVSSNDAANNWIRQLSPSIRGLEWLGRYYYSK
WYKNYSVVSNSBRYIDTSKQNSLQLNSVTPGDATAVVYCARGGPTAAYFDYWGQGT
LVTVSS (SEQ ID NO: 91)

**Nucleotide sequence of light chain variable region:**
5' CTTCCTGGCCCTGACTCATCGCTCCGGTCTGGTCTCTGCTGGACAGTCGATCAC
CATCCTCTGCACTGGAAACAGCAGTATGTTGGGAAATTATAACCTTGCTCTCTGTGA
CCAACAGTATCGCAAGCCACTCCAAACTCTGATTTAATGAGTCAAGTACGCAG
CCTCAGGGTTTCTATGGGTCCAGCTCCGGCTCAAGCTGGCAACACGGCTCCCTGGA
CAATTCATGGCTCGCTCCAGCGTGAGGACAGGCTGATTATTACGGCTGGCTCTCATATGCA
GTACTGACACTTTGGTCTCCGGGAGAGGACAGCCAAGCTGCCCTCTCA3' (SEQ ID NO: 131)

**Amino acid sequence of light chain variable region:**
LSALTQPSAVSGPGQTSITCTGTSDDVGNYNLVSQNYQPSGKAPKLMYEVSKRPSGV
SNRFSGKSSGNTASLTISGLQAEDEADYYCSCYAGSSSLVFGGTGTKLTVL (SEQ ID NO: 28)

**FIG. 3 Y**
9C9

Nucleotide sequence of heavy chain variable region:
5’GAGGTGCAAGTTGGTGGAGCTGCTGTCCAGCTGCTGGGGGCCAGGCTGGTCGCTCCTGA
GACTCTCTGTTGTAGCTGTCCAGCTCCTTGAAGCTAGCTATGGATGAGCTGGTCGCC
CCAGGGCTCAAGGGAAGGGGCTGGAAGGTCGCTGCGCCAAAACAAAGCAAGAGCTGG
GAGAAATACTATGTGGACTCTGTAAGGCGATTCCATATCCAGAGACACG
CAAGAAGTACACTGTATCTTGAGACACGGGAGGACACGGGAGGAGCCAGGCA
ATTACTGTGCGAGAGAGTGCAACACTGGGAGATTGGCTTTTAGATATCTGGGCGCAAGGGA
CAATGGTCACCGCTCTTCA3’  (SEQ ID NO: 132)

Amino acid sequence of heavy chain variable region:
EVQLVESGGGLVQPGGLRLSCVSVSASGGFTSSYWMWVRQAPGKGLEWVANIKLQDGSE
KYYVDSVKGRFTISRDNLYQMLNRAEDTAVYYCARESNWGFADTGQGTM
VTVSS  (SEQ ID NO: 64)

Nucleotide sequence of light chain variable region:
5’CAGTCTGTGTGCTAGTCCACCTCAAGCTCGTCTGGGACCACCCGGCCAGGGAGCTCA
CCATCTCTCTGGTAGACTGCTCAACACTGGAAGTGAATGACTGGTAAACTGATACC
AACAGGTCCAGGAACGGCCCAAACTCTCTATGTAGATAATACGCGGCC
TTAGGGCTCCAGCCATCTCTGGCTCAAGCTCAACACTCCATCTCTGCC
ATACGTTGGGTGGGATGAGGTGCTATATTATCTGTACGACATGGAGTGAC
AGCCTGAAATTGGGTGCCGCGGAGGGACACAAGCTGAGCTGCTCA3’  (SEQ ID NO: 133)

Amino acid sequence of light chain variable region:
QSVLTQPSASGTPGQRVTISCGSSNNNGSKTVNWYQQVPGLAPKLLYRNNQRPLGVP
DRFSGSKSASLAIASGLQSEDEADYYCAAADSLNWVGFAGTKLTVL  (SEQ ID NO: 30)

FIG. 3Z
9H6

Nucleotide sequence of heavy chain variable region:
5’GAGGTGCAGCTGTTGGAGTGCTCTGGGCCAGGCTTGGTCCAAGCCTGCGGGTTCCCTGA
GACTCTCTCTGTGACAGCCTCTTGATACCTTATTAGGATAGCTGGTCCG
CCAGGCTTCCAGGGAAGGGCTGGACTGGTGGGTGCCAACATAAAAGGACTATGGAGAAGTG
AGAAATCACTGTTGACTCTGTGAAGGCGCGATTCCACATTCCAGAGACAACGCC
AAAGACTCTACTGTATCTGCACAAATGAGACAGCCTGAGACCGAGACACGCCTGTTGA
TTACTGTGCGAGAGATGCTCAAAGCTGGGATTGGCTTTTGTGTCTGGGGCCACGGGAC
AATGCTTACCCGTCTCCTTCA3’ (SEQ ID NO: 134)

Amino acid sequence of heavy chain variable region:
EVQLVESGGGLVQPGSRSLRLSCAASGFTSFYWGWSWVRQAPGKGLEWVANIHDGSE
KYVDDSVKGRFTISRSDNALKSLYLMQNSLRALDRATAVYVCARESNWGFAFDVWGHGTM
MVTSS (SEQ ID NO: 62)

Nucleotide sequence of light chain variable region:
5’CAGTCTGTGCTGACTCACACACCTGCTGGCCACCCCGAGAGCTCA
CCATCTCTTCTGTGGAAAGCAAGCTCAACATCGGAAGTAATACTGTAAACTGTCCTACC
AGGCACCCCTGAGAAGCGGCCCGAAAATCTCTCATATAGTAAATAATCGGCGGCCCT
CAGGGTCTCCTGACCCGAATCTCTCAGCTCAGCTCCACCTGCGCCAAGCTCAGCTCCACCC
TCAGTGGGCTTCCAGCTGAGATGAGCTGAATTATTACTGTGACGATGGATGACA
GCCTGAATTGGTGTTCCGGCGAGGACCAAGAGCTGACCCGTCTA3’ (SEQ ID NO:
135)

Amino acid sequence of light chain variable region:
QSVLTQPSASGGPGQRVTSASGSNSNIGSTVNWYQQLPGTAPKLLIESNRRPSGVPD
RFSGSKSGTSAASLSQEDADEYAAWDDSLNWWVFGGGTTLTVL (SEQ ID NO:
31)

FIG. 3AA
Nucleotide sequence of heavy chain variable region:
5'GAGGTCACGCTGGTGGGAGTGCTGTCAGCAGGGGCCCTCAAGGCAAGGCTGAGTGGTACCAGCTGGTGGTAC
GACTCTCCTGGCAGCCTTGGATTACCTTTAATCGAGCTATGCAAGCAGCTGGTCCGGCAGCTCGCTGCTGA
AGGACATATTACGAGACCTCCGTGAAGGGCCTGTTACCATCACCAGAGACAAATTC
CAAGAACACGCTGTATCCTGCAATGAAAACAGCTGGAGGCAGCAGACAGGCGGTAT ATTACTGTGGCAAGAAGTGGCAGTCCCTTGGACTCTGGGGCCAGGGAACCTGG
TCACCGTCTCCTCA3'  (SEQ ID NO: 136)

Amino acid sequence of heavy chain variable region:
EVQLLESGGGLVQPGGLVRLSCAASGGFTSSYAMSWVRQAPGKGLEWVTSTISGSGRTY
YADSVKGRFTISGRDKNTLYQMLNRAEDTAVYYCAEVGSFFYWGQGTLVTVSS
(SEQ ID NO: 69)

Nucleotide sequence of light chain variable region:
5'CAGTCTGTGTTGACGCAACGCCCCCTCATGCTGGCCAGGACAGAAGGTTACA CCACTCCTGCTCTGGGAATCTCAAACTCCTGATTTATGACAATAATAAGCCACCTG CAGGGAATTCTGACCCGATCTCTGGGTCACCTGCAACCTGCAAGCCAACCTGGTAC TCCCGCGACTCCAGACTGGGAGGCGAGGCGATTTACTTGTGGGAACATGGGACAGC AGCGTGAGCTGTGGTATTCCGGGAGGGAAGAAGCTGAGAGCCTTCA3'  (SEQ ID NO: 137)

Amino acid sequence of light chain variable region:
QSVLTQPSVSAAPQKVTSCGSGNSNIGNNYVSWYQQLPGTAPKLITYDNNKRPSGIP DRFSGNSGTSAFLGTTQLTQVEADYYCGTWDSLSAVVFGGGTKLTVL  (SEQ ID NO: 42)

FIG. 3BB
Nucleotide sequence of heavy chain variable region:
5'CAGGTGCAAGCTGGTGAGGCTGGGACGGTGGATCCAGCTGGGAGCAGTCCCTGAG
GACTGCCCTGAGCCAGCTGGGATTACCTCTTGAGCCTAGGAGGTGCCTACC
CCAGGCTCAAGGAGCCGCTGGGATGGGCTGGCAGAACTATTATATGGATTGGAGAAGT
AATAAAATCATATGGACTCATCCGGTAAGGCGCAGGGTTACCATCTCCAGAGCAATTCC
AAGAAACACACTGTATCTTCAAAATGAAACAGCCTGAGAGCGAGGACACCGGCTGTA
TTACTGCTGCGAGAGGGGGCTGGCTGCAGCTGGAGCCGGGCTATGGACGTCTGGG
GCCAAGGGACACGGCTCCGTCCTCTCTCA3'  (SEQ ID NO: 138)

Amino acid sequence of heavy chain variable region:
QVQLVESGGGLVQPSLLRLSCAASGFVTSSYGMHWVRQAPGKGLEWVATIWYDSDN
KYYADSVKRFRISIDNSKNTLYQLMNSLRAEDTAVYYCARRGLAARPGMDVWGG
QGTVTVSS  (SEQ ID NO: 81)

Nucleotide sequence of light chain variable region:
5'TCCTATGAGCTGACTCCACCCACCCACTGATCTGCTGTGCACAGGACAGACGCCAG
AATCACCTGCTCTGAGATAAAATTGGGGATAAATATGCTTGGCTATGAGCAGAAGA
ACCAGCCAGTCCCCTGTGCTGTCATCTATCAACATCCACAGTGCCCCCTGGGAT
CCTGAGGATTTCTCTGCTCAAGGAGCAGATCACTGACTGCCAATCCAGGCG
GACCCAGGCTATGAGGAGGCTGACTATTACTGTCAGGGCTGGGACACAGCAGACTG
TTGATTCGCGAGGGAGGACACAGCTCCTCTCTCA3'  (SEQ ID NO: 139)

Amino acid sequence of light chain variable region:
SYELTQPPSVPQSPQRTARITCSDKGLKDHYACWYYQQPGSPLVIVYQNTKWPGLIPE
RFSGKSGNTVTLTISGTQAMDEAAYQCAWDSSTTVFGGTKLTVL  (SEQ ID NO: 44)

Alternative Nucleotide sequence of light chain variable region:
5'TCCTATGAGCTGACTCCACCCACCCACTGATCTGCTGTGCACAGGACAGACGCCAG
AATCACCTGCTCTGAGATAAAATTGGGGATAAATATGCTTGGCTATGAGCAGAAGA
ACCAGCCAGTCCCCTGTGCTGTCATCTATCAACATCCACAGTGCCCCCTGGGAT
CCTGAGGATTTCTCTGCTCAAGGAGCAGATCACTGACTGCCAATCCAGGCG
GACCCAGGCTATGAGGAGGCTGACTATTACTGTCAGGGCTGGGACACAGCAGACTG
TTGATTCGCGAGGGAGGACACAGCTCCTCTCTCA3'  (SEQ ID NO: 295)

FIG. 3CC
3C4

Nucleotide sequence of heavy chain variable region:
5' CAGGTGCAGCTGAGGGAGGAGCTGAGGTACCTTCAAGATGACCTGTCTTCTGCTGGTCTCCTCACTGACGACGATGTGATTACTACTGCCGAGCT
GGGACGCCAGCACCAGGAGAAGGGCCTGGAGAGATGGATTCTCAATCTATTAGTG
GGGAGCACCCTACTACAACCCAGTCCTCAAGATCTGAATTACCATATGCAGTACGCAC
GTCTAAGAACCCTTCTCTCGTGAACTTGAGCTCTGTGACTGCGCGGGACCAGCGCGGT
GTTAATAGTGTGAGGAGGGGGGTGACTACGTACTACTACGCTATGGACGTCTGGG
GCGCAAGGGACGCCGTACCCGCTCCTCCTCA3'  (SEQ ID NO: 140)

Amino acid sequence of heavy chain variable region:
QVQLQESGPGLVKPSQTLSSLTCTVSGGSISISSDYWSWIRQHPGKLEWIGYIYYSSTY
YNPSLKRITISVDTSKNLFSKLSSVTAAADTVAYYCARGGVTVYYVYMDDVWQGGTV
TVSS  (SEQ ID NO: 85)

Nucleotide sequence of light chain variable region:
5' GACATACAGATGACCGCACTCCATCTCCCTCTTGACATCTGAGAGACAGAGTAGCTCAGTACATGTCGCGCGGCAAAGTCAGCGCATAGAACACTATTAAGGGTGATTCTCGCA
GAAACCAGGGATTGCCCCCTAGCTCCTGATCTAAGCTCGTACCTAGTTGCAATGGAGATGG
GGTCCACATCAAGGGTCATTTGCGACATCTGGGACAGATTTCTACCTACCATAG
CAGTCTGCAATCTCAGAGATTTGGCAACCTACTACTGCTACCACAGATACGTTACCCGC
GCTCATTCTCGGCGGAGGGGACAGGTGGATCAAA3'  (SEQ ID NO: 141)

Amino acid sequence of light chain variable region:
DIQMTQSPSSLSASVGDRVTITCRASQIRSYNLWYFLQPGIAAPKLLYAAPSLQSSVPSR
FSGSGSTDFTLTISSLQSEDFAWTYECQYQSYSTPLIFGGGTKVEIK  (SEQ ID NO: 7)

FIG. 3DD
Nucleotide sequence of heavy chain variable region:
5'CAGGTGCAGTGTGGAGTTTCAGTGGGGGAGGCTGGCTCCAGCGCTGGAAGTCCCTGA
GACTCTCTGTACAGGCTCTGAGTCTCACTACACAGCTGAATAGCTATGGCATGACACAGCTG
GCCAGCTCGAGCAAGGGGCTGAGTGGGTGCGACAGTTATGGCTATGGCATGAGATG
GATAAATATCTATGCACTCGTGAGGGGCGATTCCACCTACCTACGCAGAGACTCC
AAGAACACGCTGTATCTGAAATGAAACAGCTGGAAGGCGAGGACACGCGCTGTA
TTAAGTGCGAGAGAGACTGCTGTCTTGAAACCTACTACACGCAGTGATGACATGC
GGGCAAGGGAGCCACCGCTCACGTCATTCA3'  (SEQ ID NO: 142)

Amino acid sequence of heavy chain variable region:
QVQLVESGGGLVQPGGSLRLSCAASGFTSSYVMHWVRQAPGKLEWAVITWYDGSD
KYYADSVKGRFTISRDNSKNTLYQNLNQSLRAEDTAVYYCARETGPLLQLYYGMDWG
QGTTTVSS  (SEQ ID NO: 74)

Nucleotide sequence of light chain variable region:
5'GATATTGATGACTCTACCTCCCTCCCTCCGCTCCCTCCAGGGAGAGCCGCG
CTCCATCTCGAGTCTGATGACGCTCTCGTCTGATGAGTACTCCACACTTGGGTCT
CTCCAGTGCTGGGCGGCTCTGCACAGTTGTCAGTGGGACACTGACAGATTT
AAGCTGGAATTACACAGATGGGAGCTGAGGTATGTTGGGTGGTTATTACTGCA
GTTTCTACAAACTCTCATTCTTCTGCGCCCTGGGACAAAGTGGATATCAA3'  (SEQ ID NO: 143)

Amino acid sequence of light chain variable region:
DIVMTQSPDSLSSVTPGEPSISCRSSQSLHSNYNFLNWLQKPGQSLLIYLGHSRAS
GVDPDFSGGSSTDFTLIEISRVEAEDVGVYYCMQVLQTPFTFGPGBKDIK  (SEQ ID NO: 5)

FIG. 3EE
**Nucleotide sequence of heavy chain variable region:**

5'GAGGTGCAGCTGTGGAGTCTCTGCTGGGAGAGGCCTTGACCAGCTGGGGGTCCCTGA
GACTCTCTCTGACAGCTCTGAGTCTCTCAGCTTGACACTTCTTAGTAACTTTTTGAGATGAGCTCGTGCC
CCAGGCTCCAGGAGAGGGCGCTGGAGGTGGTGCGACACACATAAGAAGCAAAGATGGAAGGT
GAGAAATACATATGTGGACTCTGTGAAGGGCCGATTCCATCCTCCAGAGACAACGC
CAAGAATCTCACCACGGTATCTGAACATGGAGACACCCGGAGACACACGGCTTG
ATCCTGTACGGAGAGATGCAAACTGGGGATTGCTTTTGGATATCTTGGGCCAGGGGA
CAATGGTCCACCGTCTCTTAC3'  (SEQ ID NO: 144)

**Amino acid sequence of heavy chain variable region:**

EVQLVESGGGLVQPGGLRLSQAASGLFTFSNFWMWSVRQAPGKGLEWVANIKQGDSE
KYVVSQVKGRFTISRDNAGKSLQLQVNLRAEDTAAYVYSCTRESNWFAPFIDGQTM
VTVSS  (SEQ ID NO: 65)

**Nucleotide sequence of light chain variable region:**

5'CAGTCTCGTCTGAGCTCAGCCACCCTCCAGCTGGGACCCCGGGGACAGGGGCTA
CCATCCTCTGTCTGGAAGAGCAGCTCCAACACATCGGAAGTAAAAACTGTAAAACCTGTACC
AGCAGTCCAGGAAGGCGCCCAATCTCTCATCTATAGTAAATACGCGGGCGCCCT
CCAGGCGGTCCTGACCGATTCTCTGCTGCTCCAAAGCTTGCGACCTCAGCTCCCTGGCCA
TCAGTGCGCTGCTGAGTGGACGCTGGCGCTGATTATTACTGTGACGATGGATGACA
GCCTGAAATTGGTGGTGTCGGCCAGGGACACAGCTGACCCGTCTA3'  (SEQ ID NO: 145)

**Amino acid sequence of light chain variable region:**

QSVLTQPSASGTPGQRVTISCSGSSNIGSKTVNWYFQGTPAPKLILLYSNNRRPSGVPD
RFSGSKSGTSALSASLQSEDEADYYCAAWDDSLNWVFGAGTKLTVL  (SEQ ID NO: 33)

FIG. 3FF
3B6

Nucleotide sequence of heavy chain variable region:
5'CAGGTTTGCTGGCTGACTCTGGAGCTGAGGCTAAGCAGCCTGGGCTGCAGTA
AGGCCTCTGGCAAGGGCTCTGGTACCACCTTTACACGTTGTTGACGCAGTGC
GACAGGGCCCTTCGTGACAGGCTGTGAGGAGGCTGCACGCACTTCATAGGT
AACACACACTATGCACAGAGAAGCTCGAAGTGGCTACATGACAGTCCTGACC
CAGCAGACACGCTTACTTTGAGGAGCTACGCTGGGCTGGGAGGACCGCTCT
GTCTGCCTCA3'  (SEQ ID NO: 146)

Amino acid sequence of heavy chain variable region:
QVQLVQSGAEVKKPGASVLYGGLLGGSTTVSYYGVSWSWVRQAIPGQGLEWWMGWISTYNG
TNYAQQKVRQRTMTDDTDSTAYMELRSLRSDTAVVYCCARGYTRDYWGQTGLVTVS
S  (SEQ ID NO: 60)

Nucleotide sequence of light chain variable region:
5'CAGCCCTGTGCGACTGACCCACCTTTTGGCATCGCAGCCTGGGACGGCTCGTCAC
ACTCACTGACACTGCAGCAGCTGTACAGTATGTTAGTGAAGTGACTGATACGCA
GAGGACCGAGGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
GATTCACAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
GGTGATCTGGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG
GCAGACACATGCGACTTCTGTTGCTGGTATTTCCGCGAGGAGGACCGCTCTCAG
GACGTCTCTCA3'  (SEQ ID NO: 147)

Amino acid sequence of light chain variable region:
QPVLQPLFASASLGAVTTLCTLSGYSSYEVQVRQRPKPGFPRFVMRVDGGGVSK
GEGIPDGRSLGLNRLYLTQKNNQEDSDYHCADHSNTNFVVFGGTGKLTLVL
(SEQ ID NO: 46)

FIG. 3GG
Nucleotide sequence of heavy chain variable region:
5'CAGGTCAGCTACAGCAGCTGGCAGGACTGTGTGGAAGCCTCGGAGAACCCTGT
CCCTCAGCTCGGGCTCTAGTGCGTACTAGTGGCAGTACTGAGGTATCC
GAGCCAGAGGAAGGGAGCTGAGTGGAT1GGGGAATCAATCATAGTGGGAAAG
ACAGACTCAAACCGTTCCTCAAGAGTGACTCAGTACCACTATCACTAGCAGACAGTC
GAAGCACAGTTCCTCCCTGAAAGCTGAACCTCTGTGACCGCCCGGACACGGCTGTGTATTA
CTGTCGAGAGGGCAGCTCGTCTCTCCCTTGGACTACTGGGGGCAGGAAACCCTGGTCAAC
CGTCTCTTCA3' (SEQ ID NO: 148)

Amino acid sequence of heavy chain variable region:
QVQLQWGLKLHPSKTSLSLTAVYGSGFASAYYWYNWIRQRPQKGLEWIGEINHSGRTD
YNPSLKSRSVLTVSDTDSKKQFSKLNSTTVAAADTVAYYCARGQLVPFDYWGQGTGVTVSS
(SEQ ID NO: 89)

Nucleotide sequence of light chain variable region:
5'CGTCTCTGCTGACTACCCAGGCTGCTGGAGCACCCCGAGAGCTCA
CCATCTCTGTGTCTGGGAAGCAGCTCCAACATCGGAAGTAAATCTGTAAATGGGATAC
AGCAACTCCAGAGGACCGCCCGGAAACTCGCTCTCAGAATATGATAATACAGCAGGCCT
CAGGGTCCCTGACCGATTCTCGGCTCAAAGTCTGGCAGCCTACGCTCTGGCCA
TCAGTGGGCTCCAGTCTGGAGTGGCAGTATTACTGTGCAATAGGACTGACT
GCCTGAATGGTGTGGGTCTCGGCGAGGGACCAAGCTGACCGTCA3' (SEQ ID NO: 149)

Amino acid sequence of light chain variable region:
QSVLQPPASGTPQVRISCSGSSNSSNTNWAYQQLPGTAPKLLIVSNQRPSGVSP
RFSGSKSTGTAASLAISSLQSEDEADYYCAYVWDDSNLNGWVFGGGTKLTVL (SEQ ID NO: 32)

FIG. 3HH
Nucleotide sequence of heavy chain variable region:
5' CAGGTTCAGCTGAGTCGACGTGACGTGGAAAGCTGGCCCTCGTGAGTGAAGGCTGGGCGCTCGA
AGGCTCTCTGCAAAGGCTCTGTTTACACCTTTCCACCTGATGGAAGCTGAGGGTGC
GACAGGCCCCTGGGACACGAGGGCTTTGAGGTGAGATGTGACCGCTCTAATGGT
AACACAAACTATGCGAGAACGCTGACAGTGAAGTCACATGACACGACACACTC
CACGAGGCAAGGCTTACTGATGAGTGAGGAGCCTGACTGAGATGCGACAGGGCGTGT
TTTACTGTGCAGAGGGCTACGTATATGAGACTGCTTGGGGGCAAGGACCAGACGTACC
GTCTCCTCT3' (SEQ ID NO: 150)

Amino acid sequence of heavy chain variable region:
QVQLVQSGAEVKPGASVKSCKASGYTFPSYGISWVRQAPGQGLEWMGWISAYNGN
TNYAEKLQGRVTMTIDTSTSTAYMEVRSLRSDDTTAVFYCARGYVMVDVWGQGTTVVS
S (SEQ ID NO: 58)

Nucleotide sequence of light chain variable region:
5' CAGTCTGCTGACCCCTGACGCCTGACGTGAGGCTTGGGTCTCTGACGAGTCAGACAC
CATCCTCTGACACTGGAACCCAGCACTGACGTGCTTATAATTCTCTGTCTCCTGGTAC
CAACACAACTCTGACCTCCCAAGGCCACCCAAAGCTGATTTGATGAGGTAGTGTAATCGGCC
CTCGAGGTTTCTACTCGTGCTCTTCAGCTTGGCAAGCTGCTTCCAGCTGCCCTCTGAC
CATCCTGTGGCCCTCACGCTTACGGACGCGCTGATATATTACTGACGCTCATATACAG
CAGCAGCTGTGGTTCTCCGCGAGGGGACCAAHTGACCGTCTCTA3' (SEQ ID NO:
151)

Amino acid sequence of light chain variable region:
QSALTQPASVSQPQSQITISCTGTSSDVGRYNSVSWYQHIHPGKAPKVIMYEVSRPSGV
STRFSGSKSNTALSITISGLQAEDADYYCSSYTTSSSVVGGTGLTLV (SEQ ID NO:
15)

FIG. 3II
Nucleotide sequence of heavy chain variable region:
5’CAGGTTACAGCTGGTGACAGTCTGGAGCTGAGGTGAGAGCTGGCCTGAGTGA
AGGTCTCTGCAAGGCGTTCTGGTTACCACCTAACAGCTATGGTATCAGCTGGGTTGC
GACAGGCCCTGGACAAAGGCTTTAGGATGGATGGGTACATTTTATAATGGT
AACACAAAATAGCCACAGAAGCTCCAGGGCAGGCAAGGACCAGTAGCGAGCCACAGCACATC
CAGGACACAGCTCATGAGCTGAGGAGCGCTGAGATCTGACGCACACGGCGGTGT
ATTACTGTGCGAGAGCTACGGTATGGACGTCTGGGCAAGGACACCACGGTGACC
GTCTCCTCCT3’ (SEQ ID NO: 94)

Amino acid sequence of heavy chain variable region:
QVQLVQSGAEVKPGASVVKVSCKASGYTLTSYGISWVRQAPGQGLEWMGVVSYNG
NTNYAQLQGLRMTTDPSSTAYMERLRLRSDTAVYHCARGYGMVDWGGQVT
VSS (SEQ ID NO: 49)

Nucleotide sequence of light chain variable region:
5’CAGTTGCAACCTTGCTGACCTACCGCTCCGCTGTCGCTCCTTGGGACAGACGTGATCAC
CTCGCTGCTAGGCGAACGCAAGCTCAGGGCTGTTATATGACCTCTGCTGCTGTA
CCAACAGAAGCGCAAAGCCAAAACCACATGATTTATGAGGTCAGTAATCGGC
CTTCAGGGGTCTTACTGCCTCTGCTGCTTCAAAGTCTGGCAACACGCGCTCCCTG
CCACCTCTGGCCTCAGGCTAAGGAGCTGATTATTACTGCAATCTACAA
GCACACGATGGTATCGCGGAGGAGCAAGCTGACCCTCTCCTA3’ (SEQ ID NO: 296)

Amino acid sequence of light chain variable region:
QSALTQPASVSGSPQSTTSCTGTSSSVGGYNSVSWYQQHPGKAPKLIMYEVSNRPSGV
SNRFSGSKSNGTASLTISGLQAEDAYYCNYSYTSTSMVFGGTLLTVL (SEQ ID NO: 23)

FIG. 3JJ
**Constant Domains**

Human IgG2:

ASTKGPSVFPLAPCSRSTSESTAA(ALGLV)KDYFPEPVTVSWSGALTSGVHTFPALQSSGLYSLSSVT
VPSSNFGTQTYYTCNVDHKS(N)TKVDKTVERKCCVECPPAPPPVAGPSVFLLFPKKPD(L)IMISRTPETVCT
VVVDVSHEDEPVQFNYVYDGEVHNA(K)TPREEQFNSFTRVSVT(V)TVH(Q)DWLNGK(KE)YCKVSNKG
LAPIEKTSKOGPREPQVYTLPPSREEMTNQVSLTCVKGFGYPSDIAVEWESNGQPENNYKTTTPMLD
SDGSFFLYSKLTVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLPGK (SEQ ID NO: 154)

Human IgG4:

ASTKGPSVFPLAPCSRSTSESTAA(ALGLV)KDYFPEPVTVSWSGALTSGVHTFPALQSSGLYSLSSVT
VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLLFPKPD(T)LIMISRTPETVCT
VVVDVSQEDPEVQFNYVYDGEVHNA(K)TPREEQFNSFTRVSVT(V)TVH(Q)DWLNGK(KE)YCKVSNKG
LPSIEKTISAKGQPREPQVYTLPPSQEMTNQVSLTCVKGFGYPSDIAVEWESNGQPENNYKTTTPVVL
DSDGSFFLYSRTLVDKSRWQGNVFSCSVMHEALHNHYTQKSLSLPGK (SEQ ID NO: 155)

Human lambda:

QPKAAPSVTLLFPSSSEELQANKATLVLISDFYPGAVTVAWKADSSPVKAGVETTPSKQSNNKYAASSY
LSTIPEQWKHRSYCQVTHEGSTVEKTVAPTECS (SEQ ID NO: 156)

Human kappa:

TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREADKQWKVDNALQSGSNQESVTEQDSKSTYSS
TLTSLKACYE(H)KVACEVTQHQLSSPVT(K)SNRGGC (SEQ ID NO: 157)

**FIG. 3KK**
5H5.1

Nucleotide sequence of heavy chain variable region:

5' CAGGTGCAGTGTTGCTGAGTGTGGAAGAGCCTGGGCTCTC
AGGAAAGTTCTCTGCAAGGGCTCCTGAGATACACCTTACCCGCTACTATA
ACGAGGTGTGCGACAGGCCTCTGGGACAAGGGCTGAGTGGATGGATGCCAGTCA
CTCTCAGTGTGGCTGGGCAAATACATGCGACAGAAGTGTGATGTCAGGCTACC
ATGACCAGGACACGTCATCAAGACAGCCTACATGGAGTGGACAGGCCTGA
GATCTGACGACACGGCCTGTTACTGAGGTCGAGGGCAACTGGAACATACGA
CTACTACGGTTAGGACGTCTGGGCGCAAGGACCACCGTACGCCTCTCCTCA
3' (SEQ ID NO:418)

Amino acid sequence of heavy chain variable region:

QVQQVOSGAEVKKPGASVKSCKASQGTFTGYYIHWVRQAPGQGLEWMMGWIN
PHSSGANYQAQKFGVQRTMTDTSISAYMELSRLDSTAVYVYCAIRGNWNYD
YYGMDVWGGQGTTTVSS (SEQ ID NO:419)

Nucleotide sequence of light chain variable region:

5' GACATCCAGATGACACCTCTCTCTCCTCTTGTGTGCTAGAGGAC
AGAGTCACCATCAGTGGCCGGGAGTGCAATTAGCAATTATCTGCTCT
GGTTACTAGCAAGGAAACCTCTACCTCGTGGAAGATGGGATCTGGGACA
GATTTCACTCTACACCAGCATGAGCTACAGCTAGCTGCAAGATGTGCAACTAT
CTTGCTAAAAAGGTACAGTAGTCCTCCTGGCCTGGGAGCAAGGGTGG
GATATACAA3' (SEQ ID NO:420)

Amino acid sequence of light chain variable region:

DIQMTGQSPSSLASVGVDRVTITCRASQDINSYLAWSYQQKPGKVPKLLIYAASTLO
SGVPSRFSGSRSAGTDFTLTISSLQEPEDVAYFCQRYQIAPFTFGPGTKVDIK (SEQ
ID NO:421)

FIG. 3 LL
Nucleotide sequence of heavy chain variable region:

5' CAGGTGCACTGGTGAGTCTGGGGAGGCCTTGAGTCTGGCCCTGGGAGG GCCTTGCCCTGGAGCGGAGGTCCTGGAGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCT

Amino acid sequence of heavy chain variable region:

QVQLVESGGGVPGVRSLRLSGVHAASGFTSSYGMHVRQAPGKGLEWVAVLV YDGSTKYGYSVKGRSTISRDNSKNTLYLQMNSLRAEDTAVYYCARSVAGYHY YYGMDVWGQGTWTVSS (SEQ ID NO: 423)

Nucleotide sequence of light chain variable region:

5'TCAGGAAGCATCCAGGACCTGGGCTGCTGGTCTGGCTGGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCTGGGAGGTGCTGGGAGGTGCTGCCTGTGAGCTGGCT

Amino acid sequence of light chain variable region:

SSELTQDPAVSVALQVTRITCQGDLSLRYATWYYQQQPRQAPVLIYGYKNYP SGIPDRFSGTSGNTASLTTGTAQEDEADYCNRSNDSGNHLVFGGHTKLTVL (SEQ ID NO:425)
22B11.1

Nucleotide sequence of heavy chain variable region:

5ʹCAGGTGCAGCTGTTGGAGTCTGGGAGGCGTGTCCTAGCCTGGGAGGTC
CCTGAGACTCTCCTGTCAGCGCTCGGAATCCACTAAGCTATAGCTGGGC
ACTGGGTACCAGCGCTACCGAGTGAGGATGGCTGCTGAGCAGTTATATG
GGTAGATGGAAGTAAATAAACGATCAGACTCCCTGGAAGGGCGCATGCC
ATCTCCAGAAGACAATTCCAAAGAAGACAGCCTGTAATCTGCAATGACAC
GAGCGCGAGGACACGGCTGTATTACGTGGCAGAGTCAAGTCAGGCTGTGGTTAACA
CTACTACTACGGGTATGGAGCGCTCTGTTGGCGCAAGGAGGACCACCGTGGAACCCTCCTCC
TCA3ʹ (SEQ ID NO:426)

Amino acid sequence of heavy chain variable region:

QVQLVESGGGVQPGSSRSLRLSCAASGFITFSSYGLHWVRQAPGKGLEWVAVIL
DGSNKYADSVKGRSTIISRDNSKNTLYLQMNSLRAEDTAVYYCARSVAGYHYY
YGMDVWGQGTTVTVSS (SEQ ID NO:427)

Nucleotide sequence of light chain variable region:

5ʹTCTTCTGAGCTGACTCAGGACCTGCTGTGGCGCTGTGGGAGCAGACA
GTCAGCAGATCATAAGGCAAGGAGACAGCCTCAGAAGTTATATATGGAAGCTGT
ACCAGCAGAGCAGAGAGCCCTCCTTGACTTGTGATCTGCTGTTGGTAAGAAAAC
CCGGCCCTCAGGGATCCAGAAGCATTCTTGCGCTCCACCTCAGGAACACA
GCTCTCTTGACCATCAGCTGGCTCAGGCGGAAGATGAGGGCTGACTTACT
GTAACTGACGGACATCATCTTTGTAACCATCTGCTGTTGGCGAGGACCACAA
GCTGACCGTCTA3ʹ (SEQ ID NO:428)

Amino acid sequence of light chain variable region:

SSELTPQDVAVSLQPSVRLTRTCGDSLRSYYGWSWYQPKRQAPVLIIFGNNRP
SGIPDRFSGTSGNTASLATITGAAAAEADYCYNSRDIIIGDHLLFGGGKTLTVL
(SEQ ID NO:429)

FIG. 3NN
30F1.1

Nucleotide sequence of heavy chain variable region:

5’CAGGTGCAGCTGGTGGAGCTTGGGACGGTCGTGCCAGCTTGGGACAGTTCC
CTGAGCATCTCCTGTGAGGCTCCGAGATCTGCTATTCGAGAGGCTGACTG
CTGGTCCCGAGCTCCAGCGGAAGGGGCTGGAGTGCTGAGCTGGAGATATCGG
TTTGAAGAGATTAATACTCATAGCAGATCCGTTGAGGCTGCGATCTACC
ACTACACGGTATGGACGTCTGGGCGCAAGGGACACCGGTACCCGTCCTCCT
CA3’ (SEQ ID NO:430)

Amino acid sequence of heavy chain variable region:

QVQLVESGGVPSGRSLRLSCAASGFTFRNYGMHWVRQAPKGLEWVAIVW
FDGSNKYYADSVKGRSTISRDKNTLYLLMNLSLAEDTAVYYCARSVGAYHY
YYGMWDVWGQGTTTVSS (SEQ ID NO:431)

Nucleotide sequence of light chain variable region:

5’TCTTCTGAGCTGACTCAAGAGCCTGCTGTGCTTGGCCCGTCCAGACAGACA
GTACAGGACTCACTCCAGCGAGAGTACAGCCCTGAGCTGTATATGCTAAGGAG
CCAGCAGAGCGAGAGCCTTGTCTGCACTATGTTGAATGAAAACAA
CCCGCCCCCTAGGATCCAGCAGGACTCACTCCAGCTCGTCCACCCAGAAACACA
GCTCCTGAGCCACTGAGCCGCCAGAGATGAGGCGTGGGTATTACT
GTAAATCCGGGCCACATCACTTGGTACCTGCTCTGTCGCGAGGGACCCA
AAGCCGACTCTCA3’ (SEQ ID NO:432)

Amino acid sequence of light chain variable region:

SSELTQDPAVSVSLGVTITCQGSLSYASWYQQKPRQAPVLIYGGKNRP
SGIPDRISGSGTSGNTASLTITGAGAEDADYYCKSRDIIGDHLVFGGGTKLTVL
(SEQ ID NO:433)

FIG. 300
24B9.1

Nucleotide sequence of heavy chain variable region:

5' CAGGTGACGCTGAGTGGAGCTGCTGGGGAGGCGTGGTCCAGCCTGGGAGGTCC  
CCTGAGACCTCTGTGCAAGGTGCTGAGTCACCTGACGATGCTATGCGATG  
ACTGGGTCCAGCAGGCTCAAGGCAAGGGCTGGGAGTGGGATGTCAGTTATATG  
GTATGATGGAAGTAATAAATAATCATTAGATAGACTCCGCTGGAAGGCGGATTCC  
ATCTCAGAGAAGCAATTCAAAGGACAGCGTCGTATCTGCAATTGAAAGACAGCTGA  
GAGCCGAGGACACGGCCTGATATTACTGTTGAGAGATCCGGGACTGGACTG  
GGGCAGGGAACCCCTGGTCACCGTCTCCTCA3' (SEQ ID NO:434)

Amino acid sequence of heavy chain variable region:

QVQLVESGGGVVQPSRLSLCAASGFTFYSGMHWVRQAPGGGLEWAVWY  
YDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVRDRGLDW  
GQGTLLVTVSS (SEQ ID NO:435)

Nucleotide sequence of light chain variable region:

5' TTCTCTGAGCTGACAGCCCGCTGGGAGCTGCTGCTGGGACAGCA  
GTCAGAGAATCACTGCACAGCAGAGCGCTCCACCAGTAGCCTTAGCAGCTGGT  
 ACCAGCAGAAGCCAGCAGAGCAGGCCCTGTACTGTACCTCTAGATTAAACAA  
CCCGGCCCCGATGATCGACGACGGGATGGTGACGAGCTTGCCCTCAGGACACACAGA  
GCTTCTGACCCATTGCTGGGCTAGGAGCTGAGCTGACTATTACT  
GTAAGTGCCCCGGCCAGCAGTGGTGACCATGCTATGCTGGTGTTGCGGAGGACCAA  
GCTGACCGTCTCCTA3' (SEQ ID NO:436)

Amino acid sequence of light chain variable region:

SSELTPDPAVSLVALGQTVRITCQGDSLRLCYASWYQKPRQAPVLVYYGKNNRP  
SGIPDRFSGSTSNTASLTITGAAQAEDEADYYCKSRDSSGDHLVFGGGTTLTVL  
(SEQ ID NO:437)

FIG. 3PP
24B9.2

Nucleotide sequence of heavy chain variable region:

5' CAGGTGCAGGTGGATCTGGGGGAGGGGCTGGCTCACGCTGGGGTCTCCTGAGACTCTCTCTGCTGACGCTTGTGATTACCTTTGTAATACTGCGACATGCACCTGAGGATCAGCTTCAGGAGGTGGGCTGGGCAGTATTTCGTGTTGTGAATGAGAAGTGAATTTAGTAACTACTAGCAGAAGCTGGGATGTTAAGCTGACGCTGCTGGTCACTCCGACGAACAGGCTTCGAGTGGGGCCCAAGGGACACCAGTGTCACGTCGCCACCC

Amino acid sequence of heavy chain variable region:

QVQVVESGGGVQVPQGSRLSCAASQFTSFNYGMHHWVRQAPGKLEWAVWIYDGSSKYYADSDKRSTISRDNSTKNTVLQMNLSRAEDTAVYRSCARVAGYHYYYGMDVWQGQGTVTvron (SEQ ID NO:438)

Nucleotide sequence of light chain variable region:

5' TCTTCTGAGCTGAGCTCAGGACCCCTGTGCTGTGCTGGCTCGTGGGACGACAATCGGATCAGCTGCAAAGGAGACAGCTGAGGCTGTATTATGCAAGGCTGGTACCGAGAGAAGGAGGACCAGGGCCCTGATGTGCTCAGGCTGATGATGTAIIIAACAAACCGGCCATCAGGGATCCAGAGCCAGAGCCAGGCTTGACCCAGGAGAACACAAGCCTGCTGAGCTGCTGCTGACGACGCTGACGCTGACTTACTGTACGAGTGGGCTGACCATCTGACGACGATGACAGGGCGACGGGTAGCTGAGCCGAGGACCCAAGCTGAGCCGCTCCTA3' (SEQ ID NO:440)

Amino acid sequence of light chain variable region:

SSELDTQDPAVSVALGQTVRITCQGDSLRYASWYQQKPRQAPVLIVYKGKNRPSGIIPDRFSGSTSGNTASLTITIGAQAEDADEYYCKSRDSSGDHLVFGGGTKLTVL (SEQ ID NO:441)

FIG. 3QQ
20A5.1

Nucleotide sequence of heavy chain variable region:

5’CAGGTGCAGCTGGTGGAGGCTGGGAGGCCGCTGGTCCAGCCTGGGAGGTCT
CCTGAGTCCTCCTGTCACGCTGGATTCACTTTCACTGATAGCTATGCACTG
ACTGGGTCGCGACGCTCCAGGCTAGCGGCTGAGGTTGCTGGTGGGAGGTG
GATGATGGAAAGTTATGAAGAGATAGCTACATCAGACTCTCAGTGAAGGGCCGAT
ACTTCCAGAGAAGGACTCAGAAGAGACAGCTGATCTGCAAATGACACAGCTGG
GAGCGGAGGACAGCGCTGTTAGTTATTTGCGGAGGTCAGTGGCTGGTACC
CTAAGACTACGGTGATTGGACGTCTGGGCGCGAAAACAGCAGCCAGCCGTCCT
TCA3’ (SEQ ID NO:442)

Amino acid sequence of heavy chain variable region:

QVQLVESGGGVQPGSSLGSLSCAASGFTSSYGMHWVRQAPGKGLEWYAVIWy
DSYKDYADSVKGRHTISRDNSKNTLYQLMNSLAEDTAAYYCARSVAGYY
YGMDWVGQGTTVTVSS (SEQ ID NO:443)

Nucleotide sequence of light chain variable region:

5’TCTTCTGAGCTGAACGAGCCTGCTGGTCTGCTTGGCCTGGACAGACAGCA
GCAGGGATCACATGCGAAGAGACAGCCTCAGAACCTATTATATGCAAGCCTGG
ACCAGCAGAAGCCAGACAGCAGGCCCCTATCTTCGTCGCTCTATGTTAAACCA
CCGGCCCTCAGGAGCCACTCCAGAACCATTCTCTCGTGCCTCAAGGATACCA
GCTTCTTGACACATCATGGGGCTCGAGCGGAAGATGAGGCTGACTATTACT
GAAGATCCCGGGACATATGCGTACATCTGCTGCTGGCAGGACTAAG
GCTGAGCCGTCCTA3’ (SEQ ID NO:444)

Amino acid sequence of light chain variable region:

SSELTQDPAVSVALGQTVRJTCQGDSLRTYASWYQQKPRQAPILVYGIKNRPS
GIPDRFSGTSGITATLSLITGAQAEDAEEDYCKRSRDIIIGNHLLFGGTLTVL (SEQ
ID NO:445)

FIG. 3RR
Nucleotide sequence of heavy chain variable region:

```
5'CAGGTCAGGTCGCTGTGCCTGCTGGGAGGCGTGTCGTCGCTGGCCTGGGAGG'TCC
CTGAGACTCTCTGTCAGGTCCTGAGATTACCCCTCAGTACTAGCTATGGCATGCA
CTGGTCCGCGGTCGGCCGGCCAGGCAGGGCCTGGAAGTGGTGAGTGGGACGTCATATGG
TATGATGGAGATCAAAATACATATGCAGCCGCTCGTGAAGGGCCGATTCACCA
TCTCCAGAGACAAATTCCAAAGACACCGCTGTATCTGCAAATGAACAGTCTGAG
AGCCGAGACACCGCTGTATTACTGTGCAGAGGGGTTGGTTGTCGGGAGAT
CATCGCTACTACTACTACGCTATGGACGTCTGGGGCAGGCACGACGTCA
CCGTCCTCTCA3' (SEQ ID NO:446)
```

Amino acid sequence of heavy chain variable region:

```
QVQLVASGGGVQPGSRSLSLCAASGFTLSYMGHWHVRQAPGQGLEWVASVIW
YDGSNKYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAIVYVARGGGS VH
RYYGYMDVWGQGTTVTVSS (SEQ ID NO:447)
```

Nucleotide sequence of light chain variable region:

```
5'CTTTCTGAGCTGACTCAGGACCCTGCTGTCTGTGCTGGCCTTGGGACGACACA
GTCAGGATCACATGCAAGGAGACACGCTACAACGACTATTATGCAGAGCTGTT
ACCAGCAGAGCCAGAGACAGGGCCCTATTCTTGTCACTCATCTATGTAAGAAAACA
CCGGGCCCTGAGGATCSCAGGACGATATCTCTGCTGCTCACCCTACAGGAATCAA
GCTCTCTTGAACCATCTACTGGCAGCCCGAGAGTAGGCTGACTATTACTG
GTAATTCGCGGACATCCATTTGCTAAATCATTCTGCTGGTCCGCGAGGGACTAA
GCTGACCGCTCCTA3' (SEQ ID NO:448)
```

Amino acid sequence of light chain variable region:

```
SSELTQDPAVSVALGQTVRTCTGQRGDSLRTYASWYQQKPRQAPILVIYGKNNRPS
GIPDRSFGSTSGITAASLTTITGAQAEDEADYCKSRDIIGNHLLFGGKLTVL (SEQ
ID NO:449)
```

FIG. 3S
Nucleotide sequence of heavy chain variable region:

5' CAGGTGCAATGTTGAACTCTGGGAGCTGTCACGCTGCTGGGAGAGGTC
CCTGAGACTCTCTCTGTGCAGGTGATTCACTTTCAAGTAAGTATACAGCTG
ACACTGAGCCGCAAGGGGCTGAGTGGGGCGAGTGTTTATAG
GTATGATGGAGTTAAATAATCACTAGTCAGACTCCTGGAAGGCGGACCTAC
ACGACAGACAAATCTCAAGAGGACAGCTGCTATCTGCAATGAAACACAGCTGA
GAGCAGAGAACACGGGTATTTATATAGTGACGAGTCATGCTGGTACACA
TTATTACTACGTAGTTGACGTCTGGGCGCAAGGGCAGCAGGTCAGCGTCGCC
TCA3'  (SEQ ID NO:450)

Amino acid sequence of heavy chain variable region:

QVQVVEGAGGGVQQPGRSLRLSCAASGFTFSNYGMHWVRQAPKGLEWVAVIW
YDDGNNKYYADSVKGRSIISRDNSKSTLYLQMNLRAEDTAVYVVCSCVAYHY
YYMDVWGGQGTTVAS  (SEQ ID NO:451)

Nucleotide sequence of light chain variable region:

5' CAGTCTGCCCTGACTCAGCTCCGCTGCTGGGATCTCTGACAGTCGA
TCACCATCTCTGCACGTGAACAGCAGTGAGCTGGGTATAACTCTGTC
TCTCGTAGACACAGCAGCCAGCAACCCCAATACCTGAGTTATGAGG
TCTGATACGCGCCCTCACAGGTATTTCTACATCTCTGCTCTGACAGTCTG
GACACGGCCTCCCTGACACATCTCTGGGCTCCAGCTGAGCAGACGGCTATT
ATTTCTGACAGCTCATATACAAACCAACACCAATGCTTGGCGAGGGACCAA
GCTGGCCGCTCTA3'  (SEQ ID NO:452)

Amino acid sequence of light chain variable region:

QSALTQPASVGSQPSITISCTGTGSSDVGYNSVQYQQHPKPKLMIEVSN
RPGGSNRSFSGSKSGNTALTSGLAEDADYFCSYTSSTSMVFGGGTTLAVL
(SEQ ID NO:453)

FIG. 3TT
Nucleotide sequence of heavy chain variable region:

5' CAGGTGCAAGTGGTGGAGTCTGGGAGCGTGTCCAGCCTGGGAGGTC
CCTGAGAAGCTCTGCTGTCAGGGTCTCTGGATTACCTTTCAGTAACCTATGGCATTGC
ACTGGGTGCAGCCAGCTCCAGGCAAGGCGTTGGAGTGTCGCAAGTTATAATG
GTAATGAGGATGAATAAATAACTATGCAGACTCCGTGAAGGGCGGATCCAC
ATCTCAGAGACAATTCGCAAGACACGGCTGATCTGCAATATGCAACAGCTGA
GAGCCGAGGACACGGCTGTTATATTATTGTGCGAGGTCAGTGGCTGTTACCA
TTATTACTACGGATGGACGTCTGGGGCCACCAGGAGCGTGTCACGTCGCC
TCA3' (SEQ ID NO:454)

Amino acid sequence of heavy chain variable region:

QQQVQVESGGGVRQGRSLRLSCAASGFTFSNYGMHVVWVQRPGKLEWVAVIW
YDGGNKKYADSVKGRSIHSRDSNKLSTLYLQMQNLSRAEDTAVYVCARSVAGHY
YYGMDVWFGQTVTVA (SEQ ID NO:455)

Nucleotide sequence of light chain variable region:

5' TCTTCTGAGCTGAATCCAGACCCCTGCTGTGTGTGCGCTTTGGGACACGAC
GTCAAGATCACTGCAACAGACGCTCAGAGCTATTATGCAAGCTGGT
ACCAGCAAGCGGCAAGACAGGCCCCGTACTTGTCTCATCTATGTAAMGCAAA
CCGCCCCCATCAGGATCACCAGCGATTCTGGCTCCAGCTGAAACACA
GCTTTCCCCATACATCTGCGCTAGCGGCGAAGATGAGGCTGACTATTACT
GTAACCTCAGGGACACCATGGTGACCATCTGCTGTTGGCGGAGGACCAA
GCTAGCAGGCTCTA3' (SEQ ID NO:456)

Amino acid sequence of light chain variable region:

SSELTOQPAVSVLAVGQTVRITCQGDSLREGYAYSYYQKPRQAPVILVITYGKNRP
SGIPDFSGTSGNTASLATITGQAEDADDYVCSNRDINGDHDVFLVGGGDKLTLV
(SEQ ID NO:457)

FIG. 3UU
8A3.1

Nucleotide sequence of heavy chain variable region:

5'GAGGGTCAGCTGGAGTCTGGGGAGGGCAGCTGGCAGCCTGGGGGCTC
CTGAGACTCTCTGCTGGCAGCTCTCCGATCCACCTTTAAGTAGCTATTGGAGAG
CTGGGTCGCCAGCAGCTCCAGGGAGGGCTGGAGTGTTGGTGAGGAGCACGATAAA
ACAGAAGTGAGTGAGAAGAATACATCTGGAAGCTCTGGAAGGGCCAGTTACC
ATCTCAGAGACAACGCCAGAATCATCTTGATCTGCAATTGGAAGCACGCCTGA
GAGCCCGAGACAGGGCTGTGATTACTGTGGAGAGATCTTTTATTAAATGGT
GTATGGATTAGACTACTACTCTACTACCGTATGACGTCTGGGGCAAGGGACC
ACGGTCACCCGTCTCTCA3' (SEQ ID NO:458)

Amino acid sequence of heavy chain variable region:

EVQLVESGGGLVQPGGLVRLSCLAASGFTSSYWMSSWVRQAPKGLEWVASIKQ
DGSEKYYVDSVKGRFTISRDNARNSLYLQLMNSLRAEDTAVYYCARDELVALMVYD
IDYYYYGMDWGWGQGTGTAVSS (SEQ ID NO:459)

Nucleotide sequence of light chain variable region:

5'GATATTGTGATGACTGACTCAGCTCTCCACTCTCCCTGCCCAGCACCCTCCTGGAGAC
CGGCCTCCATCTCCTGCAAGGTCTACTCAGAGAGCCTCTCCTCGACTAGTAAATGGCAGAC
AACTATTGGATTTGAGACTGAGACAGCAGGGCAGAGCCAGCGTCCACAGCTCCGTA
TCTATTTGGTTCTAATCGGGGCTCTCCGAGGCTCCCTGAACAGGTCTGAGCAGT
GGATACGACAGATTTACATTAGAAATACGAACGAGAGCTGAGCTGGAAGATG
TTGGGTTATTACTGCATGCAAGCTCTACTACAAATCCCGTCTACCTCTGGCCGGA
GGGACCAAAGTGAGATCACA3' (SEQ ID NO:460)

Amino acid sequence of light chain variable region:

DIVMTQSLPLVPTEPEGAPISCRSSQSLHSGNYNLDWYLQKPGQPSPLLIFYL
SNRASGVPDRTSFSGSGTDFTLKISRVEAEDVGYYCMQALQTPLFGGGTKVEIK
(SEQ ID NO:461)

FIG. 3VV
Nucleotide sequence of heavy chain variable region:

5'GAGGTGCAGCTGGGTAGTCTGGGGAGGCTTGGTCAGCCTGGGGGGTCCCTGAGACTCTCCTCTGCTGACGCTCCCGATTCACCTTATAGTAACTATTTGGATGAGCTGGGTTCGCGACTCCAAGGAAGGGCTGGTGATTTGGCTGTCGCCAGCATAAAAACAAGATGGAAGTGAATAACTTATGTTGGAACCTGTAAGGGGCGGATTCGCCATCTCAGAGAAACGCAAGAACTCAGTCTTTCTGCAAAATGAAACAGCCTGAGACCGAGGACACCGCTGTGATTACCTGTGCGAGAGATCCTGTACTAATGCTGATGATATAGACTACTACTACTACGCTATGGACGTCTGGGGCAAAGGACCACGGTCACCAGTCTCCTCA3' (SEQ ID NO:462)

Amino acid sequence of heavy chain variable region:

EVQLVESGGGLVQPGGSLRLSCAASAGFTFNYWMSWVRQAPGKGLEWVASIKQDGSEKYYVDSVKGIRFAISRDNKNSLFLQMNSLRAEDTAVVYYCRDLVLMVYDIDYYYGMVDVWGQGTTVTVSS (SEQ ID NO:463)

Nucleotide sequence of light chain variable region:

5'GATATTTGTGATGACTCACTTCACCTGCCTGCTGTCCGACCCCTGGAGAGCCGCTCCATCTCTCTTTGAGGTCTAGTCAGAGCCCTCCTGCATAGTAAATGGTACACATTTCCTTTGCTACGTCCAGAAAGCCAGGGCTCTCCAAGCTCTCTGCTACATTCTGCATATGCTCTGTATGTTGGTTTAATCTCGAGCTCCGCTGGGTCCTGACAAGGTTCATGGCACGATGGTCAACGGCAGGCACATCITTCACCTGAAATACGACGAGTTGGAGCTAGATTTGGAGTTTTAATTACTGCATGCAAACCTCTCAAAACTCCGCTCACTTTCCGGCGGA GGACCAAGGTGGAGATCAA3' (SEQ ID NO:464)

Amino acid sequence of light chain variable region:

DIVMTQSPLSPVPGBKPGPSASCRSSQSLLHNSGYNYLQKPDQSPQLLIVLYGDNRASGVDPDFSGSGSGTHLTLKIISRVEAEVDVGYYCMQTLQTPFLOGGTKEIK (SEQ ID NO:465)

FIG. 3WW
12H11.1

Nucleotide sequence of heavy chain variable region:

5' CAGGTGCAGCTGGTGAGCTCTGAGGGAGGGCGTGGAGCCACGGCTCTGGGAGAGTC
CCTGAGACTCTCTCTTGAGATCCCTCTAGAGCTATGGGCAAATGC
ACGGTGCCGACTCCGTAAGGACGCTGCCGCTGACTGCGGACGGCTCTGGGAGAGTC
CTATGATGAAATTAAACTATATCAGACTCCGTGAAGGGCCGATCCAC
ATCTCCAGAGAAGAGATTCAGAGACGCTGTATCTGCAAAATGAAACAGCTGA
GACCCGAGGACAGCTGGGTATACTCTGCGAGAGATCGGGGACTGGACTG
GCGGCCAGGAACCTCGTCCACGTCTCTCAA3' (SEQ ID NO:466)

Amino acid sequence of heavy chain variable region:

QVQLVESGGGLVQPGRSLQALSCAVASGGFTSSYGMHWVRQAPKGLEWAVAVYY
DGINKHYADSVKVGRFTISRDNSKNTLYLQMSLRAEDTVVYCARDRGLDWGQ
GTLVTSSV (SEQ ID NO:467)

Nucleotide sequence of light chain variable region:

5' GACATCTTGAGGCGAGCTCCAGACTCCCTGCTGCTCTGGGAGAGTC
AGGTTTGCGAGCTCACGAGTTAGTTGAGCCCTATGCTCAAACA
GCTGATGGAATGTTTGTGATCCAGAGAAACCGACAGCCTCTCTTACGCT
GCTACTTTTACTGAGATCCAGCGGTAATCCGCGGCTCCGACGCTG
GCCAGCAGCTGGGAGAGTC
GACCCGAGGACAGCTGGGTATACTCTGCGAGAGATCGGGGACTGGACTG
GCGGCCAGGAACCTCGTCCACGTCTCTCAA3' (SEQ ID NO:468)

Amino acid sequence of light chain variable region:

DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNSKNLYLVWWYQQKPQPPKLIP
WASTRESQVPDRYSQGSGTFTLTITISSLQAEDVAVYYCQYYSTPWTFGQGTK
VEIK (SEQ ID NO:469)

FIG. 3XX
11H4.1

Nucleotide sequence of heavy chain variable region:

5'GAGGTGCACTGGTAGCTGGGAGGCTTGGTCACAGCTGCTGGGAGGCTGCCCT
CTGAGACTCTCTGTCAGGCCTGCAGCTGACTCACTTTAGTAACCTTTTAGAT
GAGCTGAGATCTGCTGAGGAGAGGGCTGGAAGTGGTGAGGAGCAACATA
GCAAATGAGAAATGATAATACATATGAGCTGAGGAGGCGGTACCTC
ATCTCCAGAGAACAGCCAGAACATACCTTACTGATCATCTACAAATGAGA
CAGCGAGGACAAGGCTGATGTTATACGAGGTCGAGAGAAGATCAAAGC
TGCTTTTGATATCTGGGGCAAGGACAAATGTCACCCGCTCTCTCA3' (SEQ ID NO:470)

Amino acid sequence of heavy chain variable region:

EVQLVESGGGLVQPGSGSLRLSCAASGLFTSFWRQAPGKGLEWVANI
DGNDKYYVDSVKGRFTISRDNAKNSLYLQMNLSRAEDTAVYTCARESNWGF
DIWGGQGMVTSS (SEQ ID NO:471)

Nucleotide sequence of light chain variable region:

5'CAGTGCTGTCGACTTCAGCCACTCCAGCTGCAGTGGACCCCCGAG
GTCACCATCTCTGTTCTGGAAGCTCACAGCCACACTGGAAGTAACACT
GACTGATTGACGTTCACAGGAGGCCCCAACACTCTCATTAGTAAC
TACGGGGGAGGCTAGGCTCCAGGGGCTCAGCTGAGGAGGGCTCAG
CTCCAGGCACTCCAGGCTCAGCTGAGGAGGAGGCTCACTC
TACGGGGGAGGCTAGGCTCCAGGGGCTCAGCTGAGGAGGAGGCTCAG
CTCCAGGCACTCCAGGCTCAGCTGAGGAGGAGGCTCACTC

Amino acid sequence of light chain variable region:

QSVLTQPPASGTPQORVTSICSGSNNSSKTVNWWYQQFPGTAPKLIYSNNRP
SGVPTPSGSKGTSASLAISGLQSEDEADYHCYCAWDDLSNVWGAGKLT
V (SEQ ID NO:472)

FIG. 3YY
11H8.1

Nucleotide sequence of heavy chain variable region:

5′GAGGTGAGCTGGTGAGGTCTGGGGAGGGTTGTTGCTCAGCGCTGGGGGTTCC
CTGAGACTCTCTCTGTGAGCAGCTCTGACTGACTAGTTATTAACCTTTGGATGAG
CTGGGCTGCGCAGCTCAGGAAAGGGCTGAGTGGTGTCAGCCACATCAA
GCAAGATGGAAGATAGAATACTATTGAGACTCTGTAAGGGGCGAATCC
ACCTCCAGAGCACAAGCAGAATTATCATCTGTATCTGCAAATGACACGCCTGA
GAGCCCGAACACGGCTGTATATTACTGTGCGAGAGTCAAACTGGGGATT
TGCTTTATATATCTGGGGCAAGGGGCAATGCTACAGGCTGCTTCTCA3′ (SEQ ID
NO:474)

Amino acid sequence of heavy chain variable region:

EVQLVESGGGLVQPGSGSLRLSCAASGLFTSFWSNRQAPKGLENVIANILQ
DGSEKYVLDVQVKGRFTISRDNSLYLQMNLSRAEDTA VyV YCARESNWGF
DIWGQGTMVTSS (SEQ ID NO:475)

Nucleotide sequence of light chain variable region:

5′CAGTCTCTGTGCTGACCTCAGGCACCCCTGACCTGGGACCCCGGGCAGAGG
GTCACCATCCTCTTTGTTCTGGGAGCAGCTCAGCATCGGAAAGTAAACTGTAA
ACTGGTACCGACGTTCCAGGAAAGCGCCACCAACTCTCCTATCCTAGTTAA
TAATCGGCGGGCCCTAGGTTGCTACGAGTCTGCTCGCTAAAGTCTGGCA
CTCAGCCTCCCTGGCCATCATCGTGGGCTCAGCTCAGTGGAGTGAGGGCTGATTAT
TACTGTTGCAACATGGGATGACAGACTGAAATTGGGTGTTCCGGCAGGGACCA
AGCTGACCGCTCTA3′ (SEQ ID NO:476)

Amino acid sequence of light chain variable region:

QSVLTQPPSASGTPGPVRVTISCSGSSSNISGTKVNWYQFPGTAPKLLYISNNRRP
SGVPDRFSGSKSATSAILSIGQLGQSEDEADYYCATWDDRLNVWFGAGTTLTVL
(SEQ ID NO:477)

FIG. 3ZZ
**11G1.5**

**Nucleotide sequence of heavy chain variable region:**

5' CAGGTCACCTTGAAAGGATCTGGTCCTGTGCTGGTGAAACCACAGAGACC
CTCAGCTGAACCTGCACCCCTCTCGTTCTCCTCACTCAGCAATGTTAGAATGGG
TGAGACTGAGTCGTCACAGCCACACAGGACAGGGGCTGGGAGTTGCTGTGCCCAC
ATTCTCTCAATGAGAAATTCTACTGACAACAATCTCTGAAAGAGACGGCTCA
CCATCTCAAGGACACACCTCAAAAGCAGGACGTGGTCTCTACCATGACCAACAT
GGACCTCTGTCGACACAGCAATATTACTGTGCACCGATATGCTGGGAGCTACA
ACGGATGATGCTTTTGATATCTGGGCGCAAGGACAAATGCTACCCGTCTCCT
A3' (SEQ ID NO:478)

**Amino acid sequence of heavy chain variable region:**

QVTLKESGPVLFVKTETLTLTCTVSGFSLSNVRMGVSIRQPGKALEWLAIHFS
NDENSYRTSLKSLTISKDTKSQVVLTMNMDPVTATYCARIVGATTTDCAF
DIWGQGTMVTSS (SEQ ID NO:479)

**Nucleotide sequence of light chain variable region:**

5' TCCTATGTGTGACTGACACCCACCCCTCGTGTCATGGGCAGCAGAGACGC
GCCAGGATTACCTGTGGGGAACAACATTGGAAGTAAAGTGTCAGCTGGT
ACCAGCAGAACACGCAGCCAGCGCCCTGTGCTCGTCTGCTATGATGATACGGA
CCGCGCCCTCAGGATACCTGACAGATTCCTCTGCTGCTACACCTCTCGGAACAGC
GCCACCCCTGACATGACAGGCTGCAAGCCGGGAGACTAGGCGCCACCTACT
GTCAGGTTGCGATAGTGTAGCTGCTCTGTGTATTCCGGAGGACAAAA
GCTGACCCGTCTCAA3' (SEQ ID NO:480)

**Amino acid sequence of light chain variable region:**

SYVLTPPPSVSPAVGQRTARICGCGNNIGSKSVHWWYQQKPGQPVPVLVYDDSDRP
SGIPERFSGNSNGTATLTSRVEAGDEADFYQVVVDSSDPVVFAGGTKLTVL
(SEQ ID NO:481)

**FIG. 3AAA**
8A1.2

Nucleotide sequence of heavy chain variable region:

5'GAGGTGCAGCTGGTGAGCTGCTGGGAGGCTTGCTGCAGCTGGCTGGGACCTCCTGGC
CTGAGCCTCTCTCTGTGAGCTGCTGGGACCTCACTTTAGTAACATTGGAGTACC
CTGGGTCCAGCGCCAGCTCAGAGGGGGCTGAGCTGCTGGGACCTCACTCAAA
GCAAGGATGAGATACTATGTGAGCTGCTGAGCTGGAGCCGGCTTCAC
ATCTCCAGACCCCGACCAAGAATCTCTGTATCTCAGAAATGACAGCCTGC
GAGCCGAGGACACGCTGCTGATTACTGTCGAGACCTCTCTGACTTAATGCT
GTATGCTTACACTACTACTACTACTACGTGGATGGATCCTGGGACGGACC
ACGGTCACCCGTCTCCTCA3' (SEQ ID NO:482)

Amino acid sequence of heavy chain variable region:

EVQLVESGGGLVQPGGLRLSLCASHGFTFSNYWTWVRQAPGKSGKWASIKQ
DGERYYVDSVKGRFTISRDTSKNSLYLQMNSLRAEDTADEYVCARPLVMYVA
LHYAYMDVWGHTTVTVS (SEQ ID NO:483)

Nucleotide sequence of light chain variable region:

5'GATATTGATGACTCACTCTTGCTCCACTCTCCCTGGCTGCCCTCCCTGGGAGGC
CGGCTCAGACGTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCTGCTGAGCT
ACACTTGGATTTGCTACCTGAGAAGCCAGGGCGAGCTCTGAGAGCCTCAG
CTTGGGCTTATTACGCTATGCAAGCTCTACTACAAACTCCTCCACTCTTGCGCGA
GGACCAAGGGTCGGAGATCAAA3' (SEQ ID NO:484)

Amino acid sequence of light chain variable region:

DIVMTQSPSLPVTQPGPASCRRSQQSLHSNGYNYLDWYWLYQKPQGSQPLILYLY
SNRASGVPDRFSGSGSHTDFTLKISRVEAEDVGVYCMQALQTPLTFGSGTKVEIK
(SEQ ID NO:485)

FIG. 3BBB
<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>Heavy variable</th>
<th>Germline</th>
<th>JH</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
<th>CDR1</th>
<th>FR2</th>
<th>CDR1</th>
<th>FR2</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>493</td>
<td>VH11-102</td>
<td>Germline</td>
<td>JH6</td>
<td>FR1</td>
<td>CDR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>419</td>
<td>VHH1-102</td>
<td>Germline</td>
<td>JH4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>494</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td>FR1</td>
<td>CDR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>435</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24B9.1G</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td>FR1</td>
<td>CDR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24F7.1G</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2BE11.1G</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td>FR1</td>
<td>CDR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30B5.1G</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24B9.2G</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td>FR1</td>
<td>CDR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>431</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>439</td>
<td>VHH3-33</td>
<td>Germline</td>
<td>JH6</td>
<td>FR1</td>
<td>CDR1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEQ_ID</td>
<td>Heavy variable</td>
<td>FR4</td>
<td>CDR3</td>
<td>FR4</td>
<td>CDR3</td>
<td>FR4</td>
<td>CDR3</td>
<td>FR4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>519</td>
<td>H</td>
<td>GQQGTIVYSS</td>
<td>GNYYIHGMV</td>
<td>GQQGTIVYSS</td>
<td>GNYYIHGMV</td>
<td>GQQGTIVYSS</td>
<td>GNYYIHGMV</td>
<td>GQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>493</td>
<td>R</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>494</td>
<td>V</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>435</td>
<td>T</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>423</td>
<td>L</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>427</td>
<td>Y</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>421</td>
<td>F</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>431</td>
<td>G</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>432</td>
<td>G</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>437</td>
<td>T</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>438</td>
<td>R</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>487</td>
<td>G</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>473</td>
<td>T</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>473</td>
<td>R</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>477</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>477</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>471</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>471</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>467</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>467</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>461</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>461</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>459</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>459</td>
<td>S</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td>KGQQGTIVYSS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIG. 3DDD**
<table>
<thead>
<tr>
<th>Kappa variable</th>
<th>SEQ ID NO:</th>
<th>Gerline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>5H5.1K</td>
<td>496</td>
<td>VK1</td>
<td>A20</td>
<td>DIQMTQSPSSLSALSGDRVTITC</td>
<td>RASGGISNYLA</td>
<td>WYQQHPGVPKLLIY</td>
</tr>
<tr>
<td>Lambda variable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20E5.1L v1</td>
<td>497</td>
<td>VL2</td>
<td>2a2</td>
<td>QSAALTQPASVSGPGQQITISC</td>
<td>TGTSSDVGGYNYVS</td>
<td>WYQQHPGKAPKLMYY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Germline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>30F1.1L</td>
<td>433</td>
<td>VL3</td>
<td>3i</td>
<td>SSELTQDPASVALGQTVRITC</td>
</tr>
<tr>
<td>22B11.1L</td>
<td>429</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
<tr>
<td>24B9.1L</td>
<td>437</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
<tr>
<td>24B9.2L</td>
<td>441</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
<tr>
<td>20E5.1L v2</td>
<td>457</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
<tr>
<td>24F7.1L</td>
<td>425</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
<tr>
<td>20A5.1L</td>
<td>445</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
<tr>
<td>20A5.2L</td>
<td>449</td>
<td>VL3</td>
<td>3i</td>
<td>JL2</td>
</tr>
</tbody>
</table>

**FIG. 3EEE**
<table>
<thead>
<tr>
<th>Kappa variable</th>
<th>SEQ NO:</th>
<th>CDR2</th>
<th>FR3</th>
<th>CDR3</th>
<th>FR4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>496</td>
<td>AASTLQS</td>
<td>GVPSEFGSGGSDFTLTSSLQEDVATYYC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5H5.1K</td>
<td>421</td>
<td>---------------------</td>
<td>-----------------------</td>
<td>---------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td></td>
<td>497</td>
<td>EVSNRPS</td>
<td>GVSNGFSGSQGNTSLSGLQQAEDADYYC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lambda_variable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>453</td>
<td>---------------</td>
<td>-I----------------------</td>
<td>F-</td>
<td>SSYTGSTSMV</td>
</tr>
<tr>
<td>20E5.1L v1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>498</td>
<td>GKNRPS</td>
<td>GIPDRFSGSSSGNTASLTIAGAQAEADYYC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30F1.1L</td>
<td>433</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>KSRDIIGDHLLK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>22B11.1L</td>
<td>429</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>NSRDIIGDHLLK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>24B9.1L</td>
<td>437</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>KSRDSSGDHLVKK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>24B9.2L</td>
<td>441</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>KSRDSSGDHLVKK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>20E5.1L v2</td>
<td>457</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>NSRDNIGDHLLK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>24F7.1L</td>
<td>425</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>NSRDSIGNHLVKK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>20A5.1L</td>
<td>445</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>KSRDIIGNHLKK</td>
<td>FGGTGLTVL</td>
</tr>
<tr>
<td>20A5.2L</td>
<td>449</td>
<td>---------------</td>
<td>-I--T-------------------</td>
<td>KSRDIIGNHLKK</td>
<td>FGGTGLTVL</td>
</tr>
</tbody>
</table>

**FIG. 3FF**
<table>
<thead>
<tr>
<th>Seq ID NO:</th>
<th>Germline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>486</td>
<td>VH2</td>
<td>226</td>
<td>QVTLKESGPVLKPTETTLTLCTVS</td>
<td>506</td>
<td>GFSLSNARMGVS</td>
</tr>
<tr>
<td>11G1.5</td>
<td>479</td>
<td>VH2</td>
<td>226</td>
<td>JH3</td>
<td>506</td>
</tr>
<tr>
<td>487</td>
<td>VH3</td>
<td>307</td>
<td>EVQLVESGGGLVQPGGSLRLSCAAS</td>
<td>510</td>
<td>GFTFSSYWS</td>
</tr>
<tr>
<td>11H8.1</td>
<td>475</td>
<td>VH3</td>
<td>307</td>
<td>JH3</td>
<td>510</td>
</tr>
<tr>
<td>11H4.1</td>
<td>471</td>
<td>VH3</td>
<td>307</td>
<td>JH3</td>
<td>510</td>
</tr>
<tr>
<td>8A3.1</td>
<td>459</td>
<td>VH3</td>
<td>307</td>
<td>JH6</td>
<td>510</td>
</tr>
<tr>
<td>11F1.1</td>
<td>463</td>
<td>VH3</td>
<td>307</td>
<td>JH6</td>
<td>510</td>
</tr>
<tr>
<td>8A1.2</td>
<td>483</td>
<td>VH3</td>
<td>307</td>
<td>JH6</td>
<td>510</td>
</tr>
<tr>
<td>488</td>
<td>VH3</td>
<td>3-33</td>
<td>EVQLVESGGGGLVQPGGSLRLSCAAS</td>
<td>515</td>
<td>GFTFSSYGMII</td>
</tr>
<tr>
<td>12H11.1</td>
<td>467</td>
<td>VH3</td>
<td>3-33</td>
<td>JH4</td>
<td>516</td>
</tr>
</tbody>
</table>

**FIG. 3GGG**
<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>SEQ ID NO:</th>
<th>SEQ ID NO:</th>
<th>SEQ ID NO:</th>
<th>SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDR2</td>
<td>FR3</td>
<td>CDR3</td>
<td>FR4</td>
<td></td>
</tr>
<tr>
<td>486</td>
<td>NLFSNDEKSYSTSLKS 519</td>
<td>RLTISKDSKSKQVVT4MDFVTDATYYCAR 521</td>
<td>VGATTUDAFDI 522</td>
<td>WGGGMVTVSS 523</td>
</tr>
<tr>
<td>11G1.5</td>
<td>N---R------519</td>
<td>---N-R----520</td>
<td>---N-R----521</td>
<td>---N-R----522</td>
</tr>
<tr>
<td>479</td>
<td>479</td>
<td>479</td>
<td>479</td>
<td>479</td>
</tr>
<tr>
<td>CDR2</td>
<td>FR3</td>
<td>CDR3</td>
<td>FR4</td>
<td></td>
</tr>
<tr>
<td>487</td>
<td>NIKGQDSEKSYVAVKG 526</td>
<td>RFTISRANAKSNLYLQMSLRAEIDTAVYYCAR 529</td>
<td>ESNGGAPFDI 533</td>
<td>WGGGMVTVSS 523</td>
</tr>
<tr>
<td>11H8.1</td>
<td>475</td>
<td>526</td>
<td>526</td>
<td>526</td>
</tr>
<tr>
<td>11H4.1</td>
<td>471</td>
<td>527</td>
<td>527</td>
<td>527</td>
</tr>
<tr>
<td>8A3.1</td>
<td>459</td>
<td>501</td>
<td>501</td>
<td>501</td>
</tr>
<tr>
<td>11F1.1</td>
<td>463</td>
<td>501</td>
<td>501</td>
<td>501</td>
</tr>
<tr>
<td>8A1.2</td>
<td>483</td>
<td>528</td>
<td>528</td>
<td>528</td>
</tr>
<tr>
<td>CDR2</td>
<td>FR3</td>
<td>CDR3</td>
<td>FR4</td>
<td></td>
</tr>
<tr>
<td>488</td>
<td>VIWDGSKKYYAVSKG 535</td>
<td>RFTISRNKNTLYLQMSLRAEIDTAVYYCAR 537</td>
<td>DRGLD 538</td>
<td>WGGGMVTVSS 539</td>
</tr>
<tr>
<td>12H11.1</td>
<td>Y---II-----536</td>
<td>---Y---II---537</td>
<td>---Y---II---537</td>
<td>---Y---II---537</td>
</tr>
</tbody>
</table>

FIG. 3HHH
<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>Germline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>489</td>
<td>VK2</td>
<td>A19</td>
<td>DIVMTQSLSPSVPVTPGEPASISIC</td>
<td>540</td>
<td>RSSQSLHISNNYLD</td>
</tr>
<tr>
<td>8A1.2</td>
<td>485</td>
<td>VK2</td>
<td>A19</td>
<td>JK4</td>
<td>540</td>
</tr>
<tr>
<td>8A3.1</td>
<td>461</td>
<td>VK2</td>
<td>A19</td>
<td>JK4</td>
<td>540</td>
</tr>
<tr>
<td>11F1.1</td>
<td>465</td>
<td>VK2</td>
<td>A19</td>
<td>JK4</td>
<td>540</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>Germline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>490</td>
<td>VK4</td>
<td>B3</td>
<td>DIVMTQSPDLSAVSLGERATINC</td>
<td>542</td>
<td>KSSQSVLYSSNNRNLAYA</td>
</tr>
<tr>
<td>12H11.1</td>
<td>469</td>
<td>VK4</td>
<td>B3</td>
<td>JK1</td>
<td>542</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>Germline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>491</td>
<td>VL1</td>
<td>1c</td>
<td>QSVL/QFPSASGTPGQRVTVC</td>
<td>546</td>
<td>GSSSSNIGSVNTYN</td>
</tr>
<tr>
<td>11H4.1</td>
<td>473</td>
<td>VL1</td>
<td>1c</td>
<td>JL3b</td>
<td>546</td>
</tr>
<tr>
<td>11H8.1</td>
<td>477</td>
<td>VL1</td>
<td>1c</td>
<td>JL3b</td>
<td>546</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>Germline</th>
<th>Germline</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
</tr>
</thead>
<tbody>
<tr>
<td>492</td>
<td>VL3</td>
<td>3h</td>
<td>SYVL/QFPSVSAVPKPTARIC</td>
<td>551</td>
<td>GNNIGSKSVH</td>
</tr>
<tr>
<td>11G1.5</td>
<td>481</td>
<td>VL3</td>
<td>3h</td>
<td>JL2</td>
<td>552</td>
</tr>
</tbody>
</table>

**FIG. 3III**
<table>
<thead>
<tr>
<th>SEQ ID NO:</th>
<th>CDR1</th>
<th>CDR2</th>
<th>CDR3</th>
<th>CDR4</th>
</tr>
</thead>
<tbody>
<tr>
<td>FR4</td>
<td>GVP</td>
<td>521</td>
<td>GD</td>
<td>522</td>
</tr>
<tr>
<td>FGGS</td>
<td>TGK</td>
<td>YC</td>
<td>FGGE</td>
<td>TGLK</td>
</tr>
<tr>
<td>8A1.2</td>
<td>504</td>
<td>504</td>
<td>504</td>
<td>504</td>
</tr>
<tr>
<td>8A3.3</td>
<td>461</td>
<td>461</td>
<td>461</td>
<td>461</td>
</tr>
<tr>
<td>11E1.1</td>
<td>465</td>
<td>465</td>
<td>465</td>
<td>465</td>
</tr>
<tr>
<td>12H1.1</td>
<td>469</td>
<td>469</td>
<td>469</td>
<td>469</td>
</tr>
<tr>
<td>11H4.1</td>
<td>473</td>
<td>473</td>
<td>473</td>
<td>473</td>
</tr>
<tr>
<td>11H8.1</td>
<td>477</td>
<td>477</td>
<td>477</td>
<td>477</td>
</tr>
<tr>
<td>11G1.5</td>
<td>481</td>
<td>481</td>
<td>481</td>
<td>481</td>
</tr>
</tbody>
</table>

**FIG. 3J**
$K_D = 16 \text{ pM}$

95% CI: 14 - 19 pM

FIG. 4C
$K_D = 2 \text{ pM}$

95% CI: 1−3 pM
FIG. 5A

12% Tris-Glycine gel, QuickBlue stain, 1μg/Lane

1. Marker 12
2. hPCSK9
3. mPCSK9
4. cPCSK9
5. 16F12
6. 21B12
7. 31H4
8. Marker 12
9. hPCSK9
10. mPCSK9
11. cPCSK9
12. 16F12
13. 21B12
14. 31H4
15. SeeBlue Plus2
FIG. 5C

KD ~ 11 pM
95% CI: 7-16 pM

0.1/0.3/1/3nM cPCSK9 + (1pM ~ 25nM) 21B12

Free cPCSK9 %
FIG. 5E

Epitope Binning of anti-PCS9 Abs on hPCS9

- 16F12
- 2B12
- 31H4

Binding (RU)

140 120 100 80 60 40 20 0 -20

2B12 (Fc2-1)
31H4 (Fc4-1)
16F12 (Fc2-1)
FIG. 9

<table>
<thead>
<tr>
<th>Time (h)</th>
<th>31H4</th>
<th>IgG</th>
<th>LDLR</th>
<th>β-actin</th>
<th>LDLR</th>
<th>β-actin</th>
<th>LDLR</th>
<th>β-actin</th>
<th>LDLR</th>
<th>β-actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>8h</td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>24h</td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>72h</td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>144h</td>
<td></td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
<td>+</td>
<td></td>
</tr>
</tbody>
</table>
FIG. 11A
### FIG. 12A

<table>
<thead>
<tr>
<th>Mev (µg/ml)</th>
<th>0</th>
<th>0.2</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ab (µg/ml)</td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
</tbody>
</table>

**LDLR**

**Actin**

![Relative Levels of LDLR](chart.png)

The graph shows the relative levels of LDLR at different concentrations of Mev and Ab. The y-axis represents the relative levels, while the x-axis represents various Mev concentrations.
FIG. 12C
FIG. 12D
FIG. 12F
FIG. 13D
### FIG. 13F

#### Consensus for Group 1:

<table>
<thead>
<tr>
<th>Accession</th>
<th>Consensus</th>
<th>Seq ID</th>
<th>NO.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>20D10_light-heavy_cdr</td>
<td>TGGTS3DVGGYNSGVS</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3099_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27B7_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19H9_light-heavy_cdr</td>
<td>N G</td>
<td>(SEQ ID NO:159)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21B12_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23G1_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26H5_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31D1_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27H5_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:158)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17C2_light-heavy_cdr</td>
<td>S N</td>
<td>(SEQ ID NO:156)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25A7_light-heavy_cdr</td>
<td>S M</td>
<td>(SEQ ID NO:161)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Consensus for Group 2:

<table>
<thead>
<tr>
<th>Accession</th>
<th>Consensus</th>
<th>Seq ID</th>
<th>NO.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22E2_light-heavy_cdr</td>
<td>GS5S3NIGNNTYVVS</td>
<td>(SEQ ID NO:182)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28B12_light-heavy_cdr</td>
<td>H N</td>
<td>(SEQ ID NO:181)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26D6_light-heavy_cdr</td>
<td>H P</td>
<td>(SEQ ID NO:180)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16F12_light-heavy_cdr</td>
<td>N G</td>
<td>(SEQ ID NO:182)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27A6_light-heavy_cdr</td>
<td>S G</td>
<td>(SEQ ID NO:182)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31G11_light-heavy_cdr</td>
<td>S M</td>
<td>(SEQ ID NO:184)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**U.S. Patent**

Oct. 14, 2014

Sheet 109 of 122

US 8,889,714 B2
FIG. 13G
**Group 1 (11 members)**

<table>
<thead>
<tr>
<th></th>
<th><strong>LV_CDR1</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>LV_CDR2</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>LV_CDR3</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>H_CDR1</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>H_CDR2</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>H_CDR3</strong></th>
<th><strong>SEQ</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CONSENSUS</td>
<td>TGTSSDVGGYSVS</td>
<td>305</td>
<td>EVSNRPS</td>
<td>306</td>
<td>SSYTSTSMV</td>
<td>307</td>
<td>SYGIS</td>
<td>308</td>
<td>WISAYNGNTNYAQKSVG</td>
<td>309</td>
<td>GYGMDV</td>
</tr>
<tr>
<td></td>
<td>25A7</td>
<td>............R</td>
<td>311</td>
<td>............</td>
<td>312</td>
<td>............S.V.</td>
<td>313</td>
<td>............</td>
<td>308</td>
<td>............E.L.</td>
<td>314</td>
<td>............V.</td>
</tr>
<tr>
<td></td>
<td>17C2</td>
<td>............A</td>
<td>316</td>
<td>............</td>
<td>312</td>
<td>............N</td>
<td>317</td>
<td>............</td>
<td>308</td>
<td>............F.</td>
<td>318</td>
<td>............V.</td>
</tr>
<tr>
<td></td>
<td>21B12</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>N</td>
<td>319</td>
<td>............</td>
<td>308</td>
<td>V.F.</td>
<td>320</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>23G1</td>
<td>............</td>
<td>305</td>
<td>T.</td>
<td>321</td>
<td>N</td>
<td>319</td>
<td>............</td>
<td>308</td>
<td>V.F.</td>
<td>320</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>19H9</td>
<td>............N</td>
<td>322</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>309</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>27H5</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>309</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>26H5</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>323</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>31D1</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>324</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>27E7</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>309</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>20B10</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>309</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>30B9</td>
<td>............</td>
<td>305</td>
<td>............</td>
<td>312</td>
<td>............</td>
<td>307</td>
<td>............</td>
<td>308</td>
<td>............</td>
<td>309</td>
<td>............</td>
</tr>
</tbody>
</table>

**Group 2 (6 members)**

**Light chain:**

<table>
<thead>
<tr>
<th></th>
<th><strong>LV_CDR1</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>LV_CDR2</strong></th>
<th><strong>SEQ</strong></th>
<th><strong>LV_CDR3</strong></th>
<th><strong>SEQ</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CONSENSUS</td>
<td>SGSSSNIGNNFVS</td>
<td>325</td>
<td>DYNKRP</td>
<td>326</td>
<td>GTWDSSLGYV</td>
</tr>
<tr>
<td></td>
<td>31G11</td>
<td>............</td>
<td>325</td>
<td>S.</td>
<td>331</td>
<td>............A.</td>
</tr>
<tr>
<td></td>
<td>28D6</td>
<td>............</td>
<td>325</td>
<td>............</td>
<td>326</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>28B12</td>
<td>............</td>
<td>325</td>
<td>............</td>
<td>326</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>22E2</td>
<td>............</td>
<td>325</td>
<td>............</td>
<td>326</td>
<td>............</td>
</tr>
<tr>
<td></td>
<td>16F12</td>
<td>............</td>
<td>325</td>
<td>............</td>
<td>326</td>
<td>............A.</td>
</tr>
<tr>
<td></td>
<td>27A6</td>
<td>............</td>
<td>325</td>
<td>............</td>
<td>326</td>
<td>............S.</td>
</tr>
</tbody>
</table>

**FIG. 13H**
Group 2, continued

<table>
<thead>
<tr>
<th></th>
<th>H_CDR1</th>
<th>SEQ</th>
<th>H_CDR2</th>
<th>SEQ</th>
<th>H_CDR3</th>
<th>SEQ</th>
</tr>
</thead>
<tbody>
<tr>
<td>CONSENSUS</td>
<td>SFGMH</td>
<td>328</td>
<td>LIWNDGSNKYYADSVKG</td>
<td>329</td>
<td>AIAALYYGMDV</td>
<td>330</td>
</tr>
<tr>
<td>31G11</td>
<td>.Y...</td>
<td>333</td>
<td>...H...T...V.......</td>
<td>334</td>
<td>G...VA.......</td>
<td>335</td>
</tr>
<tr>
<td>28D6</td>
<td>......</td>
<td>328</td>
<td>.................</td>
<td>329</td>
<td>.................</td>
<td>330</td>
</tr>
<tr>
<td>28B12</td>
<td>......</td>
<td>328</td>
<td>.................</td>
<td>329</td>
<td>.................</td>
<td>330</td>
</tr>
<tr>
<td>22E2</td>
<td>......</td>
<td>328</td>
<td>.................</td>
<td>329</td>
<td>.................</td>
<td>330</td>
</tr>
<tr>
<td>16F12</td>
<td>......</td>
<td>328</td>
<td>...S...DE.......</td>
<td>336</td>
<td>.................</td>
<td>330</td>
</tr>
<tr>
<td>27A6</td>
<td>......</td>
<td>328</td>
<td>...S...D.........</td>
<td>338</td>
<td>.................</td>
<td>330</td>
</tr>
</tbody>
</table>

FIG. 13I
Group 3 (3 members)

<table>
<thead>
<tr>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td>ID</td>
</tr>
<tr>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSENSUS</td>
<td>SGSSNIGSKTVN 339</td>
<td>SNNRRPS 340</td>
<td>AAWDDSLNWW 341</td>
<td>YWMS 342</td>
<td>NIQKDGEKYYVDSVKG 343</td>
<td>ESNWGFAFDI 344</td>
<td>62</td>
</tr>
<tr>
<td>9B6</td>
<td>.. N.. 345</td>
<td>.... 340</td>
<td>.. 341</td>
<td>R... 346</td>
<td>..H......... 347</td>
<td>.. V 348</td>
<td></td>
</tr>
<tr>
<td>1A12</td>
<td>....... 339</td>
<td>.... 340</td>
<td>........ 341</td>
<td>NF.. 351</td>
<td>.......... 343</td>
<td>.......... 344</td>
<td></td>
</tr>
</tbody>
</table>

Group 4 (2 members)

<table>
<thead>
<tr>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td></td>
</tr>
<tr>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSENSUS</td>
<td>RASQIS YLN 352</td>
<td>AA SLQS 353</td>
<td>QQSYS PIT 354</td>
</tr>
<tr>
<td>25G4</td>
<td>.... I... 355</td>
<td>..A... 356</td>
<td>..A... 357</td>
</tr>
<tr>
<td>23B5</td>
<td>.... S... 358</td>
<td>..S... 359</td>
<td>..S... 360</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
<th>Seq</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ID</td>
<td>ID</td>
<td>ID</td>
<td></td>
</tr>
<tr>
<td>NO:</td>
<td>NO:</td>
<td>NO:</td>
<td></td>
</tr>
<tr>
<td>71</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONSENSUS</td>
<td>SYAMN 361</td>
<td>TISGSG NTYYADSVKG 362</td>
<td>KFVLMVYAMLKY 363</td>
</tr>
<tr>
<td>25G4</td>
<td>.... 361</td>
<td>....G.......... 364</td>
<td>.......... 363</td>
</tr>
<tr>
<td>23B5</td>
<td>.... 361</td>
<td>....D.......... 365</td>
<td>.......... 363</td>
</tr>
</tbody>
</table>

FIG. 13J
<table>
<thead>
<tr>
<th>Chain Name</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
<th>SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QSLTQPASVSGSPGQSTISC</td>
<td>TGTSSDVGGYNYVS</td>
<td>WYQQHPGKAPKLMIY</td>
<td></td>
</tr>
<tr>
<td>26E10.1</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>--------------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26E10</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>--------------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17C2.1</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>F--------------------------</td>
<td>A--S--</td>
<td>R--</td>
<td></td>
</tr>
<tr>
<td>17C2</td>
<td>V1-4</td>
<td>JL2</td>
<td></td>
<td>--------------------------</td>
<td>A--S--</td>
<td>R--</td>
<td></td>
</tr>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QSVLTQPPASGTPGQRVTISC</td>
<td>SGSSSNIGSNTVN</td>
<td>WYQLPGTAPKLIIY</td>
<td></td>
</tr>
<tr>
<td>9C9.1</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>--------------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9C9.2</td>
<td>V1-16</td>
<td>JL3</td>
<td></td>
<td>--------------------------</td>
<td>F</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>SYELTQPSSVSVPQQASITC</td>
<td>SGDKLGDKYYAC</td>
<td>WYQQKPQSPVLYI</td>
<td></td>
</tr>
<tr>
<td>31A4.2</td>
<td>V2-1</td>
<td>JL2</td>
<td></td>
<td>--------------------------</td>
<td>R--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>SYELTQPSSVSVPQQASITC</td>
<td>SGDKLGDKYYAC</td>
<td>WYQQKPQSPVLYI</td>
<td></td>
</tr>
<tr>
<td>25A7.1</td>
<td>V2-1</td>
<td>JL2</td>
<td></td>
<td>I--------------------------</td>
<td>R--</td>
<td>I--</td>
<td></td>
</tr>
</tbody>
</table>

**FIG. 15A**
<table>
<thead>
<tr>
<th>Chain Name</th>
<th>CDR2</th>
<th>FR3</th>
<th>CDR3</th>
<th>FR4</th>
<th>SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>26E10.1</td>
<td>EVSNRPS</td>
<td>GVSNRFSGSKSGNTASLTISGLQAEDADYYC</td>
<td>SSYTSS$V</td>
<td>FGGGTKLTVL</td>
<td>14</td>
</tr>
<tr>
<td>26E10</td>
<td>--------</td>
<td>------------------------</td>
<td>N-----T-M-</td>
<td>----------</td>
<td>270</td>
</tr>
<tr>
<td>17C2.1</td>
<td>--------</td>
<td>------------------------</td>
<td>N-----T-M-</td>
<td>----------</td>
<td>23</td>
</tr>
<tr>
<td>17C2</td>
<td>--------</td>
<td>------------------------</td>
<td>-----TNM-</td>
<td>----------</td>
<td>271</td>
</tr>
<tr>
<td>9C9.1</td>
<td>SNNQRPS</td>
<td>GVPDRFSGSKSGTSAISGLQSEDEADYYC</td>
<td>AAWDSSLN$V</td>
<td>FGGGTKLTVL</td>
<td>29</td>
</tr>
<tr>
<td>9C9.2</td>
<td>------R--</td>
<td>------------------------</td>
<td>--------W-</td>
<td>----------</td>
<td>272</td>
</tr>
<tr>
<td>31A4.2</td>
<td>QDSKRPS</td>
<td>GIPERFSGSNSGNTATLTISGTQAMDEADYYC</td>
<td>QAWDSSTVV</td>
<td>FGGGTKLTVL</td>
<td>274</td>
</tr>
<tr>
<td>31A4.2</td>
<td>-NT-W-L</td>
<td>------------------------</td>
<td>--------V-</td>
<td>----------</td>
<td>275</td>
</tr>
<tr>
<td>25A7.1</td>
<td>QDSKRPS</td>
<td>GIPERFSGSNSGNTATLTISGTQAMDEADYYC</td>
<td>QAWDSSTAVV</td>
<td>FGGGTKLTVL</td>
<td>276</td>
</tr>
</tbody>
</table>

**FIG. 15B**
<table>
<thead>
<tr>
<th>Chain Name</th>
<th>V</th>
<th>D</th>
<th>J</th>
<th>FR1</th>
<th>CDR1</th>
<th>FR2</th>
<th>SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLVQSGAEVKPGASVKSCKAS</td>
<td>GYTFTSYGIS</td>
<td>WVRQAPGQGLEWMG</td>
<td>47</td>
</tr>
<tr>
<td>26E10.1</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>---------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>49</td>
</tr>
<tr>
<td>26E10</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>---------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>49</td>
</tr>
<tr>
<td>17C2.1</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>---------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>57</td>
</tr>
<tr>
<td>17C2</td>
<td>VH1-18</td>
<td>JH6B</td>
<td></td>
<td>---------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>57</td>
</tr>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>EVQLVESGGGLVQPGGSLRLSCAAS</td>
<td>GFTFSSYWMS</td>
<td>WVRQAPGKLEGWVA</td>
<td>63</td>
</tr>
<tr>
<td>9C9.1</td>
<td>VH3-7</td>
<td>D7-</td>
<td>27</td>
<td>---------------------</td>
<td>VV-</td>
<td></td>
<td>64</td>
</tr>
<tr>
<td>9C9.2</td>
<td>VH3-7</td>
<td>D7-</td>
<td>27</td>
<td>---------------------</td>
<td>VV-</td>
<td></td>
<td>401</td>
</tr>
<tr>
<td>Germline</td>
<td></td>
<td></td>
<td></td>
<td>QVQLQESGPGLVPSLTLTCTVS</td>
<td>GGSISYYWS</td>
<td>WIRQPPGKLEGWIG</td>
<td>400</td>
</tr>
<tr>
<td>25A7.1</td>
<td>VH4-59</td>
<td></td>
<td>19</td>
<td>---------------------</td>
<td>T-</td>
<td></td>
<td>278</td>
</tr>
</tbody>
</table>

**FIG. 15C**
<table>
<thead>
<tr>
<th>Chain Name</th>
<th>FR3</th>
<th>CDR3</th>
<th>FR4</th>
<th>SEQ ID NO:</th>
</tr>
</thead>
<tbody>
<tr>
<td>26E10.1</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>26E10</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>17C2.1</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>17C2.2</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>9C9.1</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>9C9.2</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
<tr>
<td>25A7.1</td>
<td>-----</td>
<td>------</td>
<td>-----</td>
<td>-------------</td>
</tr>
</tbody>
</table>

**FIG. 15D**
FIG. 20C
21B12
Light Chain
ESALTQPASV SGSPQGSITI SCTCTSSDVG CYNQVWNYQH HPFQA PKIMI YF/NSNRPSGVR SNRFSGSGSG
NTASLTISGL QAEKDAAYC NYSTIRNYVFGGPKLTVGQP KAAPKSVL EPPSSEELQA WAKATVLCLIS
DPYPGAVTVA WKAASQPVKA GVEETTQSVK SNNKAAASTY LSLIEEQWKS HKSSQCVTH EGSTVEKTV
PTECS (SEQ ID NO:297)

Heavy Chain
EVQIVQSGAC VKPAGAVKVK SCKASGYTLT SGISGWRQAQ PQGIEWEEMW VSFYGNTNYQ AQKLLQSGCTM
TTDDSTTAYV MELSRADDD TAVVYCARGY GMDWQCGTT VTVSSASIKG FSFLAFPSIG KTDSGTAAL
GCWVKYDFPEPVTSVWYSSA LTPSCVHTPA VLQGSSLIVSL SVTVFSPSS LQGQTVICNV YHKPSNHKVD
KVEFKSCGA DRYVHHHHHHH (SEQ ID NO:298)

31H4
Light Chain
ESVILQPSPSV SGAPQSRVTI SCTCQSSNIG AGYOQWNYQQ LPFTAPKLLI SGNSNRPSGV PDERFSGSGSG
TSALALTGL QAEEADYYC QSYDDLSGLS VPQGKTKLTV LQPKFKAAPSV TLFSSEELQ PANKAATLC
ISDYPQAVT VAWSADQV KSQNNKYAA SLYSLTPEGW KSJRSNYCQV TEGSTVERT
VAPTECS (SEQ ID NO:299)

Heavy Chain
EVQIVESGGG LWFKGSSLRL SCAASGFTPS SYSMNWRQAQ PFGKIDEWSIS ISSSSSYISY ADSVKGAPTI
SRNQANSL QMNLAIAED TAVVFCARDY DPWSAYKDAF DWPCQMTATT VSSASTKSFS VPEFLAPSAES
TSSQTAPALGC LWKDFEFPSF VTVSMQSGALT SQTVIFAPVL QSGSMQKSLS VTVFSPSSLG QTQYICNH
KPSKTV(K) VEFLSACDVEGSHHHHHH (SEQ ID NO:300)

31A4
Light Chain
ALQSVLQPSPP SASGTPQSRV TICSQSSSNJ ISGNSVNYQQ QLPFTAKPIL IYYSNQRESG
VFDRFSGSGS GTSASLAIQ LQGSEQ AYYCAYCAVWDSDLNG WFGGKTLTV LQPKFKAAPSV
TFLFSSEELQ PANKAATLC LISDYPQAVTVAWSADQV SVKAGVETTP VKQSNNKYAA
SYYLSLTPEQ WKSJRSNYCQV TEGSTVERK VAPTECS (SEQ ID NO:301)

Heavy Chain
QVQLWQQWAG LKKPSETIQL TCAYGGSPS SYWMWRIQFH PFGKILEWIGE INHSGMRDYK EPLKSKRTIS
VDTSKQFLKL QNYTTRAAAD AYVYQGQLE VDFSYQMTLV TSSASTK SGVFPLAFPG KSQSGQTVAA
LQKLVKDFPEPTVSANNSA ATLCQVHTFP AVLQSGGLYS HSSVTVSFLS SQTVICYQV YHKPSNTKV
DKVEFKSCGA DRYVHHHHHHH (SEQ ID NO:302)
<table>
<thead>
<tr>
<th>DIN 3.1</th>
<th>DIN 4 counters</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>LOW COUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>2500</td>
<td>61</td>
<td>62</td>
<td>63</td>
<td>64</td>
<td>65</td>
</tr>
<tr>
<td>200</td>
<td>2000</td>
<td>56</td>
<td>57</td>
<td>58</td>
<td>59</td>
<td>51</td>
</tr>
<tr>
<td>160</td>
<td>1600</td>
<td>52</td>
<td>53</td>
<td>54</td>
<td>55</td>
<td>49</td>
</tr>
<tr>
<td>120</td>
<td>1200</td>
<td>48</td>
<td>49</td>
<td>50</td>
<td>51</td>
<td>45</td>
</tr>
<tr>
<td>100</td>
<td>1000</td>
<td>44</td>
<td>45</td>
<td>46</td>
<td>47</td>
<td>42</td>
</tr>
<tr>
<td>80</td>
<td>800</td>
<td>40</td>
<td>41</td>
<td>42</td>
<td>43</td>
<td>38</td>
</tr>
<tr>
<td>60</td>
<td>600</td>
<td>36</td>
<td>37</td>
<td>38</td>
<td>39</td>
<td>35</td>
</tr>
<tr>
<td>40</td>
<td>400</td>
<td>32</td>
<td>33</td>
<td>34</td>
<td>35</td>
<td>32</td>
</tr>
<tr>
<td>30</td>
<td>300</td>
<td>28</td>
<td>29</td>
<td>30</td>
<td>31</td>
<td>29</td>
</tr>
<tr>
<td>25</td>
<td>250</td>
<td>24</td>
<td>25</td>
<td>26</td>
<td>27</td>
<td>25</td>
</tr>
<tr>
<td>20</td>
<td>200</td>
<td>20</td>
<td>21</td>
<td>22</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>16</td>
<td>160</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>17</td>
</tr>
<tr>
<td>12</td>
<td>120</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>8</td>
<td>80</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>60</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>4</td>
<td>40</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>30</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

**FIG. 23C**

<table>
<thead>
<tr>
<th>DIN 3.1</th>
<th>DIN 4 counters</th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>LOW COUNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>250</td>
<td>2500</td>
<td>61</td>
<td>62</td>
<td>63</td>
<td>64</td>
<td>65</td>
</tr>
<tr>
<td>200</td>
<td>2000</td>
<td>56</td>
<td>57</td>
<td>58</td>
<td>59</td>
<td>51</td>
</tr>
<tr>
<td>160</td>
<td>1600</td>
<td>52</td>
<td>53</td>
<td>54</td>
<td>55</td>
<td>49</td>
</tr>
<tr>
<td>120</td>
<td>1200</td>
<td>48</td>
<td>49</td>
<td>50</td>
<td>51</td>
<td>45</td>
</tr>
<tr>
<td>100</td>
<td>1000</td>
<td>44</td>
<td>45</td>
<td>46</td>
<td>47</td>
<td>42</td>
</tr>
<tr>
<td>80</td>
<td>800</td>
<td>40</td>
<td>41</td>
<td>42</td>
<td>43</td>
<td>38</td>
</tr>
<tr>
<td>60</td>
<td>600</td>
<td>36</td>
<td>37</td>
<td>38</td>
<td>39</td>
<td>35</td>
</tr>
<tr>
<td>40</td>
<td>400</td>
<td>32</td>
<td>33</td>
<td>34</td>
<td>35</td>
<td>32</td>
</tr>
<tr>
<td>30</td>
<td>300</td>
<td>28</td>
<td>29</td>
<td>30</td>
<td>31</td>
<td>29</td>
</tr>
<tr>
<td>25</td>
<td>250</td>
<td>24</td>
<td>25</td>
<td>26</td>
<td>27</td>
<td>25</td>
</tr>
<tr>
<td>20</td>
<td>200</td>
<td>20</td>
<td>21</td>
<td>22</td>
<td>23</td>
<td>21</td>
</tr>
<tr>
<td>16</td>
<td>160</td>
<td>16</td>
<td>17</td>
<td>18</td>
<td>19</td>
<td>17</td>
</tr>
<tr>
<td>12</td>
<td>120</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
<td>13</td>
</tr>
<tr>
<td>10</td>
<td>100</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>8</td>
<td>80</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>60</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>50</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>6</td>
</tr>
<tr>
<td>4</td>
<td>40</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>30</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>20</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>1</td>
<td>10</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>2</td>
</tr>
</tbody>
</table>

**FIG. 23C**
FIG. 23D
FIG. 26
FIG. 28A
1

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

RELATED APPLICATIONS


SEQUENCE LISTING AND TABLES IN ELECTRONIC FORMAT

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled Sequence_Listing_APMOL-003D2.txt, created and last saved Sep. 30, 2011 which is 296,708 bytes in size, and replaced by a file entitled APMOL005C11REPLACEMENT.TXT created Mar. 7, 2014 and last modified May 7, 2014, which is 313,027 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety. The present application is being filed along with a collection of Tables in electronic format. The collection of Tables is provided as a file entitled Table_35-1-4_APMOL-003D2.txt, created and last saved on Sep. 30, 2011, which is 2,024,359 bytes in size. The information in the electronic format of the collection of Tables is incorporated herein by reference in its entirety.

LENGTHY TABLES

The patent contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (http://seqdata.uspto.gov/\pageRequest\=docDetail\&DocID=US08859741B2). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

FIELD OF THE INVENTION

The present invention relates to antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 (PCSK9) and methods of using and making the antigen binding proteins.

BACKGROUND OF VARIOUS EMBODIMENTS

Proprotein convertase subtilisin kexin type 9 (PCSK9) is a serine protease involved in regulating the levels of the low density lipoprotein receptor (LDLR) protein (Horton et al., 2007; Seidah and Prat, 2007). In vitro experiments have shown that adding PCSK9 to HepG2 cells lowers the levels of cell surface LDLR (Benjannet et al., 2004; Lagace et al., 2006; Maxwell et al., 2005; Park et al., 2004). Experiments with mice have shown that increasing PCSK9 protein levels decreases levels of LDLR protein in the liver (Benjannet et al., 2004; Lagace et al., 2006; Maxwell et al., 2005; Park et al., 2004), while PCSK9 knockout mice have increased levels of the catalytic domain. Additionally, various human PCSK9 mutations that result in either increased or decreased levels of plasma LDLR have been identified (Kadowki et al., 2006; Zhao et al., 2006). PCSK9 has been shown to directly interact with the LDLR protein, be endocytosed along with the LDLR, and co-immunofluoresce with the LDLR throughout the endosomal pathway (Lagace et al., 2006). Degradation of the LDLR by PCSK9 has not been observed and the mechanism through which it lowers extracellular LDLR protein levels is uncertain.

PCSK9 is a prohormone-proprotein convertase in the subtilisin (S8) family of serine proteases (Seidah et al., 2003). Humans have nine prohormone-proprotein convertases that can be divided between the S8A and S8B subfamilies (Rawlings et al., 2006). Furin, PC1/PC3, PC2, PC4, PCs/PC6 and PC7/PC8/PC9/PC10 are classified in subfamily S8B. Crystal and NMR structures of different domains from mouse furin and PC1 reveal subtilisin-like pro- and catalytic domains, and a P domain directly C-terminal to the catalytic domain (Henrich et al., 2003; Tangrea et al., 2002). Based on the amino acid sequence similarity within this subfamily, all seven members are predicted to have similar structures (Henrich et al., 2005). SKI-1/SIP and PCSK9 are classified in subfamily S8A. Sequence comparisons with these proteins also suggest the presence of subtilisin-like pro- and catalytic domains (Nam et al., 1998; Seidah et al., 2003; Seidah et al., 1999). In these proteins the amino acid sequence C-terminal to the catalytic domain is more variable and does not suggest the presence of a P domain.

Prohormone-proprotein convertases are expressed as zymogens and they mature through a multi step process. The function of the pro-domain in this process is two-fold. The pro-domain first acts as a chaperone and is required for proper folding of the catalytic domain (Ikemura et al., 1987). Once the catalytic domain is folded, autocatalysis occurs between the pro-domain and catalytic domain. Following this initial cleavage reaction, the pro-domain remains bound to the catalytic domain where it then acts as an inhibitor of catalytic activity (Fu et al., 2000). When conditions are correct, maturation proceeds with a second autocatalytic event at a site within the pro-domain (Anderson et al., 1997). After this second cleavage event occurs the pro-domain and catalytic domain dissociate, giving rise to an active protease.

Autocatalysis of the PCSK9 zymogen occurs between Gin152 and Ser153 (VFAg/SIP) (Naureckiene et al., 2003), and has been shown to be required for its secretion from cells (Seidah et al., 2003). A second autocatalytic event at a site within PCSK9’s pro-domain has not been observed. Purified PCSK9 is made up of two species that can be separated by non-reducing SDS-PAGE; the pro-domain at 17 Kd, and the catalytic plus C-terminal domains at 65 Kd. PCSK9 has not been isolated without its inhibitory pro-domain, and measurements of PCSK9’s catalytic activity have been variable (Naureckiene et al., 2003; Seidah et al., 2003).
SUMMARY OF VARIOUS EMBODIMENTS

In some embodiments, the invention comprises an antigen binding protein to PCSK9.

In some aspects, the invention comprises an isolated antigen binding protein that binds PCSK9 comprising: A) one or more heavy chain complementary determining regions (CDRHs) selected from the group consisting of: (i) a CDRH1 from a CDRH1 in a sequence selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (ii) a CDRH2 from a CDRH2 in a sequence selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (iii) a CDRH3 from a CDRH3 in a sequence selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (iv) a CDRH of (i), (ii), and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than two amino acids; B) one or more light chain complementary determining regions (CLDRs) selected from the group consisting of: (i) a CLDR1 from a CLDR1 in a sequence selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; (ii) a CLDR2 from a CLDR2 in a sequence selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; (iii) a CLDR3 from a CLDR3 in a sequence selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; (iv) a CDR of (i), (ii), and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than four amino acids; or C) one or more light chain CDRs of (A) and one or more heavy chain CDRs of (B). In some embodiments, the antigen binding protein comprises a heavy chain variable region (VH) having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60, and/or the light chain variable region (VL) having at least 80% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; or (v) a CDR of (i), (ii), and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than four amino acids; and (vi) a CDR of (i), (ii), and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than two amino acids. In some embodiments, the CDR of a V (i) is selected from at least one of the group consisting of: (i) a CDRH1 amino acid sequence of the CDRH1 amino acid sequence in SEQ ID NO: 67; (ii) a CDRH2 amino acid sequence of the CDRH2 amino acid sequence in SEQ ID NO: 67; (iii) a CDRH3 amino acid sequence of the CDRH3 amino acid sequence in SEQ ID NO: 67; and (iv) a CDRH of (i), (ii), and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than two amino acids; and (v) a CDRL1 amino acid sequence of the CDRL1 amino acid sequence in SEQ ID NO: 12; (vi) a CDRL2 amino acid sequence of the CDRL2 amino acid sequence in SEQ ID NO: 12; (vii) a CDRL3 amino acid sequence of the CDRL3 amino acid sequence in SEQ ID NO: 12; and (viii) a CDRL of (i), (ii), and (iii) that contains one or more amino acid substitutions, deletions or insertions of no more than two amino acids; and (ix) one or more heavy chain CDRs of (A) and one or more light chain CDRs of (B). In some embodiments, the invention comprises an isolated antigen binding protein that specifically binds to an epitope that is bound by any of the ABPs disclosed herein. In some aspects, the invention comprises an isolated antigen binding protein that binds PCSK9, wherein the antigen binding protein comprises: A) one or more heavy chain CDRs (CDRHs) selected from at least one of the group consisting of: (i) a CDRH1 with at least 80% sequence identity to a CDRH1 in one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (ii) a CDRH2 with at least 80% sequence identity to a CDRH2 in one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; and (iii) a CDRH3 with at least 80% sequence identity to a CDRH3 in
one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (b) one or more light chain CDRLs (CDRL(L)s) selected from at least one of the group consisting of: (i) a CDRL(L) with at least 80% sequence identity to a CDRL(L) in one of the sequences selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; (ii) a CDRL(L) with at least 80% sequence identity to a CDRL(L) in one of the sequences selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; and (iii) a CDRL(L) with at least 80% sequence identity to a CDRL(L) in one of the sequences selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; or C) one or more heavy chain CDRLs of A) or one or more light chain CDRLs of B).

In some embodiments, the antigen binding protein comprises: A) one or more CDRLs selected from at least one of the group consisting of: (i) a CDRL1 with at least 80% sequence identity to a CDRL1 in one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; (ii) a CDRL2 with at least 80% sequence identity to a CDRL2 in one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; and (iii) a CDRL3 with at least 80% sequence identity to a CDRL3 in one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; or B) one or more CDRLs selected from at least one of the group consisting of: (i) a CDRL1 with at least 80% sequence identity to a CDRL1 in one of the sequences selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; (ii) a CDRL2 with at least 80% sequence identity to a CDRL2 in one of the sequences selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; and (iii) a CDRL3 with at least 80% sequence identity to a CDRL3 in one of the sequences selected from the group consisting of SEQ ID NO: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; or C) one or more heavy chain CDRLs of A) and one or more light chain CDRLs of B).

In some aspects, the invention comprises an isolated antigen binding protein comprising a light chain having the amino acid sequence selected from the group consisting of: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46; or D) one or more CDRLs selected from at least one of the group consisting of: (i) a CDRL1 with at least 80% sequence identity to a CDRL1 in one of the sequences selected from the group consisting of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60; or E) one or more light chain CDRLs of B).

In some aspects, the invention comprises an isolated antigen binding protein comprising a light chain having a 30 amino acid region that is bound by at least one of the antigen binding proteins disclosed herein. In some embodiments, the isolated antigen binding protein further comprises a heavy chain having the amino acid sequence selected from the group consisting of: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60. In some embodiments, the isolated antigen binding protein is isolated from a cell, tissue, or other source, or is recombinantly produced. In some embodiments, the isolated antigen binding protein is a monovalent antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof. In some embodiments, the isolated antigen binding protein is a Fab fragment, a Fab' fragment, a (Fab')2 fragment, a Fv fragment, a diabody, a single chain antibody fragment, or a single chain antibody fragment-like molecule. In some embodiments, the isolated antigen binding protein is a humanized antibody. In some embodiments, the isolated antigen binding protein is a monoclonal antibody. In some embodiments, the isolated antigen binding protein is isolated from a cell, tissue, or other source, or is recombinantly produced. In some embodiments, the isolated antigen binding protein is a monovalent antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof. In some embodiments, the isolated antigen binding protein is a Fab fragment, a Fab' fragment, a (Fab')2 fragment, a Fv fragment, a diabody, a single chain antibody fragment, or a single chain antibody fragment-like molecule. In some embodiments, the isolated antigen binding protein is isolated from a cell, tissue, or other source, or is recombinantly produced.
protein is coupled to a labeling group. In some embodiments, the isolated antigen binding protein competes for binding to PCSK9 with an antigen binding protein described herein. In some embodiments, the isolated antigen binding protein is a monovalent antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof. In some embodiments, the isolated antigen binding protein is a Fab fragment, a Fab' fragment, a F(ab)2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule. In some embodiments, the isolated antigen binding protein is coupled to a labeling group. In some embodiments, the isolated antigen binding protein reduces binding of PCSK9 to LDLR. In some embodiments, the isolated antigen binding protein the antigen binding protein decreases an amount of LDL present in a subject when administered to the subject. In some embodiments, the isolated antigen binding protein decreases an amount of serum cholesterol present in a subject when administered to the subject. In some embodiments, the isolated antigen binding protein increases an amount of LDLR present in a subject when administered to the subject.

In some aspects, the invention comprises a vector comprising a nucleic acid molecule as described herein. In some embodiments, the invention comprises a host cell comprising a nucleic acid molecule as described herein.

In some aspects, the invention comprises an isolated antigen binding protein that competes for binding to PCSK9 with an antigen binding protein disclosed herein. In some aspects, the invention comprises a nucleic acid molecule encoding the antigen binding protein according disclosed herein.

In some aspects, the invention comprises a pharmaceutical composition comprising at least one antigen binding protein described herein. In some aspects, the invention comprises a method for treating or preventing a condition associated with elevated serum cholesterol levels in a subject, comprising administering to a subject an effective amount of at least one isolated antigen binding protein disclosed herein.

In some aspects, the invention comprises a method of inhibiting binding of PCSK9 to LDLR in a subject comprising administering an effective amount of at least one antigen binding protein disclosed herein.

In some aspects, the invention comprises an antigen binding protein that selectively binds to PCSK9, wherein the antigen binding protein binds to PCSK9 with a K_d that is smaller than 100 pM.

In some aspects, the invention comprises a method for treating or preventing a condition associated with elevated serum cholesterol levels in a subject, the method comprising administering to a subject an effective amount of at least one isolated antigen binding protein as disclosed herein.

In some aspects, the invention comprises a method of lowering serum cholesterol level in a subject, the method comprising administering to a subject an effective amount of at least one isolated antigen binding protein as disclosed herein, simultaneously or sequentially with an agent that elevates the availability of LDLR protein.

In some aspects, the invention comprises a method of increasing LDLR protein level in a subject, the method comprising administering to a subject an effective amount of at least one isolated antigen binding protein as disclosed herein.

In some aspects, the invention comprises a method of increasing LDLR protein levels in a subject, the method comprising administering to a subject an effective amount of at least one isolated antigen binding protein as disclosed herein simultaneously or sequentially with an agent that elevates the availability of LDLR protein.

In some aspects, the invention comprises a pharmaceutical composition comprising an ABP as disclosed herein and an agent that elevates the availability of LDLR protein levels. In some embodiments, the agent that elevates the availability of LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosvastatin, simvastatin, and some combination thereof.

In some aspect, the invention comprises a method of making the antigen binding protein as described herein, comprising the step of preparing said antigen binding protein from a host cell that secretes said antigen binding protein.

In some aspects, the invention comprises a pharmaceutical composition comprising at least one antigen binding protein as described herein and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition further comprises an additional active agent. In some embodiments, said additional active agent is selected from the group consisting of a radioisotope, radionuclide, a toxin, or a therapeutic and a chemotherapeutic group.

In some aspects, the invention comprises a method for treating or preventing a condition associated with an elevated serum cholesterol level in a patient. The method comprises administering to a patient in need thereof an effective amount of at least one isolated antigen binding protein as disclosed herein. In some embodiments, the condition is hypercholesterolemia.

In some aspects, the invention comprises a method of inhibiting binding of PCSK9 to LDLR in a patient comprising administering an effective amount of at least one antigen binding protein according as described herein.

In some aspect, the invention comprises an antigen binding protein that binds to PCSK9 with a K_d that is smaller than 100 pM. In some embodiments, the antigen binding protein binds with a K_d that is smaller than 10 pM. In some embodiments, the antigen binding protein binds with a K_d that is less than 5 pM.

In some aspects, the invention comprises a method for treating or preventing a condition associated with elevated serum cholesterol levels in a subject, said method comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding protein described herein simultaneously or sequentially with an agent that elevates the availability of LDLR protein. In some embodiments, the agent that elevates the availability of LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combination thereof.

In some aspects, the invention comprises a method of lowering the serum cholesterol level in a subject. The method comprises administering to a subject an effective amount of at least one isolated antigen binding protein as described herein.

In some aspects, the invention comprises a method of lowering serum cholesterol levels in a subject comprising administering to a subject an effective amount of at least one isolated antigen binding protein, as described herein, simultaneously or sequentially with an agent that elevates the
availability of LDLR protein. In some embodiments, the agent that elevates the availability of LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combination thereof.

In some aspects, the invention comprises a method of increasing LDLR protein levels in a subject by administering to a subject an effective amount of at least one isolated antigen binding protein as provided herein.

In some aspects, the invention comprises a method of increasing LDLR protein levels in a subject by administering to a subject an effective amount of at least one isolated antigen binding protein, as described herein, simultaneously or sequentially with an agent that elevates the availability of LDLR protein. In some embodiments, the agent that elevates the availability of LDLR protein comprises a statin. In some embodiments, the statin is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and some combination thereof.

In some aspects, the invention comprises a neutralizing antibody that binds to PCSK9 and reduces a low density lipoprotein receptor (LDLR) lowering effect of PCSK9 on LDLR. In some embodiments, the antibody specifically binds to PCSK9. In some embodiments, the antibody binds to the catalytic domain of PCSK9. In some embodiments, the antibody binds to an epitope within residues 31-447 of SEQ ID NO: 3. In some embodiments, the antibody binds to PCSK9 having an amino acid sequence that is at least 90% identical to SEQ ID NO: 3.

In some aspects, the invention comprises a neutralizing antigen binding protein that binds to PCSK9, wherein the antigen binding protein binds to PCSK9 at a location within residues 31-447 of SEQ ID NO: 3. In some embodiments, when the antigen binding protein is bound to PCSK9, the antibody is positioned 8 angstroms or less from at least one of the following residues of PCSK9: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381. In some embodiments, the antibody is positioned 8 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or Q384. In some embodiments, the antibody is positioned 5 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or Q384.

In some embodiments, the antibody is positioned 5 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or Q384.

In some embodiments, the antibody is positioned 5 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or Q384. In some embodiments, the antibody is positioned 5 angstroms or less from at least one of the following residues of PCSK9: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, or Q384.
In some embodiments, the antibody is positioned 5 angstroms or less from at least one of the following residues of PCSK9: T468, R469, M470, A471, T472, R496, R499, E501, A502, Q503, R510, H512, F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, and E593 of SEQ ID NO: 3.

In some aspects, the invention comprises an isolated antigen binding protein. The antigen binding protein comprises: A) a CDRH1 of the CDRH1 sequence in SEQ ID NO: 89, a CDRH2 of the CDRH2 sequence in SEQ ID NO: 89, and B) a CDRL1 of the CDRL1 sequence in SEQ ID NO: 32, a CDRL2 of the CDRL2 sequence in SEQ ID NO: 32, and a CDRL3 of the CDRL3 sequence in SEQ ID NO: 32.

In some aspects, the invention comprises an isolated antigen binding protein that binds to a PCSK9 protein of SEQ ID NO: 1 where the binding between said isolated antigen binding protein and a variant PCSK9 protein is less than 50% of the binding between the isolated antigen binding protein and the PCSK9 protein of SEQ ID NO: 1 and/or SEQ ID NO: 303.

In some embodiments, the variant PCSK9 protein comprises at least one mutation of a residue at a position selected from the group consisting of or comprising 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, 129, 311, 337, 519, 521, and 554, as shown in SEQ ID NO: 1. In some embodiments, the at least one mutation selected from the group consisting or comprising of R207E, D208R, E181R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, A390R, A413R, and E582R.

In some embodiments, the at least one mutation is selected from the group consisting of D162R, R164E, E167R, S123R, E129R, A313R, D313R, D373R, R519E, H521R, and Q545R.

In some aspects, the invention comprises an antigen binding protein that binds to a PCSK9 protein of SEQ ID NO: 303 in a first manner and binds to a variant of PCSK9 in a second manner. The PCSK9 variant has at least one point mutation at a position selected from the group consisting or comprising of 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, 129, 311, 337, 519, 521, and 554 of SEQ ID NO: 303 and/or SEQ ID NO: 1. In some embodiments, the first manner comprises a first EC50, a first Bmax, or a first EC50 and a first Bmax. In some embodiments, the second manner comprises a second EC50, a second Bmax, or a second EC50 and a second Bmax. The value for the first manner is different from the value for the second manner. In some embodiments, the first manner comprises a first EC50, wherein the second manner involves a second EC50, and wherein the point mutation is selected from the group consisting or comprising: R207E, D208R, E181R, R185E, R439E, E513R, V538R, E539R, T132R, S351R, A390R, A413R, and E582R. In some embodiments, the first EC50 is at least 20% different from the second EC50. In some embodiments, the first EC50 is at least 50% different from the second EC50. In some embodiments, the first EC50 is a larger numerical value than the first EC50. In some embodiments, the first EC50 is determined by a multiplex bead binding assay.

In some embodiments, the second EC50 is greater than 1 um. In some embodiments, the antigen binding protein is a neutralizing antigen binding protein. In some embodiments, the neutralizing antigen binding protein is a competitive neutralizing antigen binding protein. In some embodiments, the neutralizing antigen binding protein is a non-competitive neutralizing antigen binding protein. In some embodiments, the first manner comprises a first Bmax and the second manner comprises a second Bmax that is different from the first Bmax. The PCSK9 variant has at least one point mutation selected from the group consisting or comprising: D162R, R164E, E167R, S123R, E129R, A313R.
In some embodiments, the invention comprises an isolated antigen binding protein that binds to a PCSK9 protein comprising a crystallized PCSK9 protein and an antigen binding protein that binds to PCSK9. The composition comprises the crystallized PCSK9 protein is such that the three dimensional structure of the PCSK9 protein can be determined to a resolution of about 2.2 angstroms or better. In some embodiments, the antigen binding protein is an antibody or a fragment thereof.

In some aspects, the invention comprises an isolated antigen binding protein comprising a heavy chain complementary determining region (CDRH1) selected from at least one of the group consisting of: (i) a CDRH1 selected from the CDRH1 within the sequences selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49, (ii) a CDRH1 that differs in amino acid sequence from the CDRH1 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRH2 amino acid sequence selected from the group consisting of X1,X8,X15,X16,X6,X10,X19,X17 (SEQ ID NO: 408), wherein X1 is selected from the group consisting of Y, S, I, and no amino acid, X8 is selected from the group consisting of F, S, and N, X15 is selected from the group consisting of S and N, X16 is selected from the group consisting of T, S, and N, X17 is selected from the group consisting of T, S, and N, X19 is selected from the group consisting of T, S, and N, X20 is selected from the group consisting of I, M, and T, W, X1 is selected from the group consisting of S, N and H, (ii) a light chain complementary determining region (CDRL1) selected from at least one of the group consisting of: (i) a CDRL1 selected from the CDRL1 within the sequences selected from the group consisting of SEQ ID NOs: 12, 32, 35, and 23, (ii) a CDRL1 that differs in amino acid sequence from the CDRL3 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRL1 amino acid sequence selected from the group consisting of X1,X8,X15,X16,X6,X10,X19,X17 (SEQ ID NO: 407), wherein X1 is selected from the group consisting of T and no amino acid, X8 is selected from the group consisting of G and S, X15 is selected from the group consisting of S, T, and G, X16 is selected from the group consisting of S, X20 is selected from the group consisting of N, D, and S, X19 is selected from the group consisting of T and N, X17 is selected from the group consisting of G and I, X16 is selected from the group consisting of A and G, X19 is selected from the group consisting of G, Y, S, and N, X17 is selected from the group consisting of D, T, S, and F, X15 is selected from the group consisting of Y and N, X16 is selected from the group consisting of V, X17 is selected from the group consisting of S, N, and H. One of skill in the art will appreciate that a single ABP or antibody can meet one or more of the above options and still fall within the described invention for this embodiment.

In some aspects, the invention comprises an isolated antigen binding protein that binds to PCSK9, the antigen binding protein comprising: A) a heavy chain complementary determining region (CDRH1) selected from at least one of the group consisting of the following: (i) a CDRH1 selected from the CDRH1 within the sequences selected from the group consisting of SEQ ID NOs: 67, 79, 89, and 49, (ii) a CDRH2 that differs in amino acid sequence from the CDRH2 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRH2 amino acid sequence selected from the group consisting of X1,X8,X15,X16,X6,X10,X19,X17 (SEQ ID NO: 408), wherein X1 is selected from the group consisting of W, S, I, and no amino acid, X8 is selected from the group consisting of F, S, and N, X15 is selected from the group consisting of Y, S, D, and H, X16 is selected from the group consisting of N, S, M, and G, X17 is selected from the group consisting of T, I, and E, X19 is selected from the group consisting of N, S, H, and D, X15 is selected from the group consisting of G, Y, S, and N, X16 is selected from the group consisting of T, I, and E, X17 is selected from the group consisting of N, S, Y, and D, X15 is selected from the group consisting of Y, X16 is selected from the group consisting of T and N, X17 is selected from the group consisting of G and S, (ii) a light chain complementary determining region (CDRL1) selected from at least one of the group consisting of the following: (i) a CDRL1 selected from the CDRL1 within the sequences selected from the group consisting of SEQ ID NOs: 12, 32, 35, and 23, (ii) a CDRL1 that differs in amino acid sequence from the CDRL3 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRL1 amino acid sequence selected from the group consisting of X1,X8,X15,X16,X6,X10,X19,X17 (SEQ ID NO: 407), wherein X1 is selected from the group consisting of T and no amino acid, X8 is selected from the group consisting of G and S, X15 is selected from the group consisting of S, T, and G, X16 is selected from the group consisting of S, X17 is selected from the group consisting of G and I, X16 is selected from the group consisting of A and G, X17 is selected from the group consisting of G, Y, S, and N, X16 is selected from the group consisting of D, T, S, and F, X15 is selected from the group consisting of Y and N, X17 is selected from the group consisting of V, X16 is selected from the group consisting of S, N, and H. One of skill in the art will appreciate that a single ABP or antibody can meet one or more of the above options and still fall within the described invention for this embodiment.
(SEQ ID NO: 409), wherein X₁ is selected from the group consisting of G, E, S, and D, X₂ is selected from the group consisting of N, V, and Y, X₃ is selected from the group consisting of S and N, X₄ is selected from the group consisting of I, Q, and K, X₅ is selected from the group consisting of R, X₆ is selected from the group consisting of F, X₇ is selected from the group consisting of W, and X₈ is selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid. In some embodiments, X₁₀ can be selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid. In some embodiments, X₁₀ can be selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid.

In some aspects, the invention comprises an isolated antigen binding protein that binds PCSK9, the antigen binding protein comprising: A) a heavy chain complimentary determining region (CDRH) selected from at least one of the group consisting of the following: (i) a CDRH3 selected from the CDRH3 within the sequences selected from the group consisting of (SEQ ID NO: 410), wherein X₁ is selected from the group consisting of Y, N, and W, X₂ is selected from the group consisting of S and D, X₃ is selected from the group consisting of S and T, X₄ is selected from the group consisting of S and I, X₅ is selected from the group consisting of W, A, and no amino acid, X₆ is selected from the group consisting of S, L, and no amino acid, X₇ is selected from the group consisting of A, Y, and no amino acid, X₈ is selected from the group consisting of Y, Q, and no amino acid, X₉ is selected from the group consisting of G, Y, and L, X₁₀ is selected from the group consisting of Y, D, and V, X₁₁ is selected from the group consisting of G, A, and P, and X₁₂ is selected from the group consisting of M and F, X₁₃ is selected from the group consisting of D, X₁₄ is selected from the group consisting of F and Y, and X₁₅ is selected from the group consisting of N, F, and no amino acid, X₁₆ is selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid, X₁₆ is selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid.

In some aspects, the invention comprises an isolated antigen binding protein that binds PCSK9, the antigen binding protein comprising: A) a heavy chain complimentary determining region (CDRH) selected from at least one of the group consisting of the following: (i) a CDRH3 selected from the CDRH3 within the sequences selected from the group consisting of (SEQ ID NO: 411), wherein X₁ is selected from the group consisting of Q, A, G, and no amino acid, X₂ is selected from the group consisting of S, V, T, and no amino acid, X₃ is selected from the group consisting of Y, N, and W, X₄ is selected from the group consisting of S and D, X₅ is selected from the group consisting of S and T, X₆ is selected from the group consisting of S and I, X₇ is selected from the group consisting of W, A, and no amino acid, X₈ is selected from the group consisting of S, L, and no amino acid, X₉ is selected from the group consisting of A, Y, and no amino acid, X₁₀ is selected from the group consisting of Y, Q, and no amino acid, X₁₁ is selected from the group consisting of G, Y, and L, X₁₂ is selected from the group consisting of Y, D, and V, X₁₃ is selected from the group consisting of G, A, and P, and X₁₄ is selected from the group consisting of M and F, X₁₅ is selected from the group consisting of D, X₁₆ is selected from the group consisting of F and Y, and X₁₇ is selected from the group consisting of N, F, and no amino acid. In some embodiments, X₂₀ can be selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid, X₁₂ is selected from the group consisting of S, L, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid, X₁₆ is selected from the group consisting of T and S, X₉ is selected from the group consisting of F, A, and no amino acid, X₁₀ is selected from the group consisting of W, A, and no amino acid, X₁₁ is selected from the group consisting of S, L, and no amino acid, X₁₂ is selected from the group consisting of A, Y, and no amino acid, X₁₃ is selected from the group consisting of Y, Q, and no amino acid, X₁₄ is selected from the group consisting of G, Y, and L, X₁₅ is selected from the group consisting of Y, D, and V, X₁₆ is selected from the group consisting of G, A, and P, and X₁₇ is selected from the group consisting of M and F, X₁₈ is selected from the group consisting of D, X₁₉ is selected from the group consisting of F and Y, and X₂₀ is selected from the group consisting of N, F, and no amino acid.
selected from the group consisting of SEQ ID NOs: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24. (ii) a CDRL2 that differs in amino acid sequence from the CDRL3 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRL2 amino acid sequence selected from the group consisting of X12-X15-X17-X14-X16 (SEQ ID NO: 415), wherein X1 is selected from the group consisting of E, and D, X2 is selected from the group consisting of V, I, M, L, F, and A, X3 is selected from the group consisting of S, T, A, and C, X4 is selected from the group consisting of N, and Q, X5 is selected from the group consisting of R, K, Q, and N, X6 is selected from the group consisting of P, and A, X7 is selected from the group consisting of S, T, A, and C.

In some aspects, the invention comprises an isolated antigen binding portion that binds PCSK9, the antigen binding protein comprising: (a) a heavy chain complementary determining region (CDRH3) selected from at least one of the group consisting of (i) a CDRH3 selected from the CDRH3 within the sequences selected from the group consisting of SEQ ID NOs: 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, and 58, (ii) a CDRH3 that differs in amino acid sequence from the CDRH3 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRH3 amino acid sequence selected from the group consisting of X12-X15-X17-X14-X16 (SEQ ID NO: 416), wherein X1 is selected from the group consisting of G, P, A and no amino acid, X2 is selected from the group consisting of Y, W, F, T, and S, X3 is selected from the group consisting of G, V, P, A, I, M, L, and F, X4 is selected from the group consisting of V, I, M, L, F, and A, X5 is selected from the group consisting of Y, W, F, T, and S, X6 is selected from the group consisting of G, V, P, A, I, M, L, and F, X7 is selected from the group consisting of V, I, M, L, F, and A, B) a light chain complementary determining region (CDRL) selected from at least one of the group consisting of: (i) a CDRL3 selected from the CDRL3 within the sequences selected from the group consisting of SEQ ID NOs: 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24, (ii) a CDRL3 that differs in amino acid sequence from the CDRL3 of (i) by an amino acid addition, deletion or substitution of not more than two amino acids; and (iii) a CDRL3 amino acid sequence selected from the group consisting of X12-X15-X17-X14-X16 (SEQ ID NO: 417), wherein X1 is selected from the group consisting of S, N, T, A, C, and Q, X2 is selected from the group consisting of S, T, A, and C, X3 is selected from the group consisting of Y, W, F, T, and S, X4 is selected from the group consisting of G, V, P, A, I, M, L, and F, X5 is selected from the group consisting of S, T, A, and C, X6 is selected from the group consisting of N, S, Q, T, A, and C, X7 is selected from the group consisting of M, V, I, L, F, and A, X8 is selected from the group consisting of V, I, M, L, F, and A.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A depicts an amino acid sequence of the mature form of the PCSK9 with the pro-domain underlined. FIGS. 1B, 1B1, 1B2 depict amino acid and nucleic acid sequences of PCSK9 with the pro-domain underlined and the signal sequence in bold.

FIGS. 2A-2D are sequence comparison tables of various light chains of various antigen binding proteins. FIG. 2C continues the sequence started in FIG. 2A. FIG. 2D continues the sequence started on FIG. 2B.

FIGS. 3A-3D are sequence comparison tables of various heavy chains of various antigen binding proteins. FIG. 3C continues the sequence started in FIG. 3A. FIG. 3D continues the sequence started on FIG. 3B.

FIGS. 3E-3JJ depict the amino acid and nucleic acid sequences for the variable domains of some embodiments of the antigen binding proteins.

FIG. 3KK depicts the amino acid sequences for various constant domains.

FIGS. 3LL-3BB depict the amino acid and nucleic acid sequences for the variable domains of some embodiments of the antigen binding proteins.

FIGS. 3CCC-3JJJ are sequence comparison tables of various heavy and light chains of some embodiments of the antigen binding proteins.

FIG. 4A is a binding curve of an antigen binding protein to human PCSK9.

FIG. 4B is a binding curve of an antigen binding protein to human PCSK9.

FIG. 4C is a binding curve of an antigen binding protein to a homologous PCSK9.

FIG. 4D is a binding curve of an antigen binding protein to a homologous PCSK9.

FIG. 4E is a binding curve of an antigen binding protein to mouse PCSK9.

FIG. 4F is a binding curve of an antigen binding protein to mouse PCSK9.

FIG. 5A depicts the results of an SDSPAGE experiment involving PCSK9 and various antigen binding proteins demonstrating the relative purity and concentration of the proteins.

FIGS. 5B and 5C depict graphs from biacore solution equilibrium assays for 21B12.

FIG. 5D depicts the graph of the kinetics from a biacore capture assay.

FIG. 5E depicts a bar graph depicting binning results for three ABPs.

FIG. 6A is an inhibition curve of antigen binding protein 31H4 IgG2 to PCSK9 in an in vitro PCSK9-LDLR binding assay.

FIG. 6B is an inhibition curve of antigen binding protein 31H4 IgG4 to PCSK9 in an in vitro PCSK9-LDLR binding assay.

FIG. 6C is an inhibition curve of antigen binding protein 21B12 IgG2 to PCSK9 in an in vitro PCSK9-LDLR binding assay.

FIG. 6D is an inhibition curve of antigen binding protein 21B12 IgG4 to PCSK9 in an in vitro PCSK9-LDLR binding assay.

FIG. 7A is an inhibition curve of antigen binding protein 31H4 IgG2 in the cell LDL uptake assay showing the effect of the ABP to reduce the LDL uptake blocking effects of PCSK9.

FIG. 7B is an inhibition curve of antigen binding protein 31H4 IgG4 in the cell LDL uptake assay showing the effect of the ABP to reduce the LDL uptake blocking effects of PCSK9.

FIG. 7C is an inhibition curve of antigen binding protein 21B12 IgG2 in the cell LDL uptake assay showing the effect of the ABP to reduce the LDL uptake blocking effects of PCSK9.

FIG. 7D is an inhibition curve of antigen binding protein 21B12 IgG4 in the cell LDL uptake assay showing the effect of the ABP to reduce the LDL uptake blocking effects of PCSK9.

FIG. 8A is a graph depicting the serum cholesterol lowering ability in mice of 31H4, changes relative to the IgG control treated mice (p < 0.01).

FIG. 8B is a graph depicting the serum cholesterol lowering ability in mice of 31H4, changes relative to time-zero hours (p = 0.05).

FIG. 8C is a graph depicting the effect of 31H4 on HDL cholesterol levels in C57Bl/6 mice (p < 0.01).
FIG. 8D is a graph depicting the effect of ABP 31H4 on HDL cholesterol levels in C57Bl/6 mice (p=0.05).

FIG. 9 depicts a western blot analysis of the ability of ABP 31H4 to enhance the amount of liver LDLR protein present after various time points.

FIG. 10A is a graph depicting the ability of an antigen binding protein 31H4 to lower total serum cholesterol in wild type mice, relative.

FIG. 10B is a graph depicting the ability of an antigen binding protein 31H4 to lower HDL in wild type mice.

FIG. 10C is a graph depicting the serum cholesterol lowering ability of various antigen binding proteins 31H4 and 16F12.

FIG. 11A depicts an injection protocol for testing the duration and ability of antigen binding proteins to lower serum cholesterol.

FIG. 11B is a graph depicting the results of the protocol in FIG. 11A.

FIG. 12A depicts LDLR levels in response to the combination of a statin and ABP 21B12 in HepG2 cells.

FIG. 12B depicts LDLR levels in response to the combination of a statin and ABP 31H4 in HepG2 cells.

FIG. 12C depicts LDLR levels in response to the combination of a statin and ABP 25A7,1, a nonneutralizing antibody, (in contrast the “25A7” a neutralizing antibody) in HepG2 cells.

FIG. 12D depicts LDLR levels in response to the combination of a statin and ABP 21B12 in HepG2 cells overexpressing PCSK9.

FIG. 12E depicts LDLR levels in response to the combination of a statin and ABP 31H4 in HepG2 cells overexpressing PCSK9.

FIG. 12F depicts LDLR levels in response to the combination of a statin and ABP 25A7,1, a nonneutralizing antibody, (in contrast the “25A7” a neutralizing antibody) in HepG2 cells overexpressing PCSK9.

FIG. 13A depicts the various light chain amino acid sequences of various ABPs to PCSK9. The dots (.) indicate no amino acid.

FIG. 13B depicts a light chain cladogram for various ABPs to PCSK9.

FIG. 13C depicts the various heavy chain amino acid sequences of various ABPs to PCSK9. The dots (.) indicate no amino acid.

FIG. 13D depicts a heavy chain dendrogram for various ABPs to PCSK9.

FIG. 13E depicts a comparison of light and heavy CDRs and designation of groups from which to derive consensus.

FIG. 13F depicts the consensus sequences for Groups 1 and 2.

FIG. 13G depicts the consensus sequences for Groups 3 and 4.

FIG. 13H depicts the consensus sequences for Groups 1 and 2. The dots (.) indicated identical residues.

FIG. 13I depicts the consensus sequences for Group 2. The dots (.) indicated identical residues.

FIG. 13J depicts the consensus sequences for Groups 3 and 4. The dots (.) indicated identical residues.

FIG. 14A is a graph depicting in vivo LDL lowering ability of various ABPs (at 10 mg/kg).

FIG. 14B is a graph depicting in vivo LDL lowering ability of various ABPs (at 30 mg/kg).

FIG. 15A and FIG. 15B are sequence comparison tables of various light chains of various embodiments of antigen binding proteins. FIG. 15B continues the sequence started in FIG. 15A.
FIG. 27A depicts the 21B12 epitope hits, as mapped onto a crystal structure of PCSK9 with the 21B12.

FIG. 27B depicts the 31H14 epitope hits, as mapped onto a crystal structure of PCSK9 with 31H14 and 21B12.

FIG. 27C depicts the 31A4 epitope hits, as mapped onto a crystal structure of PCSK9 with 31H14 and 21B12.

FIG. 27D depicts the 12I11 epitope hits, as mapped onto the crystal structure of PCSK9 with 31H14 and 21B12.

FIG. 27E depicts the 3CA4 epitope hits, as mapped onto the crystal structure of PCSK9 with 31H14 and 21B12.

FIG. 28A is a graph demonstrating the binding ability of the various APs to various parts of PCSK9.

FIG. 28B is a graph demonstrating the binding ability of the various APs to various parts of PCSK9.

FIG. 28C is a graph comparing the LDLR binding ability of two APs.

FIG. 28D is a graph comparing the cell LDL uptake activity of two APs.

DETAILED DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS

Antigen binding proteins (such as antibodies and functional binding fragments thereof) that bind to PCSK9 are disclosed herein. In some embodiments, the antigen binding proteins bind to PCSK9 and prevent PCSK9 from functioning in various ways. In some embodiments, the antigen binding proteins block or reduce the ability of PCSK9 to interact with other substances. For example, in some embodiments, the antigen binding protein binds to PCSK9 in a manner that prevents or reduces the likelihood that PCSK9 will bind to LDLR. In other embodiments, antigen binding proteins bind to PCSK9 but do not block PCSK9’s ability to interact with LDLR. In some embodiments, the antigen binding proteins are human monoclonal antibodies.

As will be appreciated by one of skill in the art, in light of the present disclosure, altering the interactions between PCSK9 and LDLR can increase the amount of LDLR available for binding to LDL, which in turn decreases the amount of serum LDL in a subject, resulting in a reduction in the subject’s serum cholesterol level. As such, antigen binding proteins to PCSK9 can be used in various methods and compositions for treating subjects with elevated serum cholesterol levels, at risk of elevated serum cholesterol levels, or which could benefit from a reduction in their serum cholesterol levels. Thus, various methods and techniques for lowering, maintaining, or preventing an increase in serum cholesterol are also described herein. In some embodiments, the antigen binding protein allows for binding between PCSK9 and LDLR, but the antigen binding protein prevents or reduces the adverse activity of PCSK9 on LDLR. In some embodiments, the antigen binding protein prevents or reduces the binding of PCSK9 to LDLR.

For convenience, the following sections generally outline the various meanings of the terms used herein. Following this discussion, general aspects regarding antigen binding proteins are discussed, followed by specific examples demonstrating the properties of various embodiments of the antigen binding proteins and how they can be employed.

DEFINITIONS AND EMBODIMENTS

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise. Also, the use of the term “portion” can include part of a moiety or the entire moiety.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose. As utilized in accordance with the present disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

The term “proprotein convertase subtilisin/kexin type 9” or “PCSK9” refers to a polypeptide as set forth in SEQ ID NO: 1 and/or 3 or fragments thereof, as well as related polypeptides, which include, but are not limited to, allelic variants, splice variants, derivative variants, substitution variants, deletion variants, and/or insertion variants including the addition of an N-terminal methionine, fusion polypeptides, and interspecies homologs. In certain embodiments, a PCSK9 polypeptide includes terminal residues, such as, but not limited to, leader sequence residues, targeting residues, amino terminal methionine residues, lysine residues, tag residues and/or fusion protein residues. “PCSK9” has also been referred to as F13, NARC1, HCHOLA3, proprotein convertase subtilisin/kexin type 9, and neutral apoptosis regulated convertase 1. The PCSK9 gene encodes a proprotein convertase protein that belongs to the protease K subfamily of the secretory subtilase family. The term “PCSK9” denotes both the proprotein and the product generated following autocatalysis of the proprotein. When only the autocatalyzed product is being referred to (such as for an antigen binding protein that selectively binds to the cleaved PCSK9), the protein can be referred to as the “mature,” “cleaved”, “processed” or “active” PCSK9. When only the inactive form is being referred to, the protein can be referred to as the “inactive”, “pro-form”, or “unprocessed” form of PCSK9. The term PCSK9 as used herein also includes naturally occurring alleles, such as the mutations D374Y, S127R and F216L. The term PCSK9 also encompasses PCSK9 molecules incorporating post-translational modifications of the PCSK9 amino acid sequence, such as PCSK9 sequences that have been glycosylated, PEYylated, PCSK9 sequences from which its signal sequence has been cleaved, PCSK9 sequence from which its pro domain has been cleaved from the catalytic domain but not separated from the catalytic domain (e.g., FIGS. 1A and 1B).

The term “PCSK9 activity” includes any biological effect of PCSK9. In certain embodiments, PCSK9 activity includes the ability of PCSK9 to interact or bind to a substrate or receptor. In some embodiments, PCSK9 activity is represented by the ability of PCSK9 to bind to a LDL receptor (LDLR). In some embodiments, PCSK9 binds to and catalyzes a reaction involving LDLR. In some embodiments, PCSK9 activity includes the ability of PCSK9 to alter (e.g., reduce) the availability of LDLR. In some embodiments, PCSK9 activity includes the ability of PCSK9 to decrease the amount of LDLR that is available to bind to LDL. In some embodiments, “PCSK9 activity” includes any biological activity
resulting from PCSK9 signaling. Exemplary activities include, but are not limited to, PCSK9 binding to LDLR, PCSK9 enzyme activity that cleaves LDLR or other proteins, PCSK9 binding to proteins other than LDLR that facilitate PCSK9 action, PCSK9 altering APOB secretion (Sun X-M et al., “Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolemia. Human Molecular Genetics 14: 1161-1169, 2005 and Ogueruam K et al., “Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9, Arterioscler Thromb Vasc Biol. 24: 1448-1453, 2004), PCSK9’s role in liver regeneration and neuronal cell differentiation (Seidah N G et al., “The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation” PNAS 100: 928-933, 2003), and PCSK9’s role in hepatic glucose metabolism (Costet et al., “Hepatic PCSK9 expression is regulated by nutritional status via insulin and steroid regulatory element-binding protein le” J. Biol. Chem. 281 (10):6211-18, 2006).

The term “hypercholesterolemia,” as used herein, refers to a condition in which cholesterol levels are elevated above a desired level. In some embodiments, this denotes that serum cholesterol levels are elevated. In some embodiments, the desired level takes into account various “risk factors” that are known to one of skill in the art (and are described or referenced herein).

The term “polynucleotide” or “nucleic acid” includes both single-stranded and double-stranded polynucleotide polymers. The nucleotides comprising the polynucleotide can be ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide. Said modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2’,3’-dideoxyribose, and internucleotide linkage modifications such as phosphorothioate, phosphorodithioate, phosphorothiolate, phosphorodiester, phosphorothionoate, phosphorothionoate, phosphorothionoate, and phosphorothiamate.

The term “oligonucleotide” means a polynucleotide comprising 200 or fewer nucleotides. In some embodiments, oligonucleotides are 1 to 50 bases in length. In other embodiments, oligonucleotides are 12, 13, 14, 15, 16, 17, 18, 19, or 20 to 40 nucleotides in length. Oligonucleotides can be single stranded or double stranded, e.g., for use in the construction of a mutant gene. Oligonucleotides can be sense or antisense oligonucleotides. An oligonucleotide can include a label, including a radiolabel, a fluorescent label, a hapten or an antigenic label, for detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers or hybridization probes.

An “isolated nucleic acid molecule” means a DNA or RNA of genomic, mRNA, cDNA, or synthetic origin or some combination thereof which is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, or is linked to a polynucleotide to which it is not linked in nature. For purposes of this disclosure, it should be understood that “a nucleic acid molecule comprising” a particular nucleotide sequence does not encompass intact chromosomes. Isolated nucleic acid molecules “comprising” specified nucleic acid sequences can include, in addition to the specified sequences, coding sequences for up to ten or even up to twenty other proteins or portions thereof, or can include operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequences, and/or can include vector sequences.

Unless specified otherwise, the left-hand end of any single-stranded polynucleotide sequence discussed herein is the 5’ end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5’ direction. The direction of 5’ to 3’ addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strands having the same sequence as the RNA transcript that are 5’ to the 3’ end of the RNA transcript are referred to as “upstream sequences;” sequence regions on the DNA strand having the same sequence as the RNA transcript that are 3’ to the 3’ end of the RNA transcript are referred to as “downstream sequences.”

The term “control sequence” refers to a polynucleotide sequence that can affect the expression and processing of coding sequences to which it is ligated. The nature of such control sequences can depend upon the host organism. In particular embodiments, control sequences for prokaryotes can include a promoter, a ribosomal binding site, and a transcription termination sequence. For example, control sequences for eukaryotes can include promoters comprising one or a plurality of recognition sites for transcription factors, transcription enhancer sequences, and transcription termination sequences. “Control sequences” can include leader sequences and/or fusion partner sequences.

The term “vector” means any molecule or entity (e.g., nucleic acid, plasmid, bacteriophage or virus) used to transfer protein coding information into a host cell.

The term “expression vector” or “expression construct” refers to a vector that is suitable for transformation of a host cell and contains nucleic acid sequences that direct and/or control (in conjunction with the host cell) expression of one or more heterologous coding regions operatively linked thereto. An expression construct can include, but is not limited to, sequences that affect or control transcription, translation, and, if introns are present, affect RNA splicing of a coding region operably linked thereto.

As used herein, “operably linked” means that the components to which the term is applied are in a relationship that allows them to carry out their inherent functions under suitable conditions. For example, a control sequence in a vector that is “operably linked” to a protein coding sequence is ligated thereto so that expression of the protein coding sequence is achieved under conditions compatible with the transcriptional activity of the control sequences.

The term “host cell” means a cell that has been transformed, or is capable of being transformed, with a nucleic acid sequence and thereby expresses a gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent cell, so long as the gene of interest is present.

The term “transfection” means the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, e.g., Graham et al., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, supra; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; Chu et al., 1981, Gene 13:197. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

The term “transformation” refers to a change in a cell’s genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA or RNA. For example, a cell is transformed where it is genetically modified from its native state by introducing new genetic material via transfection, transduction, or other techniques. Following transfection or transduction, the transforming DNA can recombine with that of the cell by physically integrating into
a chromosome of the cell, or can be maintained transiently as an episomal element without being replicated, or can replicate independently as a plasmid. A cell is considered to have been “stably transformed” when the transforming DNA is replicated with the division of the cell.

The terms “polypeptide” or “protein” means a macromolecule having the amino acid sequence of a native protein, that is, a protein produced by a naturally-occurring and non-recombinant cell; or it is produced by a genetically-engineered or recombinant cell, and comprise molecules having the amino acid sequence of the native protein, or molecules having deletions from, additions to, and/or substitutions of one or more amino acids of the native sequence. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of a corresponding naturally-occurring amino acid and polymers. The terms “polypeptide” and “protein” specifically encompass PCSK9 antigen binding proteins, antibodies, or sequences that have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein. The term “polypeptide fragment” refers to a polypeptide that has an amino-terminal deletion, a carboxyl-terminal deletion, and/or an internal deletion as compared with the full-length native protein. Such fragments can also contain modified amino acids as compared with the native protein. In certain embodiments, fragments are about five to 500 amino acids long. For example, fragments can be at least 5, 6, 8, 10, 14, 20, 50, 100, 110, 150, 200, 250, 300, 350, 400, or 450 amino acids long. Useful polypeptide fragments include immunologically functional fragments of antibodies, including binding domains. In the case of a PCSK9-binding antibody, useful fragments include but are not limited to a CDR region, a variable domain of a heavy and/or light chain, a portion of an antibody chain or just its variable region including two CDRs, and the like.

The term “isolated protein” referred means that a subject protein (1) is free of at least some other proteins with which it would normally be found, (2) is essentially free of other proteins from the same source, e.g., from the same species, (3) expressed by a cell from a different species, (4) has been separated from at least about 50 percent of polynucleotides, lipids, carbohydrates, or other materials with which it is associated in nature, (5) is operably associated (by covalent or noncovalent interaction) with a polypeptide with which it is not associated in nature, or (6) does not occur in nature. Typically, an “isolated protein” constitutes at least about 5%, at least about 10%, at least about 25%, or at least about 50% of a given sample. Genomic DNA, cDNA, miRNA or other RNA, of synthetic origin, or any combination thereof can encode such an isolated protein. Preferably, the isolated protein is substantially free from proteins or polypeptides or other contaminants that are found in its natural environment that would interfere with its therapeutic, diagnostic, prophylactic, research or other use.

The term “amino acid” includes its normal meaning in the art.

A “variant” of a polypeptide (e.g., an antigen binding protein, or an antibody) comprises an amino acid sequence wherein one or more amino acid residues are inserted into, deleted from and/or substituted into the amino acid sequence relative to another polypeptide sequence. Variants include fusion proteins.

The term “identity” refers to a relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by aligning and comparing the sequences. “Percent Identity” means the percent of identical residues between the amino acids or nucleotides in the compared molecules and is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in alignments (if any) are preferably addressed by a particular mathematical model or computer program (i.e., an “algorithm”). Methods that can be used to calculate the identity of the aligned nucleic acids or polypeptides include those described in Computational Molecular Biology, (Lesk, A. M., ed.), 1988, New York: Oxford University Press; Biocomputing Informatics and Genome Projects, (Smith, D. W., ed.), 1993, New York: Academic Press; Computer Analysis of Sequence Data, Part I, (Griffin, A. M., and Griffin, H. G., eds.), 1994, New Jersey: Humana Press; von Heijne, G., 1987, Sequence Analysis in Molecular Biology, New York: Academic Press; Sequence Analysis Primer, (Gribskov, M. and Devereux, J., eds.), 1991, New York: M. Stockton Press; and Carillo et al., 1988, SIAM J. Applied Math. 48:1073.

In calculating percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, Nuc. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or nucleotide sequences for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). A gap opening penalty (which is calculated as 3x the average diagonal, wherein the “average diagonal” is the average of the diagonal of the comparison matrix being used; the “diagonal” is the score or number assigned to each perfect amino acid match by the particular comparison matrix) and a gap extension penalty (which is usually ½10 times the gap opening penalty), as well as a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. In certain embodiments, a standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm. Examples of parameters that can be employed in determining percent identity for polypeptides or nucleotide sequences using the GAP program are the following:

Comparison matrix: BLOSUM 62 from Henikoff et al., 1992, supra
Gap Penalty: 12 (but with no penalty for end gaps)
Gap Length Penalty: 4
Threshold of Similarity: 0

Certain alignment schemes for aligning two amino acid sequences may result in matching of only a short region of the two sequences, and this small aligned region may have very high sequence identity even though there is no significant relationship between the two full-length sequences. Accordingly, the selected alignment method (GAP program) can be adjusted if so desired to result in an alignment that spans at least 50 or other number of contiguous amino acids of the target polypeptide.

As used herein, the twenty conventional (e.g., naturally occurring) amino acids and their abbreviations follow conventional usage. See Immunology—A Synthesis (2nd Edition, E. S. Golub and D. R. Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference for any purpose. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino
acids such as ω-, ω'-disubstituted amino acids, N-alkyl amino acids, lactic acid, and other unconventional amino acids can also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline, γ-carboxyglutamate, ε-N,N,N-trimethyllysine, ε-N-acetyllysine, O-phosphoserine, Ile, N-acetylseryn, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, α-N-methylarginine, and other similar amino acids and amino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the left-hand direction is the amino terminal direction and the right-hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

Similarly, unless specified otherwise, the left-hand end of single-stranded polynucleotide sequences is the 5′ end; the left-hand direction of double-stranded polynucleotide sequences is referred to as the 5′ direction. The direction of the 5′ to 3′ addition of nascent RNA transcripts is referred to as the transcription direction; sequence regions on the DNA strand having the same sequence as the RNA and which are 5′ to the 5′ end of the RNA transcript are referred to as "upstream sequences"; sequence regions on the DNA strand having the same sequence as the RNA and which are 3′ to the 3′ end of the RNA transcript are referred to as "downstream sequences."

Conservative amino acid substitutions can encompass non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in biological systems. These include peptidomimetics and other reversed or inverted forms of amino acid moieties.

Naturally occurring residues can be divided into classes based on common side chain properties:

1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;
2) neutral hydrophobic: Cys, Ser, Thr, Asn, Gln;
3) acidic: Asp, Glu;
4) basic: His, Lys, Arg;
5) residues that influence chain orientation: Gly, Pro; and
6) aromatic: Trp, Tyr, Phe.

For example, non-conservative substitutions can involve the exchange of a member of one of these classes for a member from another class. Such substituted residues can be introduced, for example, into regions of a human antibody that are homologous with non-human antibodies, or into the non-homologous regions of the molecule.

In making changes to the antigen binding protein or the PCSK9 protein, according to certain embodiments, the hydrophobicity index of amino acids can be considered. Each amino acid has been assigned a hydrophobicity index on the basis of its hydrophobicity and charge characteristics. They are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (−0.4); threonine (−0.7); serine (−0.8); tryptophan (−0.9); tyrosine (−1.3); proline (−1.6); histidine (−3.2); glutamate (−3.5); glutamine (−3.5); aspartate (−3.5); asparagine (−3.5); lysine (−3.9); and arginine (−4.5).

The importance of the hydrophobic amino acid index in conferring interactive biological function on a protein is understood in the art. Kyte et al., J. Mol. Biol., 157:105-131 (1982). It is known that certain amino acids can be substituted for other amino acids having a similar hydrophobic index or score and still retain a similar biological activity. In making changes based upon the hydrophobic index, in certain embodiments, the substitution of amino acids whose hydrophobic indices are within ±2 is included. In certain embodiments, those which are within ±1 are included, and in certain embodiments, those within ±0.5 are included.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity, particularly where the biologically functional protein or peptide thereby created is intended for use in immunological embodiments, as in the present case. In certain embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e., with a biological property of the protein.

The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0-1); glutamate (+3.0-1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (−0.4); proline (−0.5-1); alanine (−0.5); histidine (−0.5); cysteine (−1.0); methionine (−1.3); valine (−1.5); leucine (−1.8); isoleucine (−1.8); tyrosine (−2.3); phenylalanine (−2.5) and tryptophan (−3.4). In making changes based upon similar hydrophilicity values, in certain embodiments, the substitution of amino acids whose hydrophilicity values are within ±2 is included, in certain embodiments, those which are within ±1 are included, and in certain embodiments, those within ±0.5 are included. One can also identify epitopes from primary amino acid sequences on the basis of hydrophilicity. These regions are also referred to as "epitopic core regions."

Exemplary amino acid substitutions are set forth in Table 1.

<table>
<thead>
<tr>
<th>Original Residues</th>
<th>Exemplary Substitutions</th>
<th>Preferred Substitutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala</td>
<td>Val, Leu, Ile</td>
<td>Val</td>
</tr>
<tr>
<td>Arg</td>
<td>Lys, Gln, Asn</td>
<td>Lys</td>
</tr>
<tr>
<td>Asn</td>
<td>Gln</td>
<td>Gln</td>
</tr>
<tr>
<td>Asp</td>
<td>Glu</td>
<td>Glu</td>
</tr>
<tr>
<td>Cys</td>
<td>Ser, Ala</td>
<td>Ser</td>
</tr>
<tr>
<td>Gln</td>
<td>Asn</td>
<td>Asn</td>
</tr>
<tr>
<td>Glu</td>
<td>Asp</td>
<td>Asp</td>
</tr>
<tr>
<td>Gly</td>
<td>Pro, Ala</td>
<td>Ala</td>
</tr>
<tr>
<td>His</td>
<td>Asn, Gln, Lys, Arg</td>
<td>Arg</td>
</tr>
<tr>
<td>Ile</td>
<td>Leu, Val, Met, Ala, Phe</td>
<td>Leu</td>
</tr>
<tr>
<td>Leu</td>
<td>Norleucine, Ile, Val, Met, Ala, Phe</td>
<td>Norleucine, Ile, Val, Met, Ala, Phe</td>
</tr>
<tr>
<td>Lys</td>
<td>Arg, L,4 Diaminobutyric</td>
<td>Arg</td>
</tr>
<tr>
<td>Met</td>
<td>Leu, Phe, Ile</td>
<td>Leu</td>
</tr>
<tr>
<td>Phe</td>
<td>Leu, Val, Ile, Ala</td>
<td>Leu</td>
</tr>
<tr>
<td>Pro</td>
<td>Ala</td>
<td>Gly</td>
</tr>
<tr>
<td>Ser</td>
<td>Thr, Ala, Cys</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
<td>Ser</td>
</tr>
<tr>
<td>Trp</td>
<td>Tyr, Phe</td>
<td>Tyr</td>
</tr>
<tr>
<td>Tyr</td>
<td>Trp, Phe, Thr, Ser</td>
<td>Phe</td>
</tr>
<tr>
<td>Val</td>
<td>Ile, Met, Leu, Phe, Ala, Norleucine</td>
<td>Ile, Met, Leu, Phe, Ala, Norleucine</td>
</tr>
</tbody>
</table>

The term "derivative" refers to a molecule that includes a chemical modification other than an insertion, deletion, or substitution of amino acids (or nucleic acids). In certain embodiments, derivatives comprise covalent modifications, including, but not limited to, chemical bonding with polymers, lipids, or other organic or inorganic moieties. In certain embodiments, a chemically modified antigen binding protein can have a greater circulating half-life than an antigen binding protein that is not chemically modified. In certain embodiments, a chemically modified antigen binding protein can have improved targeting capacity for desired cells, tissues, and/or organs. In some embodiments, a derivative antigen binding protein is covalently modified to include one or more water soluble polymer attachments, including, but not limited to, polyethylene glycol, polyoxyethylene glycol, or polypro-
pylene glycol. See, e.g., U.S. Pat. Nos. 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192 and 4,179,337. In certain embodiments, a derivative antigen binding protein comprises one or more polymer, including, but not limited to, nonmethoxy-polyethylene glycol, dextran, cellulose, or other carbohydrate based polymers, poly-(N-vinyl pyrrolidone)-polyethylene glycol, propylene glycol homopolymers, a polypropylene oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl alcohol, as well as mixtures of such polymers.

In certain embodiments, a derivative is covalently modified with polyethylene glycol (PEG) subunits. In certain embodiments, one or more water-soluble polymer is bonded at one or more specific position, for example at the amino terminus, of a derivative. In certain embodiments, one or more water-soluble polymer is randomly attached to one or more side chains of a derivative. In certain embodiments, PEG is used to improve the therapeutic capacity for an antigen binding protein. In certain embodiments, PEG is used to improve the therapeutic capacity for a humanized antibody. Certain such methods are discussed, for example, in U.S. Pat. No. 6,153,426, which is hereby incorporated by reference for any purpose.

Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template peptide. These types of non-peptide compound are termed “peptide mimetics” or “peptidomimetics,” Fauchere, J., Adv. Drug Res., 15:29 (1986); Veber & Freidinger, TINS, p.392 (1985); and Evans et al., J. Med. Chem., 30:1229 (1987), which are incorporated herein by reference for any purpose. Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to therapeutically useful peptides can be used to produce a similar therapeutic or prophylactic effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (i.e., a polypeptide that has a biochemical property or pharmacological activity), such as human antibody, but have one or more peptide linkages optionally replaced by a linkage selected from: —CH₂—NH—, —CH₂—S—, —CH—CH—, —CH—CH-(cis and trans), —COCH₂—, —CH(OH)CH₂—, and —CH—SO₂—, by methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) can be used in certain embodiments to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation can be generated by methods known in the art (Rizo and Giersasch, Ann. Rev. Biochem., 61:387 (1992), incorporated herein by reference for any purpose); for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

The term “naturally occurring” as used throughout the specification in connection with biological materials such as polypeptides, nucleic acids, host cells, and the like, refers to materials which are found in nature or a form of the materials that is found in nature.

An “antigen binding protein” (“ABP”) as used herein means any protein that binds a specified target antigen. In the instant application, the specified target antigen is the PCSK9 protein or fragment thereof. “Antigen binding protein” includes but is not limited to antibodies and binding parts thereof, such as immunologically functional fragments. Peptidomimetics are another example of antigen binding proteins. The term “immunologically functional fragment” (or simply “fragment”) of an antibody or immunoglobin chain (heavy or light chain) antigen binding protein, as used herein, is a species of antigen binding protein comprising a portion (regardless of how that portion is obtained or synthesized) of an antibody that lacks at least some of the amino acids present in a full-length chain but which is still capable of specifically binding to an antigen. Such fragments are biologically active in that they bind to the target antigen and can compete with other antigen binding proteins, including intact antibodies, for binding to a given epitope. In some embodiments, the fragments are neutralizing fragments. In some embodiments, the fragments can block or reduce the likelihood of the interaction between LDLR and PCSK9. In one aspect, such a fragment will retain at least one CDR present in the full-length light or heavy chain, and in some embodiments will comprise a single heavy chain and/or light chain or portion thereof. These biologically active fragments can be produced by recombinant DNA techniques, or can be produced by enzymatic or chemical cleavage of antigen binding proteins, including intact antibodies. Immunologically functional immunoglobulin fragments include, but are not limited to, Fab, a diabody (heavy chain variable domain on the same polypeptide as a light chain variable domain, connected via a short peptide linker that is too short to permit pairing between the two domains on the same chain), Fab1, Fab2, Fv, domain antibodies and single-chain antibodies, and can be derived from any mammalian source, including but not limited to human, mouse, rat, camelid or rabbit. It is further contemplated that a functional portion of the antigen binding proteins disclosed herein, for example, one or more CDRs, could be covalently bound to a second protein or to a small molecule to create a therapeutic agent directed to a particular target in the body, possessing bifunctional therapeutic properties, or having a prolonged serum half-life. As will be appreciated by one of skill in the art, an antigen binding protein can include nonprotein components. In some sections of the present disclosure, examples of APBs are described herein in terms of “number/letter/number” (e.g., 25A7). In these cases, the exact name denotes a specific antibody. That is, an ABP named 25A7 is not necessarily the same as an antibody named 25A7.1 (unless they are explicitly taught as the same in the specification, e.g., 25A7 and 25A7.3). As will be appreciated by one of skill in the art, in some embodiments LDLR is not an antigen binding protein. In some embodiments, binding subregions of LDLR are not antigen binding proteins, e.g., EGFa. In some embodiments, other molecules through which PCSK9 signals in vivo are not antigen binding proteins. Such embodiments will be explicitly identified as such.

Certain antigen binding proteins described herein are antibodies or are derived from antibodies. In certain embodiments, the polypeptide structure of the antigen binding proteins is based on antibodies, including, but not limited to, monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof, respectively. In some embodiments, the ABP comprises or consists of avimers (tightly binding peptide). These various antigen binding proteins are further described herein.

An “Fc” region comprises two heavy chain fragments comprising the Cγ1 and Cγ2 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bridges and by hydrophobic interactions of the Cγ5 domains.
A “Fab fragment” comprises one light chain and the C\textsubscript{H}1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.

A “Fab’ fragment” comprises one light chain and a portion of one heavy chain that contains the VH domain and the C\textsubscript{H}1 domain and also the region between the C\textsubscript{H}1 and C\textsubscript{H}2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab’ fragments to form an F(ab’)\textsubscript{2} molecule.

A “F(ab’)\textsubscript{2} fragment” contains two light chains and two heavy chains containing a portion of the constant region between the C\textsubscript{H}1 and C\textsubscript{H}2 domains, such that an interchain disulfide bond is formed between the two heavy chains. A F(ab’)\textsubscript{2} fragment thus is composed of two Fab’ fragments that are held together by a disulfide bond between the two heavy chains.

The “Fv region” comprises the variable regions from both the heavy and light chains, but lacks the constant regions.

“Single-chain antibodies” are Fv molecules in which the heavy and light chain variable regions have been connected by a flexible linker to form a single polypeptide chain, which forms an antigen binding region. Single chain antibodies are discussed in detail in International Patent Application Publication No. WO 88/01649 and U.S. Pat. No. 4,946,778 and No. 5,260,203, the disclosures of which are incorporated by reference.

A “domain antibody” is an immunologically functional immunoglobulin fragment containing only the variable region of a heavy chain or the variable region of a light chain. In some instances, two or more V\textsubscript{H} regions are covalently joined with a peptide linker to create a bivalent domain antibody. The two V\textsubscript{H} regions of a bivalent domain antibody can target the same or different antigens.

A “bivalent antigen binding protein” or “bivalent antibody” comprises two binding sites. In some instances, the two binding sites have the same antigen specificities. Bivalent antigen binding proteins and bivalent antibodies can be bispecific, see, infra. A bivalent antibody other than a “multispecific” or “multifunctional” antibody, in certain embodiments, typically is understood to have each of its binding sites identical.

A “multispecific antigen binding protein” or “multispecific antibody” is one that targets more than one antigen or epitope.

A “bispecific,” “dual-specific” or “bifunctional” antigen binding protein or antibody is a hybrid antigen binding protein or antibody, respectively, having two different antigen binding sites. Bispecific antigen binding proteins and antibodies are a species of multispecific antigen binding protein antibody and can be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab’ fragments. See, e.g., Songsivilai and Lachmann, 1990, Clin. Exp. Immunol. 79:315-321; Kostely et al., 1992, J. Immunol. 148:1547-1553. The two binding sites of a bispecific antigen binding protein or antibody will bind to two different epitopes, which can reside on the same or different protein targets.

An antigen binding protein is said to “specifically bind” its target antigen when the dissociation constant (K\textsubscript{D}) is ≤10^{-7} M. The ABP specifically binds antigen with “high affinity” when the K\textsubscript{D} is ≤5x10^{-9} M, and with “very high affinity” when the K\textsubscript{D} is ≤5x10^{-11} M. In one embodiment, the ABP has a K\textsubscript{D} of 10^{-9} M. In one embodiment, the embodiment includes a fragment of about 10^{-9} M and 10^{-11} M, and in yet another embodiment the ABP will bind with a K\textsubscript{D} of 5x10^{-10}. As will be appreciated by one of skill in the art, in some embodiments, any or all of the antigen binding fragments can specifically bind to PCSK9.

An antigen binding protein is “selective” when it binds to one target more tightly than it binds to a second target.

“Antigen binding region” means a protein, or a portion of a protein, that specifically binds a specified antigen (e.g., a paratope). For example, that portion of an antigen binding protein that contains the amino acid residues that interact with an antigen and confer on the antigen binding protein its specificity and affinity for the antigen is referred to as “antigen binding region.” An antigen binding region typically includes one or more “complementary binding regions” (“CDRs”). Certain antigen binding regions also include one or more “framework.” A “CDR” is an amino acid sequence that contributes to antigen binding specificity and affinity. “Framework” regions can influence the proper conformation of the CDRs to promote binding between the antigen binding region and an antigen. Structurally, framework regions can be located in antibodies between CDRs. Examples of framework and CDR regions are shown in FIGS. 2A-3D, 3CCC-3JJJ, and 15A-15D. In some embodiments, the sequences for CDRs for the light chain of antibody 3B6 are as follows: CDR1 TLLSGYSSYEV (SEQ ID NO: 279); CDR2 VDTGIGVGSKE (SEQ ID NO: 280); CDR3 NADHGSSTNFV (SEQ ID NO: 281), and the FRs are as follows: FR1 QPVLTQPESALGASVT (SEQ ID NO: 282); FR2 WYQQRPGKPRVFM (SEQ ID NO: 283); FR3 GITPSVLGSGNLYT (SEQ ID NO: 284); and FR4 PGGPKTVL (SEQ ID NO: 285).

In certain aspects, recombinant antigen binding proteins that bind PCSK9, for example human PCSK9, are provided. In this context, a “recombinant antigen binding protein” is a protein made using recombinant techniques, i.e., through the expression of a recombinant nucleic acid as described herein. Methods and techniques for the production of recombinant proteins are well known in the art.

The term “antibody” refers to an intact immunoglobulin of any isotype, or a fragment thereof that can compete with the intact antibody for specific binding to the target antigen, and includes, for instance, chimeric, humanized, fully human, and bispecific antibodies. An “antibody” is a species of an antigen binding protein. An intact antibody will generally comprise at least two full-length heavy chains and two full-length light chains, but in some instances can include fewer chains such as antibodies naturally occurring in camels which can comprise only heavy chains. Antibodies can be derived solely from a single source, or can be “chimeric,” which is, different portions of the antibody can be derived from two different antibodies as described further below. The antigen binding proteins, antibodies, or binding fragments can be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term “antibody” includes, in addition to antibodies comprising two full-length heavy chains and two full-length light chains, derivatives, variants, fragments, and muteins thereof, examples of which are described below. Furthermore, unless explicitly excluded, antibodies include monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, human antibodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), and fragments thereof, respectively. In some embodiments, the term also encompasses peptides.
Naturally occurring antibody structural units typically comprise a tetramer. Each such tetramer typically is composed of two identical pairs of polypeptide chains, each pair having one full-length “light” (in certain embodiments, about 25 kDa) and one full-length “heavy” chain (in certain embodiments, about 50-70 kDa). The amino-terminal portion of each chain typically includes a variable region of about 100 to 110 or more amino acids that typically is responsible for antigen recognition. The carboxy-terminal portion of each chain typically defines a constant region that can be responsible for effector function. Human light chains are typically classified as kappa and lambda light chains. Heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody’s isotype as IgM, IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM has subclasses including, but not limited to, IgM1 and IgM2. IgA is similarly subdivided into subclasses including, but not limited to, IgA1 and IgA2. Within full-length light and heavy chains, typically, the variable and constant regions are joined by a “J” region of about 12 or more amino acids; with the heavy chain also including a “D” region of about 10 more amino acids. See, e.g., *Fundamental Immunology. Ch. 7* (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989)) (incorporated by reference in its entirety for all purposes). The variable regions of each light/heavy chain pair typically form the antigen binding site.

The variable regions typically exhibit the same general structure of relatively conserved framework regions (FR) joined by three hyper variable regions, also called complementarity determining regions or CDRs. The CDRs from the two chains of each pair are aligned by the framework regions, which can enable binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chain variable regions typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The assignment of amino acids to each domain is typically in accordance with the definitions of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk, J. Mol. Biol., 196:901-917 (1987); Chothia et al., Nature, 342:878-883 (1989).

In certain embodiments, an antibody heavy chain binds to an antigen in the absence of an antibody light chain. In certain embodiments, an antibody light chain binds to an antigen in the absence of an antibody heavy chain. In certain embodiments, an antibody binding region binds to an antigen in the absence of an antibody light chain. In certain embodiments, an individual variable region specifically binds to an antigen in the absence of other variable regions.

In certain embodiments, definitive delineation of a CDR and identification of residues comprising the binding site of an antibody is accomplished by solving the structure of the antibody and/or solving the structure of the antibody-ligand complex. In certain embodiments, that can be accomplished by any of a variety of techniques known to those skilled in the art, such as X-ray crystallography. In certain embodiments, various methods of analysis can be employed to identify or approximate the CDR regions. Examples of such methods include, but are not limited to, the Kabat definition, the Chothia definition, the AbM definition and the contact definition.


By convention, the CDR regions in the heavy chain are typically referred to as H1, H2, and H3 and are numbered sequentially in the direction from the amino terminus to the carboxy terminus. The CDR regions in the light chain are typically referred to as L1, L2, and L3 and are numbered sequentially in the direction from the amino terminus to the carboxy terminus.

The term “light chain” includes a full-length light chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length light chain includes a variable region domain, V_L, and a constant region domain, C_L. The variable region domain of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa chains and lambda chains.

The term “heavy chain” includes a full-length heavy chain and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length heavy chain includes a variable region domain, V_H, and three constant region domains, C_H1, C_H2, and C_H3. The V_H domain is at the amino-terminus of the polypeptide, and the C_H domains are at the carboxy-terminus, with the CH1 being closest to the carboxy-terminus of the polypeptide. Heavy chains can be of any isotype, including IgG (including IgG1, IgG2, IgG3 and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM and IgE.

A bispecific or bifunctional antibody typically is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites. Bispecific antibodies can be produced by a variety of methods including, but not limited to, fusion of hybridomas or linking of Fab’ fragments. See, e.g., Songsivilai et al., *Clin. Exp. Immunol.*, 79: 315-321 (1990); Kostelny et al., *J. Immunol.*, 148:1547-1553 (1992).

Some species of mammals also produce antibodies having only a single heavy chain.

Each individual immunoglobulin chain is typically composed of several “immunoglobulin domains,” each consisting of roughly 90 to 110 amino acids and having a characteristic folding pattern. These domains are the basic units of which antibody polypeptides are composed. In humans, the IgA and IgD isotypes contain four heavy chains and four light chains; the IgG and IgE isotypes contain two heavy chains and two light chains; and the IgM isotype contains five heavy chains and five light chains. The heavy chain C region typically comprises one or more domains that can be responsible for effector function. The number of heavy chain constant region domains will depend on the isotype. IgG heavy chains, for example, contain three C region domains known as C_H1, C_H2 and C_H3. The antibodies that are provided can have any of
these isotypes and subtypes. In certain embodiments of the present invention, an anti-PCSK9 antibody is of the IgG2 or IgG4 subtype.

The term “variable region” or “variable domain” refers to a portion of the light and/or heavy chains of an antibody, typically including approximately the amino-terminal 120 to 130 amino acids in the heavy chain and about 100 to 110 amino terminal amino acids in the light chain. In certain embodiments, variable regions of different antibodies differ extensively in amino acid sequence even among antibodies of the same species. The variable region of an antibody typically determines specificity of a particular antibody for its target.

The term “neutralizing antigen binding protein” or “neutralizing antibody” refers to an antigen binding protein or antibody, respectively, that binds to a ligand and prevents or reduces the biological effect of that ligand. This can be done, for example, by directly blocking a binding site on the ligand or by binding to the ligand and altering the ligand’s ability to bind through indirect means (such as structural or energetic alterations in the ligand). In some embodiments, the term can also denote an antigen binding protein that prevents the protein to which it is bound from performing a biological function. In assessing the binding and/or specificity of an antigen binding protein, e.g., an antibody or immunologically functional fragment thereof, an antibody or fragment can substantially inhibit binding of a ligand to its binding partner when an excess of antibody reduces the quantity of binding partner bound to the ligand by at least about 1-20, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, 97-98%, 98-99% or more (as measured in an in vitro competitive binding assay). In some embodiments, in the case of PCSK9 antigen binding proteins, such a neutralizing molecule can diminish the ability of PCSK9 to bind the LDLR. In some embodiments, the neutralizing ability is characterized and/or described via a competition assay. In some embodiments, the neutralizing ability is described in terms of an IC_{50} or EC_{50} value. In some embodiments, ABPs 27B2, 13H1, 13B5 and 3C4 are non-neutralizing ABPs, 3B6, 9C9 and 31A4 are weak neutralizers, and the remaining ABPs in Table 2 are strong neutralizers. In some embodiments, the antibodies or antigen binding proteins neutralize by binding to PCSK9 and preventing PCSK9 from binding to LDLR (or reducing the ability of PCSK9 to bind to LDLR). In some embodiments, the antibodies or ABPs neutralize by binding to PCSK9, and while still allowing PCSK9 to bind to LDLR, preventing or reducing the PCSK9 mediated degradation of LDLR. Thus, in some embodiments, a neutralizing ABP or antibody can still permit PCSK9/LDLR binding, but will prevent (or reduce) subsequent PCSK9 involved degradation of LDLR.

The term “target” refers to a molecule or a portion of a molecule capable of being bound by an antigen binding protein. In certain embodiments, a target can have one or more epitopes. In certain embodiments, a target is an antigen. The use of “antigen” in the phrase “antigen binding protein” simply denotes that the protein sequence that comprises the antigen can be bound by an antibody. In this context, it does not require that the protein be foreign or that it be capable of inducing an immune response.

The term “compete” when used in the context of antigen binding proteins (e.g., neutralizing antigen binding proteins or neutralizing antibodies) that compete for the same epitope means competition between antigen binding proteins as determined by an assay in which the antigen binding protein (e.g., antibody or immunologically functional fragment thereof) being tested prevents or inhibits (e.g., reduces) specific binding of a reference antigen binding protein (e.g., a ligand, or a reference antibody) to a common antigen (e.g., PCSK9 or a fragment thereof). Numerous types of competitive binding assays can be used to determine if one antigen binding protein competes with another, e.g., solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see, e.g., Stahl et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (see, e.g., Kirkland et al., 1986, J. Immunol. 137:3614-3619) solid phase direct labeled assay, solid phase direct labeled sandwich assay (see, e.g., Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct labeled RIA using 1-125 label (see, e.g., Morel et al., 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (see, e.g., Cheung, et al., 1990, Virology 176:546-552); and direct labeled RIA (Moldenauer et al., 1990, Scand. J. Immunol. 32:77-82). Typically, such an assay involves the use of purified antigen bound to a solid surface or cells bearing either of these, an unlabelled test antigen binding protein and a labeled reference antigen binding protein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test antigen binding protein. Usually the test antigen binding protein is present in excess. Antigen binding proteins identified by competition assay (competing antigen binding proteins) include antigen binding proteins binding to the same epitope as the reference antigen binding proteins and antigen binding proteins binding to an adjacent epitope sufficiently proximal to the epitope bound by the reference antigen binding protein for steric hindrance to occur. Additional details regarding methods for determining competitive binding are provided in the examples herein. Usually, when a competing antigen binding protein is present in excess, it will inhibit (e.g., reduce) specific binding of a reference antigen binding protein to a common antigen by at least 40-45%, 45-50%, 50-55%, 55-60%, 60-65%, 65-70%, 70-75% or 75% or more. In some instances, binding is inhibited by at least 80-85%, 85-90%, 90-95%, 95-97%, or 97% or more.

The term “antigen” refers to a molecule or a portion of a molecule capable of being bound by a selective binding agent, such as an antigen binding protein (including, e.g., an antibody or immunologically functional fragment thereof). In some embodiments, the antigen is capable of being used in an animal to produce antibodies capable of binding to that antigen. An antigen can possess one or more epitopes that are capable of interacting with different antigen binding proteins, e.g., antibodies.

The term “epitope” includes any determinant capable being bound by an antigen binding protein, such as an antibody or to a T-cell receptor. An epitope is a region of an antigen that is bound by an antigen binding protein that targets that antigen, and when the antigen is a protein, includes specific amino acids that directly contact the antigen binding protein. Most often, epitopes reside on proteins, but in some instances can reside on other kinds of molecules, such as nucleic acids. Epitope determinants can include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and can have specific three dimensional structural characteristics, and/or specific charge characteristics. Generally, antibodies specific for a particular target antigen will preferentially recognize an epitope on the target antigen in a complex mixture of proteins and/or macromolecules.

As used herein, “substantially pure” means that the described species of molecule is the predominant species present, that is, on a molar basis it is more abundant than any other individual species in the same mixture. In certain
embodiments, a substantially pure molecule is a composition wherein the object species comprises at least 50% (on a molar basis) of all macromolecular species present. In other embodiments, a substantially pure composition will comprise at least 80%, 85%, 90%, 95%, or 99% of all macromolecular species present in the composition. In other embodiments, the object species is purified to essential homogeneity wherein contaminating species cannot be detected in the composition by conventional detection methods and thus the composition consists of a single detectable macromolecular species.

The term “agent” is used herein to denote a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials.

As used herein, the terms “label” or “labeled” refers to incorporation of a detectable marker, e.g., by incorporation of a radiolabeled amino acid or attachment to a polypeptide of a biotin moiety that can be detected by marked avidin (e.g., streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods). In certain embodiments, the label or marker can also be therapeutic. Various methods of labeling polypeptides and glycoproteins are known in the art and can be used. Examples of labels for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g., $^3$H, $^14$C, $^{15}$N, $^{32}$P, $^{99}$Y, $^{99m}$Tc, $^{111}$In, $^{25}$I, $^{125}$I), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), enzymatic labels (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase), chemiluminescent, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In certain embodiments, labels are attached by spacer arms of various lengths to reduce potential steric hindrance.

The term “biological sample”, as used herein, includes, but is not limited to, any quantity of a substance from a living thing or formerly living thing. Such living things include, but are not limited to, humans, mice, monkeys, rats, rabbits, and other animals. Such substances include, but are not limited to, blood, serum, urine, cells, organs, tissues, bone, bone marrow, lymph nodes, and skin.

The term “pharmaceutical agent composition” (or agent or drug) as used herein refers to a chemical compound, composition, agent or drug capable of inducing a desired therapeutic effect when properly administered to a patient. It does not necessarily require more than one type of ingredient.

The term “therapeutically effective amount” refers to the amount of a PCSK9 antigen binding protein determined to produce a therapeutic response in a mammal. Such therapeutically effective amounts are readily ascertainable by one of ordinary skill in the art.

The term “modulator,” as used herein, is a compound that changes or alters the activity or function of a molecule. For example, a modulator can cause an increase or decrease in the magnitude of a certain activity or function of a molecule compared to the magnitude of the activity or function observed in the absence of the modulator. In certain embodiments, a modulator is an inhibitor, which decreases the magnitude of at least one activity or function of a molecule. Certain exemplary activities and functions of a molecule include, but are not limited to, binding affinity, enzymatic activity, and signal transduction. Certain exemplary inhibitors include, but are not limited to, proteins, peptides, antibodies, peptidomimetics, carbohydrates or small organic molecules. Peptidomimetics are described in, e.g., U.S. Pat. No. 6,660,843 (corresponding to PCT Application No. WO 01/83525).

The terms “patient” and “subject” are used interchangeably and include human and non-human animal subjects as well as those with formally diagnosed disorders, those without formally recognized disorders, those receiving medical attention, those at risk of developing the disorders, etc.

The term “treat” and “treatment” includes therapeutic treatments, prophylactic treatments, and applications in which one reduces the risk that a subject will develop a disorder or other risk factor. Treatment does not require the complete curing of a disorder and encompasses embodiments in which one reduces symptoms or underlying risk factors.

The term “prevent” does not require the 100% elimination of the possibility of an event. Rather, it denotes that the likelihood of the occurrence of the event has been reduced in the presence of the compound or method.

Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to manufacturer’s specifications or as commonly accomplished in the art as described herein. The foregoing techniques and procedures can be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose. Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

Antigen Binding Proteins to PCSK9

Proprotein convertase subtilisin kexin type 9 (PCSK9) is a serine protease involved in regulating the levels of the low density lipoprotein receptor (LDLR) protein (Horton et al., 2007; Seidah and Prat, 2007). PCSK9 is a prohormone-proprotein convertase in the subtilisin (S8) family of serine proteases (Seidah et al., 2003). An exemplary human PCSK9 amino acid sequence is presented as SEQ ID Nos: 1 and 3 in FIG. 1A (depicting the “pro” domain of the protein as underlined) and FIG. 1B (depicting the signal sequence in bold and the pro domain underlined). An exemplary human PCSK9 coding sequence is presented as SEQ ID NO: 2 (FIG. 1B). As described herein, PCSK9 proteins can also include fragments of the full length PCSK9 protein. The structure of the PCSK9 protein has recently been solved by two groups (Cunningham et al., Nature Structural & Molecular Biology, 2007, and Piper et al., Structure, 15:1-8, 2007), the entire structure of which is herein incorporated by reference. PCSK9 includes a signal sequence, a N-terminal prodomain, a subtilisin-like catalytic domain and a C-terminal domain.

Antigen binding proteins (ABPs) that bind PCSK9, including human PCSK9, are provided herein. In some embodiments, the antigen binding proteins provided are polypeptides which comprise one or more complementarily determining regions (CDRs), as described herein. In some antigen binding proteins, the CDRs are embedded into a “framework” region, which orients the CDR(s) such that the proper antigen binding properties of the CDR(s) is achieved. In some embodiments, antigen binding proteins provided herein can interfere with, block, reduce or modulate the interaction between PCSK9 and LDLR. Such antigen binding proteins are denoted as “neutralizing.” In some embodiments, binding
between PCSK9 and LDLR can still occur, even though the antigen binding protein is neutralizing and bound to PCSK9. For example, in some embodiments, the ABP prevents or reduces the adverse influence of PCSK9 on LDLR without blocking the LDLR binding site on PCSK9. Thus, in some embodiments, the ABP modulates or alters PCSK9’s ability to result in the degradation of LDLR, without having to prevent the binding interaction between PCSK9 and LDLR. Such ABPs can be specifically described as “non-competitively neutralizing” ABPs. In some embodiments, the neutralizing ABP binds to PCSK9 in a location and/or manner that prevents PCSK9 from binding to LDLR. Such ABPs can be specifically described as “competitively neutralizing” ABPs. Both of the above neutralizers can result in a greater amount of free LDLR being present in a subject, which results in more LDLR binding to LDL (thereby reducing the amount of LDL in the subject). In turn, this results in a reduction in the amount of serum cholesterol present in a subject.

In some embodiments, the antigen binding proteins provided herein are capable of inhibiting PCSK9-mediated activity (including binding). In some embodiments, the antigen binding proteins binding to these epitopes inhibit, inter alia, interactions between PCSK9 and LDLR and other physiological effects mediated by PCSK9. In some embodiments, the antigen binding proteins are human, such as fully human antibodies to PCSK9.

In some embodiments, the ABP binds to the catalytic domain of PCSK9. In some embodiments, the ABP binds to the mature form of PCSK9. In some embodiments the ABP binds in the prodomain of PCSK9. In some embodiments, the ABP selectively binds to the mature form of PCSK9. In some embodiments, the ABP binds to the catalytic domain in a manner such that PCSK9 cannot bind or bind as efficiently to LDLR. In some embodiments, the antigen binding protein does not bind to the c-terminus of the catalytic domain. In some embodiments, the antigen binding protein does not bind to the n-terminus of the catalytic domain. In some embodiments, the ABP does not bind to the n- or c-terminus of the PCSK9 protein. In some embodiments, the ABP binds to any one of the epitopes bound by the antibodies discussed herein. In some embodiments, this can be determined by competition assays between the antibodies discussed herein and other antibodies. In some embodiments, the ABP binds to an epitope bound by one of the antibodies described in Table 2. In some embodiments, the antigen binding proteins bind to a specific conformational state of PCSK9 so as to prevent PCSK9 from interacting with LDLR. In some embodiments, the ABP binds to the V domain of PCSK9. In some embodiments, the ABP binds to the V domain of PCSK9 and prevents (or reduces) PCSK9 from binding to LDLR. In some embodiments, the ABP binds to the V domain of PCSK9, and while it does not prevent (or reduce) the binding of PCSK9 to LDLR, the ABP prevents or reduces the adverse activities mediated through PCSK9 on LDLR.

The antigen binding proteins that are disclosed herein have a variety of utilities. Some of the antigen binding proteins, for instance, are useful in specific binding assays, affinity purification of PCSK9, in particular human PCSK9 or its ligands and in screening assays to identify other antagonists of PCSK9 activity. Some of the antigen binding proteins are useful for inhibiting binding of PCSK9 to LDLR, or inhibiting PCSK9-mediated activities.

The antigen binding proteins can be used in a variety of therapeutic applications, as explained herein. For example, in some embodiments the PCSK9 antigen binding proteins are useful for treating conditions associated with PCSK9, such as cholesterol related disorders (“serum cholesterol related disorders”) such as hypercholesterolemia, as further described herein. Other uses for the antigen binding proteins include, for example, diagnosis of PCSK9-associated diseases or conditions and screening assays to determine the presence or absence of PCSK9. Some of the antigen binding proteins described herein are useful in treating consequences, symptoms, and/or the pathology associated with PCSK9 activity.

In some embodiments, the antigen binding proteins that are provided comprise one or more CDRs (e.g., 1, 2, 3, 4, 5 or 6 CDRs). In some embodiments, the antigen binding protein comprises (a) a polypeptide structure and (b) one or more CDRs that are inserted into and/or joined to the polypeptide structure. The polypeptide structure can take a variety of different forms. For example, it can be, or comprise, the framework of a naturally occurring antibody, or fragment or variant thereof, or can be completely synthetic in nature. Examples of various polypeptide structures are further described below.

In certain embodiments, the polypeptide structure of the antigen binding proteins is an antibody or is derived from an antibody, including, but not limited to, monoclonal antibodies, bispecific antibodies, minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), chimeric antibodies, humanized antibodies, antibody fusions (sometimes referred to as “antibody conjugates”), and portions or fragments of each, respectively. In some instances, the antigen binding protein is an immunological fragment of an antibody (e.g., a Fab, a Fab’, a F(ab’)2, or a scFv). The various structures are further described and defined herein.

Certain of the antigen binding proteins as provided herein specifically and/or selectively bind to human PCSK9. In some embodiments, the antigen binding protein specifically and/or selectively binds to human PCSK9 protein having and/or consisting of residues 153-692 of SEQ ID NO: 3. In some embodiments the ABP specifically and/or selectively binds to human PCSK9 having and/or consisting of residues 31-152 of SEQ ID NO: 3. In some embodiments, the ABP selectively binds to a human PCSK9 protein as depicted in FIG. IA (SEQ ID NO: 1). In some embodiments, the antigen binding protein specifically binds to at least a fragment of the PCSK9 protein and/or a full length PCSK9 protein, with or without a signal sequence.

In embodiments where the antigen binding protein is used for therapeutic applications, an antigen binding protein can inhibit, interfere with or modulate one or more biological activities of PCSK9. In one embodiment, an antigen binding protein binds specifically to human PCSK9 and/or substantially inhibits binding of human PCSK9 to LDLR by at least about 20%-40%, 40-60%, 60-80%, 80-85%, or more (for example, by measuring binding in an in vitro competitive binding assay). Some of the antigen binding proteins that are provided herein are antibodies. In some embodiments, the ABP has a Kd of less (binding more tightly) than 10^-7, 10^-8, 10^-9, 10^-10, 10^-11, 10^-12, 10^-13 M. In some embodiments, the ABP has an IC50 for blocking the binding of LDLR to PCSK9 (D374Y, high affinity variant) of less than 1 microM, 1000 nM to 100 nM, 100 nM to 10 nM, 10 nM to 1 nM, 1000 pM to 500 pM, 500 pM to 200 pM, less than 200 pM, 200 pM to 150 pM, 200 pM to 100 pM, 100 pM to 10 pM, 10 pM to 1 pM. One example of an IgG2 heavy chain constant domain of an anti-PCS9 antibody of the present invention has the amino acid sequence as shown in SEQ ID NO: 154, FIG. 3KK.
One example of an IgG4 heavy chain constant domain of an anti-PCSK9 antibody of the present invention has the amino acid sequence as shown in SEQ ID NO: 155, FIG. 3K.

One example of a kappa light chain constant domain of an anti-PCSK9 antibody has the amino acid sequence as shown in SEQ ID NO: 157, FIG. 3K.

One example of a lambda light chain constant domain of an anti-PCSK9 antibody has the amino acid sequence as shown in SEQ ID NO: 156, FIG. 3K.

Variable regions of immunoglobulin chains generally exhibit the same overall structure, comprising relatively conserved framework regions (FR) joined by three hypervariable regions, more often called “complementarity determining regions” or CDRs. The CDRs from the two chains of each heavy chain/light chain pair mentioned above typically are aligned by the framework regions to form a structure that binds specifically with a specific epitope on the target protein (e.g., PCSK9). From N-terminal to C-terminal, naturally occurring light and heavy chain variable regions both typically conform with the following order of these elements: FR1, CDRL1, FR2, CDRL2, FR3, CDRH1, CDRL3, FR4. A numbering system has been devised for assigning numbers to amino acids that occupy positions in each of these domains. This numbering system is defined in Kabat Sequences of Proteins of Immunological Interest (1987 and 1991, NIV, Bethesda, Md), or Chothia & Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883.

Various heavy chain and light variable regions are provided herein and are depicted in FIGS. 2A-3JJ and 3LL-31BB. In some embodiments, each of these variable regions can be attached to the above heavy and light chain constant regions to form a complete antibody heavy and light chain, respectively. Further, each of the so generated heavy and light chain sequences can be combined to form a complete antibody structure.

Specific examples of some of the variable regions of the light and heavy chains of the antibodies that are provided and their corresponding amino acid sequences are summarized in TABLE 2.

**TABLE 2**

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Light/Heavy</th>
<th>SEQ ID NO</th>
</tr>
</thead>
<tbody>
<tr>
<td>36A4</td>
<td>5/74</td>
<td></td>
</tr>
<tr>
<td>3C4</td>
<td>7/85</td>
<td></td>
</tr>
<tr>
<td>23B5</td>
<td>9/71</td>
<td></td>
</tr>
<tr>
<td>25A4</td>
<td>10/72</td>
<td></td>
</tr>
<tr>
<td>31H4</td>
<td>12/67</td>
<td></td>
</tr>
<tr>
<td>27B2</td>
<td>13/87</td>
<td></td>
</tr>
<tr>
<td>25A7</td>
<td>15/58</td>
<td></td>
</tr>
<tr>
<td>27H5</td>
<td>16/52</td>
<td></td>
</tr>
<tr>
<td>26H5</td>
<td>17/51</td>
<td></td>
</tr>
<tr>
<td>31D1</td>
<td>18/53</td>
<td></td>
</tr>
<tr>
<td>20D10</td>
<td>19/48</td>
<td></td>
</tr>
<tr>
<td>27E7</td>
<td>20/54</td>
<td></td>
</tr>
<tr>
<td>30B9</td>
<td>21/55</td>
<td></td>
</tr>
<tr>
<td>19H9</td>
<td>22/56</td>
<td></td>
</tr>
<tr>
<td>26E10</td>
<td>23/49</td>
<td></td>
</tr>
<tr>
<td>21B12</td>
<td>23/49</td>
<td></td>
</tr>
<tr>
<td>17C2</td>
<td>24/57</td>
<td></td>
</tr>
<tr>
<td>23G1</td>
<td>26/50</td>
<td></td>
</tr>
<tr>
<td>13H1</td>
<td>28/91</td>
<td></td>
</tr>
<tr>
<td>9C5</td>
<td>30/64</td>
<td></td>
</tr>
<tr>
<td>9H6</td>
<td>31/62</td>
<td></td>
</tr>
<tr>
<td>31A4</td>
<td>32/89</td>
<td></td>
</tr>
<tr>
<td>1A12</td>
<td>33/65</td>
<td></td>
</tr>
<tr>
<td>16F12</td>
<td>35/79</td>
<td></td>
</tr>
</tbody>
</table>

Again, each of the exemplary variable heavy chains listed in Table 2 can be combined with any of the exemplary variable light chains shown in Table 2 to form an antibody. Table 2 shows exemplary light and heavy chain pairings found in several of the antibodies disclosed herein. In some instances, the antibodies include at least one variable heavy chain and one variable light chain from those listed in Table 2. In other instances, the antibodies contain two identical light chains or two identical heavy chains. As an example, an antibody or antigen binding protein can include a heavy chain and a light chain, two heavy chains, or two light chains. In some embodiments, the antibody or antigen binding protein comprises (and/or consists of) 1, 2, and/or 3 heavy and/or light CDRs from at least one of the sequences listed in Table 2 (CDRs for the sequences are outlined in FIGS. 2A-3D, and other embodiments in FIGS. 3CC-3JJ and 15A-15D). In some embodiments, all 6 CDRs (CDR1-3 from the light (CDRL1, CDRL2, CDRL3) and CDR1-3 from the heavy (CDRH1, CDRH2, and CDRH3)) are part of the ABP. In some embodiments, 1, 2, 3, 4, or 5 CDRs are included in the ABP. In some embodiments, one heavy and one light CDR from the CDRs in the sequences in Table 2 is included in the ABP (CDRs for the sequences in table 2 are outlined in FIGS. 2A-3D). In some embodiments, additional sections (e.g., as depicted in FIGS. 2A-2D, 3A-3D, and other embodiments in FIGS. 3CC-3JJ and 15A-15D) are also included in the ABP. Examples of CDRs and FRs for the heavy and light chains noted in Table 2 are outlined in FIGS. 2A-3D (and other embodiments in FIGS. 3CC-3JJ and 15A-15D). Optional light chain variable sequences (including CDRL1, CDRL2, CDRL3, FR1, FR2, FR3, and FR4) can be selected from the following: 5, 7, 9, 10, 12, 13, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 28, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 42, 44, and 46. Optional heavy chain variable sequences (including CDRH1, CDR2, CDR3, FR1, FR2, FR3, and FR4) can be selected from the following: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 83, 69, 81, and 60. In some of the entries in FIG. 2A-3D, variations of the sequences or alternative boundaries of the CDRs and FRs are identified. These alternatives are identified with a "v1" following the ABP name. As most of these alternatives are minor in nature, only sections with differences are displayed in the table. It is understood that the remaining section of the light or heavy chain is the same as shown for the base ABP in the other panels. Thus, for example, 19H9v1 in FIG. 2C has the same FR1, CDRL1, and FR2 as 19H9 in FIG. 2A as the only difference is noted in FIG. 2C. For three of the nucleic acid sequences (ABPs 26E10, 30B9, and 31B12), additional alternative nucleic acid sequences are provided in the figures. As will be appreciated by one of skill in the art, no more than one such sequence need actually be used in the creation of an
antibody or ABP. Indeed, in some embodiments, only one or neither of the specific heavy or light chain nucleic acids need be present.

In some embodiments, the ABP is encoded by a nucleic acid sequence that can encode any of the protein sequences in Table 2.

In some embodiments, the ABP binds selectively to the form of PCSK9 that binds to LDLR (e.g., the autocatalyzed form of the molecule). In some embodiments, the antigen binding protein does not bind to the C-terminus of the catalytic domain (e.g., the 5-510, 10-15, 15-20, 20-25, 25-30, 30-40 most amino acids in the C-terminus). In some embodiments, the antigen binding protein does not bind to the N-terminus of the catalytic domain (e.g., the 5-510, 10-15, 15-20, 20-25, 25-30, 30-40 most amino acids in the N-terminus). In some embodiments, the ABP binds to amino acids within amino acids 1-100 of the mature form of PCSK9. In some embodiments, the ABP binds to amino acids within (and/or amino acid sequences consisting of) amino acids 31-100, 100-200, 31-150, 150-200, 310-400, 400-500, 500-600, 600-700, 31-499, 31-699, or 600-900. In some embodiments, the ABP binds to the catalytic domain. In some embodiments, the neutralizing and/or non-neutralizing ABP binds to the prodomain. In some embodiments, the ABP binds to both the catalytic and pro domains. In some embodiments, the ABP binds to the catalytic domain so as to obstruct an area on the catalytic domain that interacts with the pro domain. In some embodiments, the ABP binds to the catalytic domain at a location or surface that the pro-domain interacts with as outlined in Piper et al. (Structure 15:1-8 (2007), the entirety of which is hereby incorporated by reference, including the structural representations therein). In some embodiments, the ABP binds to the catalytic domain and restricts the mobility of the prodomain. In some embodiments, the ABP binds to the catalytic domain without binding to the pro-domain. In some embodiments, the ABP binds to the catalytic domain, without binding to the pro-domain, while preventing the pro-domain from reorienting to allow PCSK9 to bind to LDLR. In some embodiments, the ABP binds in the same epitope as those surrounding residues 149-152 of the pro-domain in Piper et al. In some embodiments, the ABP binds to the groove (as outlined in Piper et al.) on the V domain. In some embodiments, the ABP bind to the histidine-rich patch proximal to the groove on the V domain. In some embodiments, such antibodies (that bind to the V domain) are not neutralizing. In some embodiments, antibodies that bind to the V domain are neutralizing. In some embodiments, the neutralizing ABPs prevent the binding of PCSK9 to LDLR. In some embodiments, the neutralizing ABPs, while preventing the PCSK9 degradation of LDLR, do not prevent the binding of PCSK9 to LDLR (for example ABP 31A4). In some embodiments, the ABP binds to or blocks at least one of the histidines depicted in FIG. 4 of the Piper et al. paper. In some embodiments, the ABP blocks the catalytic triad in PCSK9.

In some embodiments, the antibody binds selectively to variant PCSK9 proteins, e.g., D374Y over wild type PCSK9.

In some embodiments, these antibodies bind to the variant at least twice as strongly as the wild type, and preferably 2-5, 5-10, 10-100, 100-1000, 1000-10,000 fold more to the mutant than the wild type (as measured via an I$_{	ext{50}}$). In some embodiments, the antibody selectively inhibits variant D374Y PCSK9 from interacting with LDLR over wild type PCSK9’s ability to interact with LDLR. In some embodiments, these antibodies block the variant’s ability to bind to LDLR more strongly than the wild type’s ability, e.g., at least twice as strongly as the wild type, and preferably 2-5, 5-10, 10-100, 100-1000 fold more to the mutant than the wild type (as measured via an I$_{	ext{50}}$). In some embodiments, the antibody binds to and neutralizes both wild type PCSK9 and variant forms of PCSK9, such as D374Y at similar levels. In some embodiments, the antibody binds to PCSK9 to prevent variants of LDLR binding to PCSK9. In some embodiments, the variants of LDLR are at least 50% identical to human LDLR. It is noted that variants of LDLR are known to those of skill in the art (e.g., Brown M S et al., “Calcium cages, acid baths and recycling receptors” Nature 388: 629-630, 1997). In some embodiments, the ABP can raise the level of effective LDLR in heterozygote familial hypercholesterolemia (where a loss-of-function variant of LDLR is present).

In some embodiments, the ABP binds to (but does not block) variants of PCSK9 that are at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99, or greater percent identity to the form of PCSK9 depicted in FIG. 1A and/or FIG. 1B. In some embodiments, the ABP binds to (but does not block) variants of PCSK9 that are at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99, or greater percent identity to the form of PCSK9 depicted in FIG. 1A and/or FIG. 1B. In some embodiments, the ABP binds to and prevents variants of PCSK9 that are at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99, or greater percent identity to the form of PCSK9 depicted in FIG. 1A and/or FIG. 1B from interacting with LDLR. In some embodiments, the ABP binds to and prevents variants of PCSK9 that are at least 50%, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99, or greater percent identity to the form of PCSK9 depicted in FIG. 1B from interacting with LDLR. In some embodiments, the variant of PCSK9 is a human variant, such as variants at position 474, E620G, and/or E670G. In some embodiments, the amino acid at position 474 is valine (as in other humans) or threonine (as in cyno and mouse). Given the cross-reactivity data presented herein, it is believed that the present antibodies will readily bind to the above variants.

In some embodiments, the ABP binds to an epitope bound by one of the antibodies described in Table 2. In some embodiments, the antigen binding proteins bind to a specific conformational state of PCSK9 so as to prevent PCSK9 from interacting with LDLR.

Humanized Antigen Binding Proteins (e.g., Antibodies)

As described herein, an antibody binding protein to PCSK9 can comprise a humanized antibody and/or part thereof. An important practical application of such a strategy is the "humanization" of the mouse humoral immune system.

In certain embodiments, a humanized antibody is substantially non-immunogenic in humans. In certain embodiments, a humanized antibody has substantially the same affinity for a target as an antibody from another species from which the humanized antibody is derived. See, e.g., U.S. Pat. No. 5,530,101, U.S. Pat. No. 5,693,761; U.S. Pat. No. 5,693,762; U.S. Pat. No. 5,585,089.

In certain embodiments, amino acids of an antibody variable domain that can be modified without diminishing the native affinity of the antigen binding domain while reducing its immunogenicity are identified. See, e.g., U.S. Pat. Nos. 5,766,886 and 5,869,619.

In certain embodiments, modification of an antibody by methods known in the art is typically designed to achieve increased binding affinity for a target and/or to reduce immunogenicity of the antibody in the recipient. In certain embodiments, humanized antibodies are modified to eliminate glycosylation sites in order to increase affinity of the antibody for its cognate antigen. See, e.g., Co et al., Mol. Immunol., 30:1361-1367 (1993). In certain embodiments, techniques such as "reshaping," "hyperchimerization," or "vesicering/resurfacing" are used to produce humanized antibodies. See,
By exploiting the mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains can yield high affinity fully human antibodies against any antigen of interest, including human antigens. Using the hybridoma technology, antigen-specific human MAbs with the desired specificity can be produced and selected. Certain exemplary methods are described in WO 98/24893, U.S. Pat. No. 5,545,807, EP 546073, and EP 546073.

In certain embodiments, one can use constant regions from species other than human along with the human variable region(s).

The ability to clone and reconstruct megabase sized human loci in yeast artificial chromosomes (YACs) and to introduce them into the mouse germline provides an approach to elucidating the functional components of very large or crudely mapped loci as well as generating useful models of human disease. Furthermore, the utilization of such technology for substitution of mouse loci with their human equivalents could provide insights into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression.

Human antibodies avoid some of the problems associated with antibodies that possess murine or rat variable and/or constant regions. The presence of such murine or rat derived proteins can lead to the rapid clearance of the antibodies or can lead to the generation of an immune response against the antibody by a patient. In order to avoid the utilization of murine or rat derived antibodies, fully human antibodies can be generated through the introduction of functional human antibody loci into a rodent, other mammal or animal so that the rodent, other mammal or animal produces fully human antibodies.

Humanized antibodies are those antibodies that, while initially starting off containing antibody amino acid sequences that are not human, have had at least some of these nonhuman antibody amino acid sequences replaced with human antibody sequences. This is in contrast with human antibodies, in which the antibody is encoded (or capable of being encoded) by genes possessed a human.

Antigen Binding Protein Variants

Other antibodies that are provided are variants of the ABPs listed above formed by combination or subparts of the variable heavy and variable light chains shown in Table 2 and comprise variable light and/or variable heavy chains that each have at least 50%, 50-60, 60-70, 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, 97-99%, or above 99% identity to the amino acid sequences of the sequences in Table 2 (either the entire sequence or a subpart of the sequence, e.g., one or more CDR). In some instances, such antibodies include at least one heavy chain and one light chain, whereas in other instances the variant forms contain two identical light chains and two identical heavy chains (or subparts thereof). In some embodiments, the sequence comparison in FIGS. 2A-3D (and FIGS. 13A-13J and other embodiments in FIGS. 15A-15D) can be used in order to identify sections of the antibodies that can be modified by observing those variations that impact binding and those variations that do not appear to impact binding. For example, by comparing similar sequences, one can identify those sections (e.g., particular amino acids) that can be modified and how they can be modified while still retaining (or improving) the functionality of the ABP. In some embodiments, variants of ABPs include those consensus groups and sequences depicted in FIGS. 13A, 13C, 13I, 13G, 13H, 13J and/or 13J and variations are allowed in the positions identi-
fied as variable in the figures. The CDRs shown in FIGS. 13A, 13C, 13F, and 13G were defined based upon a hybrid combination of the Chothia method (based on the location of the structural loop regions, see, e.g., “Standard conformations for the canonical structures of immunoglobulins,” Bissam Al-Lazikani, Arthur M. Lask and Cyrus Chothia, *Journal of Molecular Biology*, 273(4): 927-948, 7 November (1997)) and the Kabat method (based on sequence variability, see, e.g., *Sequences of Proteins of Immunological Interest*, Fifth Edition. NIH Publication No. 91-3242, Kabat et al., (1991)). Each residue determined by either method, was included in the final list of CDR residues (and is presented in FIGS. 13A, 13C, 13F, and 13G). The CDRs in FIGS. 13I, 13J, and 13K were obtained by the Kabat method alone. Unless specified otherwise, the defined consensus sequences, CDRs, and FRs in FIGS. 13H-13J will define and control the noted CDRs and FRs for the referenced ABPs in FIG. 13.

In certain embodiments, an antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In certain embodiments, an antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In certain embodiments, an antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In some embodiments, the antigen binding protein comprises a sequence that is at least 90%, 90-95%, and/or 95-99% identical to one or more CDRs from the CDRs in at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In some embodiments, the antigen binding protein comprises a sequence that is at least 90%, 90-95%, and/or 95-99% identical to one or more CDRs from the CDRs in at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In some embodiments, the antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In some embodiments, the antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In some embodiments, the antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60. In some embodiments, the antigen binding protein comprises a heavy chain comprising a variable region comprising an amino acid sequence at least 95% identical to an amino acid sequence selected from at least one of the sequences of SEQ ID NO: 74, 85, 71, 72, 67, 87, 58, 52, 51, 53, 48, 54, 55, 56, 49, 57, 50, 91, 64, 62, 89, 65, 79, 80, 76, 77, 78, 78, 83, 69, 81, and 60.
13(2):222-245 (1974); Chou et al., Biochemistry, 11(2):211-222 (1974); Chou et al., Adv. Enzymol. Relat. Areas Mol. Biol., 47:45-148 (1978); Chou et al., Ann. Rev. Biochern., 47:251-276 and Chou et al., Biophys. J., 26:367-384 (1979). Moreover, computer programs are currently available to assist with predicting secondary structure. One method of predicting secondary structure is based upon homology modeling. For example, two polypeptides or proteins which have a sequence identity of greater than 30%, or similarity greater than 40% often have similar structural topologies. The recent growth of the protein structural database (PDB) has provided enhanced predictability of secondary structure, including the potential number of folds within a polypeptide’s or protein’s structure. See Holm et al., Nucl. Acid. Res., 27(1):244-247 (1999). It has been suggested (Brenner et al., Curr. Op. Struct. Biol., 7(3):369-376 (1997)) that there are a limited number of folds in a given polypeptide or protein and that in that a critical number of structures have been resolved, structural prediction will become dramatically more accurate.


In certain embodiments, antigen binding protein variants include glycosylation variants wherein the number and/or type of glycosylation site has been altered compared to the amino acid sequences of a parent polypeptide. In certain embodiments, protein variants comprise a greater or a lesser number of N-linked glycosylation sites than the native protein. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue designated as X can be any amino acid residue except proline. The substitution of amino acid residues to create this sequence provides a potential new site for the addition of an N-linked carbohydrate chain. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain. Also provided is a rearrangement of N-linked carbohydrate chains wherein one or more N-linked glycosylation sites (typically those that are naturally occurring) are eliminated and one or more new N-linked sites are created. Additional preferred antibody variants include cysteine variants wherein one or more cysteine residues are deleted from or substituted for another amino acid (e.g., serine) as compared to the parent amino acid sequence. Cysteine variants can be useful when antibodies must be refolded into a biologically active conformation such as after the isolation of insoluble inclusion bodies. Cysteine variants generally have fewer cysteine residues than the native protein, and typically have an even number to minimize interactions resulting from unpaired cysteines.

According to certain embodiments, amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinities, and/or (4) confer or modify other physicochemical or functional properties on such polypeptides. According to certain embodiments, single or multiple amino acid substitutions (in certain embodiments, conservative amino acid substitutions) can be made in the naturally-occurring sequence (in certain embodiments, in the portion of the polypeptide outside the domain(s) forming intermolecular contacts). In certain embodiments, a conservative amino acid substitution typically may not substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to break a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Proteins: Structures and Molecular Principles (Creighton, Ed., W. H. Freeman and Company, New York (1984)); Introduction to Protein Structure (C. Branden & J. Tooze, eds., Garland Publishing, New York, N.Y. (1991)); and Thornton et al., Nature, 354:105 (1991), which are each incorporated herein by reference.

In some embodiments, the variants are variants of the nucleic acid sequences of the ABPs disclosed herein. One skill in the art will appreciate that the above discussion can be used for identifying, evaluating, and creating ABP protein variants and also for nucleic acid sequences that can encode for those protein variants. Thus, nucleic acid sequences encoding for those protein variants (as well as nucleic acid sequences that encode for the ABPs in Table 2, but are different from those explicitly disclosed herein) are contemplated. For example, an AIP variant can have at least 90, 80-85, 85-90, 90-95, 95-97, 97-99 or greater identity to at least one nucleic acid sequence described in SEQ ID NOs: 152, 153, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151 or at least one to six (and various combinations thereof) of the CDR(s) encoded by the nucleic acid sequences in SEQ ID NOs: 152, 153, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, and 151.

In some embodiments, the antibody (or nucleic acid sequence encoding it) is a variant if the nucleic acid sequence that encodes the particular ABP (or the nucleic acid sequence itself) can selectively hybridize to any of the nucleic acid sequences that encode the proteins in Table 2 (such as, but not limited to SEQ ID NO: 152, 153, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, and 151) under stringent conditions. In one embodiment, suitable moderately stringent conditions include prewashing in a solution of 5xSSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0); hybridizing at 50°C, -65°C, 5xSSC, overnight or, in the event of cross-species homology, at 45°C, with 0.5xSSC; followed by washing twice at 65°C for 20 minutes with each of 2x, 0.5x, and 0.2xSSC containing 0.1% SDS. Such hybridizing DNA sequences are also within the scope of this invention, as are nucleotide sequences that, due to code degeneracy, encode an antibody polypeptide that is encoded by this hybridizing DNA sequence and the amino acid sequences that are encoded by these nucleic acid sequences. In some embodiments, variants of CDRs include nucleic acid sequences and the amino acid sequences encoded by those sequences, that hybridize to one or more of the CDRs within the sequences noted above (individual CDRs can readily be determined in light of FIGS. 2A-3D, and other embodiments in FIGS. 3CC-3JJJ and 15A-15D). The phrase “selectively hybridize” referred to in this context means to detectably and selectively bind. Polynucleotides, oligonucleotides and fragments thereof in accordance with the invention selectively hybridize to nucleic acid strands under hybridization and
wash conditions that minimize appreciable amounts of detectable binding to nonspecific nucleic acids. High stringency conditions can be used to achieve selective hybridization conditions as known in the art and discussed herein. Generally, the nucleic acid sequence homology between the polynucleotides, oligonucleotides, and fragments of the invention and a nucleic acid sequence of interest will be at least 80%, and more typically with preferably increasing homologies of at least 85%, 90%, 95%, 99%, and 100%. Two amino acid sequences are homologous if there is a partial or complete identity between their sequences. For example, 85% homology means that 85% of the amino acids are identical when the two sequences are aligned for maximum matching. Gaps (in either of the two sequences being matched) are allowed in maximizing matching; gap lengths of 5 or less are preferred with 2 or less being more preferred. Alternatively and preferably, two protein sequences (or polypeptide sequences derived from them of at least 50 amino acids in length) are homologous, as this term is used herein, if they have an alignment score of at more than 5 (in standard deviation units) using the program ALIGN with the mutation data matrix and a gap penalty of 6 or greater. See Dayhoff, M. O., in Atlas of Protein Sequence and Structure, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)) and Supplement 2 to this volume, pp. 1-10. The two sequences or parts thereof are more preferably homologous if their amino acids are greater than or equal to 50% identical when optimally aligned using the ALIGN program. The term “corresponds to” is used herein to mean that a polynucleotide sequence is homologous (i.e., is identical, not strictly evolutionary related) to all or a portion of a reference polynucleotide sequence, or that a polypeptide sequence is identical to a reference polypeptide sequence. In contradistinction, the term “complementary to” is used herein to mean that the complementary sequence is homologous to all or a portion of a reference polynucleotide sequence. For illustration, the nucleotide sequence “TATA” corresponds to a reference sequence “TATA” and is complementary to a reference sequence “GTAT”. Preparation of Antigen Binding Proteins (e.g., Antibodies)

In certain embodiments, antigen binding proteins (such as antibodies) are produced by immunization with an antigen (e.g., PCSK9). In certain embodiments, antibodies can be produced by immunization with full-length PCSK9, a soluble form of PCSK9, the catalytic domain alone, the mature form of PCSK9 shown in FIG. 1A, a splice variant form of PCSK9, or a fragment thereof. In certain embodiments, the antibodies of the invention can be polyclonal or monoclonal, and/or can be recombinant antibodies. In certain embodiments, antibodies of the invention are human antibodies prepared, for example, by immunization of transgenic animals capable of producing human antibodies (see, for example, PCT Published Application No. WO 93/12227).

In certain embodiments, certain strategies can be employed to manipulate inherent properties of an antibody, such as the affinity of an antibody for its target. Such strategies include, but are not limited to, the use of site-specific or random mutagenesis of the polynucleotide molecule encoding an antibody to generate an antibody variant. In certain embodiments, such generation is followed by screening for antibody variants that exhibit the desired change, e.g. increased or decreased affinity.

In certain embodiments, the amino acid residues targeted in mutagenic strategies are those in the CDRs. In certain embodiments, amino acids in the framework regions of the variable domains are targeted. In certain embodiments, such framework regions have been shown to contribute to the target binding properties of certain antibodies. See, e.g., Hudson, Curr. Opin. Biotech., 9:395-402 (1999) and references therein.

In certain embodiments, smaller and more effectively screened libraries of antibody variants are produced by restricting random or site-directed mutagenesis to hyper-mutation sites in the CDRs, which are sites that correspond to areas prone to mutation during the somatic affinity maturation process. See, e.g., Chowdhury & Pastan, Nature Biotech., 17: 568-572 (1999) and references therein. In certain embodiments, certain types of DNA elements can be used to identify hyper-mutation sites including, but not limited to, certain direct and inverted repeats, certain consensus sequences, certain secondary structures, and certain palindromes. For example, such DNA elements that can be used to identify hyper-mutation sites include, but are not limited to, a tetra-base sequence comprising a purine (A or G), followed by guanine (G), followed by a pyrimidine (C or T), followed by either adenosine or thymine (A or T) (i.e., A/G-G-C/T-A/ T). Another example of a DNA element that can be used to identify hyper-mutation sites is the serine codon, A/G-C/T.

Preparation of Fully Human ABPs (e.g., Antibodies)

In certain embodiments, a phage display technique is used to generate monoclonal antibodies. In certain embodiments, such techniques produce fully human monoclonal antibodies. In certain embodiments, a polynucleotide encoding a single Fab or Fv antibody fragment is expressed on the surface of a phage particle. See, e.g., Hoogenboom et al., J. Mol. Biol., 227: 381 (1991); Marks et al., J Mol Biol 222: 581 (1991); U.S. Pat. No. 5,885,793. In certain embodiments, phage are “screened” to identify those antibody fragments having affinity for target. Thus, certain such processes mimic immune selection through the display of antibody fragment repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to target. In certain such procedures, high affinity functional neutralizing antibody fragments are isolated. In certain such embodiments (discussed in more detail below), a complete repertoire of human antibody genes is created by cloning naturally rearranged human V genes from peripheral blood lymphocytes. See, e.g., Mullinax et al., Proc Natl Acad Sci (USA), 87: 8095-8099 (1990).

According to certain embodiments, antibodies of the invention are prepared through the utilization of a transgenic mouse that has a substantial portion of the human antibody producing genome inserted but that is rendered deficient in the production of endogenous, murine antibodies. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving this result are disclosed in the patents, applications and references disclosed in the specification, herein. In certain embodiments, one can employ methods such as those disclosed in PCT Published Application No. WO 98/24893 or in Mendez et al., Nature Genetics, 15:146-156 (1997), which are hereby incorporated by reference for any purpose.

Generally, fully human monoclonal ABPs (e.g., antibodies) specific for PCSK9 can be produced as follows. Transgenic mice containing human immunoglobulin genes are immunized with the antigen of interest, e.g. PCSK9, lymphatic cells (such as B-cells) from the mice that express antibodies are obtained. Such recovered cells are fused with a myeloid-type cell line to produce immortal hybridoma cell lines, and such hybridoma cell lines are screened and selected to identify hybridoma cell lines that produce antibodies specific to the antigen of interest. In certain embodiments, the
production of a hybridoma cell line that produces antibodies specific to PCSK9 is provided.

In certain embodiments, fully human antibodies are produced by exposing human splenocytes (B or T cells) to an antigen in vitro, and then reconstituting the exposed cells in an immunocompromised mouse, e.g., SCID or nude/SCID. See, e.g., Bruns et al., J. Immunol. 160: 2051-2058 (1998); Carballido et al., Nat. Med., 6: 103-106 (2000). In certain such approaches, engraftment of human fetal tissue into SCID mice (SCID-hu) results in long-term hematopoiesis and human T-cell development. See, e.g., McCune et al., Science, 241:1532-1639 (1988); Ijiverson et al., Sem. Immunol., 8:243-248 (1996). In certain instances, humoral immune response in such chimeric mice is dependent on co-development of human T-cells in the animals. See, e.g., Martensson et al., Immunol., 83:1271-179 (1994). In certain approaches, human peripheral blood lymphocytes are transplanted into SCID mice. See, e.g., Mosier et al., Nature, 335:256-259 (1988). In such embodiments, when such transplanted cells are treated either with a priming agent, such as Staphylococcal Enterotoxin A (SEA), or with anti-human CD40 monoclonal antibodies, higher levels of B cell production is detected. See, e.g., Martensson et al., Immunol., 84: 224-230 (1995); Murphy et al., Blood, 86: 1946-1953 (1995).

Thus, in certain embodiments, fully human antibodies can be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells. In other embodiments, antibodies can be produced using the phage display techniques described herein.

The antibodies described herein were prepared through the utilization of the XenoMouse® technology, as described herein. Such mice, then, are capable of producing human immunoglobulin molecules and antibodies and are deficient in the production of murine immunoglobulin molecules and antibodies. Technologies utilized for achieving the same are disclosed in the patents, applications, and references disclosed in the Background section herein. In particular, however, a preferred embodiment of transgenic production of mice and antibodies therefrom is disclosed in U.S. patent application Ser. No. 08/759,620, filed Dec. 3, 1996 and International Patent Application Nos. WO 98/24893, published Jun. 11, 1998 and WO 99/076310, published Dec. 21, 2000, the disclosures of which are hereby incorporated by reference. See also Mendez et al., Nature Genetics, 15:146-156 (1997), the disclosure of which is hereby incorporated by reference.

Through the use of such technology, fully human monoclonal antibodies to a variety of antigens have been produced. Essentially, XenoMouse® lines of mice are immunized with an antigen of interest (e.g., PCSK9), lymphatic cells (such as B-cells) are recovered from the hyper-immunized mice, and the recovered lymphocytes are fused with a myeloid-type cell line to prepare immortal hybridoma cell lines. These hybridoma cell lines are screened and selected to identify hybridoma cell lines that produced antibodies specific to the antigen of interest. Provided herein are methods for the production of multiple hybridoma cell lines that produce antibodies specific to PCSK9. Further, provided herein are characterization of the antibodies produced by such cell lines, including nucleotide and amino acid sequence analyses of the heavy and light chains of such antibodies.


Kirin has also demonstrated the generation of human antibodies from mice in which, through microcell fusion, large pieces of chromosomes, or entire chromosomes, have been introduced. See European Patent Application Nos. 773 288 and 843 961, the disclosures of which are hereby incorporated by reference. Additionally, KM™ mice, which are the result of cross-breeding of Kirin’s Tc mice with Medarex’s minilocus (Humab) mice have been generated. These mice possess the human IgG1 transchromosome of the Kirin mice and the kappa chain transgene of the Genpharm mice (Ishida et al., Cloning Stem Cells, (2002) 4:91-102).
Human antibodies can also be derived by in vitro methods. Suitable examples include but are not limited to phage display (CAT, Morphosys, Dyax, Biosite/Medarex, Xoma, Symphogen, Alexion (formerly Proliferon), Affimed) ribosome display (CAT), yeast display, and the like.

In some embodiments, the antibodies described herein possess human IgG4 heavy chains as well as IgG2 heavy chains. Antibodies can also be of other human isotypes, including IgG1. The antibodies possessed high affinities, typically possessing a Kd of from about 10^{-9} through about 10^{-13} M or below, when measured by various techniques.

As will be appreciated, antibodies can be expressed in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies can be used to transform a suitable mammalian host cell. Transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Pat. Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference). The transformation procedure used depends upon the host to be transformed. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocyte carcinoma cells (e.g., Hep G2), human epithelial kidney 293 cells, and a number of other cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels and produce antibodies with constitutive PCSK9 binding properties.

In certain embodiments, antibodies and/or ABP are produced by at least one of the following hybridomas: 21B12, 31H4, 16F12, any of the other hybridomas listed in Table 2 or disclosed in the examples. In certain embodiments, antigen binding proteins bind to PCSK9 with a dissociation constant (Kd) of less than approximately 1 nM, e.g., 100 pM to 100 pM, 100 pM to 10 pM, 10 pM to 1 pM, and/or 1 pM to 0.1 pM or less.

In certain embodiments, antigen binding proteins comprise an immunoglobulin molecule of at least one of the IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD, and IgM isotype. In certain embodiments, antigen binding proteins comprise a human kappa light chain and/or a human heavy chain. In certain embodiments, the heavy chain is of the IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD, or IgM isotype. In certain embodiments, antigen binding proteins have been cloned for expression in mammalian cells. In certain embodiments, antigen binding proteins comprise a constant region other than any of the constant regions of the IgG1, IgG2, IgG3, IgG4, IgE, IgA, IgD, and IgM isotype.

In certain embodiments, antigen binding proteins comprise a human lambda light chain and a human IgG2 heavy chain. In certain embodiments, antigen binding proteins comprise a human lambda light chain and a human IgG4 heavy chain. In certain embodiments, antigen binding proteins comprise a human lambda light chain and a human IgG1, IgG3, IgE, IgA, IgD or IgM heavy chain. In certain embodiments, antigen binding proteins comprise a human kappa light chain and a human IgG2 heavy chain. In certain embodiments, antigen binding proteins comprise a human kappa light chain and a human IgG4 heavy chain. In certain embodiments, antigen binding proteins comprise a human kappa light chain and a human IgG1, IgG3, IgE, IgA, IgD or IgM heavy chain. In certain embodiments, antigen binding proteins comprise variable regions of antibodies ligated to a constant region that is either the constant region for the IgG2 isotype, or the constant region for the IgG4 isotype. In certain embodiments, antigen binding proteins have been cloned for expression in mammalian cells.

In certain embodiments, conservative modifications to the heavy and light chains of antibodies from at least one of the hybridoma lines: 21B12, 31H4 and 16F12 (and corresponding modifications to the encoding nucleotides) will produce antibodies to PCSK9 having functional and chemical characteristics similar to those of the antibodies from the hybridoma lines: 21B12, 31H4 and 16F12. In contrast, in certain embodiments, substantial modifications in the functional and/or chemical characteristics of antibodies to PCSK9 can be accomplished by selecting substitutions in the amino acid sequence of the heavy and light chains that differ significantly in their effect on maintaining (a) the structure of the molecular backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain.

For example, a “conservative amino acid substitution” can involve a substitution of a native amino acid residue with a normative residue such that there is little or no effect on the polarity or charge of the amino acid residue at that position. Furthermore, any native residue in the polypeptide can also be substituted with alanine, as has been previously described for “alanine scanning mutagenesis.”

Desired amino acid substitutions (whether conservative or non-conservative) can be determined by those skilled in the art at the time such substitutions are desired. In certain embodiments, amino acid substitutions can be used to identify important residues of antibodies to PCSK9, or to increase or decrease the affinity of the antibodies to PCSK9 as described herein.

In certain embodiments, antibodies of the present invention can be expressed in cell lines other than hybridoma cell lines. In certain embodiments, sequences encoding particular antibodies can be used for transformation of a suitable mammalian host cell. According to certain embodiments, transformation can be by any known method for introducing polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus (or into a viral vector) and transducing a host cell with the virus (or vector) or by transfection procedures known in the art, as exemplified by U.S. Pat. Nos. 4,399,216, 4,912,040, 4,740,461, and 4,959,455 (which patents are hereby incorporated herein by reference for any purpose). In certain embodiments, the transformation procedure used can depend upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include, but are not limited to, dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are well known in the art and include, but are not limited to, many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to Chi-
nese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines. In certain embodiments, cell lines can be selected through determining which cell lines have high expression levels and produce antibodies with constitutive HGF binding properties. Appropriate expression vectors for mammalian host cells are well known.

In certain embodiments, antigen binding proteins comprise one or more polypeptides. In certain embodiments, any of a variety of expression vector/host systems can be utilized to express polynucleotide molecules encoding polypeptides comprising one or more ABP components or the ABP itself. Such systems include, but are not limited to, microorganisms, such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with baculovirus expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., cauliflower mosaic virus, CaMV, tobacco mosaic virus, TMV) or transformed with bacterial expression vectors (e.g., Ti or pBR322 plasmid); or animal cell systems.

In certain embodiments, a polypeptide comprising one or more ABP components or the ABP itself is recombinantly expressed in yeast. Certain such embodiments use commercially available expression systems, e.g., the Pichia Expression System (Invitrogen, San Diego, Calif.), following the manufacturer’s instructions. In certain embodiments, such a system relies on the pre-pro-alpha sequence to direct secretion. In certain embodiments, transcription of the insert is driven by the alcohol oxidase (AOX1) promoter upon induction by methanol.

In certain embodiments, a secreted polypeptide comprising one or more ABP components or the ABP itself is purified from yeast growth medium. In certain embodiments, the methods used to purify a polypeptide from yeast growth medium is the same as those used to purify the polypeptide from bacterial and mammalian cell supernatants.

In certain embodiments, a nucleic acid encoding a polypeptide comprising one or more ABP components or the ABP itself is cloned into a baculovirus expression vector, such as pVL1393 (PharMingen, San Diego, Calif.). In certain embodiments, such a vector can be used according to the manufacturer’s directions (PharMingen) to infect Spodoptera frugiperda cells in sf9 protein-free media and to produce recombinant polypeptide. In certain embodiments, a polypeptide is purified and concentrated from such media using a heparin-Sepharose column (Pharmacia).

In certain embodiments, a polypeptide comprising one or more ABP components or the ABP itself is expressed in an insect system. Certain insect systems for polypeptide expression are well known to those of skill in the art. In one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. In certain embodiments, a nucleic acid molecule encoding a polypeptide can be inserted into a nonessential gene of the virus, for example, within the polyhedrin gene, and placed under control of the promoter for that gene. In certain embodiments, successful insertion of a nucleic acid molecule will render the nonessential gene inactive. In certain embodiments, that inactivation results in a detectable characteristic. For example, inactivation of the polyhedrin gene results in the production of virus lacking coat protein.

In certain embodiments, recombinant viruses can be used to infect S. frugiperda cells or Trichoplusia larvae. See, e.g., Smith et al., J. Virol., 46: 584 (1983); Engelhard et al., Proc. Natl. Acad. Sci. (USA), 91: 3224-7 (1994).

In certain embodiments, polypeptides comprising one or more ABP components or the ABP itself made in bacterial cells are produced as insoluble inclusion bodies in the bacteria. In certain embodiments, host cells comprising such inclusion bodies are collected by centrifugation; washed in 0.15 M NaCl, 10 mM Tris, pH 8, 1 mM EDTA; and treated with 0.1 mg/ml lysozyme (Sigma, St. Louis, Mo.) for 15 minutes at room temperature. In certain embodiments, the lysate is cleared by sonication, and cell debris is pelleted by centrifugation for 10 minutes at 12,000 g. In certain embodiments, the polypeptide-containing pellet is resuspended in 50 mM Tris, pH 8, and 10 mM EDTA; layered over 50% glycerol; and centrifuged for 30 minutes at 6000 g. In certain embodiments, that pellet can be resuspended in standard phosphate buffered saline solution (PBS) free of Mg"⁺ and Ca"⁺. In certain embodiments, the polypeptide is further purified by fractionating the resuspended pellet in a denaturing SDS polyacrylamide gel (See, e.g., Sambrook et al., supra). In certain embodiments, such a gel can be soaked in 0.4 M KCl to visualize the protein, which can be excised and electroeluted in gel-running buffer lacking SDS. According to certain embodiments, a Glutathione-S-Transferase (GST) fusion protein is produced in bacteria as a soluble protein. In certain embodiments, such GST fusion protein is purified using a GST Purification Module (Pharmacia).

In certain embodiments, it is desirable to “refold” certain polypeptides, e.g., polypeptides comprising one or more ABP components or the ABP itself. In certain embodiments, such polypeptides are produced using certain recombinant systems discussed herein. In certain embodiments, polypeptides are “refolded” and/or oxidized to form desired tertiary structure and/or to generate disulfide linkages. In certain embodiments, such structure and/or linkages are related to certain biological activity of a polypeptide. In certain embodiments, refolding is accomplished using any of a number of procedures known in the art. Exemplary methods include, but are not limited to, exposing the solubilized polypeptide agent to a pH typically above 7 in the presence of a chaotrope agent. An exemplary chaotrope agent is guanidine. In certain embodiments, the refolding/oxidation solution also contains a reducing agent and the oxidized form of that reducing agent. In certain embodiments, the reducing agent and its oxidized form are present in a ratio that will generate a particular redox potential that allows disulfide shuffling to occur. In certain embodiments, such shuffling allows the formation of cysteine bridges. Exemplary redox couples include, but are not limited to, cysteine/cysteamine, glutathione/dithiothreitol (GSH), cupric chloride, diithiothreitol DTT/dithio-DTT, and 2-mercaptoethanol (bME)/dithio-bME. In certain embodiments, a cosolvent is used to increase the efficiency of refolding. Exemplary cosolvents include, but are not limited to, glycerol, polyethylene glycol of various molecular weights, and arginine.

In certain embodiments, one substantially purifies a polypeptide comprising one or more ABP components or the ABP itself. Certain protein purification techniques are known to those of skill in the art. In certain embodiments, protein purification involves crude fractionation of polypeptide fractions from non-polypeptide fractions. In certain embodiments, polypeptides are purified using chromatographic and/or electrophoretic techniques. Exemplary purification methods include, but are not limited to, precipitation with ammonium sulphate; precipitation with PEG; immunoprecipitation; heat denaturation followed by centrifugation; chromatography, including, but not limited to, affinity chro-
matography (e.g., Protein-A-Sepharose), ion exchange chromatography, exclusion chromatography, and reverse phase chromatography; gel filtration; hydroxyapatite chromatography; isoelectric focusing; polyacrylamide gel electrophoresis; and combinations of such and other techniques. In certain embodiments, a polypeptide is purified by fast protein liquid chromatography or by high pressure liquid chromatography (HPLC). In certain embodiments, purification steps can be changed or certain steps can be omitted, and still result in a suitable method for the preparation of a substantially purified polypeptide.

In certain embodiments, one quantitates the degree of purification of a polypeptide preparation. Certain methods for quantifying the degree of purification are known to those of skill in the art. Certain exemplary methods include, but are not limited to, determining the specific binding activity of the preparation and assessing the amount of a polypeptide within a preparation by SDS/PAGE analysis. Certain exemplary methods for assessing the amount of purification of a polypeptide preparation comprise calculating the binding activity of a preparation and comparing it to the binding activity of an initial extract. In certain embodiments, the results of such a calculation are expressed as “fold purification.” The units used to represent the amount of binding activity depend upon the particular assay performed.

In certain embodiments, a polypeptide comprising one or more ABP components or the ABP itself is partially purified. In certain embodiments, partial purification can be accomplished by using fewer purification steps or by utilizing different forms of the same general purification scheme. For example, in certain embodiments, cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater “fold purification” than the same technique utilizing a low-pressure chromatography system. In certain embodiments, methods resulting in a lower degree of purification can have advantages in total recovery of polypeptide, or in maintaining binding activity of a polypeptide.

In certain instances, the electrophoretic migration of a polypeptide can vary, sometimes significantly, with different conditions of SDS/PAGE. See, e.g., Capaldi et al., Biochem. Biophys. Res. Comm., 76: 425 (1977). It will be appreciated that under different electrophoresis conditions, the apparent molecular weights of purified or partially purified polypeptide can be different.

Exemplary Epitopes

Epitopes to which anti-PCSK9 antibodies bind are provided. In some embodiments, epitopes that are bound by the presently disclosed antibodies are particularly useful. In some embodiments, antigen binding proteins that bind to any of the epitopes that are bound by the antibodies described herein are useful. In some embodiments, the epitopes bound by any of the antibodies listed in Table 2 and FIGS. 2 and 3 are especially useful. In some embodiments, the epitope is on the catalytic domain PCSK9.

In certain embodiments, a PCSK9 epitope can be utilized to prevent (e.g., reduce) binding of an anti-PCSK9 antibody or antigen binding protein to PCSK9. In certain embodiments, a PCSK9 epitope can be utilized to decrease binding of an anti-PCSK9 antibody or antigen binding protein to PCSK9. In certain embodiments, a PCSK9 epitope can be utilized to substantially inhibit binding of an anti-PCSK9 antibody or antigen binding protein to PCSK9.

In certain embodiments, a PCSK9 epitope can be utilized to isolate antibodies or antigen binding proteins that bind to PCSK9. In certain embodiments, a PCSK9 epitope can be utilized to generate antibodies or antigen binding proteins which bind to PCSK9. In certain embodiments, a PCSK9 epitope or a sequence comprising a PCSK9 epitope can be utilized as an immunogen to generate antibodies or antigen binding proteins that bind to PCSK9. In certain embodiments, a PCSK9 epitope can be administered to an animal, and antibodies that bind to PCSK9 can subsequently be obtained from the animal. In certain embodiments, a PCSK9 epitope or a sequence comprising a PCSK9 epitope can be utilized to interfere with normal PCSK9-mediated activity, such as association of PCSK9 with the LDLR.

In some embodiments, antigen binding proteins disclosed herein bind specifically to N-terminal prodomain, a subtilisin-like catalytic domain and/or a C-terminal domain. In some embodiments, the antigen binding protein binds to the substrate-binding groove of PCSK9 (described in Cunningham et al., incorporated herein in its entirety by reference).

In some embodiments, the domain(s)/region(s) containing residues that are in contact with or are buried by an antibody can be identified by mutating specific residues in PCSK9 (e.g., a wild-type antigen) and determining whether the antigen binding protein can bind the mutated or variant PCSK9 protein. By making a number of individual mutations, residues that play a direct role in binding or that are in sufficiently close proximity to the antibody such that a mutation can affect binding between the antigen binding protein and antigen can be identified. From a knowledge of these amino acids, the domain(s) or region(s) of the antigen that contain residues in contact with the antigen binding protein or covered by the antibody can be elucidated. Such a domain can include the binding epitope of an antigen binding protein. One specific example of this general approach utilizes an arginine/glutamic acid scanning protocol (see, e.g., Nanveux, T., et al., 1995, J. Biol. Chem., 270:37, 21619-21625 and Zupnick, A., et al., 2006, J. Biol. Chem., 281:29, 20464-20473). In general, arginine and glutamic acids are substituted (typically individually) for an amino acid in the wild-type polypeptide because these amino acids are charged and bulky and thus have the potential to disrupt binding between an antigen binding protein and an antigen in the region of the antigen where the mutation is introduced. Arginines that exist in the wild-type antigen are replaced with glutamic acid. A variety of such individual mutants are obtained and the collected binding results analyzed to determine what residues affect binding.

Example 39 describes one such arginine/glutamic acid scanning of PCSK9 for PCSK9 antigen binding proteins provided herein. A series of mutant PCSK9 antigens were created, with each mutant antigen having a single mutation. Binding of each mutant PCSK9 antigen with various PCSK9 ABPs was measured and compared to the ability of the selected ABPs to bind wild-type PCSK9 (SEQ ID NO: 305). An alteration (for example a reduction or increase) in binding between an antigen binding protein and a variant PCSK9 as used herein means that there is a change in binding affinity (e.g., as measured by known methods such as Biacore testing or the bead based assay described below in the examples), EC_{50} and/or a change (for example a reduction) in the total binding capacity of the antigen binding protein (for example, as evidenced by a decrease in Bmax in a plot of antigen binding protein concentration versus antigen concentration). A significant alteration in binding indicates that the mutated residue is directly involved in binding to the antigen binding protein or is in close proximity to the binding protein when the binding protein is bound to antigen.

In some embodiments, a significant reduction in binding means that the binding affinity, EC_{50}, and/or capacity between an antigen binding protein and a mutant PCSK9
antigen is reduced by greater than 10%, greater than 20%, greater than 40%, greater than 50%, greater than 55%, greater than 60%, greater than 65%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90% or greater than 95% relative to binding between the antigen binding protein and a wild-type PCSK9 (e.g., shown in SEQ ID NO: 1 and/or SEQ ID NO: 303). In certain embodiments, binding is reduced below detectable limits. In some embodiments, a significant reduction in binding is evidenced when binding of an antigen binding protein to a variant PCSK9 protein is less than 50% (for example, less than 40%, 35%, 30%, 25%, 20%, 15% or 10%) of the binding observed between the antigen binding protein and a wild-type PCSK9 protein (for example, the protein of SEQ ID NO: 1 and/or SEQ ID NO: 303). Such binding measurements can be made using a variety of binding assays known in the art. A specific example of one such assay is described in Example 39.

In some embodiments, antigen binding proteins are provided that exhibit significantly lower binding for a variant PCSK9 protein in which a residue in a wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303) is substituted with arginine or glutamic acid. In some embodiments, binding of an antigen binding protein is significantly reduced or increased for a variant PCSK9 protein having one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 244) of the following mutations: R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S3351R, A390R, A413R, and S582R within SEQ ID NO: 1 or SEQ ID NO: 303, as compared to a wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). In some embodiments, the binding is reduced. In some embodiments, the reduction in binding is observed as a change in EC50. In some embodiments, the change in EC50 is an increase in the numerical value of the EC50 (and thus is a decrease in binding).

In some embodiments, binding of an ABP is significantly reduced or increased for a mutant PCSK9 protein having one or more (e.g., 1, 2, 3, 4, 5, etc.) of the following mutations: R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S3351R, A390R, A413R, E582R, D162R, R164E, R167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R within SEQ ID NO: 1, as compared to a wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). In some embodiments, the binding is reduced. In some embodiments, the reduction in binding is observed as a change in Bmax. In some embodiments, the shift in Bmax is a reduction of the maximum signal generated by the ABP. In some embodiments, for an amino acid to be part of an epitope, the Bmax is reduced by at least 10%, for example, reductions of at least any of the following amounts: 20, 30, 40, 50, 60, 70, 80, 90, 95, 98, 99, or 100 percent can, in some embodiments, indicate that the residue is part of the epitope.

Although the variant forms just listed are referenced with respect to the wild-type sequence shown in SEQ ID NO: 1 or SEQ ID NO: 303, it will be appreciated that in an allelic variant of PCSK9 the amino acid at the indicated position could differ. Antigen binding proteins showing significantly lower binding for such allelic forms of PCSK9 are also contemplated. Accordingly, in some embodiments, any of the above embodiments can be compared to an allelic sequence, rather than purely the wild-type sequence shown in FIG. 1A.

In some embodiments, binding of an antigen binding protein is significantly reduced for a variant PCSK9 protein in which the residue at a selected position in the wild-type PCSK9 protein is mutated to any other residue. In some embodiments, the herein described arginine/glutamic acid replacements are used for the identified positions. In some embodiments, alanine is used for the identified positions.

As noted above, residues directly involved in binding or covered by an antigen binding protein can be identified from scanning results. These residues can thus provide an indication of the domains or regions of SEQ ID NO: 1 (or SEQ ID NO: 303 or SEQ ID NO: 3) that contain the binding region(s) to which antigen binding proteins bind. As can be seen from the results summarized in Example 39, in some embodiments an antigen binding protein binds to a domain containing at least one of amino acids: 207, 208, 185, 181, 439, 513, 538, 539, 132, 351, 390, 413, 582, 162, 164, 167, 123, 129, 311, 313, 337, 519, 521, and 554, as shown in SEQ ID NO: 1 and/or SEQ ID NO: 303, as compared to a wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). In some embodiments, as compared to a wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303).

In some embodiments, binding of an ABP is significantly reduced or increased for a mutant PCSK9 protein having one or more (e.g., 1, 2, 3, 4, 5) of the following mutations: R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S3351R, A390R, A413R, E582R, D162R, R164E, E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R within SEQ ID NO: 1 and/or SEQ ID NO: 303. In some embodiments, as compared to a wild-type PCSK9 protein (e.g., SEQ ID NO: 1 or SEQ ID NO: 303). In some embodiments, binding of an ABP is significantly reduced or increased for a mutant PCSK9 protein having one or more (e.g., 1, 2, 3, 4, 5, etc.) of the following mutations: R207E, D208R, R185E, R439E, E513R, V538R, E539R, T132R, S3351R, A390R, A413R, E582R, D162R, R164E, E167R, S123R, E129R, A311R, D313R, D337R, R519E, H521R, and Q554R within SEQ ID NO: 1 and/or SEQ ID NO: 303.
In some embodiments, the antigen binding protein binds to a region containing at least one of amino acid 185 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, the ABP competes with ABP 311H4.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 439, 513, 538, and/or 539 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than one (e.g., 2, 3, or 4) of the identified residues are part of the region that is bound by the ABP. In some embodiments, the ABP competes with ABP 31A4.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acids 123, 129, 311, 313, 337, 132, 351, 390, and/or 413 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than one (e.g., 2, 3, 4, 5, 6, 7, 8, or 9) of the identified residues are part of the region that is bound by the ABP. In some embodiments, the ABP competes with ABP 12H11.

In some embodiments, the antigen binding protein binds to a region containing at least one of amino acid 582, 519, 521, and/or 554 of SEQ ID NO: 1 or SEQ ID NO: 303. In some embodiments, more than one (e.g., 2, 3, or 4) of the identified residues are part of the region that is bound by the ABP. In some embodiments, the ABP competes with ABP 3C4.

In some embodiments, the antigen binding proteins binds to the foregoing regions within a fragment or the full length sequence of SEQ ID NO: 1 or SEQ ID NO: 303. In other embodiments, antigen binding proteins bind to polypeptides consisting of these regions. The reference to “SEQ ID NO: 1 or SEQ ID NO: 303” denotes that one or both of these sequences can be employed or relevant. The phrase does not denote that only one should be employed.

As noted above, the above description references specific amino acid positions with reference to SEQ ID NO: 1. However, throughout the specification generally, reference is made to a ProCat domain that commences at position 31, which is provided in SEQ ID NO: 3. As noted below, SEQ ID NO: 1 and SEQ ID NO: 303 lack the signal sequence of PCSK9. As such, any comparison between these various disclosures should take this difference in numbering into account. In particular, any amino acid position in SEQ ID NO: 1, will correspond to an amino acid position 30 amino acids further into the protein in SEQ ID NO: 3. For example, position 207 of SEQ ID NO: 1, corresponds to position 237 of SEQ ID NO: 3 (the full length sequence, and the numbering system used in the present specification generally). Table 39.6 outlines how the above noted positions, which reference SEQ ID NO: 1 (and/or SEQ ID NO: 303) correspond to SEQ ID NO: 3 (which includes the signal sequence). Thus, any of the above noted embodiments that are described in regard to SEQ ID NO: 1 (and/or SEQ ID NO: 303), are described in reference to SEQ ID NO: 3, by the noted corresponding positions.

In some embodiments, ABP 21B12 binds to an epitope including residues 162-167 (e.g., residues D162-E167 of SEQ ID NO: 1). In some embodiments, ABP 12H11 binds to an epitope that includes residues 123-132 (e.g., residues S123-T132 of SEQ ID NO: 1). In some embodiments, ABP 12H11 binds to an epitope that includes residues 311-313 (e.g., residues A311-D313 of SEQ ID NO: 1). In some embodiments, ABPs can bind to an epitope that includes any one of these strands of sequences. Competing Antigen Binding Proteins

In another aspect, antigen binding proteins are provided that compete with one of the exemplified antibodies or functional fragments binding to the epitope described herein for specific binding to PCSK9. Such antigen binding proteins can also bind to the same epitope as one of the herein exemplified antigen binding proteins, or an overlapping epitope. Antigen binding proteins and fragments that compete with or bind to the same epitope as the exemplified antigen binding proteins are expected to show similar functional properties. The exemplified antigen binding proteins and fragments include those described above, including those with the heavy and light chains, variable region domains and CDRs included in TABLE 2. And/or FIGS. 2-3 and 15. Thus, as a specific example, the antigen binding proteins that are provided include those that compete with an antibody or antigen binding protein having:

(a) all 6 of the CDRs listed for an antibody listed in FIGS. 2-3 and 15;
(b) a VH and a VL listed for an antibody listed in Table 2; or
(c) two light chains and two heavy chains as specified for an antibody listed in Table 2.

Certain Therapeutic Uses and Pharmaceutical Compositions

In certain instances, PCSK9 activity correlates with a number of human disease states. For example, in certain instances, too much or too little PCSK9 activity correlates with certain conditions, such as hypercholesterolemia. Therefore, in certain instances, modulating PCSK9 activity can be therapeutically useful. In certain embodiments, a neutralizing antigen binding protein to PCSK9 is used to modulate at least one PCSK9 activity (e.g., binding to LDLR). Such methods can treat and/or prevent and/or reduce the risk of disorders that relate to elevated serum cholesterol levels or in which elevated cholesterol levels are relevant.

As will be appreciated by one of skill in the art, in light of the present disclosure, disorders that relate to, involve, or can be influenced by varied cholesterol, LDL, or LDLR levels can be addressed by various embodiments of the antigen binding proteins. In some embodiments, a “cholesterol related disorder” (which includes “serum cholesterol related disorders”) includes any one or more of the following: hypercholesterolemia, heart disease, metabolic syndrome, diabetes, coronary heart disease, stroke, cardiovascular diseases, Alzheimer disease and generally dyslipidemias, which can be manifested, for example, by an elevated total serum cholesterol, elevated LDL, elevated triglycerides, elevated VLDL, and/or low HDL. Some non-limiting examples of primary and secondary dyslipidemias that can be treated using an ABP, either alone, or in combination with one or more other agents include the metabolic syndrome, diabetes mellitus, familial combined hyperlipidemia, familial hypertriglyceridemia, familial hypercholesterolemias, including heterozygous hypercholesterolemia, homozigous hypercholesterolemia, familial defective apolipoprotein B-100, polygenic hypercholesterolemia; remnant removal disease, hepatic lipase deficiency; dyslipidemia secondary to any of the following: dietary indiscretion, hypothyroidism, drugs including estrogen and progestin therapy, beta-blockers, and thiazide diuretics; nephrotic syndrome, chronic renal failure, Cushing’s syndrome, primary biliary cirrhosis, glycogen storage diseases, hepatitis, cholestasis, acromegaly, insulinoma, isolated growth hormone deficiency, and alcohol-induced hypertriiglyceridemia. ABP can also be useful in preventing or treating atherosclerotic diseases, such as, for example, coronary heart disease, coronary artery disease, peripheral arterial disease, stroke (ischaemic and hemorrhagic), angina pectoris, or cerebrovascular disease and acute coronary syndrome, myocardial infarction. In some embodiments, the ABP is useful in reducing the risk of: nonfatal heart attacks, fatal and non-fatal strokes, certain types of heart surgery, hospitalization for heart failure, chest pain in patients with heart disease, and/or cardiovascular events because of established heart disease such as prior heart attack, prior heart surgery, and/or chest pain with evidence of clogged arteries.
In some embodiments, the ABP and methods can be used to reduce the risk of recurrent cardiovascular events.

As will be appreciated by one of skill in the art, diseases or disorders that are generally addressable (either treatable or preventable) through the use of statins can also benefit from the application of the instant antigen binding proteins. In addition, in some embodiments, disorders or disease that can benefit from the prevention of cholesterolemia synthesis or increased LDLR expression can also be treated by various embodiments of the antigen binding proteins. In addition, as will be appreciated by one of skill in the art, the use of the anti-PCSK9 antibodies can be especially useful in the treatment of Diabetes. Not only is Diabetes a risk factor for coronary heart disease, but insulin increases the expression of PCSK9. That is, people with Diabetes have elevated plasma lipid levels (which can be related to high PCSK9 levels) and are therefore at higher risk of developing diabetes. This is generally discussed in more detail in Costet et al. ("Hepatic PCSK9 Expression is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-Binding Protein IC", J. Biol. Chem., 281: 6211-6218, 2006), the entirety of which is incorporated herein by reference.

In some embodiments, the antigen binding protein is administered to those who have diabetes mellitus, abdominal aortic aneurysm, atherosclerosis and/or peripheral vascular disease in order to decrease their serum cholesterol levels to a safer range. In some embodiments, the antigen binding protein is administered to patients at risk of developing any of the herein described disorders. In some embodiments, the ABPs are administered to subjects that smoke, have hypertension or a familial history of early heart attacks.

In some embodiments, a subject is administered an ABP if they are at a moderate risk or higher on the 2004 NCEP treatment goals. In some embodiments, the ABP is administered to a subject if the subject’s LDL cholesterol level is greater than 100 mg/dL. In some embodiments, the ABP is administered if the subjects LDL cholesterol level is greater than 130 (and they have a moderate or moderately high risk according to the 2004 NCEP treatment goals). In some embodiments, the ABP is administered if the subjects LDL cholesterol level is greater than 100 (and they have a high or very high risk according to the 2004 NCEP treatment goals).

A physician will be able to select an appropriate treatment indications and target lipid levels depending on the individual profile of a particular patient. One well-accepted standard for guiding treatment of hyperlipidemia is the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of the High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report, National Institutes of Health, NIH Publication No. 02-5215 (2002), the printed publication of which is hereby incorporated by reference in its entirety.

In some embodiments, antigen binding proteins to PCSK9 are used to decrease the amount of PCSK9 activity from an abnormally high level or even a normal level. In some embodiments, antigen binding proteins to PCSK9 are used to treat or prevent hypercholesterolemia and/or in the preparation of medications therefore and/or for other cholesterol related disorders (such as those noted herein). In certain embodiments, an antigen binding protein to PCSK9 is used to treat or prevent conditions such as hypercholesterolemia in which PCSK9 activity is normal. In such conditions, for example, reduction of PCSK9 activity to below normal can provide a therapeutic effect.

In some embodiments, more than one antigen binding protein to PCSK9 is used to modulate PCSK9 activity.

In certain embodiments, methods are provided of treating a cholesterol related disorder, such as hypercholesterolemia comprising administering a therapeutically effective amount of one or more antigen binding proteins to PCSK9 and another therapeutic agent.

In certain embodiments, an antigen binding protein to PCSK9 is administered alone. In certain embodiments, an antigen binding protein to PCSK9 is administered prior to the administration of at least one other therapeutic agent. In certain embodiments, an antigen binding protein to PCSK9 is administered concurrent with the administration of at least one other therapeutic agent. In certain embodiments, an antigen binding protein to PCSK9 is administered subsequent to the administration of at least one other therapeutic agent. In other embodiments, an antigen binding protein to PCSK9 is administered prior to the administration of at least one other therapeutic agent. Therapeutic agents (apart from the antigen binding protein), include, but are not limited to, at least one other cholesterol-lowering (serum and/or total body cholesterol) agent or an agent. In some embodiments, the agent increases the expression of LDLR, have been observed to increase serum HDL levels, lower LDL levels or lower triglyceride levels. Exemplary agents include, but are not limited to, statins (atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin), Nicotinic acid (Nicacin) (NIACOR, NIASPAN (slow release nicacin), SLO-NIACIN (slow release nicain)), Fibric acid (LOPİD (Gemfibrozil), TRİCOR (fenofibrate), Bile acid sequestrants (QUESTRAN (cholestyramine), colesevelam (WELCHOL), COLESTİD (colestipol)), Cholesterol absorption inhibitors (ZETIA (ezetimibe)), Combining nicotinic acid with statin (ADVİCOR (LOVASTİTİN and NIASPAN), Combining a statin with an absorption inhibitor (VYTORİN (ZOCOR and ZETIA)) and/or lipid modifying agents. In some embodiments, the ABP is combined with PPAR gamma agonists, PPAR alpha/gamma agonists, squalene synthase inhibitors, CETP inhibitors, anti-hypertensives, anti-diabetic agents (such as sulphonylureas, insulin, GLP-1 analogs, DDP14 inhibitors), ApoB modulators, MTP inhibitors and/or arteriosclerosis obliterans treatments. In some embodiments, the ABP is combined with an agent that increases the level of LDLR protein in a subject, such as statins, certain cytokines like oncostatin M, estrogen, and/or certain herbal ingredients such as berberine. In some embodiments, the ABP is combined with an agent that increases serum cholesterol levels in a subject (such as certain anti-psycotic agents, certain HIV protease inhibitors, dietary factors such as high fructose, sucrose, cholesterol or certain fatty acids and certain nuclear receptor agonists and antagonists for RXR, RAR, LXR, FXR). In some embodiments, the ABP is combined with an agent that increases the level of PCSK9 in a subject, such as statins and/or insulin. The combination of the two can allow for the undesirable side-effects of other agents to be mitigated by the ABP. As will be appreciated by one of skill in the art, in some embodiments, the ABP is combined with the other agent/compound. In some embodiments, all the ABP and other agent are administered concurrently. In some embodiments, the ABP and other agent are not administered simultaneously, with the ABP being administered before or after the agent is administered. In some embodiments, the subject receives both the ABP and the other agent (that increases the level of LDLR) during a same period of prevention, occurrence of a disorder, and/or period of treatment.

Pharmaceutical compositions of the invention can be administered in combination therapy, i.e., combined with other agents. In certain embodiments, the combination therapy comprises an antigen binding protein capable of
binding PCSK9, in combination with at least one anti-cholesterol agent. Agents include, but are not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, and combinations and conjugates thereof. In certain embodiments, an agent can act as an agonist, antagonist, allosteric modulator, or toxin. In certain embodiments, an agent can act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition), and thereby promote increased expression of LDLR or decrease serum cholesterol levels.

In certain embodiments, an antigen binding protein to PCSK9 can be administered prior to, concurrently with, and subsequent to treatment with a cholesterol-lowering (serum and/or total cholesterol) agent. In certain embodiments, an antigen binding protein to PCSK9 can be administered prophylactically to prevent or mitigate the onset of hypercholesterolemia, heart disease, diabetes, and/or any of the cholesterol related disorder. In certain embodiments, an antigen binding protein to PCSK9 can be administered for the treatment of an existing hypercholesterolemia condition. In some embodiments, the ABP delays the onset of the disorder and/or symptoms associated with the disorder. In some embodiments, the ABP is provided to a subject lacking any symptoms of any one of the cholesterol related disorders or a subset thereof.

In certain embodiments, an antigen binding protein to PCSK9 is used with particular therapeutic agents to treat various cholesterol related disorders, such as hypercholesterolemia. In certain embodiments, in view of the condition and the desired level of treatment, two, three, or more agents can be administered. In certain embodiments, such agents can be provided together by inclusion in the same formulation. In certain embodiments, such agent(s) and an antigen binding protein to PCSK9 can be provided together by inclusion in the same formulation. In certain embodiments, such agents can be formulated separately and provided together by inclusion in a treatment kit. In certain embodiments, such agents and an antigen binding protein to PCSK9 can be formulated separately and provided together by inclusion in a treatment kit. In certain embodiments, such agents can be provided separately. In certain embodiments, when administered by gene therapy, the genes encoding protein agents and/or an antigen binding protein to PCSK9 can be included in the same vector. In certain embodiments, the genes encoding protein agents and/or an antigen binding protein to PCSK9 can be under the control of the same promoter region. In certain embodiments, the genes encoding protein agents and/or an antigen binding protein to PCSK9 can be in separate vectors.

In certain embodiments, the invention provides for pharmaceutical compositions comprising an antigen binding protein to PCSK9 together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant.

In certain embodiments, the invention provides for pharmaceutical compositions comprising an antigen binding protein to PCSK9 and a therapeutically effective amount of at least one additional therapeutic agent, together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and/or adjuvant.

In certain embodiments, an antigen binding protein to PCSK9 can be used with at least one therapeutic agent for inflammation. In certain embodiments, an antigen binding protein to PCSK9 can be used with at least one therapeutic agent for an immune disorder. Exemplary therapeutic agents for inflammation and immune disorders include, but are not limited to cyclooxygenase type 1 (COX-1) and cyclooxygenase type 2 (COX-2) inhibitors small molecular weight modulators of 38 kDa mitogen-activated protein kinase (p38-MAK); small molecule modulators of intracellular molecules involved in inflammation pathways, wherein such intracellular molecules include, but are not limited to, jnk, IKK, NF-kB, ZAP70, and lck. Certain exemplary therapeutic agents for inflammation are described, e.g., in C. A. Dinarello & L. L. Moldawer Proinflammatory and Anti-Inflammatory Cytokines in Rheumatoid Arthritis: A Primer for Clinicians Third Edition (2001) Amgen Inc. Thousand Oaks, Calif.

In certain embodiments, pharmaceutical compositions will include more than one different antigen binding protein to PCSK9. In certain embodiments, pharmaceutical compositions will include more than one antigen binding protein to PCSK9 wherein the antigen binding proteins to PCSK9 bind more than one epitope. In some embodiments, the various antigen binding proteins will not compete with one another for binding to PCSK9. In some embodiments, any of the antigen binding proteins depicted in Table 2 and FIGS. 2 and/or 3 can be combined together in a pharmaceutical composition.

In certain embodiments, acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed. In some embodiments, the formulation material(s) are for s.c. and/or I.V. administration. In certain embodiments, the pharmaceutical composition can contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In certain embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfate or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzolic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as phuronic, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxaopal); stability enhancing agents (such as sucrose or sorbitol); toxicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. (Remington's Pharmaceutical Sciences, 18th Edition, A. R. Gennaro, ed., Mack Publishing Company (1995). In some embodiments, the formulation comprises PBS; 20 mM NaOAc, pH 5.2, 50 mM NaCl; and/or 10 mM NaOAC, pH 5.2, 9% Sucrose.

In certain embodiments, an antigen binding protein to PCSK9 and/or a therapeutic molecule is linked to a half-life extending vehicle known in the art. Such vehicles include, but are not limited to, polyethylene glycol, glycogen (e.g., glycosylation of the ABP), and dextran. Such vehicles are
In certain embodiments, the optimal pharmaceutical composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format and desired dosage. See, for example, Remington's Pharmaceutical Sciences, supra. In certain embodiments, such compositions may influence the physical state, stability, rate of in vivo release and rate of in vivo clearance of the antibodies of the invention.

In certain embodiments, the primary vehicle or carrier in a pharmaceutical composition can be either aqueous or non-aqueous in nature. For example, in certain embodiments, a suitable vehicle or carrier can be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other excipients common in compositions for parenteral administration. In some embodiments, the saline comprises isotonic phosphate-buffered saline. In certain embodiments, neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. In certain embodiments, pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of about pH 4.0-5.5, which can further include sorbitol or a suitable substitute therefore. In certain embodiments, a composition comprising an antigen binding protein to PCSK9, with or without at least one additional therapeutic agents, can be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (Remington's Pharmaceutical Sciences, supra) in the form of a lyophilized cake or an aqueous solution. Further, in certain embodiments, a composition comprising an antigen binding protein to PCSK9, with or without at least one additional therapeutic agents, can be formulated as a lyophilize using appropriate excipients such as sucrose.

In certain embodiments, the pharmaceutical composition can be selected for parenteral delivery. In certain embodiments, the compositions can be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the ability of one skilled in the art.

In certain embodiments, the formulation components are present in concentrations that are acceptable to the site of administration. In certain embodiments, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8.

In certain embodiments, when parenteral administration is contemplated, a therapeutic composition can be in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising a desired antigen binding protein to PCSK9, with or without additional therapeutic agents, in a pharmaceutically acceptable vehicle. In certain embodiments, a vehicle for parenteral injection is sterile distilled water in which an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, is formulated as a sterile, isotonic solution, preferably preserved. In certain embodiments, the preparation can involve the formulation of the desired molecule with an agent, such as injectable microparticles, bio-erodible particles, polymeric compounds (such as polyactic acid or polylactic acid), beads or liposomes, that can provide for the controlled or sustained release of the product which can then be delivered via a depot injection. In certain embodiments, hyaluronic acid can also be used, and have the effect of promoting sustained duration in the circulation. In certain embodiments, implantable drug delivery devices can be used to introduce the desired molecule.

In certain embodiments, a pharmaceutical composition can be formulated for inhalation. In certain embodiments, an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, can be formulated as a dry powder for inhalation. In certain embodiments, an inhalation solution comprising an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, can be formulated with a propellant for aerosol delivery. In certain embodiments, solutions can be nebulized. Pulmonary administration is further described in PCT application no. PCT/US94/001875, which describes pulmonary delivery of chemically modified proteins.

In certain embodiments, it is contemplated that formulations can be administered orally. In certain embodiments, an antigen binding protein to PCSK9, with or without at least one additional therapeutic agents, that is administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. In certain embodiments, a capsule can be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. In certain embodiments, at least one additional agent can be included to facilitate absorption of an antigen binding protein to PCSK9 and/or any additional therapeutic agents. In certain embodiments, diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspended agents, tablet disintegrating agents, and binders can also be employed.

In certain embodiments, a pharmaceutical composition can involve an effective quantity of an antigen binding protein to PCSK9, with or without at least one additional therapeutic agents, in a mixture with non-toxic excipients which are suitable for the manufacture of tablets. In certain embodiments, by dissolving the tablets in sterile water, or another appropriate vehicle, solutions can be prepared in unit-dose form. In certain embodiments, suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or sacc; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional pharmaceutical compositions will be evident to those skilled in the art, including formulations involving antigen binding proteins to PCSK9, with or without at least one additional therapeutic agent(s), in sustained- or controlled-delivery formulations. In certain embodiments, techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See for example, PCT Application No. PCT/US93/00829 which describes the controlled release of porous polymeric microparticles for the delivery of pharmaceutical compositions. In certain embodiments, sustained-release preparations can include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices can include polyesters, hydrogels, polyalkydes (U.S. Pat. No. 3,773,919 and EP 058,481), copolymers of 1-glutamic acid and gamma ethyl-L-glutamate (Sidman et al., Biopolymers, 22:547-556 (1983)), poly(2-hydroxyethyl-methacrylate) (Langer et al., J. Biomed. Mater. Res., 15:167-277 (1981) and Langer, Chem. Tech., 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., supra) or poly(eX)-3-hydroxybutyric acid (EP 133,988). In certain embodiments, sustained release
compositions can also include liposomes, which can be prepared by any of several methods known in the art. See, e.g., Eppstein et al., Proc. Natl. Acad. Sci. USA, 82:3688-3692 (1985); EP 056,676; EP 088,046 and EP 143,949.

The pharmaceutical composition to be used for in vivo administration typically is sterile. In certain embodiments, this can be accomplished by filtration through sterile filtration membranes. In certain embodiments, where the composition is lyophilized, sterilization using this method can be conducted either prior to or following lyophilization and reconstitution. In certain embodiments, the composition for parenteral administration can be stored in lyophilized form or in a solution. In certain embodiments, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierced by a hypodermic injection needle.

In certain embodiments, once the pharmaceutical composition has been formulated, it can be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or as a dehydrated or lyophilized powder. In certain embodiments, such formulations can be stored either in a ready-to-use form or in a form (e.g., lyophilized) that is reconstituted prior to administration.

In certain embodiments, kits are provided for producing a single-dose administration unit. In certain embodiments, the kit can contain both a first container having a dried protein and a second container having an aqueous formulation. In certain embodiments, kits containing single and multi-chambered pre-filled syringes (e.g., liquid syringes and lysis syringes) are included. In certain embodiments, the effective amount of a pharmaceutical composition comprising an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment, according to certain embodiments, will thus vary depending, in part, upon the molecule delivered, the indication for which an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, is being used, the route of administration, and the size (body weight, body surface or organ size) and/or condition (the age and general health) of the patient. In certain embodiments, the clinician can titrate the dosage and modify the route of administration to obtain the optimal therapeutic effect. In certain embodiments, a typical dosage can range from about 0.1 μg/kg up to about 100 mg/kg or more, depending on the factors mentioned above. In certain embodiments, the dosage can range from 0.1 μg/kg up to about 100 mg/kg; or 1 μg/kg up to about 100 mg/kg; or 5 μg/kg up to about 100 mg/kg.

In certain embodiments, the frequency of dosing will take into account the pharmacokinetic parameters of an antigen binding protein to PCSK9 and/or any additional therapeutic agents in the formulation used. In certain embodiments, a clinician will administer the composition until a dosage is reached that achieves the desired effect. In certain embodiments, the composition can therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via an implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. In certain embodiments, appropriate dosages can be ascertained through use of appropriate dose-response data. In some embodiments, the amount and frequency of administration can take into account the desired cholesterol level (serum and/or total) to be obtained and the subject’s present cholesterol level, LDL level, and/or LDL-R levels, all of which can be obtained by methods that are well known to those of skill in the art.

In certain embodiments, the route of administration of the pharmaceutical composition is in accord with known methods, e.g., orally, through injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, subcutaneously, intra-ocular, intraarterial, intraportal, or intraduodenal routes; by sustained release systems or by implantation devices. In certain embodiments, the compositions can be administered by bolus injection or continuously by infusion, or by implantation device.

In certain embodiments, the composition can be administered locally via implantation of a membrane, sponge or another appropriate material onto which the desired molecule has been absorbed or encapsulated. In certain embodiments, where an implantation device is used, the device can be implanted into any suitable tissue or organ, and delivery of the desired molecule can be via diffusion, timed-release bolus, or continuous administration.

In certain embodiments, it can be desirable to use a pharmaceutical composition comprising an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, in an ex vivo manner. In such instances, cells, tissues and/or organs that have been removed from the patient are exposed to a pharmaceutical composition comprising an antigen binding protein to PCSK9, with or without at least one additional therapeutic agent, after which the cells, tissues and/or organs are subsequently implanted back into the patient.

In certain embodiments, an antigen binding protein to PCSK9 and/or any additional therapeutic agents can be delivered by implanting certain cells that have been genetically engineered, using methods such as those described herein, expressing and secreting polypeptides. In certain embodiments, such cells can be animal or human cells, and can be autologous, heterologous, or xenogeneic. In certain embodiments, the cells can be immortalized. In certain embodiments, in order to decrease the chance of an immunological response, the cells can be encapsulated to avoid infiltration of surrounding tissues. In certain embodiments, the encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient’s immune system or by other detrimental factors from the surrounding tissues.

Based on the ability of ABPs to significantly neutralize PCSK9 activity (as demonstrated in the Examples below), these ABPs will have therapeutic effects in treating and preventing symptoms and conditions resulting from PCSK9-mediated activity, such as hypercholesterolemia.

Diagnostic Applications

In some embodiments, the ABP is used as a diagnostic tool. The ABP can be used to assay the amount of PCSK9 present in a sample and/or subject. As will be appreciated by one of skill in the art, such ABPs need not be neutralizing ABPs. In some embodiments, the diagnostic ABP is not a neutralizing ABP. In some embodiments, the diagnostic ABP binds to a different epitope than the neutralizing ABP binds to. In some embodiments, the two ABPs do not compete with one another.

In some embodiments, the ABPs disclosed herein are used or provided in an assay kit and/or method for the detection of PCSK9 in mammalian tissues or cells in order to screen for a disease or disorder associated with changes in
levels of PCSK9. The kit comprises an ABP that binds PCSK9 and means for indicating the binding of the ABP with PCSK9, if present, and optionally PCSK9 protein levels. Various means for indicating the presence of an ABP can be used. For example, fluorophores, other molecular probes, or enzymes can be linked to the ABP and the presence of the ABP can be observed in a variety of ways. The method for screening for such disorders can involve the use of the kit, or simply the use of one of the disclosed ABPs and the determination of whether the ABP binds to PCSK9 in a sample. As will be appreciated by one of skill in the art, high or elevated levels of PCSK9 will result in larger amounts of the ABP binding to PCSK9 in the sample. Thus, degree of ABP binding can be used to determine how much PCSK9 is in a sample. Subjects or samples with an amount of PCSK9 that is greater than a predetermined amount (e.g., an amount or range that a person without a PCSK9 related disorder would have) can be characterized as having a PCSK9 mediated disorder. In some embodiments, the ABP is administered to a subject taking a statin, in order to determine if the statin has increased the amount of PCSK9 in the subject.

In some embodiments, the ABP is a non-neutralizing ABP and is used to determine the amount of PCSK9 in a subject receiving an ABP and/or statin treatment.

EXAMPLES

The following examples, including the experiments conducted and results achieved, are provided for illustrative purposes only and are not to be construed as limiting the present invention.

Example 1

Immunization and Titering

The protocol used to titer the XenoMouse animals was as follows: Costar 3368 medium binding plates were coated with neutravidin @ 8 ug/ml (50 ul/well) and incubated at 4°C in 1xPBS/0.05% azide overnight. They were washed using TiterTek 3-cycle wash with RO water. Plates were blocked using 250 ul of 1xPBS/1% milk and incubated for at least 30 minutes at RT. Block was washed off using TiterTek 3-cycle wash with RO water. One then captured b-human PCSK9 @ 2 ug/ml in 1xPBS/1% milk/10 mM CaCl2 (assay diluent) 50 ul/well and incubated for 1 hr at RT. One then washed using TiterTek 3-cycle wash with RO water. For the primary antibody, sera was titrated 1:3 in duplicate from 1:100. This was done in assay diluent 50 ul/well and incubated for 1 hr at RT. One then washed using TiterTek 3-cycle wash with RO water. The secondary antibody was goat anti-human IgG Fc HRP @ 400 ng/ml in assay diluent at 50 ul/well. This was incubated for 1 hr at RT. This was then washed using TiterTek 3-cycle wash with RO water and potted dry on paper towels. For the substrate, one step TMB solution (Neogen, Lexington, Ky.) was used (50 ul/well) and it was allowed to develop for 30 min at RT.

The protocols followed in the ELISA assays was as follows: For samples comprising b-PCSK9 with no V5H is tag the following protocol was employed: Costar 3368 medium binding plates (Corning Life Sciences) were employed. The plates were coated with neutravidin at 8 g/ml in 1xPBS/0.05% Azide, (50 ul/well). The plates were incubated at 4°C overnight. The plates were then washed using a TiterTek M384 plate washer (TiterTek, Huntsville, Ala.). A 3-cycle
wash was performed. The plates were blocked with 250 µl of 1×PBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the M384 plate washer. A 3-cycle wash was performed. The capture was b-hu PCSK9, without a V5 tag, and was added at 2 µg/ml in 1×PBS/1% milk/10 mM CaCl₂ (401/well). The plates were then incubated for 1 hour at room temperature. A 3-cycle wash was performed. Sera were titrated 1:3 in duplicate from 1:100, and row H was blank for sera. The titration was done in assay diluent, at a volume of 50 µl/well. The plates were incubated for 1 hour at room temperature. Next, a 3-cycle wash was performed. Goat anti Human IgG Fc HRP at 100 ng/ml (1:4000) in 1×PBS/1% milk/10 mM CaCl₂ (501/well) was added to the plate and was incubated 1 hour at room temperature. The plates were washed once again, using a 3-cycle wash. The plates were then patted dry with paper towel. Finally, 1 step TMB (Neogen, Lexington, Ky.) (50 µl/well) was added to the plate and was quenched with 1N hydrochloric acid (50 µl/well) after 30 minutes at room temperature. OD’s were read immediately at 450 nm using a Titertek plate reader.

Positive controls to detect plate bound PCSK9 were soluble LDL receptor (R&D Systems, Cat #214LR.DC7F) and a polyclonal rabbit anti-PCSK9 antibody (Cayman Chemical #10007185) titrated 1:3 in duplicate from 3 µg/ml in assay diluent. LDLR was detected with goat anti LDLR (R&D Systems, Cat #AF2148) and rabbit anti goat IgG Fc HRP at a concentration of 400 ng/ml; the rabbit polyclonal was detected with goat anti-rabbit IgG Fc at a concentration of 400 ng/ml in assay diluent. Negative control was naive XMG2-KL and XMG4-KL sera titrated 1:3 in duplicate from 1:100 in assay diluent.

For samples comprising b-PCSK9 with a V5H tag the following protocol was employed: Costar 3368 medium binding plates (Corning Life Sciences) were employed. The plates were coated with neutraadvin at 8 µg/ml in 1×PBS/0.05% Azide, (50 µl/well). The plates were incubated at 4°C overnight. The plates were then washed using a Titertek M384 plate washer (Titertek, Huntsville, Ala.). A 3-cycle wash was performed. The plates were blocked with 250 µl of 1×PBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the M384 plate washer. A 3-cycle wash was performed. The capture was b-hu PCSK9, with a V5 tag, and was added at 2 µg/ml in 1×PBS/1% milk/10 mM CaCl₂ (401 µl/well). The plates were then incubated for 1 hour at room temperature. A 3-cycle wash was performed. Sera were titrated 1:3 in duplicate from 1:100, and row H was blank for sera. The titration was done in assay diluent, at a volume of 50 µl/ml. The plates were incubated for 1 hour at room temperature. Next, the plates were washed using the M384 plate washer operating using a 3-cycle wash. Goat anti Human IgG Fc HRP at 400 ng/ml in 1×PBS/1% milk/10 mM CaCl₂ was added at 50 µl/well to the plate and the plate was incubated 1 hour at room temperature. The plates were washed once again, using a 3-cycle wash. The plates were then patted dry with paper towel. Finally, 1 step TMB (Neogen, Lexington, Ky.) (50 µl/well) was added to the plate and the plate was quenched with 1N hydrochloric acid (50 µl/well) after 30 minutes at room temperature. OD’s were read immediately at 450 nm using a Titertek plate reader.

Positive control was LDLR, rabbit anti-PCSK9 titrated 1:3 in duplicate from 3 µg/ml in assay diluent. LDLR detect with goat anti-LDLR (R&D Systems, Cat #AF2148) and rabbit anti-goat IgG Fc HRP at a concentration of 400 ng/ml; rabbit polyclonal detected with goat anti-rabbit IgG Fc at a concentration of 400 ng/ml in assay diluent. Human anti-His 1.2.3 and anti-V5 1.7.1 titrated 1:3 in duplicate from 1 µg/ml in assay diluent; both detected with goat anti-human IgG Fc HRP at a concentration of 400 ng/ml in assay diluent. Negative control was naive XMG2-KL and XMG4-KL sera titrated 1:3 in duplicate from 1:100 in assay diluent.

Titers of the antibody against human PCSK9 were tested by ELISA assay for mice immunized with soluble antigen as described. Table 4 summarizes the ELISA data and indicates that there were some mice which appeared to be specific for PCSK9. See, e.g., Table 4. Therefore, at the end of the immunization program, 10 mice (in bold in Table 4) were selected for harvest, and splenocytes and lymphocytes were isolated from the spleens and lymph nodes respectively, as described herein.

<table>
<thead>
<tr>
<th>Animal ID</th>
<th>B-hu PCSK9 (V5His) @ 2 µg/ml</th>
<th>B-hu PCSK9 @ 2 µg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgG2k1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P175807</td>
<td>&gt;72000 @ OD 2.2</td>
<td>68359</td>
</tr>
<tr>
<td>P175808</td>
<td>&gt;72000 @ OD 2.3</td>
<td>&gt;72000 @ OD 2.5</td>
</tr>
<tr>
<td>P175810</td>
<td>&gt;72000 @ OD 3.2</td>
<td>&gt;72000 @ OD 3.0</td>
</tr>
<tr>
<td>P175811</td>
<td>&gt;72000 @ OD 3.4</td>
<td>&gt;72000 @ OD 3.2</td>
</tr>
<tr>
<td>P175820</td>
<td>&gt;72000 @ OD 3.4</td>
<td>&gt;72000 @ OD 3.5</td>
</tr>
<tr>
<td>P175821</td>
<td>&gt;72000 @ OD 3.4</td>
<td>&gt;72000 @ OD 3.0</td>
</tr>
<tr>
<td>P175830</td>
<td>&gt;72000 @ OD 2.6</td>
<td>&gt;72000 @ OD 2.5</td>
</tr>
<tr>
<td>P175831</td>
<td>&gt;72000 @ OD 3.1</td>
<td>&gt;72000 @ OD 3.5</td>
</tr>
<tr>
<td>P175832</td>
<td>&gt;72000 @ OD 3.6</td>
<td>&gt;72000 @ OD 3.6</td>
</tr>
<tr>
<td>P175833</td>
<td>&gt;72000 @ OD 2.6</td>
<td>&gt;72000 @ OD 3.5</td>
</tr>
<tr>
<td>P174501</td>
<td>19369</td>
<td>17109</td>
</tr>
<tr>
<td>P174503</td>
<td>31616</td>
<td>23548</td>
</tr>
<tr>
<td>P174504</td>
<td>48472</td>
<td>30996</td>
</tr>
<tr>
<td>P174509</td>
<td>23380</td>
<td>21628</td>
</tr>
</tbody>
</table>

| Group 2    |                               |                      |
| IgG4k1     |                                |                      |
| P175410    | 15120                          | 9673                 |
| P175773    | 30467                          | 15973                |
| P175774    | 54580                          | 44424                |
| P175775    | 60713                          | 55667                |
| P175776    | 30871                          | 22899                |
| P175777    | 16068                          | 12332                |
| Naive G2   | <100 @ OD 0.34                 | <100 @ OD 0.48      |
| Naive G4   | <100 @ OD 1.57                 | <100 @ OD 1.32      |

**Example 2**

**Recovery of Lymphocytes, B-cell Isolations, Fusions and Generation of Hybridomas**

This example outlines how the immune cells were recovered and the hybridomas were generated. Selected immunized mice were sacrificed by cervical dislocation and the draining lymph nodes were harvested and pooled from each cohort. The B cells were dissociated from lymphoid tissue by grinding in DMEM to release the cells from the tissues, and the cells were suspended in DMEM. The cells were counted, and 0.9 ml DMEM per 100 million lymphocytes was added to the cell pellet to resuspend the cells gently but completely.

Lymphocytes were mixed with nonsecretory myeloma P3X63Ag8.653 cells purchased from ATCC, cat. #CRL 1580 (Kearney et al., 1979, *J. Immunol.* 123, 1548-1550) at a ratio of 1:4. The cell mixture was gently pelleted by centrifugation at 400xg 4 min. After decanting of the supernatant, the cells were gently mixed using a 1 ml pipette. Preheated PEG/DMO solution from Sigma (cat#P7306) (1 ml per million of B-cells) was slowly added with gentle agitation over 1 min followed by 1 min of incubation. Preheated IDEM (2 ml per million of B cells) (DMEM without glutamine, L-glutamine,
pen/strep, MEM non-essential amino acids (all from Invitrogen), was then added over 2 minutes with gentle agitation. Finally preheated IDMEM (8 ml per 10^6 B-cells) was added over 5 minutes.

The fused cells were spun down 400g 6 min and resuspended in 20 ml selection media (DME/M (Invitrogen), 15% FBS (HyClone), supplemented with 1-glutamine, pen/strep, MEM Non-essential amino acids, Sodium Pyruvate, 2-Mercaptoethanol (all from Invitrogen), HA-Azaserine Hypoxanthine and OPI (oxaloacetate, pyruvate, bovine insulin) (both from Sigma) and IL-6 (Boehringer Mannheim)) per million B-cells. Cells were incubated for 20-30 min at 37 C and then resuspended in 200 ml selection media and cultured for 3-4 days in T175 flask prior to 96 well plating. Thus, hybridomas that produced antigen binding proteins to PCSK9 were produced.

Example 3

Selection of PCSK9 Antibodies

The present example outlines how the various PCSK9 antigen binding proteins were characterized and selected. The binding of secreted antibodies (produced from the hybridomas produced in Examples 1 and 2) to PCSK9 was assessed. Selection of antibodies was based on binding data and inhibition of PCSK9 binding to LDLR and affinity. Binding to soluble PCSK9 was analyzed by ELISA, as described below. BIAcore® (surface plasmon resonance) was used to quantify binding affinity.

Primary Screen

A primary screen for antibodies which bind to wild-type PCSK9 was performed. The primary screen was performed on two harvests. The primary screen comprised an ELISA assay and was performed using the following protocol:

Costar 3702 medium binding 384 well plates (Corning Life Sciences) were employed. The plates were coated with neutravidin at a concentration of 4 μg/ml in 1xPBS/0.05% Azide, at a volume of 40 μl/well. The plates were then incubated overnight. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Ala.). A 3-cycle wash was performed. The plates were then incubated with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed. Again, a 3-cycle wash was performed. The capture sample was biotinylated-PCSK9, without a V5 tag, and was at 0.9 μg/ml in 1xPBS/1% milk/10 mM Ca^2+ at a volume of 40 μl/well. The plates were then incubated for 1 hour at room temperature. Next, the plates were washed using the Titertek plate washer operated using a 3-cycle wash. 10 μl of supernatant was transferred into 40 μl of 1xPBS/1% milk/10 mM Ca^2+ and incubated 1.5 hours at room temperature. Again the plates were washed using the Titertek plate washer operated using a 3-cycle wash. 40 μl/well of Goat anti-Human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1xPBS/1% milk/10 mM Ca^2+ was added to the plate and the plate was incubated 1 hour at room temperature. The plates were then washed using the Titertek plate washer operated using a 3-cycle wash. 40 μl/well of Goat anti-Human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1xPBS/1% milk/10 mM Ca^2+ was added to the plate and the plate was incubated 1 hour at room temperature. The plates were then washed using the Titertek plate washer operated using a 3-cycle wash. 50 μl of supernatant was transferred to the plates and incubated 1 hour at room temperature. Again the plates were washed using the Titertek plate washer operated using a 3-cycle wash. 40 μl/well of Goat anti-Human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1xPBS/1% milk/10 mM Ca^2+ was added to the plate and the plate was incubated 1 hour at room temperature. The plates were then washed using the Titertek plate washer operated using a 3-cycle wash. 50 μl of supernatant was transferred to the plates and incubated 1 hour at room temperature. The plates were washed once again, using a 3-cycle wash. Finally, 40 μl/well of One-step TMB (Neogen, Lexington, Ky.) was added to the plate and quenching with 40 μl/well of 1N hydrochloric acid was performed after 30 minutes at room temperature. OD’s were read immediately at 450 nm using a Titertek plate reader.

The primary screen resulted in a total of 3104 antigen specific hybridomas being identified from the two harvests. Based on highest ELISA OD, 1500 hybridomas per harvest were advanced for a total of 3000 positives.

Confirmatory Screen

The 3000 positives were then rescreened for binding to wild-type PCSK9 to confirm stable hybridomas were established. The screen was performed as follows: Costar 3702 medium binding 384 well plates (Corning Life Sciences) were employed. The plates were coated with neutravidin at 5 μg/ml in 1xPBS/0.05% Azide at a volume of 40 μl/well. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Ala.). A 3-cycle wash was performed. The plates were then incubated for 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the M384 plate washer. A 3-cycle wash was performed. The capture sample was b-PCSK9, without a V5 tag, and was at 0.9 μg/ml in 1xPBS/1% milk/10 mM Ca^2+ and incubated 1.5 hours at room temperature. The plates were then washed using the Titertek plate washer operated using a 3-cycle wash. 40 μl/well of Goat anti-Human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1xPBS/1% milk/10 mM Ca^2+ was added to the plate, and the plate was incubated 1 hour at room temperature. The plates were then washed using a Titertek plate washer operated using a 3-cycle wash. Finally, 40 μl/well of One-step TMB (Neogen, Lexington, Ky.) was added to the plate and was quenched with 40 μl/well of 1N hydrochloric acid after 30 minutes at room temperature. OD’s were read immediately at 450 nm using a Titertek plate reader. A total of 2441 positives repeated in the second screen. These antibodies were then used in the subsequent screenings.

Mouse Cross-reactivity Screen

The panel of hybridomas was then screened for cross-reactivity to mouse PCSK9 to make certain that the antibodies could bind to both human and mouse PCSK9. The following protocol was employed in the cross-reactivity screen: Costar 3702 medium binding 384 well plates (Corning Life Sciences) were employed. The plates were coated with neutravidin at 3 μg/ml in 1xPBS/0.05% Azide at a volume of 40 μl/well. The plates were then washed using a Titertek plate washer (Titertek, Huntsville, Ala.). A 3-cycle wash was performed. The plates were then incubated for 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer operated using a 3-cycle wash. 40 μl/well of Goat anti-Human IgG Fc POD at a concentration of 100 ng/ml (1:4000) in 1xPBS/1% milk/10 mM Ca^2+ was added to the plate and was incubated 1 hour at room temperature. The plates were washed once again, using a 3-cycle wash. Finally, 40 μl/well One-step TMB (Neogen, Lexington, Ky.) was added to the plate and was quenched with 40 μl/well of 1N hydrochloric acid after 30 minutes at room temperature. OD’s were read immediately at 450 nm using a Titertek plate reader. 579 antibodies were observed to cross-react with mouse PCSK9. These antibodies were then used in the subsequent screenings.
D374Y Mutant Binding Screen

The D374Y mutation in PCSK9 has been documented in the human population (e.g., Timms K M et al., "A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree", Hum. Genet. 114: 349-353, 2004). In order to determine if the antibodies were specific for the wild type or also bound to the D374Y form of PCSK9, the samples were then screened for binding to the mutant PCSK9 sequence comprising the mutation D374Y. The protocol for the screen was as follows: Costar 3702 medium binding 384 well plates (Corning Life Sciences) were employed in the screen. The plates were coated with neutravidin at 4 μg/ml in 1xPBS/0.05% Azide at a volume of 40 μl/well. The plates were incubated at 4°C overnight. The plates were then washed using a Titertek plate washer (Tiettke, Huntsville, Ala.). A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were then washed using a Titertek plate washer (Tiettke, Huntsville, Ala.). A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The capture sample was LDLR(R&D, Cat #2148LD/C) and was added at 0.4 μg/ml in 1xPBS/1% milk/10 mM Ca²⁺ at a volume of 40 μl/well. The plates were then incubated for 1 hour and 10 minutes at room temperature.

Receptor Ligand Binding Assay on Blocker Subset

The receptor ligand assay was then repeated using the mutant enzyme on the 384 member subset of neutralizers identified in the first large scale receptor ligand inhibition assay. The same protocol was employed in the screen of the 384 member blocker subset assay as was done in the large scale receptor ligand blocking screen. This screen confirmed the initial screening data.

This screen of the 384 member subset identified 85 antibodies that blocked interaction between the PCSK9 mutant enzyme and the LDLR greater than 90%.

Receptor Ligand Binding Assay of Blockers that Bind the Wild Type PCSK9 but not the D374Y Mutant

In the initial panel of 3000 ups there were 86 antibodies shown to specifically bind to the wild-type PCSK9 and not to the hupPCS9(D374Y) mutant. These 86 ups were tested for the ability to block wild-type PCSK9 binding to the LDLR receptor. The following protocol was employed: Costar 3702 medium binding 384 well plates (Corning Life Sciences) were employed in the screen. The plates were coated with anti-His 1.2.3 at 10 μg/ml in 1xPBS/0.05% Azide at a volume of 40 μl/well. The plates were incubated at 4°C overnight. The plates were then washed using a Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature. The plates were then washed using the Titertek plate washer. A 3-cycle wash was performed. The plates were blocked with 90 μl of 1xPBS/1% milk and incubated approximately 30 minutes at room temperature.

Contemporaneously, 20 ng/ml of biotinylated human D374Y PCSK9 was incubated with 15 microliters of hydridoma exhaust supernatant in Nunc polypropylene plates and the exhaust supernatant concentration was diluted 1:5. The plates were then pre-incubated for about 1 hour and 30 minutes at room temperature. Next, the plates were washed using the Titertek plate washer operated using a 3-cycle wash. 50 μl/well of the pre-incubated mixture was transferred onto the LDLR bound 3-PCS9, 40 μl/well streptavidin HRP at 500 ng/ml in assay diluent was added to the plates. The plates were incubated for 1 hour at room temperature. The plates were again washed using a Titertek plate washer. A 3-cycle wash was performed. Finally, 40 μl/well of One-step TMB (NeoGen, Lexington, Ky.) was added to the plate and was quenched with 40 μl/well of 1N hydrochloric acid after 30 minutes at room temperature. OD's were read immediately at 450 nm using a Titertek plate reader. The screen identified 384 antibodies that blocked the interaction between PCSK9 and the LDLR well, 100 antibodies blocked the interaction strongly (OD>0.3). These antibodies inhibited the binding interaction of PCSK9 and LDLR greater than 90% (greater than 90% inhibition).
A 3-cycle wash was performed. 40 μl/well streptavidin HRP at 500 ng/ml in assay diluent was added to the plates. The plates were incubated for 1 hour at room temperature. The plates were then washed using a Titertek plate washer. A 3-cycle wash was performed. Finally, 40 μl/well of One-step TMB (Neogen, Lexington, Ky.) was added to the plate and was quenched with 40 μl/well of 1N hydrochloric acid after 30 minutes at room temperature. OD’s were read immediately at 450 nm using a Titertek plate reader.

Screening Results

Based on the results of the assays described, several hybridoma lines were identified as producing antibodies with desired interactions with PCSK9. Limiting dilution was used to isolate a manageable number of clones from each line. The clones were designated by hybridoma line number (e.g. 21B12) and clone number (e.g. 21B12.1). In general, no difference among the different clones of a particular line were detected by the functional assays described herein. In a few cases, clones were identified from a particular line that behaved differently in the functional assays, for example, 25A7.1 was found not to block PCSK9/LDLR but 25A7.3 (referred to herein as 25A7) was neutralizing. The isolated clones were each expanded in 50-100 ml of hybridoma media and allowed to grow to exhaustion, (i.e., less than about 10% cell viability). The concentration and potency of the antibodies to PCSK9 in the supernatants of those cultures were determined by ELISA and by in vitro functional testing, as described herein. As a result of the screening described herein, the hybridomas with the highest titers of antibodies to PCSK9 were identified. The selected hybridomas are shown in FIGS. 2A-3D and Table 2.

Example 4.1

Production of Human 31H4 IgG4 Antibodies from Hybridomas

This example generally describes how one of the antigen binding proteins was produced from a hybridoma line. The production work used 50 ml exhaust supernatant generation followed by protein A purification. Induction was performed in shake flasks in 20 ml of media (Integra Media, Table 5). When the hybridoma was nearly confluent in the T75 flasks, it was transferred to an Integra flask (Integra Biosciences, Integra CL.1000, cat#90005).

The Integra flask was a cell culture flask that is divided by a membrane into two chambers, a small chamber and a large chamber. A volume of 20-30 ml hybridoma cells at a minimum cell density of 1x10^6 cells per ml from the 31H4 hybridoma line was placed into the small chamber of an Integra flask in Integra media (see Table 5 for components of Integra media). Integra media alone (1 L) was placed in the large chambers of the Integra flasks. The membrane separating the two chambers is permeable to small molecular weight nutrients but is impermeable to hybridoma cells and to antibodies produced by those cells. Thus, the hybridoma cells and the antibodies produced by those hybridoma cells were retained in the small chamber.

After one week, media was removed from both chambers of the Integra flask and was replaced with fresh Integra media. The collected media from the small chambers was separately retained. After a second week of growth, the media from the small chamber was again collected. The collected media from week 1 from the hybridoma line was combined with the collected media from week 2 from the hybridoma line. The resulting collected media sample from the hybridoma line was spun to remove cells and debris (15 minutes at 3000 rpm) and the resulting supernatant was filtered (0.22 μm). Clarified conditioned media was loaded onto a Protein A-Sepharose column. Optionally, the media can be first concentrated and then loaded onto a Protein A Sepharose column. Non-specific bindings were removed by an extensive PBS wash. Bound antibody proteins on the Protein A column were recovered by standard acidic antibody elution from Protein A columns (such as 50 mM Citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography or binding ion exchange chromatography on anion exchanger resin such as Q-Sepharose resin. The specific IEX conditions for the 31H4 proteins are Q-Sepharose HP at pH 7.8-8.0. Antibody was eluted with a NaCl gradient of 10 mM-500 mM in 25 column volumes.

Table 5

<table>
<thead>
<tr>
<th>Composition of Media</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTegra MEDIA</td>
</tr>
<tr>
<td>ISFM</td>
</tr>
<tr>
<td>10% Ultra Low IgG serum</td>
</tr>
<tr>
<td>2 mmol/L L-glutamine</td>
</tr>
<tr>
<td>1% NEAA</td>
</tr>
<tr>
<td>4 g/L glucose</td>
</tr>
</tbody>
</table>

Example 4.2

Production of Recombinant 31H4 Human IgG2 Antibodies from Transfected Cells

The present example outlines how 31H4 IgG2 antibodies were produced from transfected cells. 293 cells for transient expression and CHIO cells for stable expression were transfected with plasmids that encode 31H4 heavy and light chains. Conditioned media from transfected cells was recovered by removing cells and cell debris. Clarified conditioned media was loaded onto a Protein A-Sepharose column. Optionally, the media can be first concentrated and then loaded onto a Protein A Sepharose column. Non-specific bindings were removed by an extensive PBS wash. Bound antibody proteins on the Protein A column were recovered by standard acidic antibody elution from Protein A columns (such as 50 mM citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography or binding ion exchange chromatography on anion exchanger resin such as Q-Sepharose resin. The specific IEX conditions for the 31H4 proteins are Q-Sepharose HP at pH 7.8-8.0. Antibody was eluted with a NaCl gradient of 10 mM-500 mM in 25 column volumes.

Example 5

Production of Human 21B12 IgG4 Antibodies from Hybridomas

The present example outlines how antibody 21B12 IgG4 was produced from hybridomas. Hybridoma line 21B12 was grown in T75 flasks in media (Integra Media, Table 5). When the hybridomas were nearly confluent in the T75 flasks, they were transferred to Integra flasks (Integra Biosciences, Integra CL.1000, cat#90005). The Integra flask is a cell culture flask that is divided by a membrane into two chambers, a small chamber and a large chamber. A volume of 20-30 ml hybridoma cells at a minimum cell density of 1x10^6 cells per ml from the 31H4 hybrid-
doma line was placed into the small chamber of an Integra flask in Integra media (see Table 5 for components of Integra media). Integra media alone (1 L) was placed in the large chambers of the Integra flasks. The membrane separating the two chambers is permeable to small molecular weight nutrients but is impermeable to hybridoma cells and to antibodies produced by those cells. Thus, the hybridoma cells and the antibodies produced by those hybridoma cells were retained in the small chamber. After one week, media was removed from both chambers of the Integra flask and was replaced with fresh Integra media. The collected media from the small chambers was separately retained. After a second week of growth, the media from the small chamber was again collected. The collected media from week 1 from the hybridoma line was combined with the collected media from week 2 from the hybridoma line. The resulting collected media sample from the hybridoma line was spun to remove cells and debris (15 minutes at 3000 rpm) and the resulting supernatant was filtered (0.22 μm). Clarified conditioned media were loaded onto a Protein A Sepharose column. Optionally, the media are first concentrated and then loaded onto a Protein A Sepharose column. Non-specific bindings were removed by an extensive PBS wash. Bound antibody proteins on the Protein A column were recovered by standard acidic antibody elution from Protein A columns (such as 50 mM Citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography or binding ion exchange chromatography on anion exchanger resin such as Q Sepharose resin. The specific IEX conditions for the 21B12 proteins are Q-Sepharose HP at pH 7.8-8.0. The antibody was eluted with a NaCl gradient of 10 mM-500 mM in 25 column volumes.

Example 6

Production of Human 21B12 IgG2 Antibodies from Transfected Cells

The present example outlines how 21B12 IgG2 antibodies were produced from transfected cells. Cells (293 cells for transient expression and CHO cells for stable expression) were transfected with plasmids that encode 21B12 heavy and light chains. Conditioned media from hybridoma cells were recovered by removing cells and cell debris. Clarified conditioned media were loaded onto a Protein A-Sepharose column. Optionally, the media can be first concentrated and then loaded onto a Protein A-Sepharose column. Non-specific bindings were removed by extensive PBS wash. Bound antibody proteins on the Protein A column were recovered by standard acidic antibody elution from Protein A columns (50 mM Citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography or binding ion exchange chromatography on cation exchanger resin such as SP-Sepharose resin. The specific IEX conditions for the 21B12 proteins were SP-Sepharose HP at pH 5.2. Antibodies were eluted with 25 column volumes of buffer that contains a NaCl gradient of 10 mM-500 mM in 20 mM sodium acetate buffer.

Example 7

Production of Human 16F12 IgG4 Antibodies from Hybridomas

The present example outlines how antibody 16F12 IgG4 was produced from hybridomas. Hybridoma line 16F12 was grown in T75 flasks in media (see Table 5). When the hybridomas were nearly confluent in the T75 flasks, they were transferred to Integra flasks (Integra Biosciences, Integra CL1000, cat#90 005).

The Integra flask is a cell culture flask that is divided by a membrane into two chambers, a small chamber and a large chamber. A volume of 20-30 ml Hybridoma cells at a minimum cell density of 1×10^6 cells per ml from the 311H4 hybridoma line was placed into the small chamber of an Integra flask in Integra media (see Table 5 for components of Integra media). Integra media alone (1 L) was placed in the large chambers of the Integra flasks. The membrane separating the two chambers is permeable to small molecular weight nutrients but is impermeable to hybridoma cells and to antibodies produced by those cells. Thus, the hybridoma cells and the antibodies produced by those hybridoma cells were retained in the small chamber.

After one week, media was removed from both chambers of the Integra flask and was replaced with fresh Integra media. The collected media from the small chambers was separately retained. After a second week of growth, the media from the small chamber was again collected. The collected media from week 1 from the hybridoma line was combined with the collected media from week 2 from the hybridoma line. The resulting collected media sample from the hybridoma line was spun to remove cells and debris (15 minutes at 3000 rpm) and the resulting supernatants were filtered (0.22 μm). Clarified conditioned media were loaded onto a Protein A Sepharose column. Optionally, the media can be first concentrated and then loaded onto a Protein A Sepharose column. Non-specific bindings were removed by extensive PBS wash. Bound antibody proteins on the Protein A column were recovered by standard acidic antibody elution from Protein A columns (50 mM Citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography or binding ion exchange chromatography on anion exchanger resin such as Q Sepharose resin. The specific IEX conditions for the 16F12 proteins are Q Sepharose HP at pH 7.8-8.0. Antibody was eluted with a NaCl gradient of 10 mM-500 mM in 25 column volumes.

Example 8

Production of Human 16F12 IgG2 Antibodies from Transfected Cells

The present example outlines how 16F12 IgG2 antibodies were produced from transfected cells. Cells (293 cells for transient expression and CHO cells for stable expression) were transfected with plasmids that encode 16F12 heavy and light chains. Conditioned media from hybridoma cells were recovered by removing cells and cell debris. Clarified conditioned media were loaded onto a Protein A-Sepharose column. Optionally, the media can be first concentrated and then loaded onto a Protein A-Sepharose column. Non-specific bindings were removed by extensive PBS wash. Bound antibody proteins on the Protein A column were recovered by standard acidic antibody elution from Protein A columns (50 mM Citrate, pH 3.0). Aggregated antibody proteins in the Protein A Sepharose pool were removed by size exclusion chromatography or binding ion exchange chromatography on cation exchanger resin such as SP-Sepharose resin. The specific IEX conditions for the 16F12 proteins were SP-Sepharose HP at pH 5.2. Antibody was eluted with 25 column volumes of buffer that contains a NaCl gradient of 10 mM-500 mM in 20 mM sodium acetate buffer.
Sequence Analysis of Antibody Heavy and Light Chains

The nucleic acid and amino acid sequences for the light and heavy chains of the above antibodies were then determined by Sanger (dideoxy) nucleotide sequencing. Amino acid sequences were then deduced for the nucleic acid sequences. The nucleic acid sequences for the variable domains are depicted in FIGS. 3E-3J.

The cDNA sequences for the lambda light chain variable regions of 31H4, 21B12, and 16F12 were determined and are disclosed as SEQ ID NOs: 153, 95, and 105 respectively.

The cDNA sequences for the heavy chain variable regions of 31H4, 21B12, and 16F12 were determined and are disclosed as SEQ ID NOs: 152, 94, and 104 respectively.

The lambda light chain constant region (SEQ ID NO: 156), and the IgG2 and IgG4 heavy chain constant regions (SEQ ID NOs: 154 and 155) are shown in FIG. 3K.

The polypeptide sequences predicted from each of those cDNA sequences were determined. The predicted polypeptide sequences for the lambda light chain variable regions of 31H4, 21B12, and 16F12 were predicted and are disclosed as SEQ ID NOs: 12, 23, and 35 respectively, the lambda light chain constant region (SEQ ID NO: 156), the heavy chain variable regions of 31H4, 21B12, and 16F12 were predicted and are disclosed as (SEQ ID NOs: 67, 49, and 79 respectively. The IgG2 and IgG4 heavy chain constant regions (SEQ ID NOs: 154 and 155).

The FR1, CDRI, FR2, CDRII, FR3, CDRIII, FR4 divisions are shown in FIG. 2A-3D.

Based on the sequence data, the germline genes from which each heavy or light chain variable region was derived was determined. The identity of the germline genes are indicated next to the corresponding hybridoma in FIGS. 2A-3D and each is represented by a unique SEQ ID NO. FIGS. 2A-3D also depict the determined amino acid sequences for additional antibodies that were characterized.

Example 8

Determination of Isoelectric Points of Three Antibodies

The theoretical pIs of the antibodies based on amino acid sequence were determined to be 7.36 for 16F12; 8.47 for 21B12; and 6.84 for 31H4.

Example 9

Characterization of Binding of Antibodies to PCSK9

Having identified a number of antibodies that bind to PCSK9, several approaches were employed to quantify and further characterize the nature of the binding. In one aspect of the study, a Biacore affinity analysis was performed. In another aspect of the study a KinExA® affinity analysis was performed. The samples and buffers employed in these studies are presented in Table 6 below.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Sample</th>
<th>[sample]</th>
<th>Buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>lPCS9</td>
<td>[sample]</td>
<td>mg/ml</td>
<td>Buffer</td>
</tr>
<tr>
<td>mPCS9</td>
<td>[sample]</td>
<td>uM</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sample</th>
<th>Sample</th>
<th>[sample]</th>
<th>Buffer</th>
</tr>
</thead>
<tbody>
<tr>
<td>lPCS9</td>
<td>1.26</td>
<td>PBS</td>
<td>16.6</td>
</tr>
<tr>
<td>mPCS9</td>
<td>1.44</td>
<td>PBS</td>
<td>18.9</td>
</tr>
</tbody>
</table>

BIAcore® Affinity Measurements

A BIAcore® (surface plasmon resonance device, Biacore, Inc., Piscataway, N.J.) affinity analysis of the 21B12 antibodies to PCSK9 described in this Example was performed according to the manufacturer’s instructions.

Briefly, the surface plasmon resonance experiments were performed using Biacore 2000 optical biosensors (Biacore, GE Healthcare, Piscataway, N.J.). Each individual anti-PCS9 antibody was immobilized to a research-grade CM5 biosensor chip by amine-coupling at levels that gave a maximum analyte binding response (Rmax) of no more than 200 resonance units (RU). The concentration of PCS9 protein was varied at 2 fold intervals (the analyte) and was injected over the immobilized antibody surface (at a flow rate of 100 μl/min for 1.5 minutes). Fresh HBS-P buffer (pH 7.4, 0.01 M Heps, 0.15 M NaCl, 0.005% surfactant P-20, Biacore) supplemented with 0.01% BSA was used as binding buffer. Binding affinities of each anti-PCS9 antibody were measured in separate experiments against each of the human, mouse, and cynomolgus monkey PCS9 proteins at pH 7.4 (the concentrations used were 100, 50, 25, 12.5, 6.25, 3.125, and 0 nM).

In addition, the binding affinities of antibody to human PCS9 were also measured at pH 6.0 with the pH 6.0 HBS-P buffer (pH 6.0, 0.01 M Heps, 0.15 M NaCl, 0.005% surfactant P-20, Biacore) supplemented with 0.01% BSA. The binding signal obtained was proportional to the free PCS9 in solution. The dissociation equilibrium constant (Kd) was obtained from nonlinear regression analysis of the competition curves using a dual-curve one-site homogeneous binding model (KinExA® software, Sapiodyne Instruments Inc., Boise, Id.) (n=1 for the 6.0 pH runs). Interestingly, the antibodies appeared to display a tighter binding affinity at the lower pH (where the Kd was 12.5, 7.3, and 29 nM for 31H14, 21B12, and 16F12 respectively).

Antibody binding kinetic parameters including k_a (association rate constant), k_d (dissociation rate constant), and K_d (dissociation equilibrium constant) were determined using the BIA evaluation 3.1 computer program (BiaCore, Inc. Piscataway, N.J.). Lower dissociation equilibrium constants indicate greater affinity of the antibody for PCS9. The K_d values determined by the BIAcore® affinity analysis are presented in Table 7.1, shown below.

<table>
<thead>
<tr>
<th>Antibody</th>
<th>lPCS9</th>
<th>CynoPCS9</th>
<th>mPCS9</th>
</tr>
</thead>
<tbody>
<tr>
<td>31H4</td>
<td>210 nM</td>
<td>190 nM</td>
<td>6 nM</td>
</tr>
<tr>
<td>21B12</td>
<td>190 nM</td>
<td>360 nM</td>
<td>460 nM</td>
</tr>
<tr>
<td>16F12</td>
<td>470 nM</td>
<td>870 nM</td>
<td>6.4 nM</td>
</tr>
</tbody>
</table>
KinExA® Affinity Measurements

A KinExA® (Sapidyne Instruments, Inc., Boise, Id.) affinity analysis of 16F12 and 31H4 was performed according to the manufacturer’s instructions. Briefly, Reacti-Gel™ (6x) (Pierce) was pre-coated with one of human, V5-tagged cyto or His-tagged mouse PCSK9 proteins and blocked with BSA. 10 or 100 pm of either antibody 16F12 or antibody 31H4 and one of the PCSK9 proteins was then incubated with various concentrations (0.1 PM-25 nM) of PCSK9 proteins at room temperature for 8 hours before being passed through the PCSK9-coated beads. The amount of the bead-bound 16F12 or 31H4 was quantified by photoluminiscence (Cy5) labeled goat anti-human IgG (H+L) antibody (Jackson ImmunoResearch). The binding signal is proportional to the concentration of free 16F12 or 31H4 at binding equilibrium. Equilibrium dissociation constant (Kd) were obtained from non-linear regression of the two sets of competition curves using a one-site homogeneous binding model. The KinExA® Pro software was employed in the analysis. Binding curves generated in this analysis are presented as FIGS. 4A 4F.

Both the 16F12 and 31H4 antibodies showed similar affinity to human and cyto PCSK9, but approximately 10-25 fold lower affinity to mouse PCSK9. Of the two antibodies tested using the KinExA® system, antibody 31H4 showed higher affinity to both human and cyto PCSK9 with 3 and 2 pM Kd, respectively. 16F12 showed slightly weaker affinity at 15 PM Kd to human PCSK9 and 16 PM Kd to cyto PCSK9.

The results of the KinExA® affinity analysis are summarized in Table 8.1, shown below.

<table>
<thead>
<tr>
<th>Sample</th>
<th>hPCSK9 (pM)</th>
<th>cPCSK (pM)</th>
<th>mPCSK (pM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16F12</td>
<td>15</td>
<td>11–22</td>
<td>16</td>
</tr>
<tr>
<td>31H4</td>
<td>3</td>
<td>1–5</td>
<td>2</td>
</tr>
</tbody>
</table>

In addition, a SDS PAGE was run to check the quality and quantity of the samples and is shown in FIG. 5A. cPCSK9 showed around 50% less on the gel and also from the active binding concentration calculated from KinExA® assay, Therefore, the Kd of the mAbs to cPCSK9 was adjusted as 50% of the active cPCSK9 in the present.

A BIAcore solution equilibrium binding assay was used to measure the Kd values for ABP 21B12. 21B12.1 showed little signal using KinExA assay, therefore, biacore solution equilibrium assay was applied. Since no significant binding was observed on binding of antibodies to immobilized PCSK9 surface, 21B12 antibody was immobilized on the flow cell 4 of a CM5 chip using amine coupling with density around 7000 RU. Flow cell 3 was used as a background control. 0.3, 1, and 3 nM of human PCSK9 or cyo PCSK9 were mixed with a serial dilutions of 21B12.1 antibody samples (ranged from 0.001–25 nM) in PBS plus 0.1 mg/ml BSA, 0.005% P20. Binding of the free PCSK9 in the mixed solutions were measured by injecting over the 21B12.1 antibody surface.

100% PCSK9 binding signal on 21B12.1 surface was determined in the absence of mAb in the solution. A decreased PCSK9 binding response with increasing concentrations of mAb indicated that PCSK9 binding to mAb in solution, which blocked PCSK9 from binding to the immobilized peptidyl surface. Plotting the PCSK9 binding signal versus mAb concentrations, Kd was calculated from 3 sets of curves (0.3, 1 and 3 nM fixed PCSK9 concentration) using a one-site homogeneous binding model in KinExA Pro™ software. Although cPCSK9 has lower protein concentration observed from KinExA assay and SDS-gel, its concentration was not adjusted here since the concentration of cPCSK9 was not used for calculation of Kd. The results are displayed in Table 8.2 below and in FIGS. 5B-5D. FIG. 5B depicts the results from the solution equilibrium assay at three different hPCSK9 concentrations for hPCSK9. FIG. 5C depicts a similar set of results for mPCSK9. FIG. 5D depicts the results from the above biacore capture assay.

<table>
<thead>
<tr>
<th>Sample</th>
<th>hPCSK9 (pM)</th>
<th>cPCSK (pM)</th>
<th>mPCSK (pM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>21B12.1</td>
<td>15</td>
<td>9–23</td>
<td>11</td>
</tr>
</tbody>
</table>

Example 10

Epitope Binning

Competition ELISA was used for anti-PCSK9 antibody binning. Briefly, to determine if two antibodies belong to the same epitope bin, one of the antibodies (mAb1) was first coated onto an ELISA plate (NUNC) at 2 μg/ml by overnight incubation. The plate was then washed and blocked with 3% BSA. Meanwhile, 30 ng/mL of biotinylated hPCSK9 was incubated with the second antibody (mAb2) for 2 hours at room temperature. The mixture was then coated to mAb1 and incubated for 1 hour at room temperature. The ELISA plate was then washed and incubated with Neutravidin-HRP (Pierce) at 1:5000 dilutions for 1 hour. After another wash, the plate was incubated with TMB substrate and signal was detected at 650 nm using a Titertek plate reader. Antibodies with the same binding profiles were grouped together into the same epitope bin. The results of the antibody binning studies are presented in Table 8.3.

<table>
<thead>
<tr>
<th>Clone</th>
<th>Bin</th>
</tr>
</thead>
<tbody>
<tr>
<td>21B12.2</td>
<td>1</td>
</tr>
<tr>
<td>31H4</td>
<td>3</td>
</tr>
<tr>
<td>20D10</td>
<td>1</td>
</tr>
<tr>
<td>25A7.1</td>
<td>2</td>
</tr>
<tr>
<td>25A7.3</td>
<td>1</td>
</tr>
<tr>
<td>23G1</td>
<td>1</td>
</tr>
<tr>
<td>20M15</td>
<td>1</td>
</tr>
<tr>
<td>31D1</td>
<td>1</td>
</tr>
<tr>
<td>16F12</td>
<td>3</td>
</tr>
<tr>
<td>28D6</td>
<td>3</td>
</tr>
<tr>
<td>27A6</td>
<td>3</td>
</tr>
<tr>
<td>31G1</td>
<td>1</td>
</tr>
<tr>
<td>27B2</td>
<td>ND</td>
</tr>
<tr>
<td>28D12</td>
<td>3</td>
</tr>
<tr>
<td>22E2</td>
<td>3</td>
</tr>
<tr>
<td>1A12.2</td>
<td>1</td>
</tr>
<tr>
<td>3B6</td>
<td>1</td>
</tr>
<tr>
<td>3G4</td>
<td>4</td>
</tr>
</tbody>
</table>
TABLE 8.3-continued

<table>
<thead>
<tr>
<th>Clone</th>
<th>Bia</th>
</tr>
</thead>
<tbody>
<tr>
<td>9C9</td>
<td>1</td>
</tr>
<tr>
<td>9H6</td>
<td>1</td>
</tr>
<tr>
<td>13B5</td>
<td>6</td>
</tr>
<tr>
<td>13H1</td>
<td>1</td>
</tr>
<tr>
<td>17C2</td>
<td>1</td>
</tr>
<tr>
<td>19B2</td>
<td>1</td>
</tr>
<tr>
<td>21B5</td>
<td>1</td>
</tr>
<tr>
<td>25G4</td>
<td>1</td>
</tr>
<tr>
<td>26E10</td>
<td>1</td>
</tr>
<tr>
<td>27E7</td>
<td>1</td>
</tr>
<tr>
<td>27H5</td>
<td>1</td>
</tr>
<tr>
<td>30A4</td>
<td>1</td>
</tr>
<tr>
<td>30B9</td>
<td>1</td>
</tr>
<tr>
<td>31A4</td>
<td>5</td>
</tr>
<tr>
<td>31B12</td>
<td>5</td>
</tr>
</tbody>
</table>

Additional examination of the epitope binning was performed using BIAcore. Three mAbs, 16F12, 21B12 and 31H14, were immobilized on flow cells 2, 3 and 4 with density around 800 RU. 5 nM PCSK9 from human, mouse and cyno were injected over the mAbs surfaces to reach around 100 to 500 RU. 10 nM mAbs were then injected over the PCSK9 surface. Binding of three mAbs to three different PCSK9 proteins over the three mAbs was then recorded.

If the two mAbs had a similar epitope on the antigen, mAb 1 will not show the binding to the antigen already bound to the mAb 2. If the two mAbs have the different epitope on the antigen, mAb 1 will show the binding to the antigen bound to the mAb 2. FIG. 5E depicts these epitope binning results in graph form for three mAbs on human PCSK9. A similar pattern was observed for mPCSK9 and ePCSK9. As shown in the graph, 16F12 and 31H14 appear to share a similar epitope, while 21B12 appears to have a different epitope.

Example 11

Efficacy of 31H4 and 21B12 for Blocking D374Y PCSK9/LDLR Binding

This example provides the IC50 values for two of the antibodies in blocking PCSK9 D374Y’s ability to bind to LDLR. Clear 384 well plates (Costar) were coated with 2 micrograms/ml of goat anti-LDL receptor antibody (R&D Systems) diluted in buffer A (100 mM sodium cacodylate, pH 7.4). Plates were washed thoroughly with buffer A and then blocked for 2 hours with buffer B (1% milk in buffer A). After washing, plates were incubated for 1.5 hours with 0.4 micrograms/ml of LDL receptor (R&D Systems) diluted in buffer C (buffer B supplemented with 10 mM CaCl2). Concurrent with this incubation, 20 ng/ml of biotinylated D374Y PCSK9 was incubated with various concentrations of the 31H4 IgG, 31H14 IgG4, 21B12 IgG2 or 21B12 IgG4 antibody, which was diluted in buffer A, or buffer A alone (control). The LDL receptor containing plates were washed and the biotinylated D374Y PCSK9/antibody mixture was transferred to them and incubated for 1 hour at room temperature. Binding of the biotinylated D374Y to the LDL receptor was detected by incubation with streptavidin-HRP (Biosource) at 500 ng/ml in buffer C followed by TMB substrate (KPL). The signal was quenched with 1N HCl and the absorbance read at 450 nm.

The results of this binding study are shown in FIGS. 6A-6D. Summarily, IC50 values were determined for each antibody and found to be 199 pM for 31H4 IgG2 (FIG. 6A), 156 pM for 31H14 IgG (FIG. 6B), 170 pM for 21B12 IgG2 (FIG. 6C), and 169 pM for 21B12 IgG4 (FIG. 6D).

The antibodies also blocked the binding of wild-type PCSK9 to the LDLR in this assay.

Example 12

Cell LDL Uptake Assay

This example demonstrates the ability of various antigen binding proteins to reduce LDL uptake by cells. Human HepG2 cells were seeded in black, clear bottom 96-well plates (Costar) at a concentration of 5x10^5 cells per well in DMEM medium (Mediatech, Inc) supplemented with 10% FBS and incubated at 37° C. (5% CO2) overnight. To form the PCSK9 and antibody complex, 2 µg/ml of D374Y human PCSK9 was incubated with various concentrations of antibody diluted in uptake buffer (DMEM with 1% FBS) or uptake buffer alone (control) for 1 hour at room temperature. After washing the cells with PBS, the D374Y PCSK9/antibody mixture was transferred to the cells, followed by LDL-BODIPY (Invitrogen) diluted in uptake buffer at a final concentration of 6 µg/ml. After incubation for 3 hours at 37° C. (5% CO2), cells were washed thoroughly with PBS and the cell fluorescence signal was detected by Safire™ (TECAN) at 480-520 nm (excitation) and 520-600 nm (emission).

The results of the cellular uptake assay are shown in FIGS. 7A-7D. Summarily, IC50 values were determined for each antibody and found to be 1.67 nM for 31H4 IgG2 (FIG. 7A), 13.3 nM for 31H4 IgG4 (FIG. 7B), 13.3 nM for 21B12 IgG2 (FIG. 7C), and 18 nM for 21B12 IgG4 (FIG. 7D). These results demonstrate that the applied antigen binding proteins can reduce the effect of PCSK9 (D374Y) to block LDL uptake by cells. The antibodies also blocked the effect of wild-type PCSK9 in this assay.

Example 13

Serum cholesterol Lowering Effect of the 31H4 Antibody in 6 Day Study

In order to assess total serum cholesterol (TC) lowering in wild type (WT) mice via antibody therapy against PCSK9 protein, the following procedure was performed. Male WT mice (C57BL/6 strain, aged 9-10 weeks, 17-27 g) obtained from Jackson Laboratory (Bar Harbor, Me.) were fed a normal chow (Harlard-Teklad, Diet 2918) through out the duration of the experiment. Mice were administered either anti-PCSK9 antibody 31H4 (2 mg/ml in PBS) or control IgG (2 mg/ml in PBS) at a level of 10 mg/kg through the mouse’s tail vein at T=0. Naive mice were also set aside as a naive control group. Dosing groups and time of sacrifice are shown in Table 9.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Time point after dosing</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IgG</td>
<td>8 hr</td>
<td>7</td>
</tr>
<tr>
<td>2</td>
<td>31H4</td>
<td>8 hr</td>
<td>7</td>
</tr>
<tr>
<td>3</td>
<td>IgG</td>
<td>24 hr</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>31H4</td>
<td>24 hr</td>
<td>7</td>
</tr>
<tr>
<td>5</td>
<td>IgG</td>
<td>72 hr</td>
<td>7</td>
</tr>
<tr>
<td>6</td>
<td>31H4</td>
<td>72 hr</td>
<td>7</td>
</tr>
<tr>
<td>7</td>
<td>IgG</td>
<td>144 hr</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>31H4</td>
<td>144 hr</td>
<td>7</td>
</tr>
<tr>
<td>9</td>
<td>Naive</td>
<td>n/a</td>
<td>7</td>
</tr>
</tbody>
</table>

Mice were sacrificed with CO2 asphyxiation at the predetermined time points shown in Table 9. Blood was collected via vena cava into eppendorf tubes and was allowed to clot at
room temperature for 30 minutes. The samples were then spun down in a table top centrifuge at 12,000g for 10 minutes to separate the serum. Serum total cholesterol and HDL-C were measured using Hitachi 912 clinical analyzer and Roche/Hitachi TC and HDL-C kits.

The results of the experiment are shown in FIGS. 8A-8D. Summarily, mice to which antibody 31H4 was administered showed decreased serum cholesterol levels over the course of the experiment (FIG. 8A and FIG. 8B). In addition, it is noted that the mice also showed decreased HDL levels (FIG. 8C and FIG. 8D). For FIG. 8A and FIG. 8C, the percentage change is in relation to the control IgG at the same time point (**P<0.01, #P<0.05). For FIG. 8B and FIG. 8D, the percentage change is in relation to total serum cholesterol and HDL levels measured in naïve animals at t=0 hrs (**P<0.01, #P<0.05).

In respect to the lowered HDL levels, it is noted that one of skill would anticipate that increase in HDL in mice is not indicative that an HDL decrease will occur in humans and merely further reflects that the serum cholesterol level in the organism has decreased. It is noted that mice transport the majority of serum cholesterol in high density lipoprotein (HDL) particles which is different to humans who carry most serum cholesterol on LDL particles. In mice the measurement of total serum cholesterol most closely resembles the level of serum HDL-C. Mouse HDL contains apolipoprotein E (apoE) which is a ligand for the LDL receptor (LDLR) and allows it to be cleared by the LDLR. Thus, examining HDL is an appropriate indicator for the present example, in mice (with the understanding that a decrease in HDL is not expected for humans). For example, human HDL, in contrast, does not contain apoE and is not a ligand for the LDLR. As PCSK9 antibodies increase LDLR expression in mouse, the liver can clear more HDL and therefore lowers serum HDL-C levels.

Example 14

Effect of Antibody 31H4 on LDLR Levels in a 6 Day Study

The present example demonstrates that an antigen binding protein alters the level of LDLR in a subject, as predicted, over time. A Western blot analysis was performed in order to ascertain the effect of antibody 31H4 on LDLR levels. 50-100 mg of liver tissue obtained from the same mice described in Example 13 was homogenized in 0.3 ml of RIPA buffer (Santa Cruz Biotechnology Inc.) containing complete protease inhibitor (Roche). The homogenate was incubated on ice for 30 minutes and centrifuged to pellet cellular debris. Protein concentration in the supernatant was measured using BioRad protein assay reagents (BioRad laboratories). 100 µg of protein was denatured at 70°C for 10 minutes and separated on 4-12% Bis-Tris SDS gradient gel (Invitrogen). Proteins were transferred to a 0.45 µm PVDF membrane (Invitrogen) and blocked in washing buffer (50 mM Tris pH7.5, 150 mM NaCl, 2 mM CaCl2 and 0.05% Tween 20) containing 5% non-fat milk for 1 hour at room temperature. The blot was then probed with goat anti-mouse LDLR antibody (R&D system) 1:2000 or anti-β actin (sigma) 1:2000 for 1 hour at room temperature. The blot was washed briefly and incubated with bovine anti-goat IgG-HRP (Santa Cruz Biotechnology Inc.) 1:2000 or goat anti-mouse IgG-HRP (Upstate) 1:2000. After a 1 hour incubation at room temperature, the blot was washed thoroughly and immunoreactive bands were detected using ECL plus kit (Amer sham biosciences). The Western blot showed an increase in LDLR protein levels in the presence of antibody 31H4, as depicted in FIG. 9.

Example 15

Serum cholesterol Lowering Effect of Antibody 31H4 in a 13 Day Study

In order to assess total serum cholesterol (TC) lowering in wild type (WT) mice via antibody therapy against PCSK9 protein in a 13 day study, the following procedure was performed.

Male WT mice (C57BL/6 strain, aged 9-10 weeks, 17-27 g) obtained from Jackson Laboratory (Bar Harbor, Me.) were fed a normal chow (Harland-Teklad, Diet 2918) through out the duration of the experiment. Mice were administered either anti-PCSK9 antibody 31H4 (2 mg/ml in PBS) or control IgG (2 mg/ml in PBS) at a level of 10 mg/kg through the mouse's tail vein at T=0. Naïve mice were also set aside as naïve control group.

Dosing groups and time of sacrifice are shown in Table 10. Animals were sacrificed and livers were extracted and prepared as in Example 13.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Time point after dosing</th>
<th>Number</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IgG</td>
<td>72 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>2</td>
<td>31H4</td>
<td>72 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>3</td>
<td>31H4</td>
<td>72 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>4</td>
<td>IgG</td>
<td>144 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>5</td>
<td>31H4</td>
<td>144 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>6</td>
<td>31H4</td>
<td>144 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>7</td>
<td>IgG</td>
<td>192 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>8</td>
<td>31H4</td>
<td>192 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>9</td>
<td>31H4</td>
<td>192 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>10</td>
<td>IgG</td>
<td>240 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>11</td>
<td>31H4</td>
<td>240 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>12</td>
<td>31H4</td>
<td>240 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>13</td>
<td>IgG</td>
<td>312 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>14</td>
<td>31H4</td>
<td>312 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>15</td>
<td>31H4</td>
<td>312 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>16</td>
<td>Naïve</td>
<td>n/a</td>
<td>6</td>
<td>n/a</td>
</tr>
</tbody>
</table>

When the 6 day experiment was extended to a 13 day study, the same serum cholesterol lowering effect observed in the 6 day study was also observed in the 13 day study. More specifically, animals dosed at 10 mg/kg demonstrated a 31% decrease in serum cholesterol on day 3, which gradually returned to pre-dosing levels by day 13. FIG. 10A depicts the results of this experiment. FIG. 10C depicts the results of repeating the above procedure with the mg/kg dose of 31H4, and with another antibody, 16F12, also at 10 mg/kg. Dosing groups and time of sacrifice are shown in Table 11.

<table>
<thead>
<tr>
<th>Group</th>
<th>Treatment</th>
<th>Time point after dosing</th>
<th>Number</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IgG</td>
<td>24 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>2</td>
<td>16F12</td>
<td>24 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>3</td>
<td>31H4</td>
<td>24 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>4</td>
<td>IgG</td>
<td>72 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>5</td>
<td>16F12</td>
<td>72 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>6</td>
<td>31H4</td>
<td>72 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>7</td>
<td>IgG</td>
<td>144 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>8</td>
<td>16F12</td>
<td>144 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>9</td>
<td>31H4</td>
<td>144 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>10</td>
<td>IgG</td>
<td>192 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>11</td>
<td>16F12</td>
<td>192 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td>12</td>
<td>31H4</td>
<td>192 hr</td>
<td>6</td>
<td>10 mg/kg</td>
</tr>
</tbody>
</table>
As shown in FIG. 10C, both 16F12 and 31H4 resulted in significant and substantial decreases in total serum cholesterol after just a single dose and provided benefits for over a week (10 days or more). The results of the repeated 13 day study were consistent with the results of the first 13 day study, with a decrease in serum cholesterol levels of 26% on day 3 being observed. For FIG. 10A and FIG. 10B, the percentage change is in relation to the control IgG at the same time point (*P<0.01). For FIG. 10C, the percentage change is in relation to the control IgG at the same time point (**P<0.05).

Example 16

Effect of Antibody 31H4 on HDL Levels in a 13 Day Study

The HDL levels for the animals in Example 15 were also examined. HDL levels decreased in the mice. More specifically, animals dosed at 10 mg/kg demonstrated a 33% decrease in HDL levels on day 3, which gradually returned to pre-dosing levels by day 13. FIG. 10B depicts the results of the experiment. There was a decrease in HDL levels of 34% on day 3. FIG. 10B depicts the results of the repeated 13 day experiment.

As will be appreciated by one of skill in the art, while the antibodies will lower mouse HDL, this is not expected to occur in humans because of the difference in HDL in humans and other organisms (such as mice). Thus, the decrease in mouse HDL is not indicative of a decrease in human HDL.

Example 17

Repeated Administration of Antibodies Produce Continued Benefits of Antigen Binding Peptides

In order to verify that the results obtained in the Examples above can be prolonged for further benefits with additional doses, the Experiments in Examples 15 and 16 were repeated with the dosing schedule depicted in FIG. 11A. The results are displayed in FIG. 11B. As can be seen in the graph in FIG. 11B, while both sets of mice displayed a significant decrease in total serum cholesterol because all of the mice received an initial injection of the 31H4 antigen binding protein, the mice that received additional injections of the 31H4-ABP displayed a continued reduction in total serum cholesterol, while those mice that only received the control injection eventually displayed an increase in their total serum cholesterol. For FIG. 11, the percentage change is in relation to the naïve animals at t=0 hours (*P<0.01, **P<0.001).

The results from this example demonstrate that, unlike other cholesterol treatment methods, in which repeated applications lead to a reduction in efficacy because of biological adjustments in the subject, the present approach does not seem to suffer from this issue over the time period examined. Moreover, this suggests that the return of total serum cholesterol or HDL cholesterol levels to baseline, observed in the previous examples is not due to some resistance to the treatment being developed by the subject, but rather the depletion of the antibody availability in the subject.

Example 18

Epitope Mapping of Human Anti PCSK9 Antibodies

This example outlines methods for determining which residues in PCSK9 are involved in forming or part of the epitope for the antigen binding proteins disclosed herein to PCSK9.

In order to determine the epitopes to which certain of the ABPs of the present invention bind, the epitopes of the ABPs can be mapped using synthetic peptides derived from the specific PCSK9 peptide sequence. A SPOT peptide array (Sigma Genosys) can be used to study the molecular interaction of the human anti-PCS9 antibodies with their peptide epitope. SPOT technology is based on the solid-phase synthesis of peptides in a format suitable for the systematic analysis of antibody epitopes. Synthesis of custom arrayed oligopeptides is commercially available from Sigma-Genosys. A peptide array of overlapping oligopeptides derived from the amino-acid sequence of the PCSK9 peptide can be obtained. The array can comprise a series of 12-mer peptides as spots on a polypropylene membrane sheets. The peptide array can span the entire length of the PCSK9 mature sequence. Each consecutive peptide can be offset by 1 residue from the previous one, yielding a nested, overlapping library of arrayed oligopeptides. The membrane carrying the peptides can be reacted with different anti-PCS9 antibodies (1 micrograms/ml). The binding of the mAbs to the membrane-bound peptides can be assessed by an enzyme-linked immunosorbent assay using HRP-conjugated secondary antibody followed by enhanced chemiluminescence (ECL).

In addition, functional epitopes can be mapped by combinatorial alanine scanning. In this process, a combinatorial alanine-scanning strategy can be used to identify amino acids in the PCSK9 protein that are necessary for interaction with anti-PCS9 ABPs. To accomplish this, a second set of SPOT arrays can be used for alanine scanning. A panel of variant peptides with alanine substitutions in each of the 12 residues can be scanned as above. This will allow for the epitopes for the ABPs to the human PCSK9 to be mapped and identified.

In the alternative, given that it is possible that the epitope is conformational, a combination of alanine scanning and/or arginine scanning, antibody FAB/PCSK9 co-crystallization, and limited proteolysis/LC-MS (liquid chromatography mass spec.) can be employed to indentify the epitopes.

Example 19

Uses of PCSK9 Antibodies for the Treatment of Cholesterol Related Disorders

A human patient exhibiting a Cholesterol Related Disorder (in which a reduction in cholesterol (such as serum cholesterol) can be beneficial) is administered a therapeutically effective amount of PCSK9 antibody, 31H4 (or, for example, 21B12 or 16F12). At periodic times during the treatment, the patient is monitored to determine whether the symptoms of the disorder has subsided. Following treatment, it is found that patients undergoing treatment with the PCSK9 antibody have reduced serum cholesterol levels, in comparison to patients that are not treated.
Example 20

Uses of PCSK9 Antibodies for the Treatment of Hypercholesterolemia

A human patient exhibiting symptoms of hypercholesterolemia is administered a therapeutically effective amount of PCSK9 antibody, such as 311H4 (or, for example, 21B12 or 16F12). At periodic times during the treatment, the human patient is monitored to determine whether the serum cholesterol level has declined. Following treatment, it is found that the patient receiving the treatment with the PCSK9 antibodies has reduced serum cholesterol levels in comparison to arthritis patients not receiving the treatment.

Example 21

Uses of PCSK9 Antibodies for the Prevention of Coronary Heart Disease and/or Recurrent Cardiovascular Events

A human patient at risk of developing coronary heart disease is identified. The patient is administered a therapeutically effective amount of PCSK9 antibody, such as 311H4 (or, for example, 21B12 or 16F12), either alone, concurrently or sequentially with a statin, e.g., simvastatin. At periodic times during the treatment, the human patient is monitored to determine whether the patient’s total serum cholesterol level changes. Throughout the preventative treatment, it is found that the patient receiving the treatment with the PCSK9 antibodies has reduced serum cholesterol thereby reducing their risk to coronary heart diseases or recurrent cardiovascular events in comparison to patients not receiving the treatment.

Example 22

Use of PCSK9 Antibodies as a Diagnostic Agent

An Enzyme-Linked Immunosorbent Assay (ELISA) for the detection of PCSK9 antigen in a sample can be used to diagnose patients exhibiting high levels of PCSK9 production. In the assay, wells of a microtiter plate, such as a 96-well microtiter plate or a 384-well microtiter plate, are adsorbed for several hours with a first fully human monoclonal antibody directed against PCSK9. The immobilized antibody serves as a capture antibody for any of the PCSK9 antigen that may be present in a test sample. The wells are rinsed and treated with a blocking agent such as milk protein or albumin to prevent nonspecific adsorption of the analyte. Subsequently the wells are treated with a test sample suspected of containing the PCSK9, or with a solution containing a standard amount of the antigen. Such a sample may be, for example, a serum sample from a subject suspected of having levels of circulating antigen considered to be diagnostic of a pathology. After rinsing away the test sample or standard, the wells are treated with a second fully human monoclonal PCSK9 antibody that is labeled by conjugation with biotin. A monoclonal or mouse or other species origin can also be used. The labeled PCSK9 antibody serves as a detecting antibody. After rinsing away excess second antibody, the wells are treated with avidin-conjugated horseradish peroxidase (HRP) and a suitable chromogenic substrate. The concentration of the antigen in the test samples is determined by comparison with a standard curve developed from the standard samples.

95

This ELISA assay provides a highly specific and very sensitive assay for the detection of the PCSK9 antigen in a test sample.

Determination of PCSK9 Protein Concentration in Subjects

A sandwich ELISA can quantify PCSK9 levels in human serum. Two fully human monoclonal PCSK9 antibodies from the sandwich ELISA, recognize different epitopes on the PCSK9 molecule. Alternatively, monoclonal antibodies of mouse or other species origin may be used. The ELISA is performed as follows: 50 μL of capture PCSK9 antibody in coating buffer (0.1 M NaHCO3, pH 9.6) at a concentration of 2 μg/mL is coated on ELISA plates (Fisher). After incubation at 4°C overnight, the plates are treated with 200 μL of blocking buffer (0.5% BSA, 0.1% Tween 20, 0.01% Thimerosal in PBS) for 1 hour at 25°C. The plates are washed (3x) using 0.05% Tween 20 in PBS (washing buffer, WB). Normal or patient sera (Clinomics, Bioreclamation) are diluted in blocking buffer containing 50% human serum. The plates are incubated with serum samples overnight at 4°C, washed with WB, and then incubated with 100 μL well of biotinylated detection PCSK9 antibody for 1 hour at 25°C. After washing, the plates are incubated with HRP-Streptavidin for 15 minutes, washed as before, and then treated with 100 μL well of o-phenylenediamine in H2O2 (Sigma developing solution) for color generation. The reaction is stopped with 50 μL well of H2SO4 (2M) and analyzed using an ELISA plate reader at 492 nm. Concentration of PCSK9 antigen in serum samples is calculated by comparison to dilutions of purified PCSK9 antigen using a four parameter curve fitting program.

Determination of PCSK9 Variant Protein Concentration in Subjects

The steps outlined above can be performed using antibodies noted herein that bind to both the wild type PCSK9 and the variant PCSK9 (D374Y). Next, antibodies that bind to the wild type but not the mutant can be used (again using a similar protocol as outlined above) to determine if the PCSK9 present in the subject is wild type or the D374Y variant. As will be appreciated by one of skill in the art, results that are positive for both rounds will be wild-type, while those that are positive for the first round, but not the second round of antibodies, will include the D374Y mutation. There are high frequency mutations in the population that are known and the could benefit particularly from an agent such as the ABPs disclosed herein.

Example 23

Use of PCSK9 Antigen Binding Protein for the Prevention of Hypercholesterolemia

A human patient exhibiting a risk of developing hypercholesterolemia is identified via family history analysis and/or lifestyle, and/or current cholesterol levels. The subject is regularly administered (e.g., one time weekly) a therapeutically effective amount of PCSK9 antibody, 311H4 (or, for example, 21B12 or 16F12). At periodic times during the treatment, the patient is monitored to determine whether serum cholesterol levels have decreased. Following treatment, it is found that subjects undergoing preventative treatment with the PCSK9 antibody have lowered serum cholesterol levels, in comparison to subjects that are not treated.

Example 24

PCSK9 ABPs Further Upregulated LDLR in the Presence of Statins

This example demonstrates that ABPs to PCSK9 produced further increases in LDLR availability when used in the pres-
ence of statins, demonstrating that further benefits can be achieved by the combined use of the two.

HepG2 cells were seeded in DMEM with 10% fetal bovine serum (FBS) and grown to ~90% confluence. The cells were treated with indicated amounts of mevinolin (a statin, Sigma) and PCSK9 ABPs (Figs. 12A-12C) in DMEM with 5% FBS for 48 hours. Total cell lysates were prepared. 50 mg of total proteins were separated by gel electrophoresis and transferred to PVDF membrane. Immunoblotting were performed using rabbit anti-human LDL receptor antibody (Fitzgerald) or rabbit anti-human b-actin antibody. The enhanced chemiluminescent results are shown in the top panels of FIGS. 12A-12C. The intensity of the bands were quantified by ImageJ software and normalized by b-actin. The relative levels of LDLR are shown in the lower panels of FIGS. 12A-12C. ABPs 21B12 and 31H4 are PCSK9 neutralizing antibodies, while 25A7.1 is a non-neutralizing antibody.

HepG2-PCSK9 cells were also created. These were stable HepG2 cell line transduced with human PCSK9. The cells were seeded in DMEM with 10% fetal bovine serum (FBS) and grew to ~90% confluence. The cells were treated with indicated amounts of mevinolin (Sigma) and PCSK9 ABPs (Figs. 12D-12F) in DMEM with 5% FBS for 48 hours. Total cell lysates were prepared. 50 mg of total proteins were separated by gel electrophoresis and transferred to PVDF membrane. Immunoblotting were performed using rabbit anti-human LDL receptor antibody (Fitzgerald) or rabbit anti-human b-actin antibody. The enhanced chemiluminescent results are shown in the top panels. The intensity of the bands were quantified by ImageJ software and normalized by b-actin.

As can be seen in the results depicted in FIGS. 12A-12F, increasing amounts of the neutralizing antibody and increasing amounts of the statin generally resulted in increases in the level of LDLR. This increase in effectiveness for increasing levels of the ABP is especially evident in FIGS. 12D-12F, in which the cells were also transduced with PCSK9, allowing the ABPs to demonstrate their effectiveness to a greater extent.

Interestingly, as demonstrated by the results in the comparison of FIGS. 12D-12F to 12A-12C, the influence of the ABP concentrations on LDLR levels increased dramatically when PCSK9 was being produced by the cells. In addition, it is clear that the neutralizing ABPs (21B12 and 31H4) resulted in a greater increase in LDLR levels, even in the presence of statins, than the 25A7.1 ABP (a non-neutralizer), demonstrating that additional benefits can be achieved by the use of both statins and ABPs to PCSK9.

Example 25

Consensus Sequences

Consensus sequences were determined using standard phylogenic analyses of the CDRs corresponding to the V_{H} and V_{L} of anti-PCS99 ABPs. The consensus sequences were determined by keeping the CDRs contiguous within the same sequence corresponding to a V_{H} or V_{L}. Briefly, amino acid sequences corresponding to the entire variable domains of either V_{H} or V_{L} were converted to FASTA formatting for ease in processing comparative alignments and inferring phylogenies. Next, framework regions of these sequences were replaced with an artificial linker sequence ("bbbbbbbbbb" placeholders, non-specific nucleic acid construct) so that examination of the CDRs alone could be performed without introducing any amino acid position weighting bias due to coincident events (e.g., such as unrelated antibodies that serially share a common germline framework heritage) while still keeping CDRs contiguous within the same sequence corresponding to a V_{H} or V_{L}. V_{H} or V_{L} sequences of this format were then subjected to sequence similarity alignment interrogation using a program that employs a standard ChulaW-like algorithm (see, Thompson et al., 1994, *Nucleic Acids Res.* 22:4673-4680). A gap creation penalty of 8.0 was employed along with a gap extension penalty of 2.0. This program likewise generated phylogenies (phylogenetic tree illustrations) based on sequence similarity alignments using either UPGMA (unweighted pair group method using arithmetic averages) or Neighbor-Joining methods (see, Saitou and Nei, 1987, *Molecular Biology and Evolution* 4:406-425) to construct and illustrate similarity and distinction of sequence groups via branch length comparison and grouping.

Both methods produced similar results but UPGMA-derived trees were ultimately used as the method employs a simpler and more conservative set of assumptions. UPGMA-derived trees were generated where similar groups of sequences were defined as having fewer than 15 substitutions per 100 residues (see, legend in tree illustrations for scale) amongst individual sequences within the group and were used to define consensus sequence collections. The results of the comparisons are depicted in FIGS. 13A-13J. In FIGS. 13E, the groups were chosen so that sequences in the light chain that clade are also a clade in the heavy chain and have fewer than 15 substitutions.

As will be appreciated by one of skill in the art, the results presented in FIGS. 13A-13J present a large amount of guidance as to the importance of particular amino acids (for example, those amino acids that are conserved) and which amino acid positions can likely be altered (for example, those positions that have different amino acids for different ABPs).

Example 26

Mouse Model for PCS99 and ABP Ability to Lower LDL In Vivo

To generate mice which over-expressed human PCS99, three week old WT C57B1/6 mice were injected via tail vein administration with various concentrations of adenovirus (AAV), recombinantly modified to express human PCS99, to determine the correct titer which would provide a measurable increase of LDL-cholesterol in the mice. Using this particular virus that expressed human PCS99, it was determined that 4.5x10E12 pfu of virus would result in an LDL-cholesterol level of approximately 40 mg/dl in circulating blood (normal levels of LDL in a WT mice are approximately 10 mg/dl.). The human PCS99 levels in these animals was found to be approximately 13 ug/ml. A colony of mice were generated using this injection criteria.

One week after injection, mice were assessed for LDL-cholesterol levels, and randomized into different treatment groups. Animals were then administered, via tail vein injection, a single bolus injection of either 10 mg/kg or 30 mg/kg of 16F12, 21B12, or 31H4 antigen binding proteins. IgG2 ABP was administered in a separate group of animals as a dosing control. Subgroups of animals (n=6-7) were then euthanized at 24 and 48 hours after ABP administration. There were no effects on LDL-cholesterol levels following IgG2 administration at either dose. Both 31H4 and 21B12 demonstrated significant LDL-cholesterol lowering up to and including 48 hours post-administration, as compared to IgG2 control (shown in FIGS. 14A and 14B at two different doses). 16F12 shows an intermediary LDL-cholesterol lowering response, with levels returning to baseline of approximately 40 mg/dl by the 48 hour time point. This data is consistent
with in vitro binding data (Biacore and Kinexa), which shows near equivalent binding affinity between 31H4 and 21B12, and a lesser affinity of 16F12 to human PCSK9. As can be seen in the results, total cholesterol and HDL-cholesterol were reduced by the PCSK9 ABPs in the model (both total and HDL-C are elevated above WT mice due to the overexpression of PCSK9). While cholesterol lowering in this model appears to occur over a relatively short period of time, this is believed to be due to the levels of human PCSK9 that are present, which are supraphysiologically high in this model. In addition, given that the expression is governed by AAV, there is no regulation of PCSK9 expression. In these figures, (*) denotes a P<0.05, and (**) denotes a P<0.005 as compared to LDL-cholesterol levels observed in IgG2 control injected animals at the same time point. The 13 microgram/ml level of serum human PCSK9 in the mice corresponds to an approximately 520-fold increase above the endogenous mouse PCSK9 levels (~25 ng/ml), and an approximately 75-fold increase above average human serum levels (~175 ng/ml). Thus, the antigen binding proteins should be even more effective in humans.

As will be appreciated by one of skill in the art, the above results demonstrate that the antigen binding proteins’ ability to alter serum cholesterol in a subject. One of skill in the art will also recognize that the use of mouse HDL to monitor serum cholesterol levels in a mouse, while useful for monitoring mouse serum cholesterol levels, is not indicative of the ABP’s impact on human HDL in humans. For example, Cohen et al. (“Sequence variations in PCSK9, low LDL-C, and protection against coronary heart disease”, N Engl J Med, 354:1264-1272, 2006) demonstrated the lack of any effect of the PCSK9 loss-of-function mutations on human HDL levels (the entirety of which is incorporated by reference). Thus, one of skill in the art will appreciate that the ability of the ABP to lower mouse HDL (which lacks LDL) is not indicative of the ABP’s ability to lower human HDL. Indeed, as shown by Cohen, this is unlikely to occur for neutralizing antibodies in humans.

Example 27

31H4 and 21B12 Bind to the ProCat Region of PCSK9

The present example describes one method for determining where various antibodies bind to PCSK9. The ProCat (31-449 of SEQ ID NO: 3) or V domain (450-692 of SEQ ID NO: 3) of the PCSK9 protein was combined with either antibody 31H4 or 21B12. The samples were analyzed by Native PAGE for complex formation. As can be seen in FIG. 16A and FIG. 16B, gel shifts were present for the ProCat/31H4 and ProCat/21B12 samples, demonstrating that the antibodies bound to the ProCat domain.

Example 28

The LDLR EGFα Domain Binds to the Catalytic Domain of PCSK9

The present example presents the solved crystal structure of PCSK9 ProCat (31-454 of SEQ ID NO: 3) bound to the LDLR EGFα domain (293-334) at 2.9 Å resolution (the conditions for which are described in the below Examples). A representation of the structure of PCSK9 bound to EGFα is shown in FIG. 17. The crystal structure (and its depiction in FIG. 17) reveals that the EGFα domain of LDLR binds to the catalytic domain of PCSK9. In addition, the interaction of PCSK9 and EGFα appears to occur across a surface of PCSK9 that is between residues D374 and S153 in the structure depicted in FIG. 17.

Specific core PCSK9 amino acid residues of the interaction interface with the LDLR EGFα domain were defined as PCSK9 residues that are within 5 Å of the EGFα domain. The core residues are as follows: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, and S381.

Boundary PCSK9 amino acid residues of the interaction interface with the LDLR EGFα domain were defined as PCSK9 residues that are 5-8 Å from the EGFα domain. The boundary residues are as follows: W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I368, G370, A371, S373, S376, and Q382. Residues that are underlined are nearly or completely buried within PCSK9.

As will be appreciated by one of skill in the art, the results from this example demonstrate where PCSK9 and EGFα interact. Thus, antibodies that interact with or block any of these residues can be useful as antibodies that inhibit the interaction between PCSK9 and the EGFα domain of LDLR (and/or LDLR generally). In some embodiments, antibodies that, when bound to PCSK9, interact with or block any of the above residues or are within 15-8, 8-5, or 5 angstroms of the above residues are contemplated to provide useful inhibition of PCSK9 binding to LDLR.

Example 29

31H4 Interacts with Amino Acid Residues from Both the Pro- and Catalytic Domains of PCSK9

The present example presents the crystal structure of full length PCSK9 (N533A mutant of SEQ ID NO: 3) bound to the Fab fragment of 31H4, determined to 2.3 Å resolution (the conditions for which are described in the below Examples). This structure, depicted in FIGS. 18A and 18B, shows that 31H4 binds to PCSK9 in the region of the catalytic site and makes contacts with amino acid residues from both the prodomain and catalytic domain.

The depicted structure also allows one to identify specific core PCSK9 amino acid residues for the interaction interface of 31H4 with PCSK9. This was defined as residues that are within 5 Å of the 31H4 protein. The core residues are as follows: W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, I366, D367, D374, V380, S381, Q382, S383, and G384.

The structures were also used to identify boundary PCSK9 amino acid residues for the interaction interface with 31H4. These residues were PCSK9 residues that were 5-8 Å from the 31H4 protein. The boundary residues are as follows: K69, D70, P71, S148, V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, G316, R319, Y325, V346, G352, T353, G365, I368, I369, S372, S373, C378, F379, T385, S386, and Q387. Amino acid residues completely buried within the PCSK9 protein are underlined.

As will be appreciated by one of skill in the art, FIG. 18B depicts the interaction between the CDRs on the antigen binding protein and PCSK9. As such, the model allows one of skill in the art to identify the residues and/or CDRs that are especially important in the paratope, and which residues are less critical to the paratope. As can be seen in FIG. 18B, the heavy chain CDR1, CDR2, and CDR3 are most directly involved in the antigen binding protein’s binding to the
101

epitope, with the CDRs from the light chain being relatively far away from the epitope. As such, it is probable that larger variations in the light chain CDRs are possible, without unduly interfering with the binding of the antigen binding protein to PCSK9. In some embodiments, residues in the structures that directly interact are conserved (or alternatively conservatively replaced) while residues that are not directly interacting with one another can be altered to a greater extent. As such, one of skill in the art, given the present teachings, can predict which residues and areas of the antigen binding proteins can be varied without unduly interfering with the antigen binding protein’s ability to bind to PCSK9. For example, those residues that are located closest to PCSK9 when the antigen binding protein is bound to PCSK9 are those that likely play a more important role in the binding of the antigen binding protein to PCSK9. As above, these residues can be divided into those that are within 5 angstroms of PCSK9 and those that are between 5 and 8 angstroms. Specific core 311H4 amino acid residues of the interaction interface with PCSK9 were defined as 311H4 residues that are within 5 Å of the PCSK9 protein. For the heavy chain, the residues that are within 5 angstroms include the following: T28, S30, S31, Y32, S54, S55, S56, Y57, 158, S59, Y60, N74, A75, R98, Y100, F102, W103, S104, A105, Y106, Y107, D108, A109, and Dill. For the light chain, those residues that are within 5 angstroms include the following: L48, S51, Y93, and S98. For the heavy chain, those residues that are 5-8 Å from the PCSK9 protein include the following: G26, F27, F29, W47, S50, 151, S52, S53, K65, F68, T69, 170, S71, R72, D73, K76, N77, D99, D101, F110, and V112. For the light chain, those residues that are within 5-8 angstroms of PCSK9 include A31, G32, Y33, D34, H36, Y38, 150, G52, N55, R56, P57, S58, D94, S95, S96, L97, G99, and S100.

As will be appreciated by one of skill in the art, the results from Example 29 demonstrate where antibodies to PCSK9 can interact on PCSK9 and still block PCSK9 from interacting with EGFa (and thus LDLR). Thus, antigen binding proteins that interact with any of these residues of PCSK9 residues, or that block any of these residues (e.g., from other antigen binding proteins that bind to these residues), can be useful as antibodies that inhibit the interaction of PCSK9 and EGFa (and LDLR accordingly). Thus, in some embodiments, antigen binding proteins that interact with any of the above residues or interact with residues that are within 5 Å of the above residues are contemplated to provide useful inhibition of PCSK9 binding to LDLR. Similarly, antigen binding proteins that block any of the above residues (which can be determined, for example, via a competition assay) can also be useful for inhibition of the PCSK9/LDLR interaction.

Example 30

21B12 binds to the Catalytic Domain of PCSK9, has a Distinct Binding Site from 311H4 and can bind to PCSK9 Simultaneously with 311H4

The present example presents the crystal structure of PCSK9 ProtCat (31-449 of SEQ ID NO: 3) bound to the Fab fragments of 311H4 and 21B12, determined at 2.8 Å resolution (the conditions for which are described in the below Examples). This crystal structure, depicted in FIG. 19A and FIG. 19B, shows that 311H4 and 21B12 have distinct binding sites on PCSK9 and that both antigen binding proteins can bind to PCSK9 simultaneously. The structure shows that 21B12 interacts with amino acid residues from PCSK9’s catalytic domain. In this structure, the interaction between PCSK9 and 311H4 is similar to what was observed above.

Specific core PCSK9 amino acid residues of the interaction interface with 21B12 were defined as PCSK9 residues that are within 5 Å of the 21B12 protein. The core residues are as follows: S153, S188, I189, Q190, S191, D192, R194, E197, G198, R199, V200, D224, R237, D238, K243, S373, D374, S376, T377, and F379.

Boundary PCSK9 amino acid residues of the interaction interface with 21B12 were defined as PCSK9 residues that were 5-8 Å from the 21B12 protein. The boundary residues are as follows: I154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, and C378. Amino acid residues nearly or completely buried within the PCSK9 protein are underlined.

As will be appreciated by one of skill in the art, FIG. 19B depicts the interaction between the CDRs on the antigen binding protein and PCSK9. As such, the model allows one of skill in the art to identify the CDRs which are especially important for the paratope and which residues are less critical to the paratope. As can be seen in the structure, heavy chain CDR2 and light chain CDR1 appear to closely interact with the epitope. Next, heavy chain CDR1, heavy chain CDR3 and light chain CDR3, appear to be close to the epitope, but not as close as the first set of CDRs. Finally, light chain CDR2 appears to be some distance from the epitope. As such, it is probable that larger variations in the more distant CDRs are possible without unduly interfering with the binding of the antigen binding protein to PCSK9. In some embodiments, residues in the structures that directly interact are conserved (or alternatively conservatively replaced) while residues that are not directly interacting with one another can be altered to a greater extent. As such, one of skill in the art, given the present teachings, can predict which residues and areas of the antigen binding proteins can be varied without unduly interfering with the antigen binding protein’s ability to bind to PCSK9. For example, those residues that are located closest to PCSK9 when the antigen binding protein is bound to PCSK9 are those that likely play a more important role in the binding of the antigen binding protein to PCSK9.

As above, these residues can be divided into those that are within 5 angstroms of PCSK9 and those that are between 5 and 8 angstroms. Specific core 21B12 amino acid residues of the interaction interface with PCSK9 were defined as 21B12 residues that are within 5 Å of the PCSK9 protein. For the heavy chain, the residues that are within 5 angstroms include the following: T28, L29, I34, S35, W47, V51, G56, T58, Y60, T72, M102, and D103. For the light chain, those residues that are within 5-8 angstroms of PCSK9 include the following: S26, V29, V35, Y51, N55, S92, M98, and V99.

As will be appreciated by one of skill in the art, the results from Example 30 demonstrate where antigen binding proteins to PCSK9 can interact on PCSK9 and still block PCSK9 from interacting with EGFa (and thus LDLR). Thus, antigen binding proteins that interact with any of these residues can be useful as antibodies that inhibit the interaction of PCSK9 and EGFa (and LDLR accordingly). Thus, in some embodiments, antibodies that interact with any of the above residues or interact with residues that are within 5 Å of the above residues are contemplated to provide useful inhibition of PCSK9 binding to LDLR. Similarly, antigen binding proteins that block any of
the above residues (which can be determined, for example, via a competition assay) can also be useful for inhibition of PCSK9/LDLR interaction.

### Example 31

**Interaction Between EGFa, PCSK9, and the Antibodies**

The structure of the ternary complex (PCSK9/31H4/21B12) from the above example was overlaid on the PCSK9/EGFa structure (determined as described in Example 28) and the result of this combination is depicted in FIG. 20A. This figure demonstrates areas on PCSK9 which can be usefully targeted to inhibit PCSK9 interaction with EGFa. The figure shows that both 31H4 and 21B12 partially overlap with the position of the EGFa domain of LDLR and sterically interfere with its binding to PCSK9. In addition, as can be seen in the structures, 21B12 directly interacts with a subset of amino acid residues that are specifically involved in binding to the LDLR EGFa domain.

As noted above, analysis of the crystal structures identified specific amino acids involved in the interaction between PCSK9 and the partner proteins (the core and boundary regions of the interface on the PCSK9 surface) and the spatial requirements of these partner proteins to interact with PCSK9. The structures suggest ways to inhibit the interaction between PCSK9 and the LDLR. First, as noted above, binding an agent to PCSK9 where it shares residues in common with the binding site of the EGFa domain of the LDLR would inhibit the interaction between PCSK9 and the LDLR. Second, an agent that binds outside of the residues in common can sterically interfere with the EGFa domain or regions of the LDLR that are either N- or C-terminal to the EGFa domain to prevent the interaction between PCSK9 and the LDLR.

In some embodiments, the residues that are involved in both EGFa binding and are close to the areas where the above noted antigen binding proteins bind are especially useful for manipulating PCSK9 binding to LDLR. For example, amino acid residues from interfaces in common in both the core region and boundary region for the different binding partners are listed in Table 12 below. Amino acid residues completely buried within the PCSK9 protein are underlined.

### TABLE 12

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Amino acid position(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>31H4/EGFa both under 5 Å</td>
<td>D374, V380, S381</td>
</tr>
<tr>
<td>31H4 under 5 Å/EGFa 5-8 Å</td>
<td>D367, Q382</td>
</tr>
<tr>
<td>31H4 at 5-8 Å/EGFa under 5 Å</td>
<td>I369, S372, C378, F379</td>
</tr>
<tr>
<td>31H4/EGFa both at 5-8 Å</td>
<td>H229, S373</td>
</tr>
<tr>
<td>21B12/EGFa both under 5 Å</td>
<td>S153, R194, D238, D374, T377, F379</td>
</tr>
<tr>
<td>21B12 under 5 Å/EGFa 5-8 Å</td>
<td>R237, K243, S373, S376</td>
</tr>
<tr>
<td>21B12 at 5-8 Å/EGFa under 5 Å</td>
<td>H154, A236, I369, S372, C375, C378</td>
</tr>
<tr>
<td>21B12/EGFa both at 5-8 Å</td>
<td>H193, E195</td>
</tr>
</tbody>
</table>

As will be appreciated by one of skill in the art, in some embodiments, the antigen binding proteins bind to and/or block at least one of the above noted residues.

### Example 32

**Structural Interaction of LDLR and PCSK9**

A model of full length PCSK9 bound to a full length representation of the LDLR was made using the PCSK9 ProCat (31-454 of SEQ ID NO: 3)/EGFa complex structure. The structure of full length PCSK9 (Piper, D. E. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15, 545-52 (2007)) was overlaid onto the PCSK9 ProCat 31-454 from the complex and the structure of the LDLR in its low pH conformation (Rudenko, G. et al. Structure of the LDL receptor extracellular domain at endosomal pH. Science 298, 2353-8 (2002)) was overlaid onto the EGFa domain from the complex. Depictions of the model are shown in FIGS. 20B and 20C. The EGFa domain is indicated by the box in the figure. The figures show regions of the LDLR outside of the immediate EGFa binding domain that lies in close proximity to PCSK9. FIGS. 20D-20I show the above interaction, along with mesh surface representations of antibody 31H4 and 21B12 from three different angles. As is clear from the depictions, not only can the antibody interact and/or interfere with LDLR’s interaction with PCSK9 at the actual binding site, but other steric interactions appear to occur as well.

In light of the above results, it is clear that antigen binding proteins that bind to PCSK9 can also inhibit the interaction between PCSK9 and the LDLR by clashing with various regions of the LDLR (not just the site at which LDLR and PCSK9 interact). For example, it can clash with repeat 7 (R7), the EGfb domain, and/or the β-propeller domain. Embodiments of Antigen Binding Molecules that Bind to or Block EGFa Interaction with PCSK9

As will be appreciated by one of skill in the art, Examples 28-32, and their accompanying figures, provide a detailed description of how and where EGFa interacts with PCSK9 and how two representative neutralizing antigen binding proteins, 21B12 and 31H4 interact with PCSK9 and produce their neutralizing effect. As such, one of skill in the art will readily be able to identify antigen binding molecules that can similarly reduce the binding between EGFa (including LDLR) and PCSK9 by identifying other antigen binding molecules that bind at or near at least one of the same locations on PCSK9. While the relevant locations (or epitopes) on PCSK9 are identified in the figures and the present description, it can also be advantageous to describe these sites as being within a set distance from residues that have been identified as close to the EGFa binding site. In some embodiments, an antigen binding molecule will bind to or within 30 angstroms of one or more of the following residues (numbering in reference to SEQ ID NO: 3): S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I369, S372, I373, S376, Q382, W72, F150, A151, Q152, T214, R215, F216, H217, A220, S221, K222, S225, H226, C255, Q256, G257, K258, N317, F318, T347, L348, G349, T350, L351, E366, D367, D374, V380, S381, Q382, S383, G384, K69, D70, P71, S148, V149, D186, T187, E211, D212, G213, R218, Q219, C223, D224, G227, H229, L253, N254, G259, P288, A290, G291, C316, R319, Y325, V346, G352, T353, G365, I368, I369, S372, S373, C378, F379, T385, S386, Q387, S153, I158, I188, Q190, S191, D192, R194, E197, G198, R199, V209, D224, R237, D238, K243, S373, D374, S376, T377, F379, I1154, T187, H193, E195, I196, M201, V202, C223, T228, S235, G236, A239, G244, M247, I369, S372, C375, or C378. In some embodiments, the antigen binding molecule binds within 30 angstroms of one or more of the following residues (numbering in reference to SEQ ID NO: 3): S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, S381, W156, N157, L158, E159, H193, E195, H229, R237, G240, K243, D367, I369, S372, I373, S376, or Q382. In some embodiments, the antigen binding molecule binds

In some embodiments, the antigen binding molecule binds within 30, 30-25, 25-20, 20-15, 15-8.8-8.5, 5-5.4, 4 or less angstroms from one or more of the above residues. In some embodiments, the antigen binding molecule, when bound to PCSK9, is within at least one of the above distances, for more than one of the above noted residues. For example, in some embodiments, the antigen binding molecule is within one of the received distances (e.g., 30, 30-25, 25-20, 20-15, 15-8.8-8.5, 5-5.4, 4 or less) for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, 70-75 or more of the above residues. In some embodiments, the antigen binding molecule is within one of the received distances for at least 1, 1-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-95, 95-99, 99-100% of the residues identified in each group of subgroup thereof (such as only those surface residues in the group). Unless specifically stated otherwise, the distance between the antigen binding molecule and PCSK9 is the shortest distance between the covalently bonded atom on PCSK9 and the covalently bonded atom of the antigen binding molecule that are the closest atoms of PCSK9 and the antigen binding molecule. Similarly, unless specifically stated otherwise, the distance between a residue (on the antigen binding molecule or PCSK9) and another protein (either PCSK9 or the antigen binding molecule respectively), is the distance from the closest point on the identified residue to the closest covalently bonded part of the other protein. In some embodiments, the distance can be measured from the backbone of the amino acid chains. In some embodiments, the distance can be measured between an edge of the paratope and an edge (closest to one another) of the epitope. In some embodiments, the distance can be measured between the center of the surface of the paratope and the center of the surface of the epitope. In some embodiments, the present description is applicable for each of the individual sets of residues listed herein. For example, the above ranges are contemplated generally and specifically for the 8 angstrom residues listed in Examples 28-32 and the 5 angstrom residues listed in Examples 28-32.

In some embodiments, the antigen binding molecule binds to a surface on PCSK9 that is bound by at least one of EGFa, 21B12, or 31H4. In some embodiments, the antigen binding molecule binds to PCSK9 at a location that overlaps with the interaction locations between PCSK9 and EGFa, Ab 31H4, and/or Ab 21B12 (as described in the above examples and figures). In some embodiments, the antigen binding molecule binds to PCSK9 at a position that is further away from one of the above recited residues. In some embodiments, such an antigen binding molecule can still be an effective neutralizing antigen binding molecule.

In some embodiments, the structure of the catalytic domain of PCSK9 can be described as generally being triangular (as shown in FIG. 19A). The first side of the triangle is shown as being bound by 31H4. The second side of the triangle is shown as being bound by 21B12, and the third side of the triangle is positioned toward the bottom of the page, immediately above the “FIG. 19A” label. In some embodiments, antigen binding molecules that bind to the first and/or second sides of the catalytic domain of PCSK9 can be useful as neutralizing antibodies as they can either directly or sterically interfere with EGFa’s binding to PCSK9. As will be appreciated by one of skill in the art, when the antigen binding molecules are large enough, such as a full antibody, the antigen binding molecule need not directly bind to the EGFa binding site in order to interfere with the binding of EGFa to PCSK9.

As will be appreciated by one of skill in the art, while the EGFa domain of the LDLR has been used in many of the examples, the models and structures are still applicable to how the full length LDLR protein will interact with PCSK9. Indeed, the additional structure present on the full length LDLR protein presents additional protein space that can further be blocked by one of the antigen binding molecules. As such, if the antigen binding molecule blocks or inhibits binding of EGFa to PCSK9, it will likely be at least as, if not more, effective with the full length LDLR protein. Similarly, antigen binding molecules that are within a set distance or block various residues that are relevant for inhibiting EGFa binding, will likely be as effective, if not more effective, for the full length LDLR.

As will be appreciated by one of skill in the art, any molecule that blocks or binds to the above noted PCSK9 residues (or within the recited distances), or that inhibits one or more of the interactions noted in the above examples and figures, can be used to inhibit the interaction of EGFa (or LDLR generally) and PCSK9. As such, the molecule need not be limited to an antigen binding “protein,” as any antigen binding molecule can also serve the required purpose. Examples of antigen binding molecules include aptamers, which can be either oligonucleic acid or peptide molecules. Other examples of antigen binding molecules include avimers, peptibodies, small molecules and polymers, and modified versions of EGFa that can increase its affinity to PCSK9 and/or half-life, such as mutation of amino acids, glycosylation, pegylation, Fe fusions, and avimer fusions. As will be appreciated by one of skill in the art, in some embodiments LDLR is not an antigen binding molecule. In some embodiments, binding subsections of LDLR are not antigen binding molecules, e.g., EGFa. In some embodiments, other molecules through which PCSK9 signals in vivo are not antigen binding molecules. Such embodiments will be explicitly identified as such.

Example 33

Expression and Purification of Protein Samples

The present example describes some embodiments for how the various embodiments of the PCSK9 proteins/variants were made and purified (including the LDLR EGFa domain). PCSK9 proteins/variants (e.g., PCSK9 31-692 N533A, PCSK9 449TEV and PCSK9 ProCat 31-454) were expressed in baculovirus infected Hi-5 insect cells with an N-terminal honeybee melittin signal peptide followed by a His, tag. The PCSK9 proteins were purified by nickel affinity chromatography, ion exchange chromatography and size exclusion chromatography. The melittin-His, tag was removed during
purification by cleavage with TEV protease. The construct PCSK9 449TEV was used to generate PCSK9 ProCat (31-449) and V domain (450-692) samples. This construct had a TEV protease cleavage site inserted between PCSK9 residues 449 and 450. For the full length N553A variant for crystallography, the PCSK9 31-454 fragment, and the PCSK9 449TEV variant for crystallography, the post-TEV protein product also included an initial GAMG sequence. Thus, post-TEV cleavage, these proteins were GAMG-PCSK9. Furthermore, the PCSK9 449TEV protein included the sequence “ENLYFQ” (SEQ ID NO: 403) inserted between positions H1449 and G450 of SEQ ID NO: 3. After cleavage with rTEV, the PCSK9 ProCat protein generated from this construct was GAMG-PCSK9 (31-449)-ENLYFQ and the V domain generated from this construct was PCSK9 (450-692) of SEQ ID NO: 3.

The 21B12 and 31H4 Fab fragments were expressed in E. coli. These proteins were purified by nickel affinity chromatography, size exclusion chromatography and ion exchange chromatography.

The LDLR EGFa domain (293-334) was expressed as a GST fusion protein in E. coli. The EGFa domain was purified by ion exchange chromatography, glutathione sepharose affinity chromatography and size exclusion chromatography. The GST protein was removed during the purification by cleavage with PreScission protease.

Example 34

Complex Formation and Crystallization

The present example describes how complexes and crystals used in the above structure examination Examples were made.

The PCSK9 31-692 N553A/31H4 complex was made by mixing a 1.5 molar excess of the 31H4Fab with PCSK9. The complex was purified by size exclusion chromatography to remove excess 31H4Fab. The PCSK9 31-692 N553A/31H4 complex crystallizes in 0.1 M Tris pH 8.3, 0.2 M sodium acetate, 15% PEG 4000, 6% dextran sulfate sodium salt (Mr 5000).

The PCSK9 ProCat 31-449/31H4/21B12 complex was made by first mixing a 1.5 molar excess of 31H4Fab with PCSK9 31-449. The complex was separated from excess 31H4 by purification on a size exclusion chromatography column. A 1.5 molar excess of 21B12 Fab was then added to the PCSK9 31-449/31H4 complex. The ternary complex was separated from excess 21B12 by purification on a size exclusion chromatography column. The PCSK9 ProCat 31-449/31H4/21B12 complex crystallizes in 0.1 M Tris pH 8.5, 0.2 M ammonium phosphate monobasic, 50% MPD.

The PCSK9 ProCat 31-454/EGFa complex was made by mixing a 1.2 molar excess of EGFa domain with PCSK9 31-454. The PCSK9 ProCat 31-454/EGFa domain complex crystallizes in 0.2 M potassium formate, 20% PEG 3350.

Example 35

Data Collection and Structure Determination

The present example describes how the datasets were collected and the structures determined for the above structure examination Examples.

Initial datasets for the PCSK9 31-692 N553A/31H4 and PCSK9 ProCat 31-449/31H4/21B12 crystals were collected on a Rigaku FR-E X-ray source. The PCSK9 ProCat 31-454/EGFa dataset and higher resolution datasets for the PCSK9 31-692 N553A/31H4 and PCSK9 ProCat 31-449/31H4/21B12 crystals were collected at the Berkeley Advanced Light Source beamline 5.0.2. All datasets were processed with denzo/scalepack or HKL2000 (Otwinowski, Z., Borek, D., Majewski, W. & Minor, W. Multiparametric scaling of diffraction intensities. Acta Crystallogr A 59, 228-34 (2003)). PCSK9/31H4 crystals grew in the C2 space group with unit cell dimensions a=264.9, b=137.4, c=69.9 Å, β=102.8° and diffract to 2.3 Å resolution. The PCSK9/31H4 structure was solved by molecular replacement with the program MOLREP (The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-3 (1994) using the PCSK9 structure (Piper, D. E. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15, 545-52 (2007)) as the starting search model. Keeping the PCSK9 31-692 solution fixed, an antibody variable domain was used as a search model. Keeping the PCSK9 31-692 antibody variable domain solution fixed, an antibody constant domain was used as a search model. The complete structure was improved with multiple rounds of model building with Quanta and refinement with cxn. (Brunger, A. T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54, 905-21 (1998)).

The PCSK9/31H4/21B12 crystals grew in the P212 space group with unit cell dimensions a=138.7, b=246.2, c=51.3 Å and diffract to 2.8 Å resolution. The PCSK9 ProCat/31H4 variable domain was used as a search model. Keeping the PCSK9 ProCat/31H4 variable domain fixed, a search for antibody constant domain was performed. Keeping the PCSK9 ProCat/31H4/21B12 constant domain fixed, an antibody variable domain was used as a search model. The complete structure was improved with multiple rounds of model building with Quanta and refinement with cxn.

The PCSK9/EGFa domain crystals grew in the space group P6,22 with unit cell dimensions a=b=70.6, c=321.8 Å and diffract to 2.9 Å resolution. The PCSK9/EGFa domain structure was solved by molecular replacement with the program MOLREP using the PCSK9 ProCat as the starting search model. Analysis of the electron density maps showed clear electron density for the EGFa domain. The LDLR EGFa domain was fit by hand and the model was improved with multiple rounds of model building with Quanta and refinement with cxn.

Core interaction interface amino acids were determined as being all amino acid residues with at least one atom less than or equal to 5 Å from the PCSK9 partner protein. 5 Å was chosen as the core region cutoff distance to allow for atoms within a van der Waals radius plus a possible water-mediated hydrogen bond. Boundary interaction interface amino acids were determined as all amino acid residues with at least one atom less than or equal to 8 Å from the PCSK9 partner protein but not included in the core interaction list. Less than or equal to 8 Å was chosen as the boundary region cutoff distance to allow for the length of an extended arginine amino acid. Amino acids that met these distance criteria were calculated with the program PyMOL. (DeLano, W. L. The PyMOL Molecular Graphics System. (Palo Alto, 2002)).

Example 36

Crystal Structure of PCSK9 and 31A4

The crystal structure of the 31A4/PCSK9 complex was determined.
Expression and Purification of Protein Samples

PCSK9 449TVEK (a PCSK9 construct with a TEV protease cleavage site inserted between residue 449 and 450, numbering according to SEQ ID NO: 3) was expressed in baculovirus infected Hi-5 insect cells with an N-terminal honeybee melitin signal peptide followed by a His$_{6}$ tag. The PCSK9 protein was purified by first by nickel affinity chromatography. TEV protease was used to remove the melitin-His$_{6}$ tag and cleave the PCSK9 protein between the catalytic domain and the V domain. The V domain was further purified by ion exchange chromatography and size exclusion chromatography. The 31A4 Fab fragment was expressed in E. coli. This protein was purified by nickel affinity chromatography, size exclusion chromatography and ion exchange chromatography.

Complex Formation and Crystallization

The PCSK9/V domain/31A4 complex was made by mixing 1 A$_{0}$ of PCSK9/V domain with 31A4 Fab. The complex was separated from excess PCSK9/V domain by purification on a size exclusion chromatography column. The PCSK9/V domain/31A4 complex crystallized in 1.1 M Sucinic acid pH 7, 2% PEG MMEI 2000.

Data Collection and Structure Determination

The dataset for the PCSK9 V domain/31A4 crystal was collected on a Rigaku FR-E x-ray source and processed with denzo/scalepack (Otwinowski, Z., Berek, D., Majewski, W. & Minor, W. Multidimensional scaling of diffraction intensities. Acta Crystallogr A 59, 228-34 (2003)).

PCSK9/V domain/31A4 crystals grow in the $P_{2}$_1, $P_{2}$_1, $P_{2}$_1 space group with unit cell dimensions $a$=74.6, b=131.1, c=197.9 Å with two complex molecules per asymmetric unit, and diffract to 2.2 Å resolution. The PCSK9 V domain/31A4 structure was solved by molecular replacement with the program MOLREP (CCP4). The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 676-3 (1994) using the V domain of the PCSK9 structure (Piper, D. E. et al. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure 15, 545-52 (2007)) as the starting search model. Keeping the PCSK9 450-692 solution fixed, an antibody variable domain was used as a search model. After initial refinement, the antibody constant domains were fit by hand. The complete structure was improved with multiple rounds of model building with Quanta and refinement with CNS (Brunger, A. T. et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54, 905-21 (1998)).

Core interaction interface amino acids were determined as being all amino acid residues with at least one atom less than or equal to 5 Å from the PCSK9 partner.

A model of full length PCSK9 bound the 31A4 Fab was made. The structure of full length PCSK9 was overlaid onto the PCSK9 V domain from the complex. A figure of this model is shown in Fig. 21D. The site of the interaction between the EGFr domain of the LDLR and PCSK9 is highlighted.

Analysis of the structure shows where this antibody interacts with PCSK9 and demonstrated that antibodies that do not bind to the LDLR binding surface of PCSK9 can still inhibit the degradation of LDLR that is mediated through PCSK9 (when the results are viewed in combination with Example 40 and 41 below). In addition, analysis of the crystal structure allows for identification of specific amino acids involved in the interaction between PCSK9 and the 31A4 antibody. Furthermore, the core and boundary regions of the interface on the PCSK9 surface were also determined. Specific core PCSK9 amino acid residues of the interaction interface with 31A4 were defined as PCSK9 residues that are within 5 Å of the 31A4 protein. The core residues are T468, R469, M470, A471, T472, R496, R499, E501, A502, Q503, R510, H512, F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, and E593. Boundary PCSK9 amino acid residues of the interaction interface with 31A4 were defined as PCSK9 residues that are 5-8 Å from the 31A4 protein. The boundary residues are as follows: S465, G466, P467, A473, I474, R476, G497, E498, M500, G504, K506, L507, V508, A511, N513, A514, G516, V536, T538, A539, A544, T548, D570, L571, H591, A594, S595, and H597. Amino acid residues nearly or completely buried within the PCSK9 protein are highlighted by underline. As noted herein, the numbering references the amino acid positions of SEQ ID NO: 3 (adjusted as noted herein).

Specific core 31A4 amino acid residues of the interaction interface with PCSK9 were defined as 31A4 residues that are within 5 Å of the PCSK9 protein. The core residues for the 31A4 antibody are as follows: Heavy Chain: G27, S28, F29, S30, A31, Y32, V33, E50, N52, H53, R56, D58, K76, G98, Q99, L100, and V101; Light Chain: S31, N32, T33, Y50, S51, N52, N53, Q54, W92, and D94. Boundary 31A4 amino acid residues of the interaction interface with PCSK9 were defined as 31A4 residues that are 5-8 Å from the PCSK9 protein. The boundary residues for 31A4 are as follows: Heavy Chain: V2, G26, W34, N35, W47, I115, S54, T57, Y59, A96, R97, P102, F103, and D104; Light Chain: S26, S27, N28, G30, V34, N35, R55, P56, K67, V91, D93, S95, N97, G98, and W99.

The crystal structure also displayed the spatial requirements of this ABP in its interaction with PCSK9. As shown in this structure, surprisingly, antibodies that bind to PCSK9 without directly preventing PCSK9's interaction with the LDLR can still inhibit PCSK9's function.

In some embodiments, any antigen binding protein that binds to, covers, or prevents 31A4 from interacting with any of the above residues can be employed to bind to or neutralize PCSK9. In some embodiments, the ABP binds to or interacts with at least one of the following PCSK9 (SEQ ID NO: 3) residues: T468, A469, M470, A471, T472, R496, R499, E501, A502, Q503, R510, H512, F515, P540, P541, A542, E543, H565, W566, E567, V568, E569, R592, and E593. In some embodiments, the ABP is within 5 angstroms of one or more of the above residues. In some embodiments, the ABP binds to or interacts with at least one of the following PCSK9 (SEQ ID NO: 3) residues: S465, G466, P467, A473, I474, R476, G497, E498, M500, G504, K506, L507, V508, A511, N513, A514, G516, V536, T538, A539, A544, T548, D570, L571, H591, A594, S595, and H597. In some embodiments, the ABP is 5 to 8 angstroms from one or more of the above residues. In some embodiments, the ABP interacts, blocks, or...
is within 8 angstroms of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, or 50 of the above residues.

The coordinates for the crystal structures discussed in the above Examples are presented in Table 35.1 (full length PCSK9 and 31H4), Table 35.2 (PCSK9 and EGFA), Table 35.3 (PCSK9, 31H4, and 21B12), and Table 35.4 (PCSK9 and 31A4). Antigen binding proteins and molecules that interact with the relevant areas or residues of the structure of PCSK9 (including those areas or residues within 15, 15-8, 8-5, 5, or fewer angstroms from where EGFA, or the antibodies, interact with PCSK9) are depicted in the figures and/or their corresponding positions on the structures from the coordinates are also contempated.

The antibodies that are described in the coordinates were raised in E. coli and thus possess some minor amino acid differences from the fully human antibodies. The first residue in the heavy chain constant region was a glutamic acid instead of a glutamine for the heavy and light chains of 21B12 and for the light chain for 31H4. In addition to the differences in the sequence of variable region, there were also some differences in the constant region of the antibodies described by the coordinates (again due to the fact that the antibody was raised in E. coli). FIG. 22 highlights (via underlining, shading, or bold) the differences between the constant regions of the 21B12, 31H4, and 31A4 Fabs (raised in E. coli) when compared to SEQ ID NO: 155, and 156. For 21B12 31H4, and 31A4, the light chain constant sequence is similar to human lambda (SEQ ID NO: 156). The underlined glycine residue is an insertion where the 21B12 and 31H4 variable sequences stop and the lambda sequence starts.

For both 21B12 and 31H4, the heavy chain constant is similar to human IgG4 (SEQ ID NO: 155). The highlighted differences in FIG. 22 are shown in Table 36.1:

<table>
<thead>
<tr>
<th>Crystal</th>
<th>SEQ ID NO: 155</th>
</tr>
</thead>
<tbody>
<tr>
<td>S</td>
<td>C</td>
</tr>
<tr>
<td>K</td>
<td>R</td>
</tr>
<tr>
<td>G</td>
<td>E</td>
</tr>
<tr>
<td>Q</td>
<td>S</td>
</tr>
<tr>
<td>I</td>
<td>T</td>
</tr>
<tr>
<td>N</td>
<td>D</td>
</tr>
<tr>
<td>K</td>
<td>R</td>
</tr>
<tr>
<td>P</td>
<td>S</td>
</tr>
</tbody>
</table>

In regard to 31A4, while it also has the same distinctions noted above, there are three additional differences. As shown in FIG. 22, there are two additional amino acids at the start, which come from incorporaion of the signal peptide in E. coli expression. In addition, there is one additional substitution in the 31A4 heavy chain constant region when compared to SEQ ID NO: 155, which is the adjustment of a L (in SEQ ID NO: 155) to a H. Finally, 31A4 does have a glutamine as the initial amino acid of the Fab, rather than the adjustment to glutamic acid noted above for 21B12 and 31H4.

For all three antibodies, the end of the heavy chain (boxed in dark grey) differs as well, but the amino acids are not ordered in the structure so they do not appear in the coordinates. As will be appreciated by one of skill in the art, his-tags are not a required part of the ABP and should not be considered as part of the ABP’s sequence, unless explicitly called out by reference to a specific SEQ ID NO that includes a histidine tag and a statement that the ABP sequence “includes the Histidine tag.”

An alternative set of binning experiments was conducted in addition to the set in Example 10. As in Example 10, ABPs that compete with each other can be thought of as binding to the same site on the target and in common parlance are said to “bin” together. A modification of the Multiplexed Binning method described by Jia, et al. (J. Immunological Methods, 288(2004) 91-98) was used. Individual bead codes of streptavidin-coated luminex beads was incubated in 100 ul 0.5 ug/ml biotinylated monoclonal mouse-anti-human IgG capture antibody (BD Pharmingen, #555785) for 1 hour at room temperature in the dark, then washed 3x with PBBSA, phosphate buffered saline (PBS) plus 1% bovine serum albumin (BSA). Each bead code was separately incubated with 100 ul 2 ug/ml anti-PCSK9 antibody (Coating Antibody) for 1 hour then washed 3x with PBBSA. The beads were pooled then dispensed to a 96-well filter plate (Millipore, #MSBWN1250). 100 ul of 2 ug/ml purified PCSK9 protein was added to half the wells. Buffer was added to the other half as control. The reaction was incubated for 1 hour then washed. 100 ul of a 2 ug/ml anti-PCSK9 antibody (Detection Ab) was added to all the wells, incubated for 1 hour then washed. An irrelevant human-IgG (Jackson, #009-000-003) was run as another control. 20 ul PE-conjugated monoclonal mouse-anti-human IgG (BD Pharmingen, #555787) was added to each well and incubated for 1 hour then washed. Beads were resuspended in 100 ul PBBSA and a minimum of 100 events/bead code were collected on the BioPlex instrument (BioRad).

Median Fluorescent Intensity (MFI) of the antibody pair without PCSK9 was subtracted from signal of the corresponding reaction containing PCSK9. For the antibody pair to be considered bound simultaneously, and therefore in different bins, the subtracted signal had to be greater than 3 times the signal of the antibody competing with itself and the 3 times the signal of the antibody competing with the irrelevant antibody.

The data from the above is depicted in FIGS. 23A-23D. The ABPs fell into five bins. The shaded boxes indicate ABPs that can bind simultaneously to PCSK9. The nonshaded boxes indicate those ABPs that compete with each other for binding. A summary of the results is shown in Table 37.1.

<table>
<thead>
<tr>
<th>BIN 1</th>
<th>BIN 2</th>
<th>BIN 3</th>
<th>BIN 4</th>
<th>BIN 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>01A12.2</td>
<td>27B2.1</td>
<td>16F12.1</td>
<td>11G1.5</td>
<td>30A4.1</td>
</tr>
<tr>
<td>03B6.1</td>
<td>27B2.5</td>
<td>22E2.1</td>
<td>03C4.1</td>
<td>13B5.1</td>
</tr>
<tr>
<td>06C9.1</td>
<td>12H11.1</td>
<td>27A6.1</td>
<td>13H1.1</td>
<td></td>
</tr>
<tr>
<td>17C2.1</td>
<td>28H12.1</td>
<td>31A4.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21B12.2</td>
<td>28D6.1</td>
<td>31B12.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23G1.1</td>
<td>31G1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25G4.1</td>
<td>31H4.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26E10.1</td>
<td>08A1.2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11H4.1</td>
<td>08A3.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11H8.1</td>
<td>11F1.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19B19.2</td>
<td>26H5.1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27E7.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27H5.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30B9.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>02B5.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23B5.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27B2.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09H6.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Bins 1 (competes with ABP 21B12) and 3 (competes with 31H4) are exclusive of each other; bin 2 competes with bins 1 and 3; and bin 4 does not compete with bins 1 and 3. Bin 5, in this example, is presented as a “catch all” bin to describe those ABPs that do not fit into the other bins. Thus, the above identified ABPs in each of the bins are representative of different types of epitope locations on PCSK9, some of which overlap with each other.

As will be appreciated by one of skill in the art, if the reference ABP prevents the binding of the probe ABP then the antibodies are said to be in the same bin. The order in which the ABPs are employed can be important. If ABP A is employed as the reference ABP and blocks the binding of ABP B the converse is not always true: ABP B used as the reference ABP will not necessarily block ABP A. There are a number of factors in play here: the binding of an ABP can cause conformational changes in the target which prevent the binding of the second ABP or epitopes which overlap but do not completely occlude each other may allow for the second ABP to still have enough high-affinity interactions with the target to allow binding. ABPs with a much higher affinity may have a greater ability to dump a blocking ABP out of the way. In general, if competition is observed in either order the ABPs are said to bin together, and if both ABPs can block each other then it is likely that the epitope overlap more completely.

Example 38

Epitope Mapping-Western Blot

The present example demonstrates whether or not the epitopes for the examined ABPs were linear or conformational. Denaturing reducing and denaturing non-reducing western blots were run to determine which antibodies have a conformational epitope. Antibodies that bind to a denaturing reducing western blot have a linear epitope and are not conformational. The results are presented in FIG. 24A and FIG. 24B. For the blot, 0.5 ug/lane of purified full-length human PCSK9 was run on a 4-12% NuPAGE Bis-Tris gel and MES SDS Running Buffer. 1 ug/ml anti-PCS9 antibodies, except 0.5 ug/ml 31G11, were used to probe the blot. 1:5000 donkey-anti-human-IR700 secondary was used and read on a LI-COR instrument. Antibody 13H11 bound to a linear epitope on the pro-domain of PCSK9. All other antibodies displayed results that were consistent with conformational epitopes. These gels split apart the pro-domain from the rest of the protein, and the pro domain ran at about 15 kDa. In addition, 3C4 and 31A4 appeared to bind to conformational epitopes which were preserved by disulfide bonds, as these antibodies bound to PCSK9 under denaturing conditions where the disulfide bonds had been preserved (left) but reducing the samples (right) eliminated binding.

Example 39

Epitope Mapping—Arginine/Glutamic Acid Scanning

Representative ABPs from each bin (from Example 37) were selected for further epitope analysis. An arginine/glutamic acid-scanning strategy was performed for mapping ABP binding to PCSK9. By way of background, this method determines if a residue is part of the structural epitope, meaning those residues in the antigen which contact or are buried by the antibody. Arginine and glutamic acid sidechains are charged and bulky and can disrupt antibody binding even if the mutated residue is not directly involved in antibody binding.

Residue Selection

The crystal structure of PCSK9 was used to select the residues to be mutated for epitope mapping. The method used to choose residues to mutate involved both computational mechanisms and interactive structure analysis. The PCSK9 structure contained gaps of missing residues and was missing 30 amino acids in the N-(i.e., the signal sequence) and 10 amino acids in the C-termini. The internal missing residues were modeled onto the structure, but the N- and C-terminal missing residues were not. The solvent exposure ratio for each residue was calculated: the surface area of each residue in the context of the protein (SA1) was divided by the surface area of the residue in a trimer with flanking glycines (SA2) with a conserved backbone. The solvent exposure ratio greater than 10% (R10) were selected as well as the 40 missing terminal residues. From these, prolines and glycines with positive 4 angles were excluded to reduce the possibility of misfolding. The number of residues to be mutated in the V domain was reduced by using a solvent exposure ratio of 37% along with visual inspection of the entire protein to bring the total number of mutations to 285. Various orientations of the surface of PCSK9 with these various classes identifies are shown in FIG. 25A-25F. In these figures, lightest gray denotes areas that were not selected or were deselected. Darker gray denotes those residues selected.

Cloning and Expression

Once the residues to be altered were identified, the various residues were altered. Human PCSK9 was cloned into the pIT5 vector with a C-terminal Flag-His tag. Mutants were made from this original construct by site-directed mutagenesis using a QuikChange II kit from Stratagene. Sense and anti-sense oligonucleotides used for mutagenesis were designed using Amgen’s MutaGenie software. All PCSK9 constructs were expressed in transiently-transfected 293-6E cells in 24-well plates and re-racked into three 96-well plates with a non-mutated PCSK9 control (wild-type, WT) in each plate. Expression levels and integrity of the recombinant proteins in conditioned media were checked by Western blot. Of the 285 mutants originally selected, 41 failed in cloning or expression. 244 mutants were used for epitope mapping. An alignment of the PCSK9 parent sequence and a representative PCSK9 sequence with the 244 mutated residues is shown in FIG. 26. Separate constructs were made containing a single mutation. For the purposes of the epitope sequences and the epitope based inventions involving changes in binding, the sequences are provided in reference to SEQ ID NO: 1 and/or SEQ ID NO: 303. The sequences used for the present binding epitope studies. One skill in the art will appreciate that the present results apply to other PCSK9 variants disclosed herein as well (e.g., SEQ ID NO: 1 and 3, as well as the other allelic variants).

Five antibodies, a representative of each bin, were chosen for fine epitope mapping. They were 21B12, 31H4, 12H11, 31A4, 3C4. All conformational epitope antibodies. Three, 21B12, 31H4, and 31A4 were also crystallized with PCSK9, as described above.

Structural and Functional Epitopes

Epitopes can be further defined as structural or functional. Functional epitopes are generally a subset of the structural epitopes and have those residues that directly contribute to the affinity of the interaction (e.g., hydrogen bonds, ionic interactions). Structural epitopes can be thought of as the patch of the target which is covered by the antibody.
The scanning mutagenesis employed was an arginine and glutamic acid scan. These two sidechains were chosen due to their large steric bulk and their charge, which allows mutations that occur in the structural epitope to have a greater effect on antibody binding. Arginine was generally employed binding to each mutant can then be compared directly its binding to the wild type in the same pool. IL-17R chimera E was used as a negative control. A summary of all the mutants examined is shown in Table 39.1 (with reference to the sequence numbering used in FIGS. 1A and 26).

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WT PCSK9</td>
<td>Y8R</td>
<td>E18R</td>
<td>P26R</td>
<td>A38R</td>
<td>T56R</td>
<td>A70R</td>
<td>H83R</td>
<td>E102R</td>
<td>L128R</td>
<td>D145R</td>
</tr>
<tr>
<td>B</td>
<td>Q1R</td>
<td>E5R</td>
<td>E15R</td>
<td>E27R</td>
<td>K39R</td>
<td>H57R</td>
<td>Q71R</td>
<td>V84R</td>
<td>L105R</td>
<td>E129R</td>
<td>S148R</td>
</tr>
<tr>
<td>C</td>
<td>E2R</td>
<td>E10R</td>
<td>D20R</td>
<td>G29R</td>
<td>D49R</td>
<td>L58R</td>
<td>A73R</td>
<td>H80R</td>
<td>K105R</td>
<td>R139E</td>
<td>pick up text</td>
</tr>
<tr>
<td>D</td>
<td>D3R</td>
<td>L11R</td>
<td>G21R</td>
<td>T30R</td>
<td>J44R</td>
<td>Q69R</td>
<td>R74E</td>
<td>K95R</td>
<td>H109R</td>
<td>T132R</td>
<td>IL17R chimera E</td>
</tr>
<tr>
<td>E</td>
<td>E4R</td>
<td>V12R</td>
<td>L22R</td>
<td>T31R</td>
<td>T47R</td>
<td>E62R</td>
<td>R75E</td>
<td>S97R</td>
<td>D111R</td>
<td>D139R</td>
<td>WT PCSK9</td>
</tr>
<tr>
<td>F</td>
<td>D3R</td>
<td>A14R</td>
<td>A23R</td>
<td>A52R</td>
<td>K53R</td>
<td>R63E</td>
<td>Y77R</td>
<td>G96R</td>
<td>A121R</td>
<td>E140R</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>C6R</td>
<td>L15R</td>
<td>D24R</td>
<td>T31R</td>
<td>E54R</td>
<td>R60E</td>
<td>L78R</td>
<td>D99R</td>
<td>S134R</td>
<td>V141R</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>D7R</td>
<td>S17R</td>
<td>A25R</td>
<td>H35R</td>
<td>E55R</td>
<td>R67E</td>
<td>L82R</td>
<td>L101R</td>
<td>W126R</td>
<td>Q142R</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>L149R</td>
<td>V172R</td>
<td>D182R</td>
<td>A190R</td>
<td>G214R</td>
<td>K243R</td>
<td>G262R</td>
<td>A311R</td>
<td>E366R</td>
<td>M368R</td>
<td>R384E</td>
</tr>
<tr>
<td>D</td>
<td>Q160R</td>
<td>D174R</td>
<td>T184R</td>
<td>K192R</td>
<td>K221R</td>
<td>Q245R</td>
<td>A269R</td>
<td>D313R</td>
<td>D344R</td>
<td>A372R</td>
<td>IL17R chimera E</td>
</tr>
<tr>
<td>E</td>
<td>S161R</td>
<td>E176R</td>
<td>R185E</td>
<td>S195R</td>
<td>Q226R</td>
<td>L246R</td>
<td>Q272R</td>
<td>Q314R</td>
<td>T347R</td>
<td>E373R</td>
<td>WT PCSK9</td>
</tr>
<tr>
<td>F</td>
<td>D162R</td>
<td>N177R</td>
<td>F186R</td>
<td>H196R</td>
<td>K228R</td>
<td>V297R</td>
<td>R276E</td>
<td>T317R</td>
<td>F349R</td>
<td>E375R</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>E167R</td>
<td>E190R</td>
<td>R188E</td>
<td>D208R</td>
<td>F240R</td>
<td>V250R</td>
<td>R289E</td>
<td>T320R</td>
<td>S351R</td>
<td>L378R</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>WT PCSK9</td>
<td>N395R</td>
<td>V405R</td>
<td>W423R</td>
<td>R446E</td>
<td>E513R</td>
<td>Q525R</td>
<td>Q554R</td>
<td>Q589R</td>
<td>S612R</td>
<td>A641R</td>
</tr>
<tr>
<td>B</td>
<td>D360R</td>
<td>E390R</td>
<td>N409R</td>
<td>Q424R</td>
<td>D450R</td>
<td>A514R</td>
<td>E437R</td>
<td>N550R</td>
<td>Q591R</td>
<td>T533R</td>
<td>R565E</td>
</tr>
<tr>
<td>C</td>
<td>H387R</td>
<td>A397R</td>
<td>A413R</td>
<td>A433R</td>
<td>A472R</td>
<td>S515R</td>
<td>V538R</td>
<td>K579R</td>
<td>A594R</td>
<td>T634R</td>
<td>R652E</td>
</tr>
<tr>
<td>F</td>
<td>K391R</td>
<td>D402R</td>
<td>H459R</td>
<td>R439E</td>
<td>E480R</td>
<td>H521R</td>
<td>H544R</td>
<td>E582R</td>
<td>V620R</td>
<td>T637R</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>D392R</td>
<td>Q403R</td>
<td>G420R</td>
<td>M440R</td>
<td>N503R</td>
<td>H523R</td>
<td>V548R</td>
<td>H583R</td>
<td>R629E</td>
<td>S638R</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>V393R</td>
<td>R404E</td>
<td>A421R</td>
<td>T442R</td>
<td>T508R</td>
<td>Q524R</td>
<td>R552E</td>
<td>G584R</td>
<td>V631R</td>
<td>E639R</td>
<td></td>
</tr>
</tbody>
</table>

except when the WT reside was arginine, and in these cases the residue was mutated to glutamic acid to switch the charge.

For the purpose of epitope mapping, a bead-based multiplexed assay was used to measure antibody binding to PCSK9 and PCSK9 mutants simultaneously. Antibody binding to mutants was then compared to its binding to the wild-type in the same well. The variants were split into three groups:

Group 1: 81 variants + 2 wt controls + 1 negative control + 1 other PCSK9 supernatant; Group 2: 81 variants + 2 wt controls + 2 negative controls; and Group 3: 82 variants + 2 wt control + 1 negative control.

The assay was run as follows: 85 sets of color-coded streptavidin-coated LumAvidin beads (Luminex) were bound with biotinylated anti-pentalHis antibody (Qiagen, #1019225) for 1 hour at room temperature (RT) then washed three times in PBS, 1% BSA, 0.1% Tween 20. Each color-coded bead set was then allowed to bind to a PCSK9 mutant, wild-type, or negative control in 150 ul supernatant overnight at 4°C.

The color-coded bead sets, each associated to a specific protein, were washed and pooled. At this point, there were 3 pools of 85 bead sets, one pool for each group of mutants and controls. The beads from each pool were divided to 24 wells (3 columns) of a 96-well filter plate (Millipore, #MSB251250). 100 ul of anti-PCSK9 antibodies in 4-fold dilutions were added to nine columns for triplicate points and incubated for 1 hour at RT and washed. 100 ul of 1:200 dilution phycoerythrin (PE)-conjugated anti-human IgG Fc (Jackson Immunoresearch, #109-1, 6-170) was added to each well and incubated for 1 hour at RT and washed.

Beads were resuspended in 1% BSA in PBS, shaken for 10 mins and read on the BioPlex instrument (Bio-Rad). The instrument identifies each bead by its color code thereby identifying the specific protein associated with the color code. At the same time, it measures the amount of antibody bound to the beads by fluorescence intensity of the PE dye. Antibody bead variability study.

Before running the epitope mapping binding assay, a validation experiment was conducted to assess the “bead region” to “bead region” (B-B) variability. In the validation experiment, all beads were conjugated with the same wild type control protein. Therefore, the difference between beads regions was due to purely B-B variance and was not confounded by difference between wild type and mutant proteins. The titration of antibody was run with twelve replications in different wells.

The objective of this statistical analysis was to estimate the B-B variability of the estimated EC50 of binding curves. The estimated B-B standard deviation (SD) was then used to build the EC50 confidence intervals of wild type and mutant proteins during curve comparison experiments.

A four-parameter logistic model was fitted to the binding data for each bead region. The resulting file, containing curve quality control (QC) results and parameter estimates for top (max), bottom (min), Hill slope (slope), and natural log of EC50 (xmid) of the curves, was used as the raw data for the analysis. B-B variability for each parameter was then estimated by fitting mixed effect model using SAS PROC MIXED procedure. Only curves with “good” QC status were included in the analysis. The final mixed effect model included only residual (i.e. individual bead regions) as random effect. Least squares means (LS-mean) for each parameter were calculated by the mixed effect model as well. B-B SD was calculated by taking square root of B-B variance. Fold change between LS-mean+2SD and LS-mean-2SD, which represent approximately upper and lower 97.5 percentile of the population, was also calculated. The results are displayed in Table 39.2.
Identifying Residues in the Structural Epitope

A residue was considered part of the structural epitope (a "hit") when mutating it to arginine or glutamic acid alters antibody binding. This is seen as a shift in the EC50 or a reduction of maximum signal compared to antibody binding to wild type. Statistical analyses of antibody binding curves to wild type and mutants were used to identify statistically significant EC50 shifts. The analysis takes into consideration variation in the assay and curve fitting.

The Identification Based on EC50 Comparison

The EC50 and Bmax values were generated from a Weighted 4-Parameter Logistical model fitted to the binding data using S-PLUS with VarPower software (Insightful Corporation, Seattle Wash.). The EC50s of the mutant binding curves and wild type binding curves were compared. Statistically significant differences were identified as hits for further consideration. The curves with "nofit" or "badfit" flags were excluded from the analysis.

The Variations in EC50 Estimates

Two sources of variations were considered in the comparison of EC50 estimates, variation from the curve fit and the bead-bead variation. Wild types and mutants were linked to different beads, hence their difference are confounded with the bead-bead difference (described above). The curve fit variation was estimated by the standard error of the log EC50 estimates. Bead-bead variation was experimentally deter-

TABLE 39.2

<table>
<thead>
<tr>
<th>Assay ID</th>
<th>Parameter</th>
<th>B-B</th>
<th>Fold Change*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCSK9 max</td>
<td>15000</td>
<td>997719</td>
<td>13002.3</td>
</tr>
<tr>
<td>PCSK9 min</td>
<td>162.09</td>
<td>1919.66</td>
<td>74.5</td>
</tr>
<tr>
<td>PCSK9 slope</td>
<td>0.8540</td>
<td>0.0000</td>
<td>0.9</td>
</tr>
<tr>
<td>PCSK9 x-axis</td>
<td>3.1715</td>
<td>0.0002</td>
<td>3.1</td>
</tr>
</tbody>
</table>

* sind is natural log of the EC50. Fold change for x-axis converted back to original scale.

curves in the nonlinear regression and two times the bead-bead variance estimated from a separate experiment. The multiple of two for the bead-bead variance was due to the assumption that both mutant and wild type beads had the same variance. The degree of freedom of the standard deviation of delta was calculated using the Satterthwaite’s (1946) approximation. Individual p-values and confidence intervals (95% and 99%) were derived based on Student's t-distribution for each comparison. In the case of multiple wild-type controls, a conservative approach was taken by picking the wild type control that was most similar to the mutant, i.e., picking the ones with the highest p-values.

Multiplicity adjustments were important to control the false positive(s) while conducting a large number of tests simultaneously. Two forms of multiplicity adjustment were implemented for this analysis: family wise error (FWE) control and false discovery rate (FDR) control. The FWE approach controls the probability that one or more hits are not real; FDR approach controls the expected proportion of false positive among the selected hits. The former approach is more conservative and less powerful than the latter one. There are many methods available for both approaches, for this analysis, the Hochberg's (1988) method for FWE analysis and Benjamini-Hochberg’s (1995) FDR method for FDR analysis were selected. Adjusted p-values for both approaches were calculated.

Results

Mutations whose EC50 is significantly different from wild type, e.g., having a False Discovery Rate adjusted p-value for the whole assay of 0.01 or less, were considered part of the structural epitope. All the hits also had a Familywise type I error rate adjusted p-value for each antibody of less than 0.01 except residue R185E for antibody 3H14 which had an FWE adjusted p-value per antibody of 0.0109. The residues in the structural epitope of the various antibodies determined by EC50 shift are shown in Table 39.3 (point mutations are with reference to SEQ ID NO: 1 and 305).

TABLE 39.3

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Mutation</th>
<th>FDR Adjusted Pval</th>
<th>FWE Adjusted Pval</th>
<th>Low95</th>
<th>Low95</th>
<th>FoldChange</th>
<th>High95</th>
<th>High95</th>
<th>RawPval</th>
</tr>
</thead>
<tbody>
<tr>
<td>21B12</td>
<td>D208R</td>
<td>0.0000</td>
<td>0.0000</td>
<td>0.3628</td>
<td>0.3844</td>
<td>0.4602</td>
<td>0.5509</td>
<td>0.5873</td>
<td>0.0000</td>
</tr>
<tr>
<td>21B12</td>
<td>E207T</td>
<td>0.0000</td>
<td>0.0000</td>
<td>1.7148</td>
<td>1.8488</td>
<td>2.3319</td>
<td>2.9090</td>
<td>3.1364</td>
<td>0.0000</td>
</tr>
<tr>
<td>31H4</td>
<td>R185E</td>
<td>0.0024</td>
<td>0.0109</td>
<td>1.2444</td>
<td>1.3525</td>
<td>1.7421</td>
<td>2.2439</td>
<td>2.4388</td>
<td>0.0000</td>
</tr>
<tr>
<td>31A4</td>
<td>E513R</td>
<td>0.0001</td>
<td>0.0003</td>
<td>1.4764</td>
<td>1.6219</td>
<td>2.1560</td>
<td>2.8660</td>
<td>3.1485</td>
<td>0.0000</td>
</tr>
<tr>
<td>31A4</td>
<td>E513R</td>
<td>0.0000</td>
<td>0.0000</td>
<td>1.6014</td>
<td>1.7461</td>
<td>2.2276</td>
<td>2.9578</td>
<td>3.2252</td>
<td>0.0000</td>
</tr>
<tr>
<td>31A4</td>
<td>R430E</td>
<td>0.0000</td>
<td>0.0000</td>
<td>3.1565</td>
<td>3.6501</td>
<td>5.5738</td>
<td>8.5113</td>
<td>9.8420</td>
<td>0.0000</td>
</tr>
<tr>
<td>31A4</td>
<td>V339R</td>
<td>0.0004</td>
<td>0.0013</td>
<td>1.4225</td>
<td>1.5700</td>
<td>2.1142</td>
<td>2.8471</td>
<td>3.1423</td>
<td>0.0000</td>
</tr>
<tr>
<td>12H11</td>
<td>A390R</td>
<td>0.0001</td>
<td>0.0001</td>
<td>1.4140</td>
<td>1.5286</td>
<td>1.9389</td>
<td>2.4594</td>
<td>2.6588</td>
<td>0.0000</td>
</tr>
<tr>
<td>12H11</td>
<td>A441R</td>
<td>0.0009</td>
<td>0.0028</td>
<td>1.2840</td>
<td>1.3891</td>
<td>1.7653</td>
<td>2.2454</td>
<td>2.4269</td>
<td>0.0000</td>
</tr>
<tr>
<td>12H11</td>
<td>T351R</td>
<td>0.0009</td>
<td>0.0009</td>
<td>1.2513</td>
<td>1.3444</td>
<td>1.6761</td>
<td>2.0896</td>
<td>2.2452</td>
<td>0.0000</td>
</tr>
<tr>
<td>12H11</td>
<td>T323R</td>
<td>0.0001</td>
<td>0.0001</td>
<td>1.3476</td>
<td>1.4392</td>
<td>1.7631</td>
<td>2.1599</td>
<td>2.3068</td>
<td>0.0000</td>
</tr>
<tr>
<td>3C4</td>
<td>E582R</td>
<td>0.0016</td>
<td>0.0069</td>
<td>1.3523</td>
<td>1.5025</td>
<td>2.0642</td>
<td>2.8359</td>
<td>3.1509</td>
<td>0.0000</td>
</tr>
</tbody>
</table>

Maximum Signal Reduction

The percent maximum signal was calculated using the maximum signal from the curve fitting (pmaxPerWT) and raw data point (RawMaxPerWT). Mutations that reduced the antibody binding maximum signal by >70% as compared to wild type signal or that reduced the signal of one antibody compared to other antibodies by >50% when all other antibodies are at least 40% of wild type were considered hits and part of the epitope. Table 39.4 displays the residues that are in the structural epitope (italics) as determined by reduction of maximum signal.
Table 39.4

<table>
<thead>
<tr>
<th>antibody</th>
<th>Mutants</th>
<th>BmaxPerWT</th>
<th>RawMaxPerWT</th>
</tr>
</thead>
<tbody>
<tr>
<td>21B12</td>
<td>A311R</td>
<td>141.5388</td>
<td>139.7010</td>
</tr>
<tr>
<td>31H4</td>
<td>A311R</td>
<td>145.2189</td>
<td>147.8244</td>
</tr>
<tr>
<td>31A4</td>
<td>A311R</td>
<td>103.4377</td>
<td>96.2214</td>
</tr>
<tr>
<td>12H11</td>
<td>A311R</td>
<td>129.0460</td>
<td>131.2060</td>
</tr>
<tr>
<td>3C4</td>
<td>A311R</td>
<td>98.8873</td>
<td>95.9258</td>
</tr>
<tr>
<td>21B12</td>
<td>D162R</td>
<td>108.8308</td>
<td>112.4904</td>
</tr>
<tr>
<td>31H4</td>
<td>D162R</td>
<td>45.8356</td>
<td>45.0013</td>
</tr>
<tr>
<td>31A4</td>
<td>D162R</td>
<td>45.6242</td>
<td>44.9706</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>49.7928</td>
<td>49.2976</td>
</tr>
<tr>
<td>31H4</td>
<td>D162R</td>
<td>101.4281</td>
<td>105.1586</td>
</tr>
<tr>
<td>31A4</td>
<td>D162R</td>
<td>45.9888</td>
<td>45.0013</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>7.0520</td>
<td>7.0520</td>
</tr>
<tr>
<td>12H11</td>
<td>D162R</td>
<td>96.6208</td>
<td>97.4928</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>31H4</td>
<td>D162R</td>
<td>97.4928</td>
<td>97.4928</td>
</tr>
<tr>
<td>31A4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>12H11</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>31H4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>31A4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>12H11</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>31H4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>31A4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
<tr>
<td>3C4</td>
<td>D162R</td>
<td>121.1418</td>
<td>121.1418</td>
</tr>
</tbody>
</table>

To further examine how these residues form part of or all of the relevant epitopes, the above noted positions were mapped onto various crystal structure models, the results are shown in FIG. 27A through 27E. FIG. 27A depicts the 21B12 epitope hits, as mapped onto a crystal structure of PCSK9 with the 21B12 antibody. The structure identifies PCSK9 residues as follows: light gray indicates those residues that were not mutated (with the exception of those residues that are explicitly indicated on the structure) and darker gray indicates those residues mutated (a minority of which failed to express). Residues that are explicitly indicated were tested (regardless of the shading indicated on the figure) and resulted in a significant change in EC50 and/or Bmax. The epitope hits were based on Bmax shift. In this figure, 31H4 is behind 21B12.

FIG. 27B depicts the 31H4 epitope hits, as mapped onto a crystal structure of PCSK9 with 31H4 and 21B12 antibodies. The structure identifies PCSK9 residues as follows: light gray indicates those residues that were not mutated (with the exception of those residues that are explicitly indicated on the structure) and darker gray indicates those residues mutated (a minority of which failed to express). Residues that are explicitly indicated were tested (regardless of the shading indicated on the figure) and resulted in a significant change in EC50 and/or Bmax. The epitope hits were based on the EC50 shift. FIG. 27C depicts the 31A4 epitope hits, as mapped onto a crystal structure of PCSK9 with 31H4 and 21B12 antibodies. The structure identifies PCSK9 residues as follows: light gray indicates those residues that were not mutated (with the exception of those residues that are explicitly indicated on the structure) and darker gray indicates those residues mutated (a minority of which failed to express). Residues that are explicitly indicated were tested (regardless of the shading indicated on the figure) and resulted in a significant change in EC50 and/or Bmax. The epitope hits were based on the EC50 shift. FIG. 27D depicts the 12H11 epitope hits, as mapped onto the crystal structure of PCSK9 with 31H4 and 21B12 antibodies. The structure identifies PCSK9 residues as follows: light gray indicates those residues that were not mutated (with the exception of those residues that are explicitly indicated on the structure) and darker gray indicates those residues mutated (a minority of which failed to express). Residues that are explicitly indicated were tested (regardless of the shading indicated on the figure) and resulted in a significant change in EC50 and/or Bmax. The epitope hits were based on the EC50 shift. FIG. 27E depicts the 3C4 epitope hits, as mapped onto the crystal structure of PCSK9 with 31H4 and 21B12 antibodies.

Table 39.5 displays a summary of all of the hits for the various antibodies.

<table>
<thead>
<tr>
<th>TABLE 39.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>EC50 shift hits</td>
</tr>
<tr>
<td>-------------</td>
</tr>
<tr>
<td>21B12</td>
</tr>
<tr>
<td>R207E</td>
</tr>
<tr>
<td>D208R</td>
</tr>
</tbody>
</table>

* decreases EC50
The structure identifies PCSK9 residues as follows: light gray indicates those residues that were not mutated (with the exception of those residues that are explicitly indicated on the structure) and darker gray indicates those residues mutated (a minority of which failed to express). Residues that are explicitly indicated were tested (regardless of the shading indicated on the figure) and resulted in a significant change in EC50 and/or Bmax.

C4 does not compete with 21B12 and 31H4 in the binnig assay. 3C4 binds to the V-domain in the domain binding assay (see results from Example 40, FIGS. 28A and 28B).

While there were approximately a dozen mutants that could have been expected to have an effect on binding (based upon the crystal structure), the present experiment demonstrated that, surprisingly, they did not. As will be appreciated by one of skill in the art, the results presented above are in good agreement with the crystal structures and PCSK9-9’s binding of these antibodies. This demonstrates that the provided structural and corresponding functional data adequately identifies the key residues and areas of interaction of the neutralizing ABPs and PCSK9. Thus, variants of the ABPs that possess the ability to bind to the above noted areas are adequately provided by the present description.

As will be appreciated by one of skill in the art, ABPs in the same bin (with the exception of bin 5, which as noted above, is a general catch all bin) likely bind to overlapping sites on the target protein. As such, the above epitopes and relevant residues can generally be extended to all such ABPs in the same bin.

To further examine the above results in regard to ABP 31H4, position E181R, which, according to the above crystal structure, was predicted to interact with R185 to form part of the surface that interacts with the ABP, was also altered (E181R). The results, while not statistically significant on their own, were, when combined with the crystal structure, demonstrative of 31H4 interacting with E181R (data not shown). Thus, position 181 also appears to form part of the epitope for the 31H4 ABP.

As noted above, the above binding data and epitope characterization references a PCSK9 sequence (SEQ ID NO: 1) that does not include the first 30 amino acids of PCSK9. Thus, the numbering system of this protein fragment, and the SEQ ID NOs that refer to this fragment, are shifted by 30 amino acids compared to the data and experiments that used a full length PCSK9 numbering system (such as that used in the crystal study data described above). Thus, to compare these results, an extra 30 amino acids should be added to the positions in each of the above epitope mapping results. For example, position 207 of SEQ ID NO: 1 (or SEQ ID NO: 303), correlates to position 237 of SEQ ID NO: 3 (the full length sequence, and the numbering system used throughout the rest of the specification). Table 39.6 outlines how the above noted positions, which reference SEQ ID NO: 1 (and/or SEQ ID NO: 303) correlate with SEQ ID NO: 3 (which includes the signal sequence).

<table>
<thead>
<tr>
<th>AMINO ACID POSITION IN SEQ ID</th>
<th>AMINO ACID POSITION IN SEQ ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO: 1 (EPI TOPE DATA)</td>
<td>NO: 3 (EPI TOPE DATA)</td>
</tr>
<tr>
<td>207</td>
<td>237</td>
</tr>
<tr>
<td>208</td>
<td>238</td>
</tr>
<tr>
<td>185</td>
<td>215</td>
</tr>
<tr>
<td>181</td>
<td>211</td>
</tr>
<tr>
<td>439</td>
<td>469</td>
</tr>
<tr>
<td>513</td>
<td>543</td>
</tr>
<tr>
<td>538</td>
<td>568</td>
</tr>
<tr>
<td>539</td>
<td>569</td>
</tr>
<tr>
<td>132</td>
<td>162</td>
</tr>
<tr>
<td>351</td>
<td>381</td>
</tr>
<tr>
<td>390</td>
<td>420</td>
</tr>
<tr>
<td>413</td>
<td>443</td>
</tr>
<tr>
<td>582</td>
<td>612</td>
</tr>
<tr>
<td>162</td>
<td>192</td>
</tr>
<tr>
<td>164</td>
<td>194</td>
</tr>
<tr>
<td>167</td>
<td>197</td>
</tr>
<tr>
<td>123</td>
<td>153</td>
</tr>
<tr>
<td>129</td>
<td>159</td>
</tr>
<tr>
<td>311</td>
<td>341</td>
</tr>
<tr>
<td>313</td>
<td>343</td>
</tr>
<tr>
<td>337</td>
<td>367</td>
</tr>
<tr>
<td>519</td>
<td>549</td>
</tr>
<tr>
<td>521</td>
<td>551</td>
</tr>
<tr>
<td>554</td>
<td>584</td>
</tr>
</tbody>
</table>

Thus, those embodiments described herein with reference to SEQ ID NO: 1 can also be described, by their above noted corresponding position with reference to SEQ ID NO: 3.

Example 40

PCSK9 Domain Binding Assay

The present example examined where on PCSK9 the various ABPs bound.

Clear, 96 well maxisorp plates (Nunc) were coated overnight with 2 μg/ml of various anti-PCSK9 antibodies diluted in PBS. Plates were washed thoroughly with PBS/0.05% Tween-20 and then blocked for two hours with 3% BSA/PBS. After washing, plates were incubated for two hours with either full length PCSK9 (aa 31-692 SEQ ID NO: 3), procat PCSK9 (aa 31-449 SEQ ID NO: 3) or v-domain PCSK9 (aa 450-692 of SEQ ID NO: 3) diluted in general assay diluent (Immunochemistry Technologies, LLC). Plates were washed and a rabbit polyclonal biotinylated anti-PCSK9 antibody (D8774), which recognizes the procat and v-domain as well as full-length PCSK9, was added at 1 μg/ml (in 1% BSA/PBS). Bound full-length, procat or v-domain PCSK9 was detected by incubation with neutravidin-HRP (Thermo Scientific) at 200 ng/ml (in 1% BSA/PBS) followed by TMB substrate (KPL) and absorbance measurement at 650 nm. The results, presented in FIGS. 28A and 28B, demonstrate the ability of the various ABs to bind to various parts of PCSK9. As shown in FIG. 28B, ABP 31A4 binds to the V domain of PCSK9.

Example 41

Neutralizing, Non-Competitive Antigen Binding Proteins

The present example demonstrates how to identify and characterize an antigen binding protein that is non-competitive with LDLR for binding with PCSK9, but is still neutralizing towards PCSK9 activity. In other words, such an antigen
binding protein will not block PCSK9 from binding to LDLR, but will prevent or reduce PCSK9 mediated LDLR degradation.

Clear, 384 well plates (Costar) were coated with 2 μg/ml of goat anti-LDL receptor antibody (R&D Systems) diluted in buffer A (100 mM sodium cacodylate, pH 7.4). Plates were washed thoroughly with buffer A and then blocked for 2 hours with buffer B (7% milk in buffer A). After washing, plates were incubated for 1.5 hours with 0.4 μg/ml of LDL receptor (R&D Systems) diluted in buffer C (buffer B supplemented with 10 mM CaCl2). Concurrent with this incubation, 20 ng/ml of biotinylated D374Y PCSK9 was incubated with 100 ng/ml of antibody diluted in buffer A or buffer A alone (control). The LDL receptor containing plates were washed and the biotinylated D374Y PCSK9/antibody mixture was transferred to them and incubated for 1 hour at room temperature. Binding of the biotinylated D374Y to the LDL receptor was detected by incubation with streptavidin-HRP (BioSource) at 500 ng/ml in buffer C followed by TMB substrate (KPL). The signal was quenched with 1N HCl and the absorbance read at 450 nm. The results are presented in FIG. 28C, which shows that while ABP 31H4 inhibits LDLR binding, ABP 31A4 does not inhibit LDLR binding to PCSK9. In combination with the results from Example 40 and shown in FIGS. 28A and 28B, it is clear that 31A4 ABP binds to the V domain of PCSK9 and does not block the interaction of PCSK9 with LDLR.

Next, the Ability of ABP 31A4 to serve as a neutralizing ABP was further confirmed via a cell LDL uptake assay (as described in the examples above). The results of this LDL uptake assay are presented in FIG. 28D. As shown in FIG. 28D, ABP 31 A4 displays significant PCSK9 neutralizing ability. Thus, in light of Example 40 and the present results, it is clear that ABPs can bind to PCSK9 without blocking the PCSK9 and LDLR binding interaction, while still being useful as neutralizing PCSK9 ABPs.

INCORPORATION BY REFERENCE

All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety. To the extent that any of the definitions or terms provided in the references incorporated by reference differ from the terms and discussion provided herein, the present terms and definitions control.

EQUIVALENTS

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The foregoing description and examples detail certain preferred embodiments of the invention and describe the best mode contemplated by the inventors. It will be appreciated, however, that no matter how detailed the foregoing may appear in text, the invention may be practiced in many ways and the invention should be construed in accordance with the appended claims and any equivalents thereof.

---

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NO: 575
<210> SEQ ID NO: 1
<211> LENGTH: 662
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 1

Gln Glu Asp Glu Asp Tyr Glu Glu Leu Val Leu Ala Leu Arg 1 5 10
Ser Glu Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala 20 25 30
Thr Phe His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Thr 35 40 45
Val Val Val Leu Lys Glu Glu Thr His Leu Ser Gin Ser Gin Arg Thr 50 55 60
Ala Arg Arg Leu Gin Ala Gin Ala Ala Arg Gly Tyr Leu Thr Lys 65 70 75 80
Ile Leu His Val Phe His Glu Leu Pro Gly Phe Leu Val Lys Met 90 95
Ser Gly Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr 100 105 110
Ile Glu Glu Asp Ser Ser Val Phe Ala Glu Ser Ser Phe Leu Trp Trp Leu 115 120 125
Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Glu Pro Pro 130 135 140
Asp Gly Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gin 145 150 155 160
Ser Asp His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu
Thr Val Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu
595 600 605

Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys
610 615 620

Val Val Arg Ser Arg Asp Val Ser Thr Thr Gly Ser Thr Ser Glu Glu
625 630 635 640

Ala Val Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln
645 650 655

Ala Ser Glu Leu Gln
660

<210> SEQ ID NO 2
<211> LENGTH: 2076
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

atgaggcaacg tcagctctgg cgccggtcgtg cacagtgtcgt gctgctgctg
120

cgtctctctg gcccggctct gcctgcggttc cagggagcctg ggagggcgat
180
caccatctg cacagctgtg gcgctggtat cggcgggtcg ctggtggggcac cgctgtggtg
240
gtggctgacg agggggcgat ctgctggctc tggagggcttc gctggctggtc
300
cggcagggcgcc gggcgggctgc cctggaggtc ctggctttctc cggcgtgggtc
360
gatctgggcc gtcggtggct ggtggatgcc gctggggtct cggcgggtgc
420
gaggggtggccc gggcgggttg cacagctgctg cggggtctgg gggcgagcgg
480
atgcgtggggcc ggctggggtgc tggaggggctg cggcgggtgc ctgggtgggtc
540
gcgggggtgc cggggtgggc gttggtgggt gcggggtgggc cggggtgggtc
600
tcggtggtggt gcgggtgggc gttggtgggt gcggggtgggt gcggggtgggt
660
agcgggggtgc gggcgggtgg cggggtgggt gcggggtgggt gcggggtgggt
720
gtgggtgggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
780
gttgggtgggc gccggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
840
ggctggggtgc gggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
900
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
960
gtgggtgggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1020
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1080
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1140
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1200
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1260
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1320
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1380
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1440
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1500
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1560
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1620
tcggtggtggt gcggggtgggt gcggggtgggt gcggggtgggt gcggggtgggt
1680
ggctgcagct ccacacttggsa ggtggaggac cttggcaccc acaagccgcc tgtgctgagg 1740
ccagcaggttc agccccaccca tgtcttgggc cacagggagg ccaacataca cgcttcctgc 1800
tgcctgcgcc cagcttctgga atggaaagtc aagagagcag gaatcgggac ccctcagggg 1860
cagctgtcagc tggctcctggc ggagggcttg acacctgactg gtgctgagcc cctcccttggg 1920
acctcccecg tgcgggggac ctaagccgta gacaacgcc tgtctggcag gagccgggac 1980
gtacagcacta cagagcagcc cagagagagc ggcgtgacac ccttgtgcaat cttgctgagg 2040
agcccggcacc tggctgacag ccctccagag cctccag 2076

<210> SEQ ID NO 3
<211> LENGTH: 692
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 3

Met Gly Thr Val Ser Ser Arg Arg Ser Trp Trp Pro Leu Pro Leu Leu
1 5 10 15
Leu Leu Leu Leu Leu Leu Leu Leu Gly Pro Ala Gly Ala Arg Ala Glu Glu
20 25 30
Asp Glu Asp Gly Asp Tyr Glu Leu Val Leu Ala Leu Arg Ser Glu
35 40 45
Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala Thr Phe
50 55 60
His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr Val Val
65 70 75 80
Val Leu Lys Glu Thr His Leu Ser Gin Ser Glu Arg Thr Ala Arg
95 100 105 110
Arg Leu Gin Ala Glu Ala Arg Arg Gly Tyr Leu Thr Lys Ile Leu
120 125
His Val Phe His Gly Leu Pro Gly Phe Leu Val Lys Met Ser Gly
130 135 140
Asp Leu Leu Glu Leu Ala Lys Leu Pro His Val Asp Tyr Ile Glu
150 155 160
Glu Asp Ser Ser Val Phe Ala Glu Ser Ile Pro Trp Asn Leu Glu Arg
170 175
Ile Thr Pro Pro Arg Tyr Arg Ala Asp Gly Tyr Gin Pro Pro Asp Gly
185 190
Gly Ser Leu Val Glu Val Tyr Leu Leu Asp Thr Ser Ile Gin Ser Asp
195 200 205
His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu Asn Val
210 215 220
Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gin Ala Ser Lys Cys Asp
225 230 235 240
Ser His Gly Thr His Leu Ala Gly Val Ser Gly Arg Asp Ala Gly
245 250 255
Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe Ile Arg
260 265 270
Lys Ser Gin Leu Val Gin Pro Val Gly Pro Leu Val Leu Leu Pro
275 280 285
Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gin Arg Leu
290 295 300
Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Asn Phe Arg Asp
305 310 315 320
Amp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile Thr Val
325 330 335
Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr Leu Gly
340 345 350
Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu Asp Ile
355 360 365
Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln Ser Gly
370 375 380
Thr Ser Gln Ala Ala His Val Ala Gly Ile Ala Ala Met Met Leu
385 390 395 400
Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Glu Arg Leu Ile
405 410 415
His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro Glu Asp
420 425 430
Gln Arg Val Leu Thr Pro Asn Leu Val Ala Ala Leu Pro Pro Ser Thr
435 440 445
His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser Ala His
450 455 460
Ser Gly Pro Thr Arg Met Ala Thr Ala Ile Ala Arg Cys Ala Pro Asp
465 470 475 480
Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys Arg Arg
485 490 495
Gly Gly Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg Ala His
500 505 510
Asn Ala Phe Gly Gly Val Tyr Ala Ile Ala Arg Cys Cys Leu
515 520 525
Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Ala Glu Ala
530 535 540
Ser Met Gly Thr Arg Val His Cys His Gln Glu Gly His Val Leu Thr
545 550 555 560
Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His Lys Pro
565 570 575
Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly His Arg
580 585 590
Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu Glu Cys
595 600 605
Lys Val Lys Glu His Gly Ile Pro Ala Pro Gly Glu Glu Val Thr Val
610 615 620
Ala Cys Glu Glu Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu Pro Gly
625 630 635 640
Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys Val Val
645 650 655
Arg Ser Arg Asp Val Ser Thr Gly Ser Thr Ser Glu Glu Ala Val
660 665 670
Thr Ala Val Ala Ile Cys Cys Arg Ser Arg His Leu Ala Gln Ala Ser
675 680 685
Gln Glu Leu Gln
690

<210> SEQ ID NO 4
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Val Pro Thr Pro Gly
1  5  10  15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20  25  30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35  40  45
Pro Gln Leu Leu Ile Tyr Leu Gln Ser Asn Arg Ala Ser Gly Val Pro
50  55  60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65  70  75  80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Ala
85  90  95
Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105 110

<210> SEQ ID NO 5
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Ser Val Thr Pro Gly
1  5  10  15
Glu Pro Pro Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20  25  30
Asn Gly Tyr Asn Phe Leu Asn Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35  40  45
Pro Gln Leu Leu Ile Tyr Leu Gln Ser His Arg Ala Ser Gly Val Pro
50  55  60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Gln Ile
65  70  75  80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln Val
85  90  95
Leu Gln Thr Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105 110

<210> SEQ ID NO 6
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Asp Ile Glu Met Thr Gln Ser Pro Ser Ser Ser Leu Ser Ala Ser Val Gly
1  5  10  15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Ser Ile Ser Ser Tyr
20  25  30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35  40  45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50  55  60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65  70  75  80
Glu Asp Phe Ala Thr Tyr Tyr Cys Glu Gln Gln Ser Tyr Ser Thr Pro Leu

Glu Asp Phe Ala Thr Tyr Tyr Cys Glu Gln Gln Ser Tyr Ser Thr Pro Leu
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 7
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Arg Ile Ser Asn Tyr
20 25 30
Leu Ser Trp Tyr Leu Gln Lys Pro Gly Ile Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Leu
85 90 95
Ile Phe Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> SEQ ID NO 8
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 8

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105

<210> SEQ ID NO 9
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 9

Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Gln Pro
45 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ser Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105

<210> SEQ ID NO 10
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 10
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile Ser Ile Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Tyr Leu Leu Ile
35 40 45
Tyr Ala Ala Ala Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ser Tyr Ser Ala Pro Ile
85 90 95
Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
100 105

<210> SEQ ID NO 11
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 11
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95
Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> SEQ ID NO 12
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 12
<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>20</th>
<th>25</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>35</th>
<th>40</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>50</th>
<th>55</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leu Ile Ser Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>65</th>
<th>70</th>
<th>75</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>85</th>
<th>90</th>
<th>95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asn Ser Ser</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>100</th>
<th>105</th>
<th>110</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Thr Val Leu</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 13
<211> LENGTH: 111
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>20</th>
<th>25</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala His</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>35</th>
<th>40</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>50</th>
<th>55</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leu Ile Tyr Gly Asn Thr Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>65</th>
<th>70</th>
<th>75</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>85</th>
<th>90</th>
<th>95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Asn Ser</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>100</th>
<th>105</th>
<th>110</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leu Ser Gly Val Val Phe Gly Gly Gly Thr Lys Leu Thr Thr Val Leu</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 14
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>20</th>
<th>25</th>
<th>30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Ser Asp Val Gly Gly Tyr</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>35</th>
<th>40</th>
<th>45</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>50</th>
<th>55</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>65</th>
<th>70</th>
<th>75</th>
<th>80</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Thr Ile Ser Gly Leu</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>85</th>
<th>90</th>
<th>95</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>100</th>
<th>105</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Thr Val Leu</td>
<td></td>
</tr>
</tbody>
</table>
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
     1     5     10     15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr
     20     25     30
Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val
     35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Thr Arg Phe
     50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
     65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
     85     90     95
Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
     100    105

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
     1     5     10     15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr
     20     25     30
Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val
     35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Thr Arg Phe
     50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
     65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
     85     90     95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
     100    105

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
     1     5     10     15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr
     20     25     30
Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val
     35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Ile Arg Phe
     50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
     65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
     85     90     95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
     100    105
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
85 90 95
Ser Met Val Phe Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO: 10
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 18
Gln Ser Ala Leu Thr Glu Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Aasn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu
35 40 45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
85 90 95
Ser Met Val Phe Gly Gly Thr Lys Leu Ala Val Leu
100 105

<210> SEQ ID NO: 19
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 19
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Aasn Ser Val Ser Trp Tyr Gln Gln Tyr Pro Gly Lys Pro Pro Lys Leu
35 40 45
Lys Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
85 90 95
Ser Met Val Phe Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO: 20
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 20
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Amn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu
   35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
   50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
   65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
   85     90     95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
  100    105

<210> SEQ ID NO 21
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 21
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
   1     5     10     15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
  20    25     30
Amn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu
   35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
   50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
   65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
   85     90     95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
  100    105

<210> SEQ ID NO 22
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 22
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
   1     5     10     15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr
  20    25     30
Amn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu
   35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Ile Ser Asn Arg Phe
   50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
   65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
   85     90     95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
  100    105

<210> SEQ ID NO 23
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 23
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
 1   5   10   15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
 20  25  30  35  40  45
Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
 50  55  60  65  70  75  80
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
 85  90  95 100 105
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
110 115 120 125 130 135 140 145 150 155 160
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr
170 175 180 185 190 195 200 205 210 215 220
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
230 235 240 245 250 255 260 265 270 275 280

<210> SEQ ID NO 24
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 24
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
 1   5   10   15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr
 20  25  30  35  40  45
Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Arg
 50  55  60  65  70  75  80
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
 85  90  95 100 105 110 115 120 125 130 135 140 145 150 155 160
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
170 175 180 185 190 195 200 205 210 215 220
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr
230 235 240 245 250 255 260 265 270 275 280
Asn Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
290 295 300 305 310 315 320 325 330 335 340

<210> SEQ ID NO 25
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 25
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
 1   5   10   15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
 20  25  30  35  40  45
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
 50  55  60  65  70  75  80
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
 85  90  95 100 105 110 115 120 125 130 135 140 145 150 155 160
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
170 175 180 185 190 195 200 205 210 215 220
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
230 235 240 245 250 255 260 265 270 275 280
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
290 295 300 305 310 315 320 325 330 335 340
Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100
105

<210> SEQ ID NO 26
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 26
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1  5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30
Aasn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Glu Val Thr Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr
85 90 95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 27
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 27
Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1  5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Ser Tyr
20 25 30
Aasn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Glu Gly Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Tyr Ala Gly Ser
85 90 96
Ser Thr Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 28
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 28
Leu Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1  5 10 15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr
20 25 30
Aasn Leu Val Ser Trp Tyr Gln Gln Tyr Ser Gly Lys Ala Pro Lys Leu
35 40 45
Met Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
<table>
<thead>
<tr>
<th>50</th>
<th>55</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser</td>
<td>Gly</td>
<td>Ser</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>Gln</td>
<td>Ala</td>
<td>Glu</td>
</tr>
<tr>
<td>85</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>Ser</td>
<td>Thr</td>
<td>Leu</td>
</tr>
<tr>
<td>100</td>
<td>105</td>
<td>110</td>
</tr>
</tbody>
</table>

`<210>`: SEQ ID NO 29  
`<211>`: LENGTH: 108  
`<212>`: TYPE: PRT  
`<213>`: ORGANISM: Homo sapiens

`<400>`: SEQUENCE: 29

<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln</td>
<td>Ser</td>
<td>Val</td>
<td>Leu</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Arg</td>
<td>Val</td>
<td>Thr</td>
<td>Ile</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
<td>Asn</td>
<td>Trp</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Tyr</td>
<td>Ser</td>
<td>Asn</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
<td>80</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly</td>
<td>Ser</td>
<td>Lys</td>
</tr>
<tr>
<td>85</td>
<td>90</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Asn</td>
<td>Val</td>
<td>Phe</td>
<td>Gly</td>
</tr>
<tr>
<td>100</td>
<td>105</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

`<210>`: SEQ ID NO 30  
`<211>`: LENGTH: 109  
`<212>`: TYPE: PRT  
`<213>`: ORGANISM: Homo sapiens

`<400>`: SEQUENCE: 30

<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln</td>
<td>Ser</td>
<td>Val</td>
<td>Leu</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Arg</td>
<td>Val</td>
<td>Thr</td>
<td>Ile</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
<td>Asn</td>
<td>Trp</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Ile</td>
<td>Tyr</td>
<td>Arg</td>
<td>Asn</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
<td>80</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly</td>
<td>Lys</td>
<td>Ser</td>
</tr>
<tr>
<td>85</td>
<td>90</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Asn</td>
<td>Val</td>
<td>Trp</td>
<td>Val</td>
</tr>
<tr>
<td>100</td>
<td>105</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

`<210>`: SEQ ID NO 31  
`<211>`: LENGTH: 109  
`<212>`: TYPE: PRT  
`<213>`: ORGANISM: Homo sapiens

`<400>`: SEQUENCE: 31

<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln</td>
<td>Ser</td>
<td>Val</td>
<td>Leu</td>
</tr>
</tbody>
</table>
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30

Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95

Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO: 32
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 32

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1  5  10  15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30

Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95

Asn Gly Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> SEQ ID NO: 33
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 33

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1  5  10  15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Asn Ile Gly Ser Lys
20 25 30

Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95

Asn Trp Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO: 34
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 34

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1  5  10  15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Aen Aen
20 25  30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40  45
Ile Tyr Asp Aen Aen Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55  60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70  75  80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90  95
Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110

<210> SEQ ID NO 35
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 35

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1  5  10  15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Aen Aen
20 25  30
Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40  45
Ile Tyr Asp Tyr Aen Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55  60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70  75  80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu
85 90  95
Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110

<210> SEQ ID NO 36
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 36

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1  5  10  15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Aen Aen
20 25  30
Phe Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40  45
Ile Tyr Asp Tyr Aen Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55  60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70  75  80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95
Ser Gly Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu 100 105 110

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>100</td>
<td>105</td>
</tr>
<tr>
<td>110</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>100</td>
<td>105</td>
</tr>
<tr>
<td>110</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>100</td>
<td>105</td>
</tr>
<tr>
<td>110</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>100</td>
<td>105</td>
</tr>
<tr>
<td>110</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
35 40 45
Ile Tyr Asp Tyr Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Cys Gly Thr Trp Asp Ser Ser Leu
90 95
Ser Gly Tyr Val Phe Gly Thr Gly Thr Arg Val Thr Val Leu
100 105 110

<210> SEQ ID NO 40
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 40
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Phe Val Ser Trp Tyr Gln Glu Leu Pro Gly Thr Ala Pro Lys Leu Gln
35 40 45
Ile Tyr Asp Ser Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Asp Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Cys Gly Thr Trp Asp Ser Ser Leu
90 95
Ser Ala Tyr Val Phe Gly Thr Gly Thr Lys Val Thr Val Leu
100 105 110

<210> SEQ ID NO 41
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 41
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln
1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn
20 25 30
Tyr Val Ser Trp Tyr Gln Glu Leu Pro Gly Thr Ala Pro Lys Leu Gln
35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln
65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Cys Gly Thr Trp Asp Ser Ser Leu
90 95
Ser Ala Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110

<210> SEQ ID NO 42
<211> LENGTH: 110
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 42
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln 1 5 10 15
Lys Val Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ser Asn Ile Gly Asn Asn 20 25 30
Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45
Ile Tyr Asp Asn Asn Lys Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60
Gly Ser Asn Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln 65 70 75 80
Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Gly Thr Trp Asp Ser Ser Leu 85 90 95
Ser Ala Val Val Phe Gly Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105 110

<210> SEQ ID NO 43
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 43
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30
Cys Trp Tyr Gln Gln Leu Pro Gly Glu Ser Pro Val Leu Val Ile Tyr 35 40 45
Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val 85 90 95
Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105

<210> SEQ ID NO 44
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 44
Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Pro Gly Gln 1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala 20 25 30
Cys Trp Tyr Gln Gln Leu Pro Gly Glu Ser Pro Val Leu Val Ile Tyr 35 40 45
Gln Asn Thr Lys Trp Pro Leu Gly Ile Pro Glu Arg Phe Ser Gly Ser 50 55 60
Lys Ser Gly Asn Thr Val Thr Leu Thr Ile Ser Gly Thr Gln Ala Met 65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Val Val 85 90 95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105
<210> SEQ ID NO 45
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 45

Gln Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Ser Leu Gly Ala
1     5     10     15
Ser Val Thr Leu Thr Cys Thr Leu Ser Ser Gly Tyr Ser Asn Tyr Lys
20    25    30
Val Asp Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met
35    40    45
Arg Val Gly Thr Gly Ile Val Gly Ser Lys Gly Asp Gly Ile Pro
50    55    60
Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr Leu Thr Ile
65    70    75    80
Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys Gly Ala Asp
85    90    95
His Gly Ser Gly Ser Asn Phe Val Val Val Val Phe Gly Gly Gly Thr Lys
100   105   110
Leu Thr Val Leu
115

<210> SEQ ID NO 46
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 46

Gln Pro Val Leu Thr Gln Pro Leu Phe Ala Ser Ala Ser Leu Gly Ala
1     5     10     15
Ser Val Thr Leu Thr Cys Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Glu
20    25    30
Val Asp Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met
35    40    45
Arg Val Asp Thr Gly Ile Val Gly Ser Lys Gly Glu Gly Ile Pro
50    55    60
Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr Leu Thr Ile
65    70    75    80
Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys Gly Ala Asp
85    90    95
His Gly Ser Gly Thr Asn Phe Val Val Val Val Phe Gly Gly Gly Thr Lys
100   105   110
Leu Thr Val Leu
115

<210> SEQ ID NO 47
<211> LENGTH: 114
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 47

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala
1     5     10     15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20    25    30
<table>
<thead>
<tr>
<th>Gly</th>
<th>Ile</th>
<th>Ser</th>
<th>Trp</th>
<th>Val</th>
<th>Arg</th>
<th>Gln</th>
<th>Ala</th>
<th>Pro</th>
<th>Gly</th>
<th>Gly</th>
<th>Gly</th>
<th>Leu</th>
<th>Glu</th>
<th>Trp</th>
<th>Met</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gly</th>
<th>Trp</th>
<th>Ile</th>
<th>Ser</th>
<th>Ala</th>
<th>Tyr</th>
<th>Asn</th>
<th>Gly</th>
<th>Asn</th>
<th>Thr</th>
<th>Asn</th>
<th>Tyr</th>
<th>Ala</th>
<th>Gln</th>
<th>Lys</th>
<th>Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gln</th>
<th>Gly</th>
<th>Arg</th>
<th>Val</th>
<th>Thr</th>
<th>Met</th>
<th>Thr</th>
<th>Thr</th>
<th>Asp</th>
<th>Thr</th>
<th>Ser</th>
<th>Thr</th>
<th>Ser</th>
<th>Thr</th>
<th>Ala</th>
<th>Tyr</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Met</th>
<th>Glu</th>
<th>Leu</th>
<th>Arg</th>
<th>Ser</th>
<th>Leu</th>
<th>Arg</th>
<th>Ser</th>
<th>Asp</th>
<th>Thr</th>
<th>Ala</th>
<th>Val</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Cys</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Ala | Arg | Gly | Tyr | Gln | Met | Asp | Val | Trp | Gly | Gln | Gln | Gly | Thr | Thr | Val |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

| Ser | Ser |     |     |     |     |     |     |     |     |     |     |     |     |     |

| <210> SEQ ID NO 48 |
|<211> LENGTH: 115 |
|<212> TYPE: PRT |
|<213> ORGANISM: Homo sapiens |

### Sequence 1

<table>
<thead>
<tr>
<th>Gln</th>
<th>Ile</th>
<th>Gln</th>
<th>Leu</th>
<th>Val</th>
<th>Gln</th>
<th>Ser</th>
<th>Gly</th>
<th>Ala</th>
<th>Gln</th>
<th>Ser</th>
<th>Gly</th>
<th>Ala</th>
<th>Lys</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ser</th>
<th>Val</th>
<th>Lys</th>
<th>Val</th>
<th>Ser</th>
<th>Cys</th>
<th>Lys</th>
<th>Ala</th>
<th>Ser</th>
<th>Gly</th>
<th>Tyr</th>
<th>Pro</th>
<th>Leu</th>
<th>Thr</th>
<th>Ser</th>
<th>Tyr</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gly</th>
<th>Ile</th>
<th>Ser</th>
<th>Trp</th>
<th>Val</th>
<th>Arg</th>
<th>Gln</th>
<th>Ala</th>
<th>Pro</th>
<th>Gly</th>
<th>Gln</th>
<th>Gly</th>
<th>Leu</th>
<th>Glu</th>
<th>Trp</th>
<th>Met</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gly</th>
<th>Trp</th>
<th>Ile</th>
<th>Ser</th>
<th>Ala</th>
<th>Tyr</th>
<th>Asn</th>
<th>Gly</th>
<th>Asn</th>
<th>Thr</th>
<th>Asn</th>
<th>Tyr</th>
<th>Ala</th>
<th>Gln</th>
<th>Lys</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gln</th>
<th>Gly</th>
<th>Ser</th>
<th>Val</th>
<th>Thr</th>
<th>Met</th>
<th>Thr</th>
<th>Thr</th>
<th>Asp</th>
<th>Thr</th>
<th>Ser</th>
<th>Thr</th>
<th>Ser</th>
<th>Thr</th>
<th>Ser</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Met</th>
<th>Glu</th>
<th>Leu</th>
<th>Arg</th>
<th>Ser</th>
<th>Leu</th>
<th>Arg</th>
<th>Ser</th>
<th>Asp</th>
<th>Thr</th>
<th>Ala</th>
<th>Val</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Cys</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ala</th>
<th>Arg</th>
<th>Gly</th>
<th>Tyr</th>
<th>Gln</th>
<th>Met</th>
<th>Asp</th>
<th>Val</th>
<th>Trp</th>
<th>Gly</th>
<th>Gln</th>
<th>Gly</th>
<th>Thr</th>
<th>Thr</th>
<th>Thr</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Val | Ser | Ser |     |     |     |     |     |     |     |     |     |     |     |     |     |

### Sequence 2

<table>
<thead>
<tr>
<th>Gln</th>
<th>Val</th>
<th>Gln</th>
<th>Leu</th>
<th>Val</th>
<th>Gln</th>
<th>Ser</th>
<th>Gly</th>
<th>Ala</th>
<th>Gln</th>
<th>Ser</th>
<th>Gly</th>
<th>Ala</th>
<th>Lys</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ser</th>
<th>Val</th>
<th>Lys</th>
<th>Val</th>
<th>Ser</th>
<th>Cys</th>
<th>Lys</th>
<th>Ala</th>
<th>Ser</th>
<th>Gly</th>
<th>Tyr</th>
<th>Thr</th>
<th>Leu</th>
<th>Thr</th>
<th>Ser</th>
<th>Tyr</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gly</th>
<th>Ile</th>
<th>Ser</th>
<th>Trp</th>
<th>Val</th>
<th>Arg</th>
<th>Gln</th>
<th>Ala</th>
<th>Pro</th>
<th>Gly</th>
<th>Gln</th>
<th>Gly</th>
<th>Leu</th>
<th>Glu</th>
<th>Trp</th>
<th>Met</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gly</th>
<th>Trp</th>
<th>Val</th>
<th>Ser</th>
<th>Phe</th>
<th>Tyr</th>
<th>Asn</th>
<th>Gly</th>
<th>Asn</th>
<th>Thr</th>
<th>Asn</th>
<th>Tyr</th>
<th>Ala</th>
<th>Gln</th>
<th>Lys</th>
<th>Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gln</th>
<th>Gly</th>
<th>Arg</th>
<th>Gly</th>
<th>Thr</th>
<th>Met</th>
<th>Thr</th>
<th>Thr</th>
<th>Asp</th>
<th>Pro</th>
<th>Ser</th>
<th>Thr</th>
<th>Ser</th>
<th>Thr</th>
<th>Ala</th>
<th>Tyr</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Met</th>
<th>Glu</th>
<th>Leu</th>
<th>Arg</th>
<th>Ser</th>
<th>Leu</th>
<th>Arg</th>
<th>Ser</th>
<th>Asp</th>
<th>Thr</th>
<th>Ala</th>
<th>Val</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Cys</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ala</th>
<th>Arg</th>
<th>Gly</th>
<th>Tyr</th>
<th>Gln</th>
<th>Met</th>
<th>Asp</th>
<th>Val</th>
<th>Trp</th>
<th>Gly</th>
<th>Gln</th>
<th>Gly</th>
<th>Thr</th>
<th>Thr</th>
<th>Thr</th>
<th>Val</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Val | Ser | Ser |     |     |     |     |     |     |     |     |     |     |     |     |     |

*Note: The sequences represent amino acid sequences of proteins.*
<210> SEQ ID NO 50
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>Residue</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln</td>
<td>Val</td>
</tr>
<tr>
<td>Val</td>
<td>Gln</td>
</tr>
<tr>
<td>Leu</td>
<td>Val</td>
</tr>
<tr>
<td>Gln</td>
<td>Ser</td>
</tr>
<tr>
<td>Gly</td>
<td>Ala</td>
</tr>
<tr>
<td>Glu</td>
<td>Val</td>
</tr>
<tr>
<td>Lys</td>
<td>Lys</td>
</tr>
<tr>
<td>Pro</td>
<td>Gly</td>
</tr>
<tr>
<td>Ala</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Val</td>
</tr>
<tr>
<td>Lys</td>
<td>Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Cys</td>
</tr>
<tr>
<td>Lys</td>
<td>Ala</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly</td>
</tr>
<tr>
<td>Tyr</td>
<td>Thr</td>
</tr>
<tr>
<td>Leu</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Tyr</td>
<td>20</td>
</tr>
<tr>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>Gly</td>
<td>Ile</td>
</tr>
<tr>
<td>Ser</td>
<td>Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Arg</td>
</tr>
<tr>
<td>Gln</td>
<td>Ala</td>
</tr>
<tr>
<td>Pro</td>
<td>Gly</td>
</tr>
<tr>
<td>Gly</td>
<td>Glu</td>
</tr>
<tr>
<td>Glu</td>
<td>Trp</td>
</tr>
<tr>
<td>Met</td>
<td>35</td>
</tr>
<tr>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>Gly</td>
<td>Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td>Phe</td>
<td>Tyr</td>
</tr>
<tr>
<td>Asn</td>
<td>Gly</td>
</tr>
<tr>
<td>Asn</td>
<td>Thr</td>
</tr>
<tr>
<td>Asn</td>
<td>Tyr</td>
</tr>
<tr>
<td>Ala</td>
<td>Gln</td>
</tr>
<tr>
<td>Lys</td>
<td>Leu</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
</tr>
<tr>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Gly</td>
</tr>
<tr>
<td>Arg</td>
<td>Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Met</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Asp</td>
</tr>
<tr>
<td>Pro</td>
<td>Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Val</td>
<td>Ala</td>
</tr>
<tr>
<td>Tyr</td>
<td>65</td>
</tr>
<tr>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Met</td>
<td>Glu</td>
</tr>
<tr>
<td>Leu</td>
<td>Arg</td>
</tr>
<tr>
<td>Ser</td>
<td>Leu</td>
</tr>
<tr>
<td>Arg</td>
<td>Ser</td>
</tr>
<tr>
<td>Asp</td>
<td>Thr</td>
</tr>
<tr>
<td>Ala</td>
<td>Val</td>
</tr>
<tr>
<td>Tyr</td>
<td>Tyr</td>
</tr>
<tr>
<td>Cys</td>
<td>85</td>
</tr>
<tr>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>Ala</td>
<td>Arg</td>
</tr>
<tr>
<td>Gly</td>
<td>Tyr</td>
</tr>
<tr>
<td>Tyr</td>
<td>Gly</td>
</tr>
<tr>
<td>Met</td>
<td>Asp</td>
</tr>
<tr>
<td>Val</td>
<td>Thr</td>
</tr>
<tr>
<td>Trp</td>
<td>Gly</td>
</tr>
<tr>
<td>Gln</td>
<td>Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>Val</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
</tr>
<tr>
<td>Thr</td>
<td>100</td>
</tr>
<tr>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>115</td>
</tr>
</tbody>
</table>

---

<210> SEQ ID NO 51
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>Residue</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln</td>
<td>Val</td>
</tr>
<tr>
<td>Val</td>
<td>Gln</td>
</tr>
<tr>
<td>Leu</td>
<td>Val</td>
</tr>
<tr>
<td>Gln</td>
<td>Ser</td>
</tr>
<tr>
<td>Gly</td>
<td>Ala</td>
</tr>
<tr>
<td>Glu</td>
<td>Val</td>
</tr>
<tr>
<td>Lys</td>
<td>Lys</td>
</tr>
<tr>
<td>Pro</td>
<td>Gly</td>
</tr>
<tr>
<td>Ala</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Val</td>
</tr>
<tr>
<td>Lys</td>
<td>Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Cys</td>
</tr>
<tr>
<td>Lys</td>
<td>Ala</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly</td>
</tr>
<tr>
<td>Tyr</td>
<td>Thr</td>
</tr>
<tr>
<td>Leu</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Tyr</td>
<td>20</td>
</tr>
<tr>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>Gly</td>
<td>Ile</td>
</tr>
<tr>
<td>Ser</td>
<td>Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Arg</td>
</tr>
<tr>
<td>Gln</td>
<td>Ala</td>
</tr>
<tr>
<td>Pro</td>
<td>Gly</td>
</tr>
<tr>
<td>Gly</td>
<td>Glu</td>
</tr>
<tr>
<td>Glu</td>
<td>Trp</td>
</tr>
<tr>
<td>Met</td>
<td>35</td>
</tr>
<tr>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>Gly</td>
<td>Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td>Phe</td>
<td>Tyr</td>
</tr>
<tr>
<td>Asn</td>
<td>Gly</td>
</tr>
<tr>
<td>Asn</td>
<td>Thr</td>
</tr>
<tr>
<td>Asn</td>
<td>Tyr</td>
</tr>
<tr>
<td>Ala</td>
<td>Gln</td>
</tr>
<tr>
<td>Lys</td>
<td>Leu</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
</tr>
<tr>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Gly</td>
</tr>
<tr>
<td>Arg</td>
<td>Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Met</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Asp</td>
</tr>
<tr>
<td>Pro</td>
<td>Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Val</td>
<td>Ala</td>
</tr>
<tr>
<td>Tyr</td>
<td>65</td>
</tr>
<tr>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Met</td>
<td>Glu</td>
</tr>
<tr>
<td>Leu</td>
<td>Arg</td>
</tr>
<tr>
<td>Ser</td>
<td>Leu</td>
</tr>
<tr>
<td>Arg</td>
<td>Ser</td>
</tr>
<tr>
<td>Asp</td>
<td>Thr</td>
</tr>
<tr>
<td>Ala</td>
<td>Val</td>
</tr>
<tr>
<td>Tyr</td>
<td>Tyr</td>
</tr>
<tr>
<td>Cys</td>
<td>85</td>
</tr>
<tr>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>Ala</td>
<td>Arg</td>
</tr>
<tr>
<td>Gly</td>
<td>Tyr</td>
</tr>
<tr>
<td>Gly</td>
<td>Met</td>
</tr>
<tr>
<td>Asp</td>
<td>Val</td>
</tr>
<tr>
<td>Trp</td>
<td>Gly</td>
</tr>
<tr>
<td>Gln</td>
<td>Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>Val</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
</tr>
<tr>
<td>Thr</td>
<td>100</td>
</tr>
<tr>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>115</td>
</tr>
</tbody>
</table>

---

<210> SEQ ID NO 52
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>Residue</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln</td>
<td>Val</td>
</tr>
<tr>
<td>Val</td>
<td>Gln</td>
</tr>
<tr>
<td>Leu</td>
<td>Val</td>
</tr>
<tr>
<td>Gln</td>
<td>Ser</td>
</tr>
<tr>
<td>Gly</td>
<td>Ala</td>
</tr>
<tr>
<td>Glu</td>
<td>Val</td>
</tr>
<tr>
<td>Lys</td>
<td>Lys</td>
</tr>
<tr>
<td>Pro</td>
<td>Gly</td>
</tr>
<tr>
<td>Ala</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Ser</td>
<td>Val</td>
</tr>
<tr>
<td>Lys</td>
<td>Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Cys</td>
</tr>
<tr>
<td>Lys</td>
<td>Ala</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly</td>
</tr>
<tr>
<td>Tyr</td>
<td>Thr</td>
</tr>
<tr>
<td>Leu</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Tyr</td>
<td>20</td>
</tr>
<tr>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>Gly</td>
<td>Ile</td>
</tr>
<tr>
<td>Ser</td>
<td>Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Arg</td>
</tr>
<tr>
<td>Gln</td>
<td>Ala</td>
</tr>
<tr>
<td>Pro</td>
<td>Gly</td>
</tr>
<tr>
<td>Gly</td>
<td>Glu</td>
</tr>
<tr>
<td>Glu</td>
<td>Trp</td>
</tr>
<tr>
<td>Met</td>
<td>35</td>
</tr>
<tr>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>Gly</td>
<td>Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td>Phe</td>
<td>Tyr</td>
</tr>
<tr>
<td>Asn</td>
<td>Gly</td>
</tr>
<tr>
<td>Asn</td>
<td>Thr</td>
</tr>
<tr>
<td>Asn</td>
<td>Tyr</td>
</tr>
<tr>
<td>Ala</td>
<td>Gln</td>
</tr>
<tr>
<td>Lys</td>
<td>Leu</td>
</tr>
<tr>
<td>50</td>
<td>55</td>
</tr>
<tr>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Gln</td>
<td>Gly</td>
</tr>
<tr>
<td>Arg</td>
<td>Val</td>
</tr>
<tr>
<td>Thr</td>
<td>Met</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Asp</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser</td>
</tr>
<tr>
<td>Val</td>
<td>Ala</td>
</tr>
<tr>
<td>Tyr</td>
<td>65</td>
</tr>
<tr>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>80</td>
<td></td>
</tr>
<tr>
<td>Met</td>
<td>Glu</td>
</tr>
<tr>
<td>Leu</td>
<td>Arg</td>
</tr>
<tr>
<td>Ser</td>
<td>Leu</td>
</tr>
<tr>
<td>Arg</td>
<td>Ser</td>
</tr>
<tr>
<td>Asp</td>
<td>Thr</td>
</tr>
<tr>
<td>Ala</td>
<td>Val</td>
</tr>
<tr>
<td>Tyr</td>
<td>Tyr</td>
</tr>
<tr>
<td>Cys</td>
<td>85</td>
</tr>
<tr>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>Ala</td>
<td>Arg</td>
</tr>
<tr>
<td>Gly</td>
<td>Tyr</td>
</tr>
<tr>
<td>Gly</td>
<td>Met</td>
</tr>
<tr>
<td>Asp</td>
<td>Val</td>
</tr>
<tr>
<td>Trp</td>
<td>Gly</td>
</tr>
<tr>
<td>Gln</td>
<td>Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
</tr>
<tr>
<td>Val</td>
<td>Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Val</td>
</tr>
<tr>
<td>Thr</td>
<td>100</td>
</tr>
<tr>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td>Val</td>
<td>Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>115</td>
</tr>
<tr>
<td>Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met</td>
<td></td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>35 40 45</td>
<td></td>
</tr>
<tr>
<td>Gly Trp Ile Ser Val Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val</td>
<td></td>
</tr>
<tr>
<td>55 60</td>
<td></td>
</tr>
<tr>
<td>Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr</td>
<td></td>
</tr>
<tr>
<td>65 70 75 80</td>
<td></td>
</tr>
<tr>
<td>Met Glu Leu Arg Ser Leu Ser Ser Asp Thr Ala Val Tyr Tyr Cys</td>
<td></td>
</tr>
<tr>
<td>85 90</td>
<td></td>
</tr>
<tr>
<td>Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr</td>
<td></td>
</tr>
<tr>
<td>100 105 110</td>
<td></td>
</tr>
<tr>
<td>Val Ser Ser</td>
<td></td>
</tr>
<tr>
<td>115</td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 53
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 5 10 25</td>
</tr>
<tr>
<td>Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr</td>
</tr>
<tr>
<td>20 25 30</td>
</tr>
<tr>
<td>Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met</td>
</tr>
<tr>
<td>35 40 45</td>
</tr>
<tr>
<td>Gly Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val</td>
</tr>
<tr>
<td>55 60</td>
</tr>
<tr>
<td>Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr</td>
</tr>
<tr>
<td>65 70 75 80</td>
</tr>
<tr>
<td>Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Phe Cys</td>
</tr>
<tr>
<td>85 90</td>
</tr>
<tr>
<td>Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr</td>
</tr>
<tr>
<td>100 105 110</td>
</tr>
<tr>
<td>Val Ser Ser</td>
</tr>
<tr>
<td>115</td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 54
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th>Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 5 10 35</td>
</tr>
<tr>
<td>Ser Leu Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Leu Thr Ser Tyr</td>
</tr>
<tr>
<td>20 25 30</td>
</tr>
<tr>
<td>Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met</td>
</tr>
<tr>
<td>35 40 45</td>
</tr>
<tr>
<td>Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val</td>
</tr>
<tr>
<td>55 60</td>
</tr>
<tr>
<td>Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr</td>
</tr>
<tr>
<td>65 70 75 80</td>
</tr>
<tr>
<td>Met Glu Val Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Tyr Cys</td>
</tr>
<tr>
<td>85 90</td>
</tr>
<tr>
<td>Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr</td>
</tr>
<tr>
<td>100 105 110</td>
</tr>
</tbody>
</table>
Val Ser Ser
115

<210> SEQ ID NO 55
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 55

Gln Val Gln Leu Val Gln Ser G1a Glu Val Lys Lys Pro Gly Ala
1     5     10    15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Pro Leu Thr Ser Tyr
20    25    30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Glu Glu Trp Met
35    40    45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val
50    55    60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr
65    70    75    80
Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Tyr Cys
85    90    95
Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
100   105   110

Val Ser Ser
115

<210> SEQ ID NO 56
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 56

Gln Val Gln Leu Val Gln Ser G1a Glu Val Lys Lys Pro Gly Ala
1     5     10    15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Leu Thr Ser Tyr
20    25    30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Glu Glu Trp Met
35    40    45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val
50    55    60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr
65    70    75    80
Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Tyr Cys
85    90    95
Ala Arg Gly Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
100   105   110

Val Ser Ser
115

<210> SEQ ID NO 57
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 57

Gln Val Gln Leu Val Gln Ser G1a Glu Val Lys Lys Pro Gly Ala
1     5     10    15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr
20
25
30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35
40
45
Gly Trp Val Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe
50
55
60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65
70
75
80
Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Cys
85
90
95
Ala Arg Gly Tyr Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
100
105
110
Val Ser Ser
115

<210> SEQ ID NO 58
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 58
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala
1
5
10
15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Pro Ser Tyr
20
25
30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35
40
45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50
55
60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65
70
75
80
Met Glu Val Arg Ser Leu Arg Ser Asp Thr Ala Val Phe Tyr Cys
85
90
95
Ala Arg Gly Tyr Val Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr
100
105
110
Val Ser Ser
115

<210> SEQ ID NO 59
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 59
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala
1
5
10
15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20
25
30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35
40
45
Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu
50
55
60
Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr
65
70
75
80
Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Cys
85
90
95
Ala Arg Gly Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser
100 105 110

Ser

<210> SEQ ID NO 60
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 60
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala
1      5      10    15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20     25     30
Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Glu Gln Glu Leu Trp Met
35     40     45
Gly Trp Ile Ser Thr Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val
50     55     60
Gln Gly Arg Val Thr Met Thr Thr Ser Thr Ser Thr Ser Ala Tyr
65     70     75    80
Met Glu Leu Arg Ser Leu Arg Ser Asp Thr Ala Val Tyr Tyr Cys
85     90    95
Ala Arg Gly Tyr Thr Arg Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
100    105   110
Val Ser Ser
115

<210> SEQ ID NO 61
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 61
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1      5      10    15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20     25     30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gln Glu Leu Trp Val
35     40     45
Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50     55     60
Lys Gly Arg Phe Thr Ile Ser Arg Asn Ala Lys Asn Ser Leu Tyr
65     70     75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85     90    95
Ala Arg Asn Trp Gly Ala Phe Asp Val Trp Gly Gln Gly Thr Met Val
100    105   110
Thr Val Ser Ser
115

<210> SEQ ID NO 62
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 62
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1      5      10    15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20  25  30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35  40

Ala Asn Ile Lys His Asp Gly Ser Gly Tyr Tyr Val Asp Ser Val

50  55  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65  70  75  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys

85  90  95

Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Val Trp Gly His Gly

100 105 110

Thr Met Val Thr Val Ser Ser

115

<210> SEQ ID NO 63
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 63

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1   5   10   15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr

20  25  30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35  40

Ala Asn Ile Lys Gly Asp Gly Ser Gly Tyr Tyr Val Asp Ser Val

50  55  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65  70  75  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys

85  90  95

Ala Arg Asn Thr Gly Ala Phe Asp Ile Thr Gly Gln Gly Thr Met Val

100 105 110

Thr Val Ser Ser

115

<210> SEQ ID NO 64
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 64

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1   5   10   15

Ser Leu Arg Leu Ser Cys Val Val Ser Gly Phe Thr Phe Ser Ser Tyr

20  25  30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35  40

Ala Asn Ile Lys Gln Asp Gly Ser Gly Lys Tyr Tyr Val Asp Ser Val

50  55  60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr

65  70  75  80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys

85  90  95

Ala Arg Asn Thr Gly Ala Phe Asp Ile Thr Gly Gln Gly Thr Met Val

100 105 110

Thr Val Ser Ser

115
Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly
  100  105  110
Thr Met Val Thr Val Ser Ser
  115

<210> SEQ ID NO 65
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 65

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
  1    5    10   15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Phe
  20   25    30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
  35   40   45
Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
  50   55    60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
  65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Ser Cys
  85    90    95
Thr Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly
 100  105  110
Thr Met Val Thr Val Ser Ser
  115

<210> SEQ ID NO 66
<211> LENGTH: 123
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 66

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Lys Pro Gly Gly
  1    5    10   15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
  20   25    30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
  35   40   45
Ser Ser Ile Ser Ser Ser Ser Tyr Ile Tyr Tyr Ala Asp Ser Val
  50   55    60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
  65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
  85    90    95
Ala Arg Asp Tyr Asp Phe Trp Ser Gly Tyr Tyr Thr Ala Phe Asp Val
 100  105  110
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
 115  120

<210> SEQ ID NO 67
<211> LENGTH: 123
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 67
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ser Ile Ser Ser Ser Ser Ser Ser Tyr Ile Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95
Ala Arg Asp Tyr Asp Phe Trp Ser Ala Tyr Tyr Asp Ala Phe Asp Val
100 105 110
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 68
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 68

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
85 90 95
Ala Lys Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
100 105 110

<210> SEQ ID NO 69
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 69

Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ser Thr Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
85 90 95
Ala Lys Glu Val Gly Ser Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115

<210> SEQ ID NO 70
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 70
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30
Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45
Ser Ala Ile Ser Gly Ser Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Gln Asp Thr Ala Val Tyr Cys 95 90 95
Ala Lys Val Leu Met Val Tyr Ala Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110
Val Thr Val Ser Ser 115

<210> SEQ ID NO 71
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 71
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Gln Trp Val 35 40 45
Ser Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Gln Asp Thr Ala Val Tyr Cys 95 90 95
Ala Lys Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr Trp Gly 100 105 110
Gln Gly Thr Leu Val Thr Val Ser Ser 115 120

<210> SEQ ID NO 72
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 72
Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1  5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20  25  30
Ala Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35  40  45
Ser Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val
50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85  90  95
Ala Lys Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr Trp Gly
100 105
Gln Gly Thr Leu Val Thr Val Ser Ser
110 120

<210> SEQ ID NO 73
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 73
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1   5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20  25  30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35  40  45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85  90  95
Ala Arg Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val
100 105
Thr Val Ser Ser
110

<210> SEQ ID NO 74
<211> LENGTH: 123
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 74
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1   5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20  25  30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35  40  45
Ala Val Ile Trp Tyr Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val
50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
Ala Arg Glu Thr Gly Pro Leu Lys Leu Tyr Tyr Tyr Gly Met Asp Val 100
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115

<SEQ> ID NO 75
<LENGTH: 116
<TYPE: PRT
<ORIGIN: Homo sapiens

<SEQUENCE: 75
Gl Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35
Ala Val Ile Trp Tyr Asp Ser Asn Lys Tyr Tyr Ala Asp Ser Val 45
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 50
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 65
Ala Arg Ile Ala Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val 75
Thr Val Ser Ser 85

<SEQ> ID NO 76
<LENGTH: 122
<TYPE: PRT
<ORIGIN: Homo sapiens

<SEQUENCE: 76
Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Phe 20
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35
Ala Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val 45
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 50
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 65
Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp 75
Gly Gln Gly Thr Thr Val Thr Val Ser Ser 85

<SEQ> ID NO 77
<LENGTH: 122
<TYPE: PRT
<ORIGIN: Homo sapiens

<SEQUENCE: 77
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
  1  5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
  20  25  30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
  35  40  45
Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
  50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Lys Asn Thr Leu Tyr
  65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
  85  90  95
Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp
 100 105 110
Gly His Gly Thr Thr Val Thr Val Val Ser Ser
 115 120

<210> SEQ ID NO 78
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 78
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
  1  5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
  20  25  30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
  35  40  45
Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
  50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Lys Asn Thr Leu Tyr
  65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
  85  90  95
Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp
 100 105 110
Gly Gln Gly Thr Thr Val Thr Val Val Ser Ser
 115 120

<210> SEQ ID NO 79
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 79
Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
  1  5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Ser Phe
  20  25  30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
  35  40  45
Ala Leu Ile Trp Ser Asp Gly Ser Asp Gly Tyr Tyr Ala Asp Ser Val
  50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Lys Asn Thr Leu Tyr
  65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95
Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120

SEQ ID NO: 80
LENGTH: 122
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 80
Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ala Leu Ile Trp Asp Gly Asp Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 95 90 95
Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120

SEQ ID NO: 81
LENGTH: 122
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 81
Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 95 90 95
Ala Arg Arg Gln Leu Ala Ala Arg Pro Gly Gly Met Asp Val Trp 100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120

SEQ ID NO: 82
LENGTH: 122
TYPE: PRT
ORGANISM: Homo sapiens
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe
45  70  75  80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85  90  95
Cys Ala Arg Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr
100 105 110
Val Thr Val Ser Ser
115

<210> SEQ ID NO 85
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 85

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1  5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Ser
20 25 30
Asp Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Gln
35 40 45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Ile Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Gly Val Thr Thr Tyr Tyr Thr Ala Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 86
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 86

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1  5 10 15
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly
20 25 30
Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly Leu Gln
35 40 45
Trp Ile Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser
50 55 60
Leu Lys Ser Arg Ile Thr Ile Ser Val Asp Thr Ser Lys Asn Leu Phe
65 70 75 80
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr
85 90 95
Cys Ala Arg Gly Gly Val Thr Thr Tyr Tyr Thr Ala Met Asp Val Trp
100 105 110
Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 87
<211> LENGTH: 121
<table>
<thead>
<tr>
<th>Residue</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gly Tyr Tyr Trp Ser Trp Ile Arg Glu His Pro Gly Lys Gly Leu Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trp Ile Gly Tyr Ile Tyr Asn Ser Gly Ser Thr Tyr Tyr Asn Pro Ser</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cys Ala Arg Glu Asp Thr Ala Met Val Pro Tyr Phe Asp Tyr Trp Gly</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gln Gly Thr Leu Val Thr Val Ser Ser</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>55</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>85</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td></td>
<td>100</td>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td></td>
<td>115</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Residue</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tyr Trp Ser Trp Ile Arg Glu His Pro Gly Lys Gly Leu Glu Trp Ile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gly Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Arg Gly Gln Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Val Ser Ser</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>115</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Residue</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Ala Tyr</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tyr Trp Asn Trp Ile Arg Glu His Pro Gly Lys Gly Leu Glu Trp Ile</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gly Glu Ile Asn His Ser Gly Arg Thr Asp Tyr Asn Pro Ser Leu Lys</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Lys Gln Phe Ser Leu
Lys Leu Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala
Arg Gly Gln Leu Val Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val Ser Ser

<210> SEQ ID NO: 90
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 90

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
Trp Leu Gly Arg Thr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser

<210> SEQ ID NO: 91
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 91

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
Trp Leu Gly Arg Thr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser

Gln Gly Thr Leu Val Thr Val Ser Ser

115

<210> SEQ ID NO: 92
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 92

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
Trp Leu Gly Arg Thr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser

Gln Gly Thr Leu Val Thr Val Ser Ser

115

<210> SEQ ID NO: 93
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 93

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
Trp Leu Gly Arg Thr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser

Gln Gly Thr Leu Val Thr Val Ser Ser

115

<210> SEQ ID NO: 94
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 94

Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
Trp Leu Gly Arg Thr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Arg Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser

Gln Gly Thr Leu Val Thr Val Ser Ser

115
cagattcagc tgcacagcct tgtacgtcct tgtgagagtgc ctgagaagctg aagctgctggt 60
ttcacagc ccccacagcct tataacgctg cactagctgctg gcacaccagc 120
cctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 180
cagctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 240
tagccagcctg acatgctgctg ttcctctctct ctgctgctgctg gcacaccagc 300
gaggtgccctg cggcccctgctg cggcccctgctg gcacaccagc 360
<210> SEQ ID NO 93
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 93
cagttgagcc tgcacagcct tgtacgtcct tgtgagagtgc ctgagaagctg aagctgctggt 60
ttcacagc ccccacagcct tataacgctg cactagctgctg gcacaccagc 120
cctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 180
cagctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 240
tagccagcctg acatgctgctg ttcctctctct ctgctgctgctg gcacaccagc 300
gaggtgccctg cggcccctgctg cggcccctgctg gcacaccagc 360
<210> SEQ ID NO 94
<211> LENGTH: 345
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 94
cagttgagcc tgcacagcct tgtacgtcct tgtgagagtgc ctgagaagctg aagctgctggt 60
ttcacagc ccccacagcct tataacgctg cactagctgctg gcacaccagc 120
cctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 180
cagctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 240
tagccagcctg acatgctgctg ttcctctctct ctgctgctgctg gcacaccagc 300
gaggtgccctg cggcccctgctg cggcccctgctg gcacaccagc 360
<210> SEQ ID NO 95
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 95
cagttgagcc tgcacagcct tgtacgtcct tgtgagagtgc ctgagaagctg aagctgctggt 60
ttcacagc ccccacagcct tataacgctg cactagctgctg gcacaccagc 120
cctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 180
cagctgctgctg ttcctctctct ctgctgctgctg gcacaccagc 240
tagccagcctg acatgctgctg ttcctctctct ctgctgctgctg gcacaccagc 300
gaggtgccctg cggcccctgctg cggcccctgctg gcacaccagc 360
caggttcagc ttggctagtc tggagctgaa gtgaagaagc ctggggccctc agtgaaagtc 60
tctgcaacgg ctctctggtta caccctgacc aacgtcggtta tctgctggtt gcggacggcc 120
cotgacgacag gcgcttgagt gatggtgatgg atcacgttttt acaatgtgtaa cacaactcat
180
goacagaagg tcaaggccgag acctacatgc accacagaca catccacagc cacagttcac
240
atggagctga ggacgctgag atctgacgac aagggcggtg attactgtgc gagaggtac 300
ggtatggaac tctgggcccag aggggcaacgc tctacgcgct cctct
345

cagtctgccg tcgaactcagc tgcctccctg tctgggttctc tctggacagt gcaccacc 60
tctgcaacct gaaccagcag tgaaggtggt ggtataact cgtctctgct gcaccaca 120
caccacgcca aaccccocac aactcatgatc ttaggtgcag gtaatcgagc ctggaggggt 180
ttatgctgt tctctggctc caagtgctgc aacacggcct cctgacact cctgggctgt 240
caggctggag aagggctgta tttttctctg agcctcata caagcacacc cagtggctctc
300
ggccccagga caagcgctgac ogctctca 327

<210> SEQ ID NO 98
<211> LENGTH: 345
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 98

cagattcagc ttggcctagt gcggagtgag gtgaagaagc ctggggccctc agtgaaagtc 60
tctgcaacgg ctctctggtta caccctgacc aacgtcggtta tctgctggtt gcggacggcc 120
cotgacgacag gcgcttgagt gatggtgatgg atcacgttttt acaatgtgtaa cacaactcat
180
goacagaagg tcaaggccgag acctacatgc accacagaca catccacagc cacagttcac
240
atggagctga ggacgctgag atctgacgac aagggcggtg attactgtgc gagaggtac 300
ggtatggaac tctgggcccag aggggcaacgc tctacgcgct cctct
345

<210> SEQ ID NO 99
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 99

cagtctgccg tcgaactcagc tgcctccctg tctgggttctc tctggacagt gcaccacc 60
tctgcaacgt gaaccagcag tgaaggtggt ggtataact cgtctctgct gcaccaca 120
caccacgcca aaccccocac aactcatgatc ttaggtgcag gtaatcgagc ctggaggggt 180
ttatgctgt tctctggctc caagtgctgc aacacggcct cctgacact cctgggctgt 240
caggctggag aagggctgta tttttctctg agcctcata caagcacacc cagtggctctc
300
ggccccagga caagcgctgac ogctctca 327
caggttcagc tgtgtcagtc tggaggctag gtgaagaagc ctgggggcc ctgggggcc 60
tctgtcagag cttcttggtta cacottaacc actatgcttg tcaacctggcg ggcacaggc 120
cctgagacag gcgttgagtc gatggggag cgcggttttt aataatgtaata cacaactat 180
gcacagacgc tccaggggag aggccacagt accacaagc accacaac gagcactctc 240
atggagctga ggacgctgag atctgcaacg aacggcggttg attactgtgc gagaacctac 300
ggtatgggac gccgggggcc aggccacag gccacgcgtc cctc 345

-continued
<table>
<thead>
<tr>
<th>Start</th>
<th>End</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>207</td>
<td>208</td>
<td>caggtctaggg atgagctgta ttagtactgc cagtcctatg acaacagcct gactgtggtgctg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>gattttgc ggaggccaa gctgacgctc cta</td>
</tr>
</tbody>
</table>

**<210> SEQ ID NO 104**
**<211> LENGTH: 366**
**<212> TYPE: DNA**
**<213> ORGANISM: Homo sapiens**

**<200> SEQUENCE: 104**

caggtcagcc ggtgtaatgtc cttggggacgc gttgctccagc cttggaggtc cctgacgctc, 60
ctctgtgact gtcgctggtt caaaccctc cagcttggagc aatcaatgctgctgc, 120
cagagggagc cgggacgcct gactgtggtc aatcaatgctgctgc, 180
goacactccg gtagggggcg attccaccag tgtccagaca atcccaagaa cagctggtat, 240
tgcaaatga agacgctgag aggacgac ccagctgttg attactgctg ccagagccata, 300
goagccctct actacacta cggtatgagc gctctgggac cagagggacac gttcagccgtc, 360
tctca, 366

**<210> SEQ ID NO 105**
**<211> LENGTH: 330**
**<212> TYPE: DNA**
**<213> ORGANISM: Homo sapiens**

**<200> SEQUENCE: 105**
cagctctgtgt tgcggcgcgc gcgctcagtg tgtgctgctgag cagacagcaga ggttacccctgct, 60
tctcgctcttg gacgccggct cagcatggg gatttttttg tttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttttt
ccaggcaag cccccaaact cctcatatat gactataata aagcaccctc agggattctt 180
gaccgatct cttgctccaa tctggcacag tgctgcaacc ccggcataac cggactccag 240
aotggggaag aggcgaatt aacatgggaga aagccttgga gctgcttgag tggctatgct 300
tctggaactg ggacacaggt ctacgcctta 330

<210> SEQ ID NO 108
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 108

cagctgcacc tgctggaagtc tgggggaaggc cttgctcacc ctggggagtct cttggaacctc 60
tctgtgtcg cgtctgggatt cacccttcaac atggttggca tgcactctggt cttggcaggt 120
cagcgggaag cggctggaagtc ggtggtcactt atatatgctg atggaagtga taattcatat 180
goagactcag tgaatgggacg attcaccacc tctgagaca attcagaaaga cagctgctatg 240
tcgcacataa agccctgagc cgccaggcag acggctgtgtg attactctgc gacagaacctc 300
goacccctct actactacta cggtatggga gctgggggccc aagcggcacc agtgacagctc 360
tccctca 366

<210> SEQ ID NO 109
<211> LENGTH: 330
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 109

cagctctgtg tgaacgcagcc gcctoagttg tctgctgacc cagggacagaa ggtoaccac 60
tctctcgttg gaagcagttc caccctgggg aataattttgg ttatctgtgt ccaagcagttc 120
cagcgggaag cccccaaact cctccttat gactataata aagcaccctc agggattctt 180
goagactcag tctgctcacc gttggcagct cagccataac cggcaccaagc 240
acctggggagc aggcgaatt aacatgggaga aagccttgga gctgcttgag tggctatgct 300
tctggaactg ggacacaggt ctacgcctta 330

<210> SEQ ID NO 110
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 110

cagctgcacc tgctggaagtc tgggggaaggc cttgctcacc ctggggagtct cttggaacctc 60
tctgtgtcg cgtctgggatt cacccttcaac atggttggca tgcactctggt cttggcaggt 120
cagcgggaag cggctggaagtc ggtggtcactt atatatgctg atggaagtga taattcatat 180
goagactcag tgaatgggacg attcaccacc tctgagaca attcagaaaga cagctgctatg 240
tcgcacataa agccctgagc cgccaggcag acggctgtgtg attactctgc gacagaacctc 360
goacccctct actactacta cggtatggga gctgggggccc aagcggcacc agtgacagctc 360
tccctca 366

<210> SEQ ID NO 111
<211> LENGTH: 330
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
cagtctctgt tgacgccgcc gcctcagttg ttcgccgccc caggacagaa ggtcaccatc 60
tctctctgt gagaacgtct caacacgtgg aataaatttg tatctcgtgta caacagcttc 120
cacggaacag cccccaaact cctaatatat gcctacccca cggagttcct 180
gacgcattct tgtgccctca tgtggtcagc tcgccaaccct tcggcaatac cggactccag 240
acgtggggac ggtccgattc ttactgcggga acatgggata gcacgcctgag tggctattgctc 300
ttcgaaactg ggccagcgtt cacgccctta 330

<210> SEQ ID NO 112
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 112
cagtctctgt tgacgccgcc gcctcagttg ttcgccgccc caggacagaa ggtcaccatc 60
ntctctctgt gagaacgtct caacacgtgg aataaatttg tatctcgtgta caacagcttc 120
cacggaacag cccccaaact cctaatatat gcctacccca cggagttcct 180
gacgcattct tgtgccctca tgtggtcagc tcgccaaccct tcggcaatac cggactccag 240
ctgcacatac acacgcttgag gcggacaggac agcgctgctt tgtactgtgc cagagctcata 300
gacgcctctt actactacta cggtattgga gttgggcttc aagggccacac ggtcaccagcc 360	tcctca 366

<210> SEQ ID NO 113
<211> LENGTH: 330
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 113
cagtctctgt tgacgccgcc gcctcagttg ttcgccgccc caggacagaa ggtcaccatc 60
tctctctgt gagaacgtct caacacgtgg aataaatttg tatctcgtgta caacagcttc 120
cacggaacag cccccaaact cctaatatat gcctacccca cggagttcct 180
gacgcattct tgtgccctca tgtggtcagc tcgccaaccct tcggcaatac cggactccag 240
acgtggggac ggtccgattc ttactgcggga acatgggata gcacgcctgag tggctattgctc 300
ttcgaaactg ggccagcgtt cacgccctta 330

<210> SEQ ID NO 114
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 114
cagtctctgt tgacgccgcc gcctcagttg ttcgccgccc caggacagaa ggtcaccatc 60
tctctctgt gagaacgtct caacacgtgg aataaatttg tatctcgtgta caacagcttc 120
cacggaacag cccccaaact cctaatatat gcctacccca cggagttcct 180
gacgcattct tgtgccctca tgtggtcagc tcgccaaccct tcggcaatac cggactccag 240
tctgcacatac acacgcttgag gcggacaggac agcgctgctt tgtactgtgc cagagctcata 300
gacgtggctt actactacta cggtattgga gttgggcttc aagggccacac ggtcaccagcc 360	tcctca 366
<210> SEQ ID NO: 115
<211> LENGTH: 350
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 115

cagctctgtg tgaacgcagc gccctcagtg tctgagggc caggacagaa ggtccacactc 60
tctgtgtcg gaagcagcg caaacttggg aataatattg tatcctggtg caagcagcgc 120
cgaggactgc cccccaaact cctcacttat gccagaattcta agggtattcct 180
gacacctct ctggtcctca gctggtcccc tggacactcag cggaccttccag 240
actgaggggc agccgagttg ttactgccga taaatggtc aagccggtgtac ggtcattgtt 300
tcggagactc ggacaccagt cagctcctca 330

<210> SEQ ID NO: 116
<211> LENGTH: 363
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 116

gagttgcagc tggggtacc ctgggtaaag cggcaggggtc cggcaggtt coccaacactc 60
tctgtgtgc aggccttgcc cccctctagc tcgaacggct cggcagggtt 120
cgagttgcgc gctggggtag ttagctttgc attacgtctca ggtcagttgc aacacacttc 180
gcagtcgttg tgcacgggcgg gttccacactc tccagagaca attcaggaag cacacgctgt 240
tcggacaata gacacccgctc agcagacagc aggcatccagc aattcgtttgc gaaaggtttt 300
gtcatctgt gcagcagttg tcgacatccg tcgacagac aggcatccagc ccagggtctgc cacacgtcctc 360
tca 363

<210> SEQ ID NO: 117
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 117

gacatgctg tgaacgcagc tcctatcctc ctggggagag tctggtcagag cagctgcacc 60
aatccttgc gggcaagtcg gacatcagc agctatttta ttatgtcgata cagacagaca 120
gggagaggg ataaatcggg gccggcagctc gccggcagctc gcggccagggtt 180
aggtctcatt gccatgtcgtg tcggacagtt ttcacgttcc cctatccagc tctgcacccc 240
gacgttggagc aggcaacgttg aatttgccttg cggcagctcg ccggcagctcg ccggcagctcg 300
gggacacgc tggagattt a 321

<210> SEQ ID NO: 118
<211> LENGTH: 363
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 118

gaggtgcagc tggggtgcgtg cggcaggagct ttggtacagc cgggccccgggtc cggcagcttc 60
tctgtgtgc cccctgttgc ttcagtttcg aagcagttgc tgcacagaag gcgcagggtt 120
cggagttgcgc gcctggagagg ttagctttgc attacgtctca ggtcagttgc aacacacttc 180
gcagtcggct gcgggtcaggg gttccacactc tccagagaca attcaggaag cacacgctgt 240
tcggacaata gacacccgctc agcagacagc aggcatccagc aattcgtttgc gaaaggtttt 300
gtactstaag tgcataagctat gcttgactac tggggccagg gacccctgtt cacgccctcc
360
tca
363

SEQ ID NO: 119
LENGTH: 321
TYPE: DNA
ORGANISM: Homo sapiens

SEQUENCE: 119

gacatcagag tgaacccagtt tcctaccccc ctaatcctctt cttggattgg acaatgctgacc 60
atcactggttc aagatcgggtg caagtattgc atctattgtt atgtgctggtc tgggaagcc 120
ggggaagcc cttaacctcttt ctatctggctc ctaagaggtg tggccctccac 180
aggtcagtg ggtctgtgtct tgggacagat tcaccttctca cctacagcag tctgcaacct 240
gagatttttg caaactactta ctgctcaacag atgtagactg ccccctacaa ctttgccca 300
gggccacgc tggagattaa a 321

SEQ ID NO: 120
LENGTH: 345
TYPE: DNA
ORGANISM: Homo sapiens

SEQUENCE: 120
caggttcgag tgggtcagttc tgggagcggag tgggaagacg cttgggcccct ccctgaggtgc 60
tcctgcagag cttccggagct caggttccgtc tgggagatgt gggccagctt 120
cctggcaggt ggctgtgggt ggtgggattc atcagcgtct acaatggttaa cacaagcatc 180
goacacgagg tcacagggcag agctcagagtc accagagga catcagcagc cagctctc 240
atgaggtgga gcagatcttg actgacagc acgggctgttt ataatggtgc gaggacgtac 300
ggtagggcg ctgctggccat agggacagct gcacagcctct ccata 345

SEQ ID NO: 121
LENGTH: 327
TYPE: DNA
ORGANISM: Homo sapiens

SEQUENCE: 121
cagtcgccc tgaactcagct ccctgtcctg tgctcttgctc ctggagctgtc gcacacacac 60
tctgcagctg gacccagcgg tggagctggg ggttataact cttgctctct gcacagcagt 120
cacccaggg caaacccecc cccttcttct cagttgtgct ttaaagggcgc cctcaggggtt 180
tctattgct ccctgtggtt caggtttctc cctctggctc actcagcgtt cctctggctc 240
cagctgtag agaagaggga cttcccttctg acgctctata ccaagacaccg cagctcttcc 300
gggcagagga ccagaggtgc cgtctaa 327

SEQ ID NO: 122
LENGTH: 345
TYPE: DNA
ORGANISM: Homo sapiens

SEQUENCE: 122
caggttcgag tgggtcagttc tgggagcggag tgggaagacg cttgggcccct ccctgaggtgc 60
tcctgcagag cttccggagct caggttccgtc tgggagatgt gggccagctt 120
cctggcaggt ggctgtgggt ggtgggattc atcagcgtct acaatggttaa cacaagcatc 180
goacacgagg tcacagggcag agctcagagtc accagagga catcagcagc cagctctc 240
caggtctgcc tggagtctag tcctctcttc tcctcctcct ggtggtggtc gctaacag gcctctcctc cctcctcctc 300

ggtatgacgc tggggtccag tggggtcccag gctggggtcct ccctggtctc 345

<210> SEQ ID NO 123
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 123

caggtctgcc tggagtctag tcctctcttc tcctcctcct ggtggtggtc gctaacag gcctctcctc cctcctcctc 60
tcctccttc gggacctag cctccctgct cctccctgct cctccctgct 120
cacccagcc aaccccacca aactccagtt tacccggtca gcataccgccc ctgcaggggc 180
ttatcgtcat tctctgtggtc cgacgctggc acacagccac cctccctgct cctccctgct 240
caggtctgcc acacagccac cctccctgct cctccctgct cctccctgct 300
ggctgaggg ccagagtagcc aatctctcta ccctctccct ccctctccct 327

<210> SEQ ID NO 124
<211> LENGTH: 345
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 124

caggtctgcc tggagtctag tcctctcttc tcctcctcct ggtggtggtc gctaacag gcctctcctc cctcctcctc 60
tcctccttc gggacctag cctccctgct cctccctgct cctccctgct 120
cacccagcc aaccccacca aactccagtt tacccggtca gcataccgccc ctgcaggggc 180
ttatcgtcat tctctgtggtc cgacgctggc acacagccac cctccctgct cctccctgct 240
caggtctgcc acacagccac cctccctgct cctccctgct cctccctgct 300
ggctgaggg ccagagtagcc aatctctcta ccctctccct ccctctccct 345

<210> SEQ ID NO 125
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 125

caggtctgcc tggagtctag tcctctcttc tcctcctcct ggtggtggtc gctaacag gcctctcctc cctcctcctc 60
tcctccttc gggacctag cctccctgct cctccctgct cctccctgct 120
cacccagcc aaccccacca aactccagtt tacccggtca gcataccgccc ctgcaggggc 180
ttatcgtcat tctctgtggtc cgacgctggc acacagccac cctccctgct cctccctgct 240
caggtctgcc acacagccac cctccctgct cctccctgct cctccctgct 300
ggctgaggg ccagagtagcc aatctctcta ccctctccct ccctctccct 327

<210> SEQ ID NO 126
<211> LENGTH: 345
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 126

caggtctgcc tggagtctag tcctcctcct ggtggtggtc gctaacag gcctctcctc 60
tcctccttc gggacctag cctccctgct cctccctgct cctccctgct 120
cacccagcc aaccccacca aactccagtt tacccggtca gcataccgccc ctgcaggggc 180
-continued

gcagagaagg tccagggcag agtcacagt accaagaga catccacagac cacagtctcac 240
atgagaagctga gaagctctag atcttgaccgac agccggtgtg atactcttgac gagaagctac 300
aggtggactg tccaggggca agggacacag gtcacgtctc cctca 345

<210> SEQ ID NO 127
<211> LENGTH : 627
<212> TYPE : DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 127

cagtctgcccg tgcctcagcc tgcctcagtt tctttggtctc ctggacagtc gtcacacctc 60
tcctgcaactg gaccaacagc tgaactttgtg ggttataaat ctgtcttcctg tgtcaacagc 120
caccacaggca aaccacccca accattgtct tattggtgtct gtaatcgggca ctcagggatt 180
ttaaatgctctcttgctcac ccagctggtgc accagccgct cctgctgctc ctgctgctc 240
cacgcagggc agcaggctgct tattaagctg agctcataata cacgcaacagc catcctgctc 300
ggcaggggga ccagctgctc gctcctca 327

<210> SEQ ID NO 128
<211> LENGTH : 345
<212> TYPE : DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 128

cacgtgtcagcc tggctgctgctg tggagctgag gtagagagag ctcgggctctc atgtgaaggtc 60
taacgccag ttcctggtta cacgtctttacc agcttatgta tccagctgggt gcgacccagcc 120
cctggacag ggtgtgagct ggtgagctct ctaatggtct acaatagct caacaaactat 180
gcagacagta tccagggcag agtcacagt accaagaga catccacagac cacagtctcac 240
atgagaagctga gaagctctag atcttgaccgac agccggtgtg atactcttgac gagaagctac 300
gtttgactg tccaggggca agggacacag gtcacgtctc cctca 345

<210> SEQ ID NO 129
<211> LENGTH : 127
<212> TYPE : DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 129

cagctgtcgcg tgcctcagcc tgcctcagtt tctttggtctc ctggacagtc gtcacacctc 60
tcctgcaactg gaccaacagc tgaactttgtg ggttataaat ctgtcttcctg tgtcaacagc 120
caccacaggca aaccacccca accattgtct tattggtgtct gtaatcgggca ctcagggatt 180
ttaaatgctctcttgctcac ccagctggtgc accagccgct cctgctgctc ctgctgctc 240
cacgcagggc agcaggctgct tattaagctg agctcataata cacgcaacagc catcctgctc 300
ggcaggggga ccagctgctc gctcctca 327

<210> SEQ ID NO 130
<211> LENGTH : 363
<212> TYPE : DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 130

cacgtgtcagcc tgcctcagcc tgcctcagtt tctttggtctc ctggacagtc gtcacacctc 60
acccgccag ttcctggtta cacgtctttacc agcttatgta tccagctgggt gcgacccagcc 120
cctggacag ggtgtgagct ggtgagctct ctaatggtct acaatagct caacaaactat 180
<210> SEQ ID NO 131  
<211> LENGTH: 330  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  
<400> SEQUENCE: 131  
cttctgccct gactctggtc tgcgctcggt tctggtcctc ctgccagcgc ggtacacctc  
60  
tctgctgtc gagccagcag tggctgtttt gataataaac ctctctctctct ctgaccaactc  
120  
ttcagcggca aagcccccct ctcctggttt tgcggtggtc gcggcctggt ggtccagctc  
180  
ttgttcctc tgtctctgcg ggaaggttgg gaaagccagc gagctgtgcgt tctggtcttc  
240  
tcggtggcgc gcagctgctc tttgtattttc ttgcttctg gttctgttctc  
300  
ttcggtgggc gggagcaagc gcaaggttcct  
330  
<210> SEQ ID NO 132  
<211> LENGTH: 367  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  
<400> SEQUENCE: 132  
gagctgctgc tgtggtggtc tgtggtgcgc gctggtgcgc gcgtggtctc ctgtggtgtc  
60  
tctcagttgt tctggtgta ccccttttagg tggatgggag tggcgggctg cgggctggc  
120  
ccagggagcg ggtgctggtgc tgtggtgcgc ctcgaggggt tgtcagaagc gtgggaagct  
180  
ggtggtcctc tgtggtggag ctcggtgcgc tgcggtggtc gcggcctggt ggtccagctc  
240  
tctggtgtgc ggagtttcctt tttgtattttc ttgcttctg gttctgttctc  
300  
ttcagcggca aagcccccct ctcctggttt tgcggtggtc gcggcctggt ggtccagctc  
357  
<210> SEQ ID NO 133  
<211> LENGTH: 327  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  
<400> SEQUENCE: 133  
cagctgctgc tgtggtggtc tgtggtgcgc gctggtgcgc gcgtggtctc ctgtggtgtc  
60  
tctcagttgt tctggtgta ccccttttagg tggatgggag tggcgggctg cgggctggc  
120  
ccagggagcg ggtgctggtgc tgtggtgcgc ctcgaggggt tgtcagaagc gtgggaagct  
180  
ggtggtcctc tgtggtggag ctcggtgcgc tgcggtggtc gcggcctggt ggtccagctc  
240  
tctggtgtgc ggagtttcctt tttgtattttc ttgcttctg gttctgttctc  
300  
ttcagcggca aagcccccct ctcctggttt tgcggtggtc gcggcctggt ggtccagctc  
327  
<210> SEQ ID NO 134  
<211> LENGTH: 357  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  
<400> SEQUENCE: 134  
gagctgctgc tgtggtggtc tgtggtgcgc gctggtgcgc gcgtggtctc ctgtggtgtc  
60
<table>
<thead>
<tr>
<th>Sequence</th>
<th>Description</th>
<th>Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>tcctgtcag</td>
<td>contgtagtt cacctattgtag ctgctatgggct gggccaggtct</td>
<td>120</td>
</tr>
<tr>
<td>cocggaggg</td>
<td>gcctggaggt ggtggcccaac ataagactg atggaaagtga gaaatcactat</td>
<td>180</td>
</tr>
<tr>
<td>gttgacactg</td>
<td>tcagggcagc acccactatt cccagaca caaccccaagaa atcactagct</td>
<td>240</td>
</tr>
<tr>
<td>cttcacggtg</td>
<td>aacgctgggag acggggagag acgggtgtgtg ataagctgct gggagagacta</td>
<td>300</td>
</tr>
<tr>
<td>aaactggggt</td>
<td>ggctgttttgaga ggctggggtga ccgggagcctaa ggggccccttc tcttc</td>
<td>387</td>
</tr>
<tr>
<td></td>
<td>SEQ ID: NO 115</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LENGTH: 327</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TYPE: DNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORGANISM: Homo sapiens</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SEQUENCE: 135</td>
<td></td>
</tr>
<tr>
<td>cagtctgtagc tcagccgccg acctctagtgc tcgggccccccc ccggacagag ggttcacctc</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>tcctgtcagc</td>
<td>ccctcttatt cacctatttgag caagcttggt ggcctcaggt</td>
<td>120</td>
</tr>
<tr>
<td>cocggaggg</td>
<td>gcctggaggt ggtggcccaac ataagactg atggaaagtga gaaatcactat</td>
<td>180</td>
</tr>
<tr>
<td>gttgacactg</td>
<td>tcagggcagc acccactatt cccagaca caaccccaagaa atcactagct</td>
<td>240</td>
</tr>
<tr>
<td>cttcacggtg</td>
<td>aacgctgggag acggggagag acgggtgtgtg ataagctgct gggagagacta</td>
<td>300</td>
</tr>
<tr>
<td>aaactggggt</td>
<td>ggctgttttgaga ggctggggtga ccgggagcctaa ggggccccttc tcttc</td>
<td>387</td>
</tr>
<tr>
<td></td>
<td>SEQ ID: NO 116</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LENGTH: 351</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TYPE: DNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORGANISM: Homo sapiens</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SEQUENCE: 136</td>
<td></td>
</tr>
<tr>
<td>gaggtgtgacgc</td>
<td>tcgggagctg tgggcccagcc ttggtaagtc cttgggggggggcc tcggagacctt</td>
<td>60</td>
</tr>
<tr>
<td>tcctgtcagc</td>
<td>ccctcttatt cacctatttgag caagcttggt ggcctcaggt</td>
<td>120</td>
</tr>
<tr>
<td>cocggaggg</td>
<td>gcctggaggt ggtggcccaac ataagactg atggaaagtga gaaatcactat</td>
<td>180</td>
</tr>
<tr>
<td>gttgacactg</td>
<td>tcagggcagc acccactatt cccagaca caaccccaagaa atcactagct</td>
<td>240</td>
</tr>
<tr>
<td>cttcacggtg</td>
<td>aacgctgggag acggggagag acgggtgtgtg ataagctgct gggagagacta</td>
<td>300</td>
</tr>
<tr>
<td>aaactggggt</td>
<td>ggctgttttgaga ggctggggtga ccgggagcctaa ggggccccttc tcttc</td>
<td>387</td>
</tr>
<tr>
<td></td>
<td>SEQ ID: NO 117</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LENGTH: 130</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TYPE: DNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORGANISM: Homo sapiens</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SEQUENCE: 137</td>
<td></td>
</tr>
<tr>
<td>cagtctgtagc tcagccgccg acctctagtgc tcgggccccccc ccggacagag ggttcacctc</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>tcctgtcagc</td>
<td>ccctcttatt cacctatttgag caagcttggt ggcctcaggt</td>
<td>120</td>
</tr>
<tr>
<td>cocggaggg</td>
<td>gcctggaggt ggtggcccaac ataagactg atggaaagtga gaaatcactat</td>
<td>180</td>
</tr>
<tr>
<td>gttgacactg</td>
<td>tcagggcagc acccactatt cccagaca caaccccaagaa atcactagct</td>
<td>240</td>
</tr>
<tr>
<td>cttcacggtg</td>
<td>aacgctgggag acggggagag acgggtgtgtg ataagctgct gggagagacta</td>
<td>300</td>
</tr>
<tr>
<td>aaactggggt</td>
<td>ggctgttttgaga ggctggggtga ccgggagcctaa ggggccccttc tcttc</td>
<td>387</td>
</tr>
<tr>
<td></td>
<td>SEQ ID: NO 118</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LENGTH: 366</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TYPE: DNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORGANISM: Homo sapiens</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SEQUENCE: 138</td>
<td></td>
</tr>
<tr>
<td>caggtgcacgc</td>
<td>tcgggagagtc ccgggagggc ggctggccagc cgggagaggt cgggacagct</td>
<td>60</td>
</tr>
</tbody>
</table>
tcctgtgca gctctggatt cacactcagt agcatatggca tgcactggtt cgcaccagct 120
cggcagca ggctggaagt ggtggcatt atatgttact atggaagtaa taatactcat 180
goacactcc gtaggagccc attcaccctc tccagagaca attcgaagaa cacaactgtat 240
cctcaatga acaacgctgag agccgagac ccggtgtgtg tatactgac gaggaggggg 300
gcctggctgc ctctggcctgg cgcattcgttgc gctggtgcac agggaccacc ggttcaccgcc 360
toctca 366

<210> SEQ ID NO 139
<211> LENGTH: 318
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 139
tcctatgagc tgcacctgcg accctcagtg tcctgtgccc caggacagac agccgagact 60
acctgctctg gagataaatt gggtgataac ttagttggct ggtatcaagca gaaaccagcc 120
cagtcctctg tgcttcctct attcaccatt accaaggtgc cctggtggtt cccgagcga 180
tcctgtgctg ccacagctgg gacacagact acctgcacca tccgagggcc ccaggtatag 240
gatgaggctg acatattactg tcagccgtgg gacagcagca ctgctgttatt cggggagggg 300
accaagctga cgtctctc 318

<210> SEQ ID NO 140
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 140
caggttcxgac tgcagggagc ggccgagaga ctcggtaagc ctcacagac cctgctcctc 60
acctggcact gtcctgtgag ccctcagcag agtagtggatt actactggag ctggtgaccg 120
cagcacccag ggaggggctc ggaggtggatt ggctacatct attaagttgg gacaaacctc 180	
tacaaccggx cctcagagc tgcagattc attaagttgg cagcagcctaa gaaactgcttc 240
tcctgacagtg tgcctgtgctg cactggcctg gacagcagggcct gtatattaoy tcgagagggg 300
ggggtgacga cgtctactca cgctatggac gctggggggcc aagggaccac ggttcaccgcc 360
toctca 366

<210> SEQ ID NO 141
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 141
gacatacaga tgaccacagc tcctcctccct cttgtctgcat ctgtagggaga cagagtccac 60
atacctggcc ggccagcctc ggccattgcg aactattttaa gttggtatct ggcagnacacc 120
gggattgccc tcaagtctct gatetgtgtg gcaacctagct gacgagttgg ggttcaccata 180
aggttctgat gcagtggacag ttcacactca cctcagagct tcctgtatct 240
ggaagatttgg cagctactca ctgctacacag agtttacagta ccccgctctcat tttcgccgga 300
gggaccaaggg gcagatcaaa a 321

<210> SEQ ID NO 142
<211> LENGTH: 369
<212> TYPE: DNA
<210> SEQ ID NO 143
<211> LENGTH: 336
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

(Sequence information)

<210> SEQ ID NO 144
<211> LENGTH: 357
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

(Sequence information)

<210> SEQ ID NO 145
<211> LENGTH: 217
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

(Sequence information)
<210> SEQ ID NO: 146
<211> LENGTH: 345
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 146

caggtctacg tggtgctgag tggagctgag gtgaagaagc cttgggccttc agtgaaggtc  
60
tctgcaagg cttctggtta cacctttaaa agctatgtga tcagctgggt gogacagggc  
120
ccttgacaaag ggtcgtgatt gttgggtgaa atccagactt acaatggttaa ccaaaactat  
180
gcacagagc tccagccgac agtcaccaatg accacagaca cattccagac cagcccctac  
240
atggccctga ggagccctgag atctgacgac agcccgtggt attacttgtgc gacaggggtat  
300
acctgggaact acctgaggcca ggaaacccctg gtcaccgtct cctca  
345

<210> SEQ ID NO: 147
<211> LENGTH: 348
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 147

caggtctgtgc tgaacgaccc acttatttgc tcagctcctcc tgggagccto ggtacacttc  
60
acctgacacc tggacgagg ccacagcattc tattgaagtgg acctgtatca gcagacacca  
120
gggaggggcc ccgggttttt tatcgagttg gacactggttg gggattgtgg gaccaaggg  
180
gaacatcct ccctgtgctgt ttcagcctttt ggtctagggcc tgaacctgta tctgacactc  
240
agaaaaaccc aggacagagc ttgagcaggti cctactccctg ggccgacccca gggcgaggg  
300
accacatcgg tggctggtatt ccgggaggg gccaaagctg caccctctta  
348

<210> SEQ ID NO: 148
<211> LENGTH: 348
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 148

caggtgcaac tcaacagcttg ggccgacagg cttgtagaag cttcggagac cctgtcctcc  
60
acctgctcg tattatgccg gtcctctcagt gctgctcact gcacatggat ccgccagccc  
120
cagggggagg ggtcggagag gtattgggaa atcaacatata tggggaagaac cgactcacaac  
180
cgctccctaa agagctgagt caccatcata gtagcactcg ccagaagagcc cttctctctg  
240
aatgctgact cttgcacgag cggcggagcc gcgtggttat attcgtgcag agggcagctc  
300
gtcccccttg acctcgccgg ccagggaccc cttgctaccc gttcctca  
348

<210> SEQ ID NO: 149
<211> LENGTH: 330
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 149

cagttcgtgcc tgaactcgcc accctagccg ttggggaccg ccgggagccag gcgcacacctc  
60
ttttgcctgg caggacgctg caacatcggg agtaaatctcg tsaatttgtaa tcagcaccct  
120
cggagaagc ccccccatac cttcctatag ataatatac gcggcccttc aggggtcctt  
180
gacggattct gttgcctcgc tgcggcctcgc ggccctaccg tgggggcaag  
240
cttgaggagg tagccgtgatt ttacctgtgca gatgggattg acagcgtctga tgggtgggtg  
300
ttcggcggag gcaccaagct gacgcctcct  
330
caggtcagc  tgggtgagtc  tggagctgag  gttgaagaag  ctgggggcttc  agtgaaggtc  60
tctgtcaagg  cttcctgatt  cacccccccc  acgtcaggtta  tcagctgggt  ggcacccggcc  120
cotgacagc  ggtcctgagt  gattggagtg  atcgacgctt  acaatgcga  cacaacactat  180
goagagaaga  tccagggcag  agtccacagt  accacagaca  catccacagc  cacagctcac  240
agggagggga  gagccctgag  actctgcacac  acgagctgtg  ttcctctgtg  gagaggtac  300
gttatggagc  tcctggggca  agggacagct  gtcacgctct  cctct  345

cagtcctgccc  tgcactcacg  tcgctctctg  tcgctggctc  ctggacagtc  gataccatac  60
tctgcactg  gaaccagccag  tgaagttggt  cgtataatt  tcgctctctg  gtaaccacac  120
cacccagcca  aagccccaca  agtcctgatt  tattagggct  gtatacggcc  tcctgagggt  180
ttcctctgtc  tcgctctctg  caagtctgcg  aaacgagcct  cccgtcagct  tcctgggttc  240
caagctggag  cagagaggtgg  tttatactgc  agctctatca  caagcagccag  ctggttatcc  300
gggggagga  cccaaagtcag  cgtcctaa  327

gaggtgcagc  tggagggagt  tggggggagc  ctggtaaagc  ctggggggtc  cctgagaccc  60
tcctgtgcaag  cccctctgct  acatataaca  tgaacttggt  cggccaggtc  120
cagggagaag  ggcctgaggt  ggttcctccc  attagctgta  gttagtgta  catttctcctc  180
goagtacccag  tcagggggcg  attccacact  tccagagaca  acgagcaagaa  tctacgtatg  240
tcgccaaatgc  acagcttgag  agcgagggac  acgcatttgt  atttcctgtg  gagagattac  300
gtatattgga  gcttgattacta  tggatgttcttt  gatgtctgag  gcacaaggggac  aatgtctaccc  360
gttcttccaa  369

cagtctgtgc  tgaagccaagcc  gcctccaagtg  tcgctgggcc  cagggcagag  ggtccacacc  60
tcctgtcactg  ggacagcctg  caaatccggg  gcagttatag  atgtcaactgt  gtaccacagc  120
tctctgagga  cagcccccaaa  acctccagct  tcgctgtaaaca  gcatccggc  tctagggtgct  180
tcgtgacgtc  tcctgtggct  caagcttgacg  acctcagccct  cccctggaac  caatggggtc  240
caggtcgagag  agagctggtga  ttattactgc  cagttctatg  acagcagctc  gatgcttctg  300
gtatcggcg gagggccaa gctgaccgc cta

<210> SEQ ID NO 154
<211> LENGTH: 326
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 154

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1  5  10  15
Ser Thr Ser Glu Ser Thr Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25  30  40  45
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
50 55  60  70  75  90  95
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
100 105 110 120 125  
Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr
130 135 140
Tyr Thr Cys Asn Val Asp His Pro Ser Asn Thr Lys Val Asp Lys
145 150 155 160
Thr Val Glu Arg Lys Ser Cys Val Glu Cys Pro Pro Cys Pro Ala Pro
165 170 175 180 185
Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
195 200 205 210
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
215 220 225
Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly
230 235 240
Val Glu Val His Arg Ala Lys Thr Lys Pro Arg Glu Gln Phe Asn
245 250 255 260
Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Glu Asp Trp
265 270 275
Leu Asn Gly Lys Glu Tyr Lys Cys Val Ser Asn Lys Gly Leu Pro
280 285 290 295 300 305
 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Glu Pro Arg Glu
310 315
Pro Glu Val Tyr Thr Leu Pro Pro Ser Arg Glu Met Thr Lys Asn
320 325 330 335 340
Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
345 350 355 360 365 370
 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Ser Tyr Lys Thr
375 380 385 390 395
Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Leu Tyr Ser Lys
400 405 410 415 420
Leu Thr Val Asp Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
425 430 435 440 445 450
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
455 460 465 470 475 480 485
Ser Leu Ser Pro Gly Lys
490 495 500 505 510 515 520

<210> SEQ ID NO 155
<211> LENGTH: 327
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr</td>
<td>20</td>
<td>25</td>
<td></td>
<td>30</td>
</tr>
<tr>
<td>Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser</td>
<td>35</td>
<td>40</td>
<td></td>
<td>45</td>
</tr>
<tr>
<td>Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser</td>
<td>50</td>
<td>55</td>
<td></td>
<td>60</td>
</tr>
<tr>
<td>Leu Ser Ser Val Val Thr Val Pro Ser Ser Leu Gly Thr Lys Thr</td>
<td>65</td>
<td>70</td>
<td>75</td>
<td>80</td>
</tr>
<tr>
<td>Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys</td>
<td>85</td>
<td>90</td>
<td></td>
<td>95</td>
</tr>
<tr>
<td>Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro</td>
<td>100</td>
<td>105</td>
<td></td>
<td>110</td>
</tr>
<tr>
<td>Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys</td>
<td>115</td>
<td>120</td>
<td></td>
<td>125</td>
</tr>
<tr>
<td>Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val</td>
<td>130</td>
<td>135</td>
<td></td>
<td>140</td>
</tr>
<tr>
<td>Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp</td>
<td>145</td>
<td>150</td>
<td>155</td>
<td>160</td>
</tr>
<tr>
<td>Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Gln Phe</td>
<td>165</td>
<td>170</td>
<td></td>
<td>175</td>
</tr>
<tr>
<td>Asn Ser Thr Tyr Arg Val Ser Val Leu Thr Val Leu His Gln Asp</td>
<td>180</td>
<td>185</td>
<td></td>
<td>190</td>
</tr>
<tr>
<td>Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu</td>
<td>195</td>
<td>200</td>
<td></td>
<td>205</td>
</tr>
<tr>
<td>Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg</td>
<td>210</td>
<td>215</td>
<td></td>
<td>220</td>
</tr>
<tr>
<td>Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gin Glu Glu Met Thr Lys</td>
<td>225</td>
<td>230</td>
<td>235</td>
<td>240</td>
</tr>
<tr>
<td>Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp</td>
<td>245</td>
<td>250</td>
<td></td>
<td>255</td>
</tr>
<tr>
<td>Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys</td>
<td>260</td>
<td>265</td>
<td></td>
<td>270</td>
</tr>
<tr>
<td>Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Leu Tyr Ser</td>
<td>275</td>
<td>280</td>
<td></td>
<td>285</td>
</tr>
<tr>
<td>Arg Leu Thr Val Asp Lys Ser Arg Trp Gin Glu Gly Asn Val Phe Ser</td>
<td>290</td>
<td>295</td>
<td></td>
<td>300</td>
</tr>
<tr>
<td>Cys Ser Val Met His Gin Ala Leu His Asn His Tyr Thr Gin Lys Ser</td>
<td>305</td>
<td>310</td>
<td>315</td>
<td>320</td>
</tr>
<tr>
<td>Leu Ser Leu Ser Leu Gly Lys</td>
<td></td>
<td></td>
<td></td>
<td>325</td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 156
<211> LENGTH: 109
<212> TYPE: PPT
<213> ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glu Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe</td>
<td>20</td>
<td>25</td>
<td>30</td>
<td></td>
</tr>
</tbody>
</table>
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
35 40
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
50 55 60
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
65 70 75 80
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
85 90 95
Lys Thr Val Ala Pro Thr Glu Cys Ser
100 105

<210> SEQ ID NO 157
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 157

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1 5 10 15
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Ala Leu Gln Ser
35 40 45
Gly Asn Ser Glu Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
50 55 60
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65 70 75 80
His Lys Val Tyr Ala Cys Glu Val Thr His Glu Gly Leu Ser Ser Pro
85 90 95
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> SEQ ID NO 158
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 158

Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Ser Val Ser
1 5 10

<210> SEQ ID NO 159
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 159

Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Ser Val Ser
1 5 10

<210> SEQ ID NO 160
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 160

Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Ser Val Ser
1 5 10
Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr Asn Ser Val Ser
1 5 10

Glu Val Ser Asn Arg Pro Ser
1 5

Glu Val Thr Asn Arg Pro Ser
1 5

Ser Ser Tyr Thr Ser Thr Ser Met Val
1 5

Asn Ser Tyr Thr Ser Thr Ser Met Val
1 5

Ser Ser Tyr Thr Ser Thr Asn Met Val
1 5

Ser Ser Tyr Thr Ser Ser Ser Val Val
1 5

Glu Val Ser Asn Arg Pro Ser
1 5
Gly Tyr Pro Leu Thr Ser Tyr Gly Ile Ser
1  5  10

Gly Tyr Ser Leu Thr Ser Tyr Gly Ile Ser
1  5  10

Gly Tyr Ala Leu Thr Ser Tyr Gly Ile Ser
1  5  10

Gly Tyr Thr Leu Thr Ser Tyr Gly Ile Ser
1  5  10

Gly Tyr Ser Phe Thr Ser Tyr Gly Ile Ser
1  5  10

Gly Tyr Thr Phe Pro Ser Tyr Gly Ile Ser
1  5  10

Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln
1  5  10  15

Gly
Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln
1  5  10  15

Gly

Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln
1  5  10  15

Gly

Trp Ile Ser Val Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln
1  5  10  15

Gly

Trp Val Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln
1  5  10  15

Gly

Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln
1  5  10  15

Gly

Gly Tyr Gly Met Asp Val
1  5

Gly

Gly
<400> SEQUENCE: 181
Gly Tyr Val Met Asp Val
1 5

<210> SEQ ID NO 182
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 182
Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Phe Val Ser
1 5 10

<210> SEQ ID NO 183
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 183
Asp Tyr Asn Lys Arg Pro Ser
1 5

<210> SEQ ID NO 184
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 184
Asp Ser Asn Lys Arg Pro Ser
1 5

<210> SEQ ID NO 185
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 185
Gly Thr Trp Asp Ser Ser Leu Ser Gly Tyr Val
1 5 10

<210> SEQ ID NO 186
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 186
Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val
1 5 10

<210> SEQ ID NO 187
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 187
Gly Thr Trp Asp Ser Ser Leu Ser Ser Tyr Val
1 5 10

<210> SEQ ID NO 188
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 188
Gly Phe Thr Phe Ser Ser Phe Gly Met His
1 5 10

<210> SEQ ID NO 189
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 189

Gly Phe Thr Phe Arg Ser Tyr Gly Met His
1 5 10

<210> SEQ ID NO 190
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 190

Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 192
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 192

Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 193
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 193

Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 194
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 194

Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Tyr Val Asp Ser Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 195
Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val
1  5  10

Gly Ile Ala Val Ala Tyr Tyr Tyr Gly Met Asp Val
1  5  10

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
1  5  10

Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn
1  5  10

Ser Asn Asn Arg Arg Pro Ser
1  5

Arg Asn Asn Gln Arg Pro Leu
1  5

Ala Ala Trp Asp Asp Ser Leu Asn Trp Val
1  5  10
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 202

Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser
  1  5  10

<210> SEQ ID NO 203
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 203

Gly Leu Thr Phe Ser Asn Phe Trp Met Ser
  1  5  10

<210> SEQ ID NO 204
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 204

Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser
  1  5  10

<210> SEQ ID NO 205
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 205

Asn Ile Lys His Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
  1  5  10  15

Gly

<210> SEQ ID NO 206
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 206

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
  1  5  10  15

Gly

<210> SEQ ID NO 207
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 207

Glu Ser Asn Trp Gly Phe Ala Phe Asp Val
  1  5  10

<210> SEQ ID NO 208
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 208

Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile
  1  5  10

<210> SEQ ID NO 209
Arg Ala Ser Glu Ser Ile Ser Tyr Leu Asn
1      5      10

Arg Ala Ser Glu Ser Ile Ser Tyr Leu Asn
1      5      10

Ala Ala Ser Ser Leu Glu Ser
1      5

Ala Ala Ala Ser Leu Glu Ser
1      5

Gln Glu Ser Tyr Ser Ser Pro Ile Thr
1      5

Gln Glu Ser Tyr Ser Ala Pro Ile Thr
1      5

Gly Phe Thr Phe Ser Ser Tyr Ala Met Asn
1      5      10
<table>
<thead>
<tr>
<th>Organism: Homo sapiens</th>
</tr>
</thead>
</table>

1. **Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys**
   - Length: 16

2. **Gly**

3. **Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys**
   - Length: 17

4. **Gly**

5. **Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr**
   - Length: 12

6. **Arg Ala Ser Gln Arg Ile Ser Asn Tyr Leu Ser**
   - Length: 11

7. **Arg Ala Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Phe Leu Asn**
   - Length: 16

8. **Arg Ser Ser Gln Ser Leu Leu His Ser Asn Gly Tyr Asn Phe Leu Asn**
   - Length: 14

9. **Thr Gly Thr Ser Ser Asp Val Gly Asn Tyr Asn Leu Val Ser**
   - Length: 14

10. **Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly Tyr Asp Val His**
    - Length: 14
The Gly Ser Ser Ser Asn Ile Gly Ala His Tyr Asp Val His
  1    5    10

Ser Gly Ser Asn Ser Asn Ile Gly Asn Tyr Val Ser
  1    5    10

Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala Cys
  1    5    10

Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Glu Val Asp
  1    5    10

Leu Gly Ser His Arg Ala Ser
  1    5

Glu Val Ser Lys Arg Pro Ser
  1    5

Gly Asn Ser Asn Arg Pro Ser
  1    5
ORGANISM: Homo sapiens

SEQUENCE: 230

Gly Asn Thr Tyr Arg Pro Ser
1 5

SEQ ID NO 231
LENGTH: 7
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 231

Ser Asn Gln Arg Pro Ser
1 5

SEQ ID NO 232
LENGTH: 7
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 232

Asp Asn Lys Arg Pro Ser
1 5

SEQ ID NO 233
LENGTH: 7
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 233

Gln Asn Thr Lys Trp Pro Leu
1 5

SEQ ID NO 234
LENGTH: 7
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 234

Val Asp Thr Gly Gly Ile Val
1 5

SEQ ID NO 235
LENGTH: 9
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 235

Gln Gln Ser Tyr Ser Thr Pro Leu Ile
1 5

SEQ ID NO 236
LENGTH: 9
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 236

Met Gln Val Leu Gln Thr Pro Phe Thr
1 5

SEQ ID NO 237
LENGTH: 10
TYPE: PRT
ORGANISM: Homo sapiens
Cys Ser Tyr Ala Gly Ser Ser Thr Leu Val
 1  5  10

Gln Ser Tyr Asp Ser Ser Leu Ser Gly Ser Val
 1  5  10

Gln Ser Tyr Asp Asp Ser Leu Ser Gly Val Val
 1  5  10

Ala Val Trp Asp Ser Leu Asn Gly Trp Val
 1  5  10

Gly Thr Trp Asp Ser Ser Leu Ser Ala Val Val
 1  5  10

Gln Ala Trp Asp Ser Ser Thr Val Val
 1  5

Ser Asp Tyr His Cys Gly Ala Asp His Gly Ser Gly Thr Asn Phe Val
 1  5  10  15

Val Val
Gly Tyr Thr Phe Thr Ser Tyr Gly Ile Ser
  1      5      10

Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser
  1      5      10

Gly Phe Thr Phe Ser Ser Tyr Gly Met His
  1      5      10

Gly Phe Thr Phe Ser Ser Tyr Ser Met Asn
  1      5      10

Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser
  1      5      10

Gly Gly Ser Ile Ser Ser Asp Tyr Tyr Trp Ser
  1      5      10

Gly Gly Ser Phe Ser Ala Tyr Tyr Trp Asn
  1      5      10
Gly Asp Ser Val Ser Ser Asn Ser Ala Ala Trp Asn
  1   5  10

<210> SEQ ID NO 252
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 252

Trp Ile Ser Thr Tyr Asn Gly Thr Asn Tyr Ala Gln Lys Val Gln
  1   5   10  15
Gly

<210> SEQ ID NO 253
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 253

Thr Ile Ser Gly Ser Gly Gly Arg Thr Tyr Tyr Ala Asp Ser Val Lys
  1   5   10  15
Gly

<210> SEQ ID NO 254
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 254

Val Ile Trp Tyr Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys
  1   5   10  15
Gly

<210> SEQ ID NO 255
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 255

Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
  1   5   10  15
Gly

<210> SEQ ID NO 256
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 256

Ser Ile Ser Ser Ser Ser Tyr Ile Ser Tyr Ala Asp Ser Val Lys
  1   5   10  15
Gly

<210> SEQ ID NO 257
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 257

Tyr Ile Tyr Asn Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser
  1   5   10  15
<210> SEQ ID NO 258
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 258

Tyr Ile Tyr Ser Gly Ser Thr Tyr Asn Pro Ser Leu Lys Ser
   1   5   10   15

<210> SEQ ID NO 259
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 259

Glu Ile Asn His Ser Gly Arg Thr Asp Tyr Asn Pro Ser Leu Lys Ser
   1   5   10   15

<210> SEQ ID NO 260
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 260

Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Lys Asn Tyr Ser Val Ser Val
   1   5   10   15

Lys Ser

<210> SEQ ID NO 261
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 261

Gly Tyr Thr Arg Asp Tyr
   1   5

<210> SEQ ID NO 262
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 262

Glu Val Gly Ser Pro Phe Asp Tyr
   1   5

<210> SEQ ID NO 263
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 263

Glu Thr Gly Pro Leu Lys Leu Tyr Tyr Gly Met Asp Val
   1   5   10

<210> SEQ ID NO 264
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 264

Arg Gly Gly Leu Ala Ala Arg Pro Gly Gly Met Asp Val
   1   5   10
<210> SEQ ID NO 265
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 265

Asp Tyr Asp Phe Trp Ser Ala Tyr Tyr Asp Ala Phe Asp Val
1  5  10

<210> SEQ ID NO 266
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 266

Glu Asp Thr Ala Met Val Pro Tyr Phe Asp Tyr
1  5  10

<210> SEQ ID NO 267
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 267

Gly Gly Val Thr Thr Tyr Tyr Tyr Ala Met Asp Val
1  5  10

<210> SEQ ID NO 268
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 268

Gly Gln Leu Val Pro Phe Asp Tyr
1  5

<210> SEQ ID NO 269
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 269

Gly Gly Pro Thr Ala Ala Phe Asp Tyr
1  5

<210> SEQ ID NO 270
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 270

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1  5 10 15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30

Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35 40 45

Met Ile Tyr Gln Val Ser Asn Arg Pro Ser Gly Val Phe Asn Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80

Gln Ala Gln Asp Ala Asp Tyr Tyr Cys Asn Ser Tyr Thr Ser Thr
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100
105

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Phe Gly Ser Pro Gly Gln
1 5 10 15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr
20 25 30

Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Arg
35 40 45

Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr
85 90 95

Asn Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100
105

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Pro Pro Gly Gln
1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30

Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Ser Leu
85 90 95

Asn Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100
105

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Pro Pro Gly Gln
1 5 10 15

Arg Val Thr Ile Phe Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
20 25 30

Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
45 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Ser Ser Leu
85 90 95
Asn Trp Val Phe Gly Gly Gly Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 274
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 274
Ser Tyr Glu Leu Thr Glu Pro Pro Ser Val Val Ser Val Pro Gly Glu
1 5 10 15
Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala
20 25 30
Cys Trp Tyr Glu Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45
Gln Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Ala Trp Asp Ser Ser Thr Val
95 95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 275
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 275
Ser Tyr Glu Leu Thr Glu Pro Pro Ser Val Val Ser Val Pro Gly Glu
1 5 10 15
Thr Ala Arg Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Tyr Ala
20 25 30
Cys Trp Tyr Glu Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr
35 40 45
Gln Asp Thr Lys Trp Pro Leu Gly Ile Pro Glu Arg Phe Ser Gly Ser
50 55 60
Lys Ser Gly Asn Thr Val Thr Ile Ser Gly Thr Gln Ala Met
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Ala Trp Asp Ser Ser Thr Val
95 95
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 276
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 276
<table>
<thead>
<tr>
<th>Sequence</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Tyr Glu Leu Thr Gln Pro Pro Ser Val Ser Val Ser Val Ser Pro Gly Gln</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Thr Ala</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cys Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Val Leu Val Ile Tyr</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly Asp Ser Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser</td>
<td>50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met</td>
<td>65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 277
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 277

<table>
<thead>
<tr>
<th>Sequence</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ser Tyr Glu Leu Ile Gln Pro Pro Ser Val Ser Val Ser Val Ser Pro Gly Gln</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr Ala Ser Ile Thr Cys Ser Gly Asp Lys Leu Gly Asp Lys Thr Ala</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cys Trp Tyr Gln Arg Lys Pro Gly Gln Ser Pro Ile Leu Val Ile Tyr</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly Asp Thr Lys Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser</td>
<td>50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Gln Ala Met</td>
<td>65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp Glu Ala Asp Tyr Tyr Cys Gln Ala Trp Asp Ser Ser Thr Ala Val</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 278
<211> LENGTH: 120
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 278

<table>
<thead>
<tr>
<th>Sequence</th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Glu</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Ser Ile Ser Thr Tyr</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile</td>
<td>35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gly Tyr Ile Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys</td>
<td>50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu</td>
<td>65</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala</td>
<td>85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arg Gly Ser Tyr Ser Gly Trp Phe Glu Phe Asp Tyr Trp Gly Gln</td>
<td>100</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Gly Thr Leu Val Thr Val Ser Ser

115
120

<210> SEQ ID NO 279
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 279
Thr Leu Ser Ser Gly Tyr Ser Ser Tyr Glu Val Asp
1      5      10

<210> SEQ ID NO 280
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 280
Val Asp Thr Gly Gly Ile Val Gly Ser Lys Gly Glu
1      5      10

<210> SEQ ID NO 281
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 281
Gly Ala Asp His Gly Ser Gly Thr Asn Phe Val Val Val
1      5      10

<210> SEQ ID NO 282
<211> LENGTH: 22
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 282
Gln Pro Val Leu Thr Gln Pro Leu Phe Ala Ser Ala Ser Leu Gly Ala
1      5      10      15
Ser Val Thr Leu Thr Cys
20

<210> SEQ ID NO 283
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 283
Trp Tyr Gln Gln Arg Pro Gly Lys Gly Pro Arg Phe Val Met Arg
1      5      10      15

<210> SEQ ID NO 284
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 284
Gly Ile Pro Asp Arg Phe Ser Val Leu Gly Ser Gly Leu Asn Arg Tyr
1      5      10      15
Leu Thr Ile Lys Asn Ile Gln Glu Glu Asp Glu Ser Asp Tyr His Cys
20      25      30

<210> SEQ ID NO 285
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 285

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
  1   5   10

<210> SEQ ID NO 286
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 286

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
  1   5   10   15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr
  20  25  30
Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val
  35  40  45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Thr Arg Phe
  50  55  60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gry Leu
  65  70  75  80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
  85  90  95
Ser Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val
  100 105

<210> SEQ ID NO 287
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 287

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
  1   5   10   15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
  20  25  30
Asn Ser Val Ser Trp Tyr Gln His His Pro Gly Lys Ala Pro Lys Val
  35  40  45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Thr Arg Phe
  50  55  60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gry Leu
  65  70  75  80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Ser
  85  90  95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val
  100 105

<210> SEQ ID NO 288
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 288

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
  1   5   10   15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Asn Ser Asp Val Gly Gly Gly Tyr
  20  25  30
Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu
35 40
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Ile Ser Asn Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Ser Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr
85 90 95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Thr Val
100 105

<210> SEQ ID NO 289
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 289

Gln Val His Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
 Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp
100 105 110
 Gly His Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 290
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 290

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
 Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Cys Val
35 40 45
 Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
 Ala Arg Arg Gly Gly Leu Ala Ala Arg Pro Gly Gly Met Asp Val Trp
100 105 110
 Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120
<210> SEQ ID NO 291
<211> LENGTH: 121
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 291

Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg
1      5     10    15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20    25
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35    40    45
Ala Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50    55    60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Gly Thr Leu Tyr
65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
95    90    95
Ala Arg Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val Trp
100   105   110
Gly Gln Gly Thr Thr Val Thr Val Ser
115   120

<210> SEQ ID NO 292
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 292

Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg
1      5     10    15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20    25
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35    40    45
Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50    55    60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Gly Thr Leu Tyr
65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
95    90    95
Ala Arg Arg Gly Gly Leu Pro Gly Gly Met Asp Val Trp Gly Gln Gly
100   105   110
Thr Thr Val Thr Val Ser Ser
115

<210> SEQ ID NO 293
<211> LENGTH: 127
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 293

cagctgccc tgacgagcc tgctctcttg tctggtgctc ctggacatc gtaaccatc  60
tctgatcgt gaacccgacg tgaagttggt ggtataaact ctgctctctg gttcaccag 120
cacccagcga aagccccccca acttagatt tatgaggtca gtaatcgggcc ctcaaggggt 180
tctttacgct ttctttgctc caagcttgcc aacagggcct cctgaccacct tctgggctc 240
caggctgagg acagggctga ttattactgc aactctata caagcaccag cattgtatctc 300
ggcggaggga ccaagotgac gctccta 327

<210> SEQ ID NO 294
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 294
cagtctgccg tgacccagcc tgccctcgtg tccttgctct tcggacagtc gtaaccacatc 60
tccctgccgt gcaccagagg cgacgtgtgt ggttatatact cttctctctg gtaccaccag 120
cacccagccg aaccccccaaa actctagatt ttgagggtca gtaactgccc ctcaggggtc 180
tctactgtct tcctcgtcgg caggctgggc cacacgcgtc ccctcgacact cttctttgctc 240
caggctgagg acagggctga ttattactgc aactctata caagcaccag cattgtatctc 300
ggcggaggga ccaagotgac gctccta 327

<210> SEQ ID NO 295
<211> LENGTH: 318
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 295
tctcttgacg tgacccagcc accctgagtt tcctgtctccc caggacagac agccgaaatc 60
acccgctgtg gacataaat gggggataat gaggctgtgc ggtatatcgc caagcaccagc 120
cagccccg tcctctgctct ctaccaataat accaagtggcc cctctggttgt cctctgaggga 180
tctctgctg ccagctgtgg gcaccagcct acccggaccct ccaggctagtc ccaggctatg 240
gatcggggtg acctcttgcg tcagccggcgg gacagccaga cttgtgattg cggcggatggg 300
acccgctgtc gctccta 318

<210> SEQ ID NO 296
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 296
cagctctgccg tgacccagcc tgccctcgtg tccttgctct tcggacagtc gtaaccacatc 60
tccctgccgt gcaccagagg cgacgtgtgt ggttatatact cttctctctg gtaccaccag 120
cacccagccg aaccccccaaa actctagatt ttgagggtca gtaactgccc ctcaggggtc 180
tctactgtct tcctcgtcgg caggctgggc cacacgcgtc ccctcgacact cttctttgctc 240
caggctgagg acagggctga ttattactgc aactctata caagcaccag cattgtatctc 300
ggcggaggga ccaagotgac gctccta 327

<210> SEQ ID NO 297
<211> LENGTH: 215
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 297
Glu Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln 1  5
Ser Tyr Ser Ser Cys Thr Gly Ile Ser Ser Asp Val Gly Gly Tyr 10 15  20
Ser Ser Ile Thr Ille Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr 25 30
<table>
<thead>
<tr>
<th>Residue</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asn</td>
<td>Ser Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Trp Tyr</td>
</tr>
<tr>
<td>Gln</td>
<td>Gln His</td>
</tr>
<tr>
<td>Gln</td>
<td>Pro Gly</td>
</tr>
<tr>
<td>Lys</td>
<td>Ala Pro</td>
</tr>
<tr>
<td>Lys</td>
<td>Leu</td>
</tr>
<tr>
<td>Met</td>
<td>Ile Tyr</td>
</tr>
<tr>
<td>Ile</td>
<td>Gln Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Asn</td>
</tr>
<tr>
<td>Ser</td>
<td>Arg Pro</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Asn</td>
</tr>
<tr>
<td>Arg</td>
<td>Phe</td>
</tr>
<tr>
<td>Ser</td>
<td>Gly Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>Lys Ser</td>
</tr>
<tr>
<td>Lys</td>
<td>Ser Gly</td>
</tr>
<tr>
<td>Asn</td>
<td>Ser Asn</td>
</tr>
<tr>
<td>Arg</td>
<td>Ser Ile</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Lys</td>
</tr>
<tr>
<td>Gly</td>
<td>Ser Ala</td>
</tr>
<tr>
<td>Ala</td>
<td>Pro Ser</td>
</tr>
<tr>
<td>Val</td>
<td>Ser Val</td>
</tr>
<tr>
<td>Thr</td>
<td>Leu Pro</td>
</tr>
<tr>
<td>Pro</td>
<td>Pro Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Gly</td>
</tr>
<tr>
<td>Glu Glu</td>
<td>Glu Leu</td>
</tr>
<tr>
<td>Glu</td>
<td>Ala Ala</td>
</tr>
<tr>
<td>Ala</td>
<td>Thr Leu</td>
</tr>
<tr>
<td>Val</td>
<td>Ala Cys</td>
</tr>
<tr>
<td>Leu</td>
<td>Ser Ala</td>
</tr>
<tr>
<td>Ile</td>
<td>Ser Asp</td>
</tr>
<tr>
<td>Ser</td>
<td>Phe Tyr</td>
</tr>
<tr>
<td>Pro</td>
<td>Ala Ala</td>
</tr>
<tr>
<td>Thr</td>
<td>Val Ala</td>
</tr>
<tr>
<td>Ala</td>
<td>Val Ala</td>
</tr>
<tr>
<td>Thr</td>
<td>Ala Trp</td>
</tr>
<tr>
<td>Lys</td>
<td>Ala Asp</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Pro</td>
</tr>
<tr>
<td>Val</td>
<td>Lys Ala</td>
</tr>
<tr>
<td>Ala</td>
<td>Gly Val</td>
</tr>
<tr>
<td>Val</td>
<td>Thr Ala</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Tyr</td>
</tr>
<tr>
<td>Tyr</td>
<td>Leu Ser</td>
</tr>
<tr>
<td>Leu</td>
<td>Thr Pro</td>
</tr>
<tr>
<td>Glu</td>
<td>Glu Ala</td>
</tr>
<tr>
<td>Pro</td>
<td>Glu Trp</td>
</tr>
<tr>
<td>Lys</td>
<td>Ser His</td>
</tr>
<tr>
<td>Ala</td>
<td>Ser Tyr</td>
</tr>
<tr>
<td>Tyr</td>
<td>Cys Gln</td>
</tr>
<tr>
<td>Gln</td>
<td>Val Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>His Glu</td>
</tr>
<tr>
<td>Gly</td>
<td>Ser Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Val Glu</td>
</tr>
<tr>
<td>Lys</td>
<td>Thr</td>
</tr>
<tr>
<td>Val</td>
<td>Ala Pro</td>
</tr>
<tr>
<td>Thr</td>
<td>Glu Cys</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser</td>
</tr>
<tr>
<td>Val</td>
<td>210</td>
</tr>
<tr>
<td>Ala</td>
<td>Pro</td>
</tr>
<tr>
<td>Thr</td>
<td>215</td>
</tr>
</tbody>
</table>

**<210> SEQ ID NO 298**  
**<211> LENGTH: 230**  
**<212> TYPE: PRT**  
**<213> ORGANISM: Homo sapiens**  
**<400> SEQUENCE: 299**

<table>
<thead>
<tr>
<th>Residue</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glu</td>
<td>Val Gln</td>
</tr>
<tr>
<td>Val</td>
<td>Leu Val</td>
</tr>
<tr>
<td>Gln</td>
<td>Ser Gly</td>
</tr>
<tr>
<td>Ala</td>
<td>Glu Val</td>
</tr>
<tr>
<td>Val</td>
<td>Lys Pro</td>
</tr>
<tr>
<td>Gly</td>
<td>Ala Ala</td>
</tr>
<tr>
<td>Glu</td>
<td>Val Ala</td>
</tr>
<tr>
<td>Lys</td>
<td>Ser Pro</td>
</tr>
<tr>
<td>Val</td>
<td>Ser Ala</td>
</tr>
<tr>
<td>Ser</td>
<td>Val Ser</td>
</tr>
<tr>
<td>Lys</td>
<td>Cys Lys</td>
</tr>
<tr>
<td>Ala</td>
<td>Ser Gly</td>
</tr>
<tr>
<td>Tyr</td>
<td>Thr Leu</td>
</tr>
<tr>
<td>Thr</td>
<td>Ser Tyr</td>
</tr>
<tr>
<td>Ser</td>
<td>Val Ile</td>
</tr>
<tr>
<td>Ile</td>
<td>Ser Trp</td>
</tr>
<tr>
<td>Val</td>
<td>Arg Gln</td>
</tr>
<tr>
<td>Ala</td>
<td>Pro Gly</td>
</tr>
<tr>
<td>Gly</td>
<td>Glu Leu</td>
</tr>
<tr>
<td>Glu</td>
<td>Trp Met</td>
</tr>
<tr>
<td>Gly</td>
<td>Trp Val</td>
</tr>
<tr>
<td>Ser</td>
<td>Phe Tyr</td>
</tr>
<tr>
<td>Asn</td>
<td>Gly Asn</td>
</tr>
<tr>
<td>Ala</td>
<td>Ser Ala</td>
</tr>
<tr>
<td>Thr</td>
<td>Ala Gln</td>
</tr>
<tr>
<td>Lys</td>
<td>Leu Ala</td>
</tr>
<tr>
<td>Gly</td>
<td>Arg Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Met Thr</td>
</tr>
<tr>
<td>Thr</td>
<td>Asp Pro</td>
</tr>
<tr>
<td>Ser</td>
<td>Thr Ser</td>
</tr>
<tr>
<td>Thr</td>
<td>Ala Tyr</td>
</tr>
<tr>
<td>Ser</td>
<td>Met Glu</td>
</tr>
<tr>
<td>Glu</td>
<td>Leu Arg</td>
</tr>
<tr>
<td>Ser</td>
<td>Leu Arg</td>
</tr>
<tr>
<td>Ser</td>
<td>Asp Ala</td>
</tr>
<tr>
<td>Asp</td>
<td>Trp Ala</td>
</tr>
<tr>
<td>Val</td>
<td>Tyr Gly</td>
</tr>
<tr>
<td>Ala</td>
<td>Met Asp</td>
</tr>
<tr>
<td>Val</td>
<td>Trp Gly</td>
</tr>
<tr>
<td>Gly</td>
<td>Glu Gly</td>
</tr>
<tr>
<td>Thr</td>
<td>Thr Val</td>
</tr>
<tr>
<td>Thr</td>
<td>Val Thr</td>
</tr>
<tr>
<td>Ala</td>
<td>Val Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>Ala Ser</td>
</tr>
<tr>
<td>Lys</td>
<td>Ser Thr</td>
</tr>
<tr>
<td>Tyr</td>
<td>Ala Leu</td>
</tr>
<tr>
<td>Ala</td>
<td>Gln Ser</td>
</tr>
<tr>
<td>Lys</td>
<td>Gln Ser</td>
</tr>
<tr>
<td>Ala</td>
<td>Ser Thr</td>
</tr>
<tr>
<td>Lys</td>
<td>Ser Val</td>
</tr>
<tr>
<td>Leu</td>
<td>Pro Ser</td>
</tr>
<tr>
<td>Ser</td>
<td>Ser Leu</td>
</tr>
<tr>
<td>Ser</td>
<td>Val Thr</td>
</tr>
<tr>
<td>Val</td>
<td>Ala Pro</td>
</tr>
<tr>
<td>Leu</td>
<td>Ala Pro</td>
</tr>
<tr>
<td>Val</td>
<td>115</td>
</tr>
<tr>
<td>Ser</td>
<td>120</td>
</tr>
<tr>
<td>Thr</td>
<td>125</td>
</tr>
<tr>
<td>Asn</td>
<td>130</td>
</tr>
<tr>
<td>Arg</td>
<td>135</td>
</tr>
<tr>
<td>Phe</td>
<td>140</td>
</tr>
<tr>
<td>Ser</td>
<td>145</td>
</tr>
<tr>
<td>Tyr</td>
<td>150</td>
</tr>
<tr>
<td>Leu</td>
<td>155</td>
</tr>
<tr>
<td>Ser</td>
<td>160</td>
</tr>
<tr>
<td>Val</td>
<td>165</td>
</tr>
<tr>
<td>Ala</td>
<td>170</td>
</tr>
<tr>
<td>Ser</td>
<td>175</td>
</tr>
<tr>
<td>Ala</td>
<td>180</td>
</tr>
<tr>
<td>Ser</td>
<td>185</td>
</tr>
<tr>
<td>Tyr</td>
<td>190</td>
</tr>
<tr>
<td>Cys</td>
<td>195</td>
</tr>
<tr>
<td>Val</td>
<td>200</td>
</tr>
<tr>
<td>Ala</td>
<td>205</td>
</tr>
<tr>
<td>Ser</td>
<td>210</td>
</tr>
<tr>
<td>Val</td>
<td>215</td>
</tr>
</tbody>
</table>
Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
195       200       205
Val Asp Lys Lys Val Glu Pro Lys Ser Cys Ala Ala Asp Glu Val Asp
210       215       220
His His His His His
225       230

<210> SEQ ID NO 299
<211> LENGTH: 217
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 299

Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gin
1        5        10        15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ala Gly
20       25       30
Tyr Asp Val His Trp Tyr Gln Gin Leu Pro Gly Thr Ala Pro Lys Leu
35       40       45
Leu Ile Ser Gly Asn Ser Arg Pro Ser Gly Val Pro Asp Arg Phe
50       55       60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65       70       75       80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gin Ser Tyr Asp Ser Ser
85       90       95
Leu Ser Gly Ser Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gin
100      105      110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115      120      125
Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130      135      140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145      150      155      160
Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gin Ser Asn Asn Lys
165      170      175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gin Trp Lys Ser
180      185      190
His Arg Ser Tyr Ser Cys Gin Val Thr His Glu Gly Ser Thr Val Glu
195      200      205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210      215

<210> SEQ ID NO 300
<211> LENGTH: 238
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 300

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gin
1        5        10        15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20       25       30
Ser Met Asn Trp Val Arg Gin Ala Pro Gly Lys Gly Leu Glu Trp Val
35       40       45
Ser Ser Ile Ser Ser Ser Ser Tyr Ile Ser Tyr Ala Asp Ser Val
50       55       60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
85    90    95
Ala Arg Asp Tyr Asp Phe Trp Ser Ala Tyr Tyr Asp Ala Phe Asp Val
100   105   110
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115   120   125
Pro Ser Val Phe Pro Leu Ala Pro Ser Lys Ser Thr Ser Gly Gly
130   135   140
Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145   150   155   160
Thr Val Ser Thr Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165   170   175
Pro Ala Val Leu Glu Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180   185   190
Thr Val Pro Ser Ser Leu Gly Thr Glu Thr Tyr Ile Cys Asn Val
195   200   205
Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Val Glu Pro Lys
210   215   220
Ser Cys Ala Ala Arg Glu Val Asp His His His His His
225   230   235

<210> SEQ ID NO 301
<211> LENGTH: 218
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 301

Ala Leu Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro
1     5     10    15
Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly
20    25    30
Ser Asn Thr Val Asn Thr Tyr Gln Glu Pro Gly Thr Ala Pro Lys
35    40    45
Leu Leu Ile Tyr Ser Asn Asn Glu Pro Ser Gly Val Pro Asp Arg
50    55    60
Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly
65    70    75    80
Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Thr Asp Asp
85    90    95
Ser Leu Asn Gly Trp Val Phe Gly Gly Gly Thr Leu Thr Val Leu
100   105   110
Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
115   120   125
Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp
130   135   140
Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro
145   150   155   160
Val Lys Ala Gly Val Glu Thr Thr Pro Ser Lys Gln Ser Asn Asn
165   170   175
Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Glu Trp Lys
180   185   190
Ser His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val
<210> SEQ ID NO 302
<211> LENGTH: 680
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 303

Gln Glu Asp Glu Asp Gly Asp Tyr Glu Glu Leu Val Ala Leu Arg
1 5 10 15
Ser Glu Glu Asp Gly Leu Ala Glu Ala Pro Glu His Gly Thr Thr Ala
20 25 30
Thr Phe His Arg Cys Ala Lys Asp Pro Trp Arg Leu Pro Gly Thr Tyr
35 40 45
Val Val Val Leu Lys Glu Thr His Leu Ser Gln Ser Glu Arg Thr
50 55 60
Ala Arg Arg Leu Gln Ala Glu Ala Ala Ala Arg Arg Gly Tyr Leu Thr Lys
Ile Leu His Val Phe His Gly Leu Leu Pro Gly Phe Leu Val Lys Met
85 90 95
Ser Gly Asp Leu Leu Glu Leu Ala Leu Lys Leu Pro His Val Asp Tyr
100 105 110
Ile Glu Glu Asp Ser Ser Val Phe Ala Gln Ser Ile Pro Trp Asn Leu
110 120 125
Glu Arg Ile Thr Pro Pro Arg Tyr Arg Ala Asp Glu Tyr Gln Pro Pro
130 135 140
Asp Gly Gly Ser Leu Val Glu Val Tyr Leu Asp Thr Ser Ile Gln
140 150 155 160
Ser Asp His Arg Glu Ile Glu Gly Arg Val Met Val Thr Asp Phe Glu
160 165 170 175
Aas Val Pro Glu Glu Asp Gly Thr Arg Phe His Arg Gln Ala Ser Lys
180 185 190
Cys Asp Ser His Gly Thr His Leu Ala Gly Val Val Ser Gly Arg Asp
190 200 205
Ala Gly Val Ala Lys Gly Ala Ser Met Arg Ser Leu Arg Val Leu Asn
210 215 220
Cys Gln Gly Lys Gly Thr Val Ser Gly Thr Leu Ile Gly Leu Glu Phe
220 230 235 240
Ile Arg Lys Ser Gln Leu Val Gln Pro Val Gly Pro Leu Val Val Leu
240 250 255
Leu Pro Leu Ala Gly Gly Tyr Ser Arg Val Leu Asn Ala Ala Cys Gln
265 270
Arg Leu Ala Arg Ala Gly Val Val Leu Val Thr Ala Ala Gly Aen Phe
275 280 285
Arg Asp Ala Cys Leu Tyr Ser Pro Ala Ser Ala Pro Glu Val Ile
290 295 300
Thr Val Gly Ala Thr Asn Ala Gln Asp Gln Pro Val Thr Leu Gly Thr
300 310 315 320
Leu Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Glu
320 330 335
Asp Ile Ile Gly Ala Ser Ser Asp Cys Ser Thr Cys Phe Val Ser Gln
335 340 345 350
Ser Gly Thr Ser Gln Ala Ala Ala Ala Val Gly Ile Ala Ala Met
350 360 365
Met Leu Ser Ala Glu Pro Glu Leu Thr Leu Ala Glu Leu Arg Glu Arg
370 375 380
Leu Ile His Phe Ser Ala Lys Asp Val Ile Asn Glu Ala Trp Phe Pro
380 390 395 400
Glu Asp Gln Arg Val Leu Thr Pro Asn Leu Val Ala Leu Pro Pro
400 410 415
Ser Thr His Gly Ala Gly Trp Gln Leu Phe Cys Arg Thr Val Trp Ser
420 425 430
Ala His Ser Gly Pro Thr Met Ala Thr Ala Ile Ala Arg Cys Ala
430 440 445
Pro Asp Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys
450 455 460
Arg Arg Gly Glu Arg Met Glu Ala Gln Gly Gly Lys Leu Val Cys Arg
460 470 475 480
Ala His Asn Ala Phe Gly Gly Glu Gly Val Tyr Ala Ile Ala Arg Cys
480 490 495
Cys Leu Leu Pro Gln Ala Asn Cys Ser Val His Thr Ala Pro Pro Ala 500 505 510
Glu Ala Ser Met Gly Thr Arg Val His Cys His Gln Gln Gln Gly His Val 515 520 525
Leu Thr Gly Cys Ser Ser His Trp Glu Val Glu Asp Leu Gly Thr His 530 535 540
Lys Pro Pro Val Leu Arg Pro Arg Gly Gln Pro Asn Gln Cys Val Gly 545 550 555 560
His Arg Glu Ala Ser Ile His Ala Ser Cys His Ala Pro Gly Leu 565 570 575 580
Glu Cys Lys Val Lys Glu His Gly Ile Pro Ala Pro Gln Glu Gln Val 585 590 595
Thr Val Ala Cys Glu Glu Gly Thr Trp Thr Leu Thr Gly Cys Ser Ala Leu 595 600 605
Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Val Asp Asn Thr Cys 610 615 620
Val Val Arg Ser Arg Asp Val Ser Thr Gly Ser Thr Ser Glu Glu 625 630 635 640
Ala Val Thr Ala Val Ala Ile Cys Arg Ser Arg His Leu Ala Gln 645 650 655
Ala Ser Gln Glu Leu Gln Gly Ser Ser Asp Tyr Lys Asp Asp Asp Lys 660 665 670
His His His His His His His 675 680

<210> SEQ ID NO 304
<211> LENGTH: 660
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 304
Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Leu Arg Arg Arg 1 5 10 15
Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg His Arg Arg Arg 20 25 30
Arg Phe Arg Arg Cys Arg Arg Arg Pro Trp Arg Arg Pro Gly Arg Tyr 35 40 45
Val Val Val Leu Arg Arg Arg Arg Arg Ser Arg Ser Arg Glu Thr 50 55 60
Ala Glu Glu Leu Gln Arg Arg Ala Arg Glu Gly Arg Thr Lys 65 70 75 80
Ile Arg Arg Arg Phe Arg Gly Leu Pro Gly Phe Leu Val Arg Met 85 90 95
Arg Arg Arg Leu Arg Arg Leu Ala Arg Arg Leu Pro Val Arg Tyr 100 105 110
Ile Glu Glu Asp Ser Ser Val Phe Arg Gln Arg Ile Pro Arg Asn Arg 115 120 125
Arg Glu Ile Arg Pro Pro Tyr Arg Ala Arg Arg Arg Arg Pro Pro 130 135 140
Arg Gly Gly Arg Val Glu Val Tyr Leu Leu Asp Thr Arg Ile Arg 145 150 155 160
Arg Arg His Glu Ile Arg Gly Arg Val Arg Arg Arg Arg Arg Phe Arg 165 170 175
Arg Arg Pro Arg Arg Arg Arg Glu Arg Glu Arg Arg Arg Arg
Cys Asp Arg Arg Gly Thr His Leu Ala Gly Val Val Ser Gly Glu Arg
180 185 190

Ala Gly Val Ala Arg Arg Arg Arg Met Arg Ser Leu Glu Val Leu Asn
195 200 205

Cys Arg Gly Arg Gly Val Ser Gly Thr Leu Ile Gly Leu Glu Arg
210 215 220

Ile Glu Arg Arg Arg Arg Arg Pro Arg Arg Pro Leu Val Val Leu
225 230 235 240

Leu Pro Leu Ala Gly Arg Tyr Ser Glu Val Leu Asn Arg Ala Cys Arg
245 250 255

Arg Leu Ala Glu Arg Gly Val Leu Val Thr Ala Ala Gly Asn Phe
260 265 270

Glu Asp Asp Ala Cys Arg Tyr Ser Pro Ala Arg Ala Pro Glu Val Ile
275 280 285

Thr Val Gly Ala Thr Asn Arg Arg Arg Arg Pro Val Arg Arg Gly Arg
290 295 300

Arg Gly Thr Asn Phe Gly Arg Cys Val Asp Leu Phe Ala Pro Gly Arg
305 310 315 320

Arg Ile Ile Gly Ala Ser Ser Arg Cys Ser Ser Arg Cys Arg Arg Arg Arg
325 330 335

Ser Gly Thr Ser Gln Ala Ala Ala His Val Ala Gly Ile Ala Ala Arg
340 345 350

Met Leu Arg Arg Arg Arg Leu Arg Arg Arg Leu Arg Arg Gly Gln
355 360 365

Leu Arg Arg Arg Ser Arg Arg Arg Arg Arg Ile Arg Arg Arg Arg Phe Pro
370 375 380

Arg Arg Arg Glu Arg Leu Thr Pro Arg Leu Val Ala Arg Leu Pro Pro
385 390 395 400

Arg Arg Arg Arg Arg Glu Arg Leu Phe Cys Arg Thr Val Trp Ser
405 410 415

Arg Arg Ser Gly Pro Arg Glu Arg Ala Arg Ala Ile Ala Glu Cys Ala
420 425 430

Pro Arg Glu Glu Leu Leu Ser Cys Ser Ser Phe Ser Arg Ser Gly Lys
435 440 445

Arg Arg Gly Glu Arg Met Glu Arg Gln Gly Gly Lys Leu Val Cys Arg
450 455 460

Ala His Asn Ala Arg Gly Arg Gly Val Tyr Ala Ile Ala Ala Arg Cys
465 470 475 480

Cys Leu Leu Pro Gln Ala Arg Cys Ser Val His Arg Ala Pro Pro Ala
485 490 495

Arg Arg Arg Arg Gly Thr Val Val Cys Arg Arg Arg Gly His Val
500 505 510

Leu Thr Gly Cys Ser Ser His Trp Arg Arg Asp Arg Gly Thr Arg
515 520 525

Lys Pro Pro Arg Leu Arg Pro Glu Gly Arg Pro Arg Gln Cys Val Gly
530 535 540

His Arg Glu Ala Ser Ile His Ala Ser Cys Cys His Ala Pro Gly Leu
545 550 555 560

Glu Cys Arg Arg Arg Arg Arg Ile Pro Ala Pro Arg Glu Arg Val
565 570 575

Thr Val Arg Cys Arg Arg Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu
580 585 590

Thr Val Arg Cys Arg Arg Gly Trp Thr Leu Thr Gly Cys Ser Ala Leu
Pro Gly Thr Ser His Val Leu Gly Ala Tyr Ala Arg Asp Arg Thr Cys
Val Val Arg Ser Glu Asp Arg Arg Arg Arg Arg Arg Arg Arg Arg Glu
Arg Val Thr Ala Val Ala Ile Cys Cys Glu Ser Glu His Leu Ala Gln
 Ala Ser Gln Glu Leu Gln Gly Ser Ser Asp Tyr Lys Asp Asp Lys
His His His His His His His

<210> SEQ ID NO 305
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 305
Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asp Ser Val Ser
1  5 10

<210> SEQ ID NO 306
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 306
Glu Val Ser Asn Arg Pro Ser
1  5

<210> SEQ ID NO 307
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 307
Ser Ser Tyr Thr Ser Thr Ser Met Val
1  5

<210> SEQ ID NO 308
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 308
Ser Tyr Gly Ile Ser
1  5

<210> SEQ ID NO 309
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 309
Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln
1  5 10 15
Gly

<210> SEQ ID NO 310
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
Gly Tyr Gly Met Asp Val
1 5

Thr Gly Thr Ser Ser Asp Val Gly Arg Tyr Asn Ser Val Ser
1 5 10

Glu Val Ser Asn Arg Pro Ser
1 5

Ser Ser Tyr Thr Ser Ser Ser Val Val
1 5

Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Glu Lys Leu Gln
1 5 10 15

Gly

Gly Tyr Val Met Asp Val
1 5

Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Asn Ser Val Ser
1 5 10

Gly Val
Ser Ser Tyr Thr Ser Thr Asn Met Val
1  5

<210> SEQ ID NO 318
LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 318
Trp Val Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Phe Gln
1  5  10  15
Gly

<210> SEQ ID NO 319
LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 319
Asn Ser Tyr Thr Ser Thr Ser Met Val
1  5

<210> SEQ ID NO 320
LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 320
Trp Val Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln
1  5  10  15
Gly

<210> SEQ ID NO 321
LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 321
Glu Val Thr Asn Arg Pro Ser
1  5

<210> SEQ ID NO 322
LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 322
Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Ser Val Ser
1  5  10

<210> SEQ ID NO 323
LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 323
Trp Ile Ser Val Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln
1  5  10  15
Gly

<210> SEQ ID NO 324
Trp Ile Ser Phe Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys Val Gln
1  5  10  15

Gly

Ser Gly Ser Ser Ser Asn Ile Gly Asn Asn Phe Val Ser
1  5  10

Asp Tyr Asn Lys Arg Pro Ser
1  5

Gly Thr Trp Asp Ser Ser Leu Ser Gly Tyr Val
1  5  10

Ser Phe Gly Met His
1  5

Leu Ile Trp Asn Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1  5  10  15

Gly

Ala Ile Ala Ala Leu Tyr Tyr Tyr Gly Met Asp Val
1  5  10
<210> SEQ ID NO 331
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 331
Amp Ser Asn Lys Arg Pro Ser 1 5

<210> SEQ ID NO 332
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 332
Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val 1 5 10

<210> SEQ ID NO 333
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 333
Ser Tyr Gly Met His 1 5

<210> SEQ ID NO 334
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 334
Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Tyr Val Asp Ser Val Lys 1 5 10 15

Gly

<210> SEQ ID NO 335
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 335
GLY Ile Ala Val Ala Tyr Tyr Tyr Gly Met Asp Val 1 5 10

<210> SEQ ID NO 336
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 336
Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Tyr Ala Asp Ser Val Lys 1 5 10 15

Gly

<210> SEQ ID NO 337
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 337
Gly Thr Trp Asp Ser Ser Leu Ser Ser Tyr Val
Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn
1 5 10

Ser Asn Asn Arg Arg Pro Ser
1 5

Ala Ala Trp Asp Asp Ser Leu Asn Trp Val
1 5 10

Tyr Trp Met Ser
1

Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15

Gly
Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile
  1  5  10

SEQ ID NO 345
LENGTH: 13
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 345

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn
  1  5  10

SEQ ID NO 346
LENGTH: 5
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 346

Arg Tyr Trp Met Ser
  1  5

SEQ ID NO 347
LENGTH: 17
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 347

Asn Ile Lys His Arg Gly Ser Gly Lys Tyr Tyr Val Asp Ser Val Lys
  1  5  10  15

Gly

SEQ ID NO 348
LENGTH: 10
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 348

Glu Ser Asn Trp Gly Phe Ala Phe Asp Val
  1  5  10

SEQ ID NO 349
LENGTH: 7
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 349

Arg Asn Asn Glu Arg Pro Leu
  1  5

SEQ ID NO 350
LENGTH: 5
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 350

Ser Tyr Trp Met Ser
  1  5

SEQ ID NO 351
LENGTH: 5
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 351
Arg Ala Ser Gln Ser Ile Ser Tyr Leu Asn
 1     5

<210> SEQ ID NO 352
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 352

Arg Ala Ser Gln Ser Ile Ser Tyr Leu Asn
 1     5

<210> SEQ ID NO 353
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 353

Ala Ala Ser Leu Gln Ser
 1     5

<210> SEQ ID NO 354
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 354

Gln Gln Ser Tyr Ser Pro Ile Thr
 1     5

<210> SEQ ID NO 355
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 355

Arg Ala Ser Gln Ser Ile Ser Tyr Leu Asn
 1     5

<210> SEQ ID NO 356
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 356

Ala Ala Ala Ser Leu Gln Ser
 1     5

<210> SEQ ID NO 357
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 357

Gln Gln Ser Tyr Ser Ala Pro Ile Thr
 1     5

<210> SEQ ID NO 358
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 358

Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn
<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>359</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>359</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ala Ala Ser Ser Leu Gln Ser</td>
<td>1</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>360</td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>360</td>
<td></td>
</tr>
<tr>
<td>Gln Gln Ser Tyr Ser Ser Pro Ile Thr</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>361</td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>361</td>
<td></td>
</tr>
<tr>
<td>Ser Tyr Ala Met Asn</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>362</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>16</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>362</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr Ile Ser Gly Ser Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys Gly</td>
<td>1</td>
<td>5</td>
<td>10</td>
<td>15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>363</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>363</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lys Phe Val Leu Met Val Tyr Ala Met Leu Asp Tyr</td>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>364</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>17</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>364</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Tyr Ala Asp Ser Val Lys</td>
<td>1</td>
<td>5</td>
<td>10</td>
<td>15</td>
</tr>
</tbody>
</table>

Gly

<table>
<thead>
<tr>
<th></th>
<th>1</th>
<th>5</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;210&gt; SEQ ID NO</td>
<td>365</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;211&gt; LENGTH:</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;212&gt; TYPE: PRT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;213&gt; ORGANISM: Homo sapiens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;400&gt; SEQUENCE:</td>
<td>365</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr Ile Ser Gly Ser Gly Asp Asn Thr Tyr Tyr Ala Asp Ser Val Lys</td>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
</tbody>
</table>
1   5   10   15

Gly

<210> SEQ ID NO 366
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 366
Gly Tyr Ser Leu Thr Ser Tyr Gly Ile Ser
1   5   10

<210> SEQ ID NO 367
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 367
Gly Tyr Ala Leu Thr Ser Tyr Gly Ile Ser
1   5   10

<210> SEQ ID NO 368
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 368
Gly Tyr Thr Leu Thr Ser Tyr Gly Ile Ser
1   5   10

<210> SEQ ID NO 369
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 369
Gly Tyr Ser Phe Thr Ser Tyr Gly Ile Ser
1   5   10

<210> SEQ ID NO 370
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 370
Gly Tyr Thr Phe Pro Ser Tyr Gly Ile Ser
1   5   10

<210> SEQ ID NO 371
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 371
Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser
1   5   10

<210> SEQ ID NO 372
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 372
Gly Phe Thr Phe Ser Arg Tyr Trp Met Ser
Thr Ile Ser Gly Ser Gly Gly Asn Thr Tyr Ala Asp Ser Val Lys Gly
  1    5   10    15

Leu Ile Trp Asn Gly Ser Asn Lys Tyr Ala Asp Ser Val Lys Gly
  1    5   10    15

Leu Ile Trp Ser Asp Gly Ser Asp Glu Tyr Ala Asp Ser Val Lys Gly
  1    5   10    15

Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Ala Asp Ser Val Lys Gly
  1    5   10    15

Leu Ile Trp Ser Asp Gly Ser Asp Lys Tyr Ala Asp Ser Val Lys Gly
  1    5   10    15

Leu Ile Trp His Asp Gly Ser Asn Thr Tyr Val Asp Ser Val Lys Gly
  1    5   10    15

Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile
  1    5   10

Glu Ser Asn Trp Gly Phe Ala Phe Asp Val
  1    5   10

Glu Ser Asn Trp Gly Phe Ala Phe Asp Val
Gly Tyr Val Met Asp Val
  1 5

Arg Ala Ser Gln Ser Ile Ser Ile Tyr Leu Aea
  1 5 10

Thr Gly Thr Asn Ser Asp Val Gly Gly Tyr Asn Ser Val Ser
  1 5 10

Thr Gly Thr Ser Ser Asp Val Gly Ala Tyr Aea Ser Val Ser
  1 5 10

Thr Gly Thr Ser Ser Asp Val Gly Asp Tyr Aea Ser Val Ser
  1 5 10

Arg Aea Aea Gln Arg Pro Leu
  1 5

Ala Ala Ala Ser Leu Gln Ser
  1 5
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 394

Gln Gln Ser Tyr Ser Ala Pro Ile Thr
1  5

<210> SEQ ID NO 395
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 395

Arg Ser Tyr Thr Ser Thr Ser Met Val
1  5

<210> SEQ ID NO 396
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 396

Ser Ser Tyr Thr Ser Ser Ser Val Val
1  5

<210> SEQ ID NO 397
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 397

Ala Ala Trp Asp Asp Ser Leu Asn Trp Val
1  5 10

<210> SEQ ID NO 398
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 398

Gly Thr Trp Asp Ser Ser Leu Ser Ser Tyr Val
1  5 10

<210> SEQ ID NO 399
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 399

Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val
1  5 10

<210> SEQ ID NO 400
<211> LENGTH: 116
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400>SEQUENCE: 400

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
1  5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr
20 25 30

Tyr Trp Ser Ser Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45
Glu Asn Leu Tyr Phe Gln
1 5

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1  5  10
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa=S or A
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (7) (7)
<223> OTHER INFORMATION: Xaa=Y or F
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (8) (8)
<223> OTHER INFORMATION: Xaa=G, S or Y
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (9) (9)
<223> OTHER INFORMATION: Xaa=I, M or W
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (10) (10)
<223> OTHER INFORMATION: Xaa=S, N or H

<400> SEQUENCE: 406
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1  5  10

<210> SEQ ID NO: 407
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 1
<223> OTHER INFORMATION: Xaa=T or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 2
<223> OTHER INFORMATION: Xaa=G or S
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 3
<223> OTHER INFORMATION: Xaa=S, T or G
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 4
<223> OTHER INFORMATION: Xaa=S
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5
<223> OTHER INFORMATION: Xaa=S
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa=N, D or S
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (7) (7)
<223> OTHER INFORMATION: Xaa=I, V or N
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (8) (8)
<223> OTHER INFORMATION: Xaa=G or I
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (9) (9)
<223> OTHER INFORMATION: Xaa=A or G
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (10) (10)
<223> OTHER INFORMATION: Xaa=G, Y, S or N
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (11) (11)
<223> OTHER INFORMATION: Xaa=Y or N
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (12) (12)
<223> OTHER INFORMATION: Xaa=D, S, T or F
<220>  SEQUENCE: 407
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1  5 10

<210>  SEQ ID NO: 408
<211>  LENGTH: 17
<212>  TYPE: PRF
<213>  ORGANISM: Homo sapiens
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (13)...(13)
<223>  OTHER INFORMATION: Xaa=W, S, L or no amino acid
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (14)...(14)
<223>  OTHER INFORMATION: Xaa=S, N or H
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (7)...(7)
<223>  OTHER INFORMATION: Xaa=S or G
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (8)...(9)
<223>  OTHER INFORMATION: Xaa=N, Y, D or R
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (9)...(9)
<223>  OTHER INFORMATION: Xaa=T, I or E
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (10)...(10)
<223>  OTHER INFORMATION: Xaa=N, S, Y or D
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (11)...(11)
<223>  OTHER INFORMATION: Xaa=Y
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (12)...(12)
<223>  OTHER INFORMATION: Xaa=A and N
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (13)...(13)
<223>  OTHER INFORMATION: Xaa=Q, D or P
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (14)...(14)
<223>  OTHER INFORMATION: Xaa=K or S
<220>  FEATURE:
<221>  NAME/KEY: VARIANT
<222>  LOCATION: (15)...(15)
<223>  OTHER INFORMATION: Xaa=L or V
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (16)...(16)
<223> OTHER INFORMATION: Xaa=G or K
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (17)...(17)
<223> OTHER INFORMATION: Xaa=G or S

<400> SEQUENCE: 409

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1  5  10 15

Xaa

<210> SEQ ID NO 409
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 1
<223> OTHER INFORMATION: Xaa=G, E, S or D
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 2
<223> OTHER INFORMATION: Xaa=N, V or Y
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 3
<223> OTHER INFORMATION: Xaa=S or N
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 4
<223> OTHER INFORMATION: Xaa=N, Q or K
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5
<223> OTHER INFORMATION: Xaa=R
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa=F
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (7)...(7)
<223> OTHER INFORMATION: Xaa=S

<400> SEQUENCE: 409

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1  5

<210> SEQ ID NO 410
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 1
<223> OTHER INFORMATION: Xaa=D or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 2
<223> OTHER INFORMATION: Xaa=Y, A or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 3
<223> OTHER INFORMATION: Xaa=D, I or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 4
<223> OTHER INFORMATION: Xaa=F, A or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5
<223> OTHER INFORMATION: Xaa=W, A or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa=S, L or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (7)...(7)
<223> OTHER INFORMATION: Xaa=A, Y, G or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (8)...(8)
<223> OTHER INFORMATION: Xaa=Y, Q or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (9)...(9)
<223> OTHER INFORMATION: Xaa=G, Y or L
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (10)...(10)
<223> OTHER INFORMATION: Xaa=Y, D or V
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (11)...(11)
<223> OTHER INFORMATION: Xaa=G, A or P
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (12)...(12)
<223> OTHER INFORMATION: Xaa=M or F
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (13)...(13)
<223> OTHER INFORMATION: Xaa=D
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (14)...(14)
<223> OTHER INFORMATION: Xaa=V or Y

<400> SEQUENCE: 410

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

1 5 10

<210> SEQ ID NO 411
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 1
<223> OTHER INFORMATION: Xaa=Q, A, G or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 2
<223> OTHER INFORMATION: Xaa=S, V, T or no amino acid
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 3
<223> OTHER INFORMATION: Xaa=Y, N or W
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 4
<223> OTHER INFORMATION: Xaa=S or D
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 5
<223> OTHER INFORMATION: Xaa=S, Y or D
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 6
<223> OTHER INFORMATION: Xaa=S or T
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (7)...(7)
<223> OTHER INFORMATION: Xaa=L or S
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: (8)...(8)
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10
FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 2

OTHER INFORMATION: Xaa=G, P or A

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 3

OTHER INFORMATION: Xaa=T or S

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 4

OTHER INFORMATION: Xaa=S, N, T, A, C or Q

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 5

OTHER INFORMATION: Xaa=S, T, A or C

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 6

OTHER INFORMATION: Xaa=D or E

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (7)...(7)

OTHER INFORMATION: Xaa=V, I, M, L, P or A

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (8)...(8)

OTHER INFORMATION: Xaa=G, P or A

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (9)...(9)

OTHER INFORMATION: Xaa=G, A, R, P, V, L, I, K, Q or N

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (10)...(10)

OTHER INFORMATION: Xaa=Y, W, F, T or S

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (11)...(11)

OTHER INFORMATION: Xaa=N or Q

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (12)...(12)

OTHER INFORMATION: Xaa=Y, S, W, P, T, S, T, A or C

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (13)...(13)

OTHER INFORMATION: Xaa=V, I, M, L, P, or A

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: (14)...(14)

OTHER INFORMATION: Xaa=S, T, A or C

SEQUENCE: 413
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

SEQ ID NO 414
LENGTH: 17
TYPE: PRT
ORGANISM: Homo sapiens
FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 1

OTHER INFORMATION: Xaa=W, Y or P

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 2

OTHER INFORMATION: Xaa=V, I, M, L, P or A

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 3

OTHER INFORMATION: Xaa=S, T, A or C

FEATURE:
- NAME/KEY: VARIANT
- LOCATION: 4

OTHER INFORMATION: Xaa=R, F, V, L, I, Y or M
FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 5

OTHER INFORMATION: Xaa=Y, W, F, T or S

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 6

OTHER INFORMATION: Xaa=N or Q

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (7)...(7)

OTHER INFORMATION: Xaa=G, P or A

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (8)...(8)

OTHER INFORMATION: Xaa=N or Q

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (9)...(9)

OTHER INFORMATION: Xaa=T or S

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (10)...(10)

OTHER INFORMATION: Xaa=N or Q

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (11)...(11)

OTHER INFORMATION: Xaa=Y, W, F, T or S

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (12)...(12)

OTHER INFORMATION: Xaa=A, V, L or I

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (13)...(13)

OTHER INFORMATION: Xaa=Q, E, N or D

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (14)...(14)

OTHER INFORMATION: Xaa=K, R, Q or N

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (15)...(15)

OTHER INFORMATION: Xaa=L, P, V, I, N, A or Y

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: (16)...(16)

OTHER INFORMATION: Xaa=E or D

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 2

OTHER INFORMATION: Xaa=V, I, M, L, P or A

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 3

OTHER INFORMATION: Xaa=S, T, A or C

FEATURE:
  NAME/KEY: VARIANT

SEQUENCE: 414

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
  1  5 10 15

Xaa

SEQ ID NO 415
 LENGTH: 7
 TYPE: PRT
 ORGANISM: Homo sapiens
 FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 1

OTHER INFORMATION: Xaa=E or D

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 2

OTHER INFORMATION: Xaa=V, I, M, L, P or A

FEATURE:
  NAME/KEY: VARIANT
  LOCATION: 3

OTHER INFORMATION: Xaa=S, T, A or C

FEATURE:
  NAME/KEY: VARIANT
Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

Xaa Xaa Xaa Xaa Xaa Xaa
1 5
Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1

SEQ ID NO 419
LENGTH: 363
TYPE: DNA
ORGANISM: Homo sapiens

SEQUENCE: 418

caggtgccagg tgggtgatgc tgaggggtgg atggaagagt ggtgagggccc cgg gggtgaggtc 60
tctgtgcagcc tctgtgtgata cactctcacc ggc tactatat tacatcgag ggc acaggggcc 120
cgggaaac ggggtggtgat ggtgggtgatg atcaacccct cagctgttgt gcacaactat 180
gccagcaaggt tgtcagggccag ggtcaccctg accaggagcac ggttcatctc cacagcctac 240
gtgaggtgtg gcagggctgg atgtgcagcag aacgcgcgtct atactgtgtgc ggagggcacc 300
tgtaactagg actactaggg tagggagtgc tgggcccag gcaccacggt cactctcctc 360
tca 363

SEQ ID NO 419
LENGTH: 121
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 419

Gln Val Glu Val Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Tyr Ile His Trp Val Arg Glu Ala Pro Gly Glu Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Pro His Ser Gly Ala Asn Tyr Ala Glu Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Thr Ala Val Tyr Tyr Cys
95 90 95
Ala Arg Gly Asn Trp Asn Tyr Asp Tyr Tyr Gly Met Asp Val Trp Gly
100 105 110
Gln Gly Thr Thr Val Thr Val Ser Ser
115 120

SEQ ID NO 420
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 420

gacatcagc tgaccaagtct tcacatctcc ctgctcatgcat ctagggaga cagagtcacc 60
atcacttggcc ggccagatcga gacattagc aatatttag cctggtatca gcagaaacc 120
gggaaggtcc ctaggctccct gatcaatgct gcattccactt tcacattcagg ggtcccacct 180
cggtcagtt gcagggagct tgtggagcatt ttaactctca cacatcagag cctatagctt 240
gagatgtgct caaacttattt cgtgtaaagg tatacgatgg ctccacattcc tttgggcctt 300
gggaacaggg tggataatgaa a 321

<210> SEQ ID NO 421
<211> LENGTH: 167
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 421

Asp Ile Glu Met Thr Glu Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asp Ile Ser Asn Tyr 20 25 30
Leu Ala Trp Tyr Gln Gln Pro Gly Lys Val Pro Lys Leu Ile 35 40 45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80
Glu Asp Val Ala Thr Tyr Phe Cys Gln Arg Tyr Gln Ile Ala Pro Phe 85 90 95
Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys 100 105

<210> SEQ ID NO 422
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 422

caagtgccag tgtgagggtc tggggagggc gttgcagcag cttggagggc cctgagactc 60
tctggtcag cgtctggatt caccttcagt agctagtggca tgcctgtggtt cgcgccaggt 120
cagggcaggg aggtgcaggtg ggtggcagtt atctgggttag atggaagttac taataactat 180
gcgcagtcgc tgaagggcgcg atccacaccac tccagagcata attccagagaa cagctgttat 240
cggtcagtaa cgccagtggag aagcggagac aaggtgtggg attacctttgc gaggtcagctg 300
gcggttaacc actaactacta cggtatggac gttctggggc aagggacacc ggtccaggctc 360
tcccata 366

<210> SEQ ID NO 423
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 423

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30
Gly Met His Trp Val Arg Gln Ala Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Val 1le Trp Tyr Asp Gly Ser Thr Lys Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
85 90 95
Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Thr Val Val Ser Ser
115 120

&lt;210&gt; SEQ ID NO 424
&lt;211&gt; LENGTH: 324
&lt;212&gt; TYPE: DNA
&lt;213&gt; ORGANISM: Homo sapiens
&lt;400&gt; SEQUENCE: 424
tttctgagctgctactcagcctccgctctgtctgctctgcctcctgtcagc 60
tgclgctgctgctactcagcctccgctctgtctgctctgcctcctgtcagcctccgctctgtcagclevelandctgctgctctgcctcctgtcagc 120
tgclgctgctgctactcagcctccgctctgtctgctctgcctcctgtcagcctccgctctgtcagclevelandctgctgctctgcctcctgtcagc 180
tgttcgctctcagcctccgctctgtctgctctgcctcctgtcagcctccgctctgtcagclevelandctgctgctctgcctcctgtcagc 240
tgclgctgctgctactcagcctccgctctgtctgctctgcctcctgtcagcctccgctctgtcagclevelandctgctgctctgcctcctgtcagc 300
gagagctgctactcagcctccgctctgtctgctctgcctcctgtcagcctccgctctgtcagclevelandctgctgctctgcctcctgtcagc 324

&lt;210&gt; SEQ ID NO 425
&lt;211&gt; LENGTH: 108
&lt;212&gt; TYPE: PRT
&lt;213&gt; ORGANISM: Homo sapiens
&lt;400&gt; SEQUENCE: 425
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1 5 10 15
Thr Val Arg 1le Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala
20 25 30
Thr Trp Tyr Gln Lys Pro Arg Gln Ala Ala Pro Val Leu Val 1le Tyr
35 40 45
Gly Lys Asn Tyr Arg Pro Ser Gly Ile Pro Asp Asp Asp Ser Gly Ser
50 55 60
Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser Ile Gly Asn His
85 90 95
Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

&lt;210&gt; SEQ ID NO 426
&lt;211&gt; LENGTH: 366
&lt;212&gt; TYPE: DNA
&lt;213&gt; ORGANISM: Homo sapiens
&lt;400&gt; SEQUENCE: 426
<table>
<thead>
<tr>
<th>Amino Acid Sequence</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg</td>
<td>1 5 10 15</td>
</tr>
<tr>
<td>Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr</td>
<td>20 25 30</td>
</tr>
<tr>
<td>Gly Leu His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val</td>
<td>35 40 45</td>
</tr>
<tr>
<td>Ala Val Ile Trp Leu Asp Gly Ser Ser Asn Gly Tyr Tyr Ala Asp Ser Val</td>
<td>50 55 60</td>
</tr>
<tr>
<td>Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr</td>
<td>65 70 75 80</td>
</tr>
<tr>
<td>Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys</td>
<td>95 90 95</td>
</tr>
<tr>
<td>Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Gly Met Asp Val Trp</td>
<td>100 105 110</td>
</tr>
<tr>
<td>Gly Gln Gly Thr Thr Val Thr Val Ser Ser</td>
<td>115 120</td>
</tr>
</tbody>
</table>

Sequence 428:

```
ttttcagct tgaactcagga ccttgctgtg tcttgccct tgggccagac agtcaagatc 60
cacggcagaag gacagacgct cagagagtaa tctggcagct gttaccagca gaagccaga 120
cacggccctgy ttcctggtag ctttggtaaa assacccggc cctccgggyt ccagacccga 180
ttccttggcc ccaacccagg acaacacgct tcctgcagga tcacccgggc tcaggccagaa 240
gatgggctg atacattcgct taacctcaggg gaactaattg gigaacctct gctctccgggc 300
gagaggccag agtgcagcct ccta 324
```
Ser Trp Tyr Glu Glu Lys Glu Pro Arg Glu Ala Pro Val Leu Val Ile Phe
    35      40
Gly Lys Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
    50      55      60
Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Glu Ala Glu
    65      70      75      80
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ile Ile Gly Asp His
    85      90      95
Leu Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
    100     105

<210> SEQ ID NO 430
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 430

ccagtgagc tggtgagtc tcggggaggg gttggccagt ctgggagct cctgagactc  60
tccctgag cgcctgtagg cacccctcag gacactggca tgcactggtg cgcgccaggt  120
ccaggggcgg cgcctgagtg gttggcagtt atatgtgttg atggagatgg taatgtctat  180
goagagtg ccagggcgcg atccacagtc tccagagaca atctcaagga cagctgtat  240
tggcttaag ggccgagcag gcgggcttt cgtcctctgg cggaggcttg gctggagttc  300
gctggtacc actactacta cggtatggac gtcctgggccc aaggaccac ggtcaccggc  360
tcctca

<210> SEQ ID NO 431
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 431

Gln Val Glu Leu Val Glu Ser Gly Gly Val Val Gln Ser Gly Arg
    1       5      10      15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Arg Asn Tyr
    20      25      30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
    35      40      45
Ala Val Ile Trp Phe Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
    50      55      60
Lys Gly Arg Ser Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
    65      70      75      80
Leu Leu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
    85      90      95
Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Gly Met Asp Val Trp
    100     105     110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser
    115     120

<210> SEQ ID NO 432
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 432

tccctgagc tgactcagga ccctgtctgg tctgtggccc tggggacagc agtcaggatc  60
acatgcacag ggacacagct cagaagctat tcaatcagct ggtaccagca gaagcacaag 120
caggccctcg tactgtggat ctagtgaaca acaaaccggg cctcagggat cccagggaca 180
atcctttgc ccaactcctag aaacacagct tctttgacca tcacttggggc tcggcggaa 240
gatggaggtg actactatcg ttaatccggg gacatcactg tgacacactc gttgtccggc 300
ggagggacca aactggacgc ctta 324

<210> SEQ ID NO 433
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 433
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1 5 10 15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala 20 25 30
Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45
Gly Lys Asn Asn Pro Ser Gly Ile Pro Asp Arg Ile Ser Gly Ser 50 55 60
Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu 65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ile Ile Gly Asp His 85 90 95
Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 100 105

<210> SEQ ID NO 434
<211> LENGTH: 342
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 434
caggtgcacgc tgctggaggtc tggtggaaggc gttgcctagc cgggtcgagtc cctagacagc 60
tctcgtgcag ctcagttggat ccaagcagct aagctagtgg aagcttggagt cgcagcttgg 120
ccgctcgag ggctgaggtg gttggctagtt atatggttatgt attgctagta taaatctctat 180
gacatcctcg tggagggccgg atcaccacat tccagagaca attccagaa cagcgctgta 240
tgcaaatga acagctgcag agcggcggac actgctgatt actacttgctg gaggacagtgg 300
gctgtggagt gggagctgag aacctcggtc actggctctct ca 342

<210> SEQ ID NO 435
<211> LENGTH: 114
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 435
Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg 1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Val Arg Asp Arg Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100 105 110
Ser Ser

<210> SEQ ID NO 436
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 436
tcttctgagc tgaactaaga cccctgtctg tctgtgacct tgggacagac agtacaggtc 60
acatgcacag gagacacgct cagaggtat tattcaagct ggttccagca gaagccagca 120
caggccctgt tacttgtcact ctaggtgaa aacaacgggc cttcgagggat cccagacgga 180
tcttcttgct ctccacccag aacaacacgt tctttgacca tcactcgggc tcacccgga 240
gatgagctgt actaattaactg taagtcggag gccagcaggtg tgcacatcct cgttgctggc 300
ggcagcaca agtgcacgct ctcg 324

<210> SEQ ID NO 437
<211> LENGTH: 188
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 437
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1 5 10 15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala
20 25 30
Ser Trp Tyr Gln Gln Gly Pro Arg Gln Ala Pro Val Leu Val Ile Tyr
35 40 45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
50 55 60
Thr Ser Gly Asn Thr Asl Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Lys Ser Arg Asp Ser Ser Gly Asp His
85 90 96
Leu Val Phe Gly Gly Gly Thr Leu Thr Val Leu
100 105

<210> SEQ ID NO 438
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 438
caggtgcagg cggctgagtc tggggaggcc gtgggtccagc ctgggggagt cctgagcctc 60
tctctgctac gcctgtgatt ccacctcag tcaactggtg ttgcagcagtct 120
cggcagcgg ggctggaggt ctggggaggt attttggtatg atgggaagt tagaactaatc 180
gcgacacctc tagggcgggct atccacacc tccagacca atccacagaa cagcgtgtat 240
tctgcaatgc aaagccctgtg aggcgggaggc aagcgtgtgt ataatgtgct ggcagctgtc 300
<210> SEQ ID NO 439
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 439

Gln Val Gln Val Val Glu Ser Gly Gly Val Val Gln Pro Gly Gly 1  5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr 20 25
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 30 35 40 45
Ala Val Ile Trp Tyr Asp Gly Ser Ser Lys Tyr Tyr Ala Asp Ser Val 50 55 60
Lys Gly Arg Ser Thr Ile Ser Arg Asp Ser Lys Ser Thr Val Tyr 65 70 75 80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys 85 90 95
Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp 100 105 110
Gly Gln Gly Thr Thr Val Thr Val Val Ser 115 120

<210> SEQ ID NO 440
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 440

tcttctgagc tgacctcagga ccttctgctg tcctgtgccct tgggacagac agtcaggctc 60
acatcgcagc cagagcgtat tctgcacagt gttacagcga gaagccaga 120
caggccccctg taccttcagt ctagtgtaaa aaccccgcc cctcagggatt ccacagcga 180
tctttcctg ctacacccgta aacacagct tcttcgacagt ctaacctgggt ctacagcga 240
gatgaggctg actattgag taaagcggg gacagcagt gttgacactc ggtgtaagcc 300
gaggggacagc agtgacagct ccta 324

<210> SEQ ID NO 441
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 441

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln 1  5  10 15
Thr Val Arg Ile Thr Cys Glu Gly Asp Ser Leu Arg Gly Tyr Tyr Ala 20 25 30
Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr 35 40 45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser 50 55 60
Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Gln 65 70 75 80
<table>
<thead>
<tr>
<th>367</th>
<th>Leu Val Phe Gly Gly Gly Gly Thr Lys Leu Thr Val Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td>368</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>210</th>
<th>SEQ ID NO 442</th>
</tr>
</thead>
<tbody>
<tr>
<td>211</td>
<td>LENGTH: 366</td>
</tr>
<tr>
<td>212</td>
<td>TYPE: DNA</td>
</tr>
<tr>
<td>213</td>
<td>ORGANISM: Homo sapiens</td>
</tr>
</tbody>
</table>

**SEQUENCE: 442**

cagggtagag tgggagcag tgggagagg ctcggtagg ctcggtagg cctcgggct ctcgggct ctcgggct ctcgggct ctcgggct ctcgggct 60
tctggtagc cctcgggct ctcgggct ctcgggct ctcgggct ctcgggct ctcgggct ctcgggct ctcgggct ctcgggct 120
cggcggtagc gctcggtgct gctcggtgct gctcggtgct gctcggtgct gctcggtgct gctcggtgct gctcggtgct gctcggtgct gctcggtgct 180
gcaggtagc ggctcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 240
tcggcagcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 300
gtctgggct gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 360
tcggcagcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 366

<table>
<thead>
<tr>
<th>210</th>
<th>SEQ ID NO 443</th>
</tr>
</thead>
<tbody>
<tr>
<td>211</td>
<td>LENGTH: 122</td>
</tr>
<tr>
<td>212</td>
<td>TYPE: PRT</td>
</tr>
<tr>
<td>213</td>
<td>ORGANISM: Homo sapiens</td>
</tr>
</tbody>
</table>

**SEQUENCE: 443**

gln val gln leu val glu ser gly gly gly val val gln pro gly arg 1 5 10 15
ser leu ser leu ser cys ala ala ser gly phe thr phe ser ser tyr 20 25 30
gly met his trp val arg gln pro gly lys gly leu glu trp val 35 40 45
ala val ile trp tyr asp gly ser tyr lys asp tyr ala asp ser val 50 55 60
lys gly arg ser thr ile ser arg asp ser lys asp thr leu tyr 65 70 75 85
leu gln met asn ser leu arg ala glu asp thr ala val tyr cys 85 90 95
ala arg ser val ala gly tyr his tyr tyr gly met asp val trp 100 105 110
gly gln gly thr thr val thr val ser ser 115 120

<table>
<thead>
<tr>
<th>210</th>
<th>SEQ ID NO 444</th>
</tr>
</thead>
<tbody>
<tr>
<td>211</td>
<td>LENGTH: 324</td>
</tr>
<tr>
<td>212</td>
<td>TYPE: DNA</td>
</tr>
<tr>
<td>213</td>
<td>ORGANISM: Homo sapiens</td>
</tr>
</tbody>
</table>

**SEQUENCE: 444**
tcggcagcag tcggcagcag tcggcagcag tcggcagcag tcggcagcag tcggcagcag tcggcagcag tcggcagcag tcggcagcag tcggcagcag 60
acggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 120
cggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 180
tcggcagcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 240
gtctggtgct gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 300
ggaggagaag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag gcaggcggcag 324
<210> SEQ ID NO 445
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 445

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1    5    10    15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala
20   25   30
Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Ile Leu Val Ile Tyr
35   40   45
Gly Lys Asn Asn Arg Pro Ser Gln Pro Gln Asp Arg Phe Ser Gly Ser
50   55   60
Thr Ser Gly Ile Thr Ala Ser Leu Thr Thr Gly Ala Gln Ala Glu
65   70   75   80
Asp Glu Ala Asp Tyr Tyr Cys Ser Arg Asp Ile Ile Gly Asn His
85   90   95
Leu Leu Phe Gly Gly Gly Gln Thr Leu Thr Val Leu
100  105

<211> SEQ ID NO 446
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 446

cagggctcgc tgggaggct tgggaggct cagggctcgc cagggctcgc cagggctcgc 60
ctcggctcgc cgctgggagt caccctgaga gcggcgcggt ctcggctcgc 120
cgccggcgc gccggcgc gcgccgcgc gccgctgccgc gccgctgccgc 180
gcccggcgc gctgggaggct caccctgccgc gccgctgccgc gccgctgccgc 240
cgggaggggc gcggcgcgc gcggcgcgc gcggcgcgc gcggcgcgc 300
cgggaggggc gcggcgcgc gcggcgcgc gcggcgcgc gcggcgcgc 360
gcgcgtgct gctgcgct ctacactac gcggcgcgc gcggcgcgc 375

cgcgtgct gctgcgct ctacactac gcggcgcgc gcggcgcgc

<211> SEQ ID NO 447
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 447

Gln Val Gln Leu Val Ala Ser Gly Gly Val Val Gln Pro Gly Arg
1    5    10    15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser Tyr
20   25   30
Gly Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val
35   40   45
Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Ala Ser Val
50   55   60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Ser Lys Asn Thr Leu Tyr
65   70   75   80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
95   90   95
Ala Arg Gly Gly Ser Gly Ser His Arg Tyr Tyr Tyr Gly Met
Asp Val Trp Gly Gln Gly Gly Thr Thr Val Thr Val Ser Ser Ser

<210> SEQ ID NO 448
<211> LENGTH: 324
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 448
tctctgagc tgacctcggc cccctgtgtg tcttgagcct tgccgacagcc agtcaggtact 60
acagtccagc gagacgacct cgaacctcttat gcagcagctca ggtacccagca gacgtccaga 120
cagccccccta tctctgtgact ctatgtgataa aacacccgccc cctcagggat cccagacga 180
tctctgagc ccacccagcc aatccacgtct ccctgtgacca tccctgggcc tcagccggaa 240
gctggagctgc acattacatgttaacctccgg gagacatatgt gtaacctctgcggttcggcc 300
ggagggacta agtgacacgctta 324

<210> SEQ ID NO 449
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 449
Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1 5 10 15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Thr Tyr Tyr Ala
20 25 30
Ser Trp Tyr Gln Glu Pro Arg Glu Ala Pro Ile Leu Val Ile Tyr
35 40 45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
50 55 60
Thr Ser Gly Ile Thr Ala Ser Leu Thr Ile Thr Gly Ala Glu Ala Glu
65 70 75 80
Asp Glu Ala Asp Tyr Tyr Cys Ser Arg Asp Ile Ile Gly Asn His
90 95
Leu Leu Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 450
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 450
caggtqccag tggqgtqagct tggggaggcgt gqgtqccagccttgqagqccccttgqacgt 60
tcctgqccagctqcttgqagg atacctqccagctqacttgqgctc qgqccqagcgt 120
cagqccqagcgtggqagqct tataqgtatqatgqgtqaggtta aatattaqctat 180
gqacctqccag tgqggtqagcgt accatqccagcctqccagqagcctqccagctqcttgqaggtc 240
tcqcaqctgqactqqccag ctqgqgtqagqct ctqgqdtqgtqtc cttqgtqatqtc 300
gtqgqdtqgtqacctqactqccagctqccagqagcctqccagqagqctctqccagqac 360
goqccqagc

<210> SEQ ID NO 451
<211> LENGTH: 122
<212> TYPE: PRT  
<213> ORGANISM: Homo sapiens  

<400> SEQUENCE: 451

Gln Val Gln Val Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg  
1     5     10    15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr  
20    25    30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Lys Leu Glu Trp Val  
35    40    45
Ala Val Ile Trp Tyr Asp Gly Gly Asn Lys Tyr Tyr Ala Asp Ser Val  
50    55    60
Lys Gly Arg Ser Ile Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr  
65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Arg Thr Ala Val Tyr Cys  
90    95
Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Tyr Gly Met Asp Val Trp  
100   105   110
Gly Gln Gly Thr Thr Val Thr Val Thr Ala Ser  
115   120

<210> SEQ ID NO 452  
<211> LENGTH: 127  
<212> TYPE: DNA  
<213> ORGANISM: Homo sapiens  

<400> SEQUENCE: 452

cagtctgcgc tcagctcgcc tgcctccgtg tctgggtctc ctggacagtc gatcaccatc  
60
tcgtgaactg gacaccagag tcagcggtgt gttataact ctgctctctg gtaaccacag  
120
cacccagcca aaccccccca actcgtgatt ttagggctca gtaatccgccc ttcagggatt  
180
tctatcgct tcttctgtgct caagctctgccc aacagcgctct cctgacactctctgcttccc  
240
caggctgagg acagaggtgca tattccctct gcacccatat caacccacag catggtctctc  
300
gcgccggaga caagcttgcc gctccta  
327

<210> SEQ ID NO 453  
<211> LENGTH: 109  
<212> TYPE: PRT  
<213> ORGANISM: Homo sapiens  

<400> SEQUENCE: 453

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln  
1     5     10    15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr  
20    25    30
Asn Ser Val Ser Trp Tyr Gln Gln His Pro Gly Lys Pro Pro Lys Leu  
35    40    45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Ile Ser Asn Arg Phe  
50    55    60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu  
65    70    75    80
Gln Ala Glu Asp Glu Ala Asp Tyr Phe Cys Ser Ser Tyr Thr Ser Thr  
85    90    95
Ser Met Val Phe Gly Gly Gly Thr Lys Leu Ala Val Leu  
100   105
caggtgcaag tgtgaggtg tggggaggg gttggtgcag cgctggaggct ctgtgacttc
60
tctgtgcaag tgtcttgaggt cacttctcaag aactatggca tgcacttgggt cggcctggct
120
cacagcagag ggtcggagggt gttggcagtt atatgtgtatg atggaggtaa taatatactat
180
gcagcatcc tgaaggggccg atccatcctc tccagagaca attgaagagc caagctgtat
240
cctccaaatga acacgccctag agccgagac acgcctgttt attattgctc gaggtcagtg
300
gcctgttacc atattacta cgctatgcac gccttgccgcc aagggacacg gctacgccgc
360
gcctca
366

Gln Val Gln Val Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg
1  5  10  15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20  25  30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35  40  45
Ala Val Ile Trp Tyr Asp Gly Gly Gly Lys Tyr Tyr Ala Asp Ser Val
50  55  60
Lys Gly Arg Ser Ile Ile Ser Arg Asp Asn Ser Lys Ser Thr Leu Tyr
65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
95  90  95
Ala Arg Ser Val Ala Gly Tyr His Tyr Tyr Gly Met Asp Val Trp
100 105 110
Gly Gln Gly Thr Thr Val Val Thr Val Ala Ser
115 120
<400> SEQUENCE: 457

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1   5   10   15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Gly Tyr Tyr Ala
20  25  30
Ser Trp Tyr Gln Gln Lys Pro Arg Gln Ala Pro Val Leu Val Ile Tyr
35  40  45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Arg Phe Ser Gly Ser
50  55  60
Thr Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
65  70  75  80
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Asn Ile Gly Asp His
85  90  95
Leu Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 450
<211> LENGTH: 381
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 458

gaggtgcgct tggtggagtct gggtggagtct gggtggagtct ctgagactc 60
tctgtgccac ctcctggagtac cgccttgtagc cttcgcttggt gcggcaggtgtgct 120
caggaggg ggggatagg tgtggcagcataaat aaggtgaaat cagggatatcctggtt 180
gtggagact gcagggagct gattcaccctc tccatagact cagggagactgtgagtc ttcgtggtt ggtgccgccg ctcctggtttttctggt 240
gtccatcgg tggagggagct caggggagactgtgagtc ttcgaggtgcagctgtggtttttctggtggtttttctggtggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggtttttctggttttt

<210> SEQ ID NO 459
<211> LENGTH: 127
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 459

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1   5   10   15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20  25  30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Leu Glu Trp Val
35  40  45
Ala Ser Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50  55  60
Lys Gly Arg Phe Thr Ile Ser Arg Arg Asn Ala Arg Asn Ser Leu Tyr
65  70  75  80
Leu Gln Met Asn Ser Leu Arg Ala Glu Thr Ala Val Tyr Cys
85  90  95
Ala Arg Asp Leu Val Leu Met Val Tyr Asp Ile Asp Tyr Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
115 120 125

<210> SEQ ID NO 460
<table>
<thead>
<tr>
<th></th>
<th>LENGTH: 336</th>
</tr>
</thead>
</table>

| ORGANISM: Homo sapiens |

<table>
<thead>
<tr>
<th>SEQUENCE: 460</th>
</tr>
</thead>
</table>

| 60 | 120 | 180 |

| 240 | 300 | 336 |

<table>
<thead>
<tr>
<th>SEQ ID NO 461</th>
</tr>
</thead>
</table>

| 1 | 5 | 10 | 15 |

| ORGANISM: Homo sapiens |

<table>
<thead>
<tr>
<th>SEQUENCE: 461</th>
</tr>
</thead>
</table>

| 20 | 25 | 30 |

| 35 | 40 | 45 |

| 50 | 55 | 60 |

| 65 | 70 | 75 | 80 |

| 95 | 90 | 95 |

| 100 | 105 | 110 |

| ORGANISM: Homo sapiens |

<table>
<thead>
<tr>
<th>SEQUENCE: 462</th>
</tr>
</thead>
</table>

| 60 | 120 |

| 180 | 240 |

| 300 | 360 | 381 |

<table>
<thead>
<tr>
<th>SEQ ID NO 463</th>
</tr>
</thead>
</table>

| 1 | 5 | 10 | 15 |

| ORGANISM: Homo sapiens |

<table>
<thead>
<tr>
<th>SEQUENCE: 463</th>
</tr>
</thead>
</table>

| 380 |
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
    20    25    30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
    35    40
Ala Ser Ile Lys Gln Asp Gly Ser Lys Tyr Tyr Val Asp Ser Val
    50    55    60
Lys Gly Arg Phe Ala Ile Ser Arg Asp Ala Lys Asn Ser Leu Phe
    65    70    75    80
Leu Gln Met Asn Ser Leu Arg Ala Glu Thr Ala Val Tyr Cys
    85    90
Ala Arg Asp Val Leu Val Leu Met Val Tyr Ile Asp Tyr Tyr Tyr
   100   105   110
Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
   115   120   125

<210> SEQ ID NO 464
<211> LENGTH: 316
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 464
gatatttgca tgacatcagtc tccactctcc ctgccttgca ccctctgagaga gcccggcttc
    60
atctcttgca ggtcttagtca gagcctctcg cataataatg ggtacaacta ttggtattgg
    120
tacctcagca agccacagga gcctccacag cctctgatct atttgggttca taatccgggcc
    180
tccgggtctcc ctggcaggtt cagttggcagtt gatcagggcca cacactctac actgaaatcc
    240
tagcaggttg aggctgagga tgtgagaggt tgtatctgca tgcacaactct acaacactcgg
    300
tccacttctcg gcggagggac caggtggtgag atcaaa
    336

<210> SEQ ID NO 465
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 465
Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
    1    5    10    15
Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
    20    25    30
Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
    35    40
Pro Gln Leu Leu Ile Tyr Leu Gln Ser Asn Arg Ala Ser Gly Val Pro
    50    55    60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr His Leu Thr Leu Lys Ile
    65    70    75    80
Ser Arg Val Gln Ala Glu Asp Val Gly Val Tyr Cys Met Gln Thr
    85    90
Leu Gln Thr Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
   100   105   110

<210> SEQ ID NO 466
<211> LENGTH: 342
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 466
caggtgcacg tcgtggagtct tgggggaggg cttggccacg ctgggggagt tcctgagacctc
tctgtgcacg ccctttgatt caaacctgcgt agctatcggca tcggtaggggt ccggcagccgt
tccggcaggg ggtgctggagt ggtggcagtt atatactatg atggaaattaa taaacactat
gccagtcccg tgtggggccgc attccactct tccagagaca atccaaagaa cagctgttat
tctgcaatga acagcttgag acgcagggac aaggtgttgtt attacgtgc gagacattcg
ggactttgacg gggccauggg aaccccttggc taccgtctct ca
c
<210> SEQ ID NO 467
<211> LENGTH: 114
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 467

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Ala Gln Pro Gly Arg
1       5       10      15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20      25      30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Lue Glu Trp Val
35      40      45
Ala Val Ile Tyr Tyr Asp Gly Ile Asn Lys His Tyr Ala Asp Ser Val
50      55      60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65      70      75      80
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Cys
85      90      95
Ala Arg Asp Arg Gly Leu Asp Trp Gly Gln Gly Thr Leu Val Thr Val
100     105     110

Ser Ser

<210> SEQ ID NO 468
<211> LENGTH: 339
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 468

gacatcgta tggacccggt tccagactcc ctggctgtgt ctctgggga gagggccacc
tataaactgca agtcggcagc gatgtttta tacaagctca acagtaaagaa tctatggtt
tgtacccagc aagacccaggg acagccctctc aagtctgctca ttactcgggc cttctaccccg
210    220    230
aatggggg gcctttgccg attcagggctt ggcagagttt cactctcacc
240
atccagcagc tcggaggtga agatgtggga gttttactaat gcacaaaga attagacta
260
ccgttgacg tctggcagacgg gaccaaggtg gaatacaaa
339

<210> SEQ ID NO 469
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 469

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1       5       10      15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser
20      25      30
Ser Asn Ser Lys Asn Tyr Leu Val Trp Tyr Gln Gln Lys Pro Gly Gln
35      40      45
Pro  Pro  Lys  Leu  Leu  Ile  Tyr  Trp  Ala  Ser  Thr  Arg  Glu  Ser  Gly  Val
50  55  60
Pro  Asp  Arg  Phe  Ser  Gly  Ser  Gly  Ser  Gly  Thr  Asp  Phe  Thr  Leu  Thr
45  70  75  80
Ile  Ser  Ser  Leu  Gln  Ala  Glu  Val  Ala  Val  Tyr  Tyr  Cys  Gln  Gln
85  90  95
Tyr  Tyr  Ser  Thr  Pro  Trp  Thr  Phe  Gly  Gln  Gly  Thr  Lys  Val  Glu  Ile
100  105  110

Lys

<210> SEQ ID NO 470
<211> LENGTH: 357
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 470
gaggtgcagc  tgggaggct  tggggagggc  tgggtcagc  cggggggtgc  cctgagactc  60
tctgtgcaag  cctctggact  cagctttagt  aaccttcgga  tgacgctggt  cgcgcagctg
120
tcggaggagc  ggtgaggctg  ggtggcacaac  ataaaagcag  atggaaatga  taataactat
180
gtggacatcg  tgaaggggctg  attcaccatc  tccagagaca  acgcacaagaa  ttcacgtgat
240
tcggaaatga  acacotgcag  agcggagtgac  acggtcgtgt  attacgtgac  gagagatgca
300
aactggggtct  ttgctttttga  ttatcgggcag  ccagggcaca  ttgctacgcg  cttcccta
357

<210> SEQ ID NO 471
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 471
Glu  Val  Gln  Leu  Val  Gln  Ser  Gly  Gln  Gly  Leu  Val  Gln  Pro  Gly  Gly
1  5  10  15
Ser  Leu  Arg  Leu  Ser  Cys  Ala  Ala  Ser  Gly  Leu  Thr  Phe  Ser  Asn  Phe
20  25  30
Trp  Met  Ser  Trp  Val  Arg  Gln  Leu  Pro  Gly  Lys  Gly  Leu  Glu  Trp  Val
35  40  45
Ala  Asn  Ile  Lys  Gln  Asp  Gly  Asn  Phe  Tyr  Val  Asp  Ser  Val
50  55  60
Lys  Gly  Arg  Phe  Thr  Ile  Ser  Arg  Asp  Asn  Ala  Lys  Asn  Ser  Leu  Tyr
65  70  75  80
Leu  Gln  Met  Asn  Ser  Leu  Arg  Ala  Glu  Asp  Thr  Ala  Val  Tyr  Cys
85  90  95
Ala  Arg  Glu  Ser  Asn  Thr  Gly  Phe  Ala  Phe  Asp  Ile  Trp  Gly  Gln  Gly
100  105  110
Thr  Met  Val  Thr  Val  Ser  Ser
115

<210> SEQ ID NO 472
<211> LENGTH: 257
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 472
cagtctgact  tgcctcaagcc  acctctagcg  tctgggaccc  cgggccagag  ggtcaccatc  60
tctgttctg  gaacagcgtc  cacaattgga  agtacacttg  tsaactggtca  ccaagcagtc
120
ccaggaaagg ccccccaacct cctcatctat agtaataact ggcggccttc aggggtcctt
180
gaccaattct ctgggcctca gctgggcaccc ttcaagtcctc cc tgggccatacg tgggtcctac
240
tctgaggtag gctgttgaatt taacctgctca gcatgggattg acaacgttga tgggtgttcc
300
gggtcaggaga ccaagtctgac ctgctctta
327

<210> SEQ ID NO 473
<211> LENGTH: 109
<212> TYPE: PRO
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 473

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Ser Ser Ser Ser Ser Asn Ile Gly Ser Lys
20 25 30
Thr Val Asn Trp Tyr Gln Gln Gln Pro Gly Thr Ala Pro Lys Leu Leu
35 40 45
Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
50 55 60
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65 70 75 80
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
85 90 95
Asn Trp Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 474
<211> LENGTH: 357
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 474
gaggtgcaagc tgttgaggct ttgggtgcacg ctggggggcttc cctgtggactc
gaggtgcaagc tgttgaggct ttgggtgcacg ctggggggcttc cctgtggactc
ttgggtgcacg cttcctgcgact accttcctact aaccttcctct aagtcctgtct tgtggcaaggtc
120
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
180
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
240
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
300
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc tgtggcaaggtc
357

<210> SEQ ID NO 475
<211> LENGTH: 119
<212> TYPE: PRO
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 475

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Asn Phe
20 25 30
Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Asn Ile Lys Gln Asp Gly Ser Glu Lys Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95

Ala Arg Glu Ser Asn Trp Gly Phe Ala Phe Asp Ile Trp Gly Gln Gly 100 105 110

Thr Met Val Thr Val Ser Ser 115

<210> SEQ ID NO 476
<211> LENGTH: 327
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 476
cagtctggtc tgacctgcc ccacctgag ccgccagcc cagccagcag ggtcacccct 60
tctgtgcctg gaagactgct ccacatgga agtaaaactg taaaacctg ccacacttg 120
cagccagcag ccctcctgct gcctaatctt ataattactt gcgcctccct gcgcctcct 180
gacctctt gcctgcaac ctcctgctct ctcctgctct tggctgctct tggctgctct 240
tctgagatgc agctctgatta ttaacgtgca acatggagtc acaagtggacat ttggtcttcc 300
gggtcgcagca ccaagctgcag cgtccta 327

<210> SEQ ID NO 477
<211> LENGTH: 109
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 477
Gln Ser Val Leu Thr Gln Pro Pro Ser Ser Ala Ser Gly Thr Pro Gly Gln 1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Ser Ser Ser Ser Lys 20 25 30

Thr Val Asn Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu 35 40 45

Ile Tyr Ser Asn Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln 65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Arg Leu 85 90 95

Asn Trp Val Phe Gly Ala Gly Thr Lys Leu Thr Val Leu 100 105

<210> SEQ ID NO 478
<211> LENGTH: 366
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 478
cagctcaccct tgaagaygtc tggctctgtg tggtyaacc ccacagacac ccctccagctg 60
aacctgaccc tctctgagtt ctctcctgcc aatgttagaa tgggtctggct cttggatcctg 120
cagcccctcag ggagccagct gccctccatt ttcggattgc cgaatatctg cgaatatctg 180
taccacacat cttctgacag cctgtcctcct acctctcctc aacccagagc aagccctgctg 240
gctctaccaacc agccacacat acctctccag ccctctccaa aagccctgctg 300

tctgatcagtc ccacgctgcag cgtcctctct ctctctctct ctctctctct ctctctctct 360
<210> SEQ ID NO 479
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 479

Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu  
   1   5  10  15
Thr Leu Thr Leu Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Asn Val  
   20  25  30
Arg Met Gly Val Ser Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu  
   35  40  45
Trp Leu Ala His Ile Phe Ser Asn Glu Asn Ser Tyr Arg Thr Ser  
   50  55  60
Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Ser Gln Val  
   65  70  75  80
Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr  
   85  90  95
Cys Ala Arg Ile Val Gly Ala Thr Thr Asp Asn Ala Phe Asp Ile Trp  
  100 105 110
Gly Gln Gly Thr Met Val Thr Val Ser Ser  
  115 120

<210> SEQ ID NO 480
<211> LENGTH: 124
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 480

tcttacgta gcacctgagc acctctggtg tcagtggccc caggagcagc gggcaggttt  
    1    5  10  15
acctgggggg gaaccaacat tgaagtaaa aagtctgcact gctaccagca gaagcagggc  
     20   25   30
ccggcctcct gcctgctgtct ctagaagctga gaggccggcg ccttggggt cctcgggct  
     35   40   45
ctctgcttg ccaaccctgg gaaccagggc acctggacca tcagcgaggt ggaagcggggg  
     50   55   60
  gatgagcgc ggatccttt ctagtgtggt gtatgtagta gtgatcctgt ggtattcggc  
     65   70   75   80
ggagggcaca agctgaccag cctata  
     85  90  95

<210> SEQ ID NO 481
<211> LENGTH: 108
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 481

Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln  
  1   5  10  15
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val  
  20  25  30
His Thr Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr  
  35  40  45
Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser  
  50  55  60
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly  
  65  70  75  80
Asp Glu Ala Asp Phe Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp Pro  
  85  90  95
Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105

<210> SEQ ID NO 483
<211> LENGTH: 127
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 483

Glu Val Glu Leu Val Glu Ser Gly Gly Leu Val Glu Pro Gly Gly
1  5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Trp Met Thr Trp Val Arg Glu Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45
Ala Ser Ile Lys Glu Asp Gly Ser Glu Arg Tyr Tyr Val Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Asn Ser Leu Tyr
65 70 75 80
Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Ala Tyr Cys
85 90 95
Ala Arg Pro Leu Val Val Leu Met Tyr Ala Leu His Tyr Tyr Tyr
100 105 110
Gly Met Asp Val Trp Gly His Gly Thr Thr Val Thr Val Ser Ser
115 120 125

<210> SEQ ID NO 484
<211> LENGTH: 136
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 484

gatattgta tgaactagct tccactctcc tgcctgctca ccctgagga gcggtgcctc
60
atccttgca gctctagct aagctctctg catagtaatg gatacaacta tttgattgg
120
tacctgaga agccagggga ggtctcacaag tctctgactt atttggttc taactcgggcc
180
tcgcggctcc tgcagaggt cagcagagca cagattttac actgaaactc
240
agcagagtgg agcttgagaa tgtggggttt tattactgca tgcaagctct acaaatcgcg
300
tcactttcgc gcggagggac caagggtgag atcaaa
336
| SEQ ID NO: 485 | LENGTH: 112 | TYPE: PRT | ORGANISM: Homo sapiens |
| Seq | Asp | Ile | Val | Met | Thr | Gln | Ser | Pro | Leu | Ser | Leu | Pro | Val | Thr | Pro | Gly |
| 1   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 2   | Glu | Pro | Ala | Ser | Ile | Ser | Cys | Arg | Ser | Ser | Gln | Ser | Leu | Leu | His | Ser |
| 5   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 3   | Arg | Gly | Tyr | Asn | Tyr | Leu | Asp | Trp | Tyr | Leu | Gln | Lys | Pro | Gly | Gln | Ser |
| 10  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 4   | Pro | Gln | Leu | Leu | Ile | Tyr | Leu | Gly | Ser | Asn | Arg | Ala | Ser | Gly | Val | Pro |
| 15  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 5   | Asp | Arg | Phe | Ser | Gly | Ser | Gly | Ser | Gly | Thr | Asp | Phe | Thr | Leu | Lys | Ile |
| 20  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 6   | Ser | Arg | Val | Glu | Ala | Glu | Asp | Val | Gly | Val | Tyr | Tyr | Cys | Met | Gln | Ala |
| 25  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 7   | Leu | Gln | Thr | Pro | Leu | Thr | Phe | Gly | Gly | Gly | Thr | Lys | Val | Gln | Ile | Lys |
| 30  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

| SEQ ID NO: 486 | LENGTH: 100 | TYPE: PRT | ORGANISM: Homo sapiens |
| Seq | Gln | Val | Thr | Leu | Lys | Glu | Ser | Gly | Pro | Val | Leu | Val | Lys | Pro | Thr | Glu |
| 1   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 2   | Thr | Leu | Thr | Leu | Thr | Cys | Thr | Val | Ser | Gly | Phe | Ser | Leu | Ser | Aen | Ala |
| 5   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 3   | Arg | Met | Gly | Val | Ser | Trp | Ile | Arg | Gln | Pro | Pro | Gly | Lys | Ala | Leu | Gln |
| 10  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 4   | Trp | Leu | Ala | His | Ile | Phe | Ser | Asn | Asp | Glu | Lys | Ser | Tyr | Ser | Thr | Ser |
| 15  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 5   | Leu | Lys | Ser | Arg | Leu | Thr | Ile | Ser | Lys | Asp | Thr | Ser | Lys | Ser | Gln | Val |
| 20  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 6   | Val | Leu | Thr | Met | Thr | Aen | Met | Asp | Pro | Val | Aep | Thr | Ala | Thr | Tyr | Tyr |
| 25  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 7   | Cys | Ala | Arg | Ile |     |     |     |     |     |     |     |     |     |     |     |     |
| 30  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

| SEQ ID NO: 487 | LENGTH: 98 | TYPE: PRT | ORGANISM: Homo sapiens |
| Seq | Glu | Val | Gln | Leu | Val | Glu | Ser | Gly | Gly | Gly | Leu | Val | Gln | Pro | Gly | Gly |
| 1   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 2   | Ser | Leu | Arg | Leu | Ser | Cys | Ala | Aen | Ser | Gly | Phe | Thr | Phe | Ser | Ser | Tyr |
| 5   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 3   | Trp | Met | Ser | Trp | Val | Arg | Gln | Ala | Pro | Gly | Lys | Gly | Leu | Glu | Trp | Val |
| 10  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 4   | Ala | Aen | Ile | Lys | Gln | Asp | Gly | Ser | Glu | Lye | Tyr | Val | Asp | Ser | Val |
| 15  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 5   | Lys | Gly | Arg | Phe | Thr | Ile | Ser | Arg | Asp | Aen | Ala | Lys | Aen | Ser | Leu | Tyr |
| 20  |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 6   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 7   |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |

Continued...
Leu  Gln  Met  Asn  Ser  Leu  Arg  Ala  Glu  Asp  Thr  Ala  Val  Tyr  Tyr  Cys  
     85      90      95

Ala  Arg

Amino Acid Sequence:

Gln  Val  Gln  Leu  Val  Glu  Ser  Gly  Gly  Val  Val  Gln  Pro  Gly  Arg
1      5      10      15

Ser  Leu  Arg  Leu  Ser  Cys  Ala  Ala  Ser  Gly  Phe  Thr  Phe  Ser  Ser  Tyr
20     25     30

Gly  Met  His  Trp  Val  Arg  Gln  Ala  Pro  Gly  Lys  Gly  Leu  Glu  Trp  Val
35     40     45

Ala  Val  Ile  Trp  Tyr  Asp  Gly  Ser  Asn  Lys  Tyr  Tyr  Ala  Asp  Ser  Val
50     55     60

Lys  Gly  Arg  Phe  Thr  Ile  Ser  Arg  Asp  Ser  Lys  Asn  Thr  Leu  Tyr
65     70     75     80

Leu  Gln  Met  Asn  Ser  Leu  Arg  Ala  Glu  Asp  Thr  Ala  Val  Tyr  Tyr  Cys
95      90      95

Ala  Arg

Amino Acid Sequence:

Asp  Ile  Val  Met  Thr  Gln  Ser  Pro  Leu  Ser  Leu  Pro  Val  Thr  Pro  Gly
1      5      10      15

Glu  Pro  Ala  Ser  Ile  Ser  Cys  Arg  Ser  Ser  Gin  Ser  Leu  Leu  His  Ser
20     25     30

Asn  Gly  Tyr  Asn  Tyr  Leu  Asp  Trp  Tyr  Leu  Gln  Lys  Pro  Gly  Gln  Ser
35     40     45

Pro  Gln  Leu  Leu  Ile  Tyr  Leu  Gly  Ser  Asn  Arg  Ala  Ser  Gly  Val  Pro
50     55     60

Asp  Arg  Phe  Ser  Gly  Ser  Gly  Ser  Gly  Thr  Asp  Phe  Thr  Leu  Lys  Ile
65     70     75     80

Ser  Arg  Val  Glu  Ala  Glu  Asp  Val  Gly  Val  Tyr  Tyr  Cys
85      90

Ala  Arg

Amino Acid Sequence:

Asp  Ile  Val  Met  Thr  Gln  Ser  Pro  Asp  Ser  Leu  Ala  Val  Ser  Leu  Gly
1      5      10      15

Glu  Arg  Ala  Thr  Ile  Asn  Cys  Lys  Ser  Ser  Gin  Ser  Val  Leu  Tyr  Ser
20     25     30

Ser  Asn  Asn  Lys  Asn  Tyr  Leu  Ala  Trp  Tyr  Gln  Gln  Lys  Pro  Gly  Gin
35     40     45

Pro  Pro  Lys  Leu  Leu  Ile  Tyr  Trp  Ala  Ser  Thr  Arg  Glu  Ser  Gly  Val
50     55     60
Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr  
Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys  
       65  70  75  80  90

SEQ ID NO: 491
LENGTH: 89
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 491
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln  
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn  
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu  
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Aep Arg Phe Ser  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln  
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys  
       1  5  10  15  20  25  30  35  40  45  50  55  60  65  70  75  80  90

SEQ ID NO: 492
LENGTH: 87
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 492
Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys  
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val  
His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr  
Tyr Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser  
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly  
Asp Glu Ala Asp Tyr Tyr Cys  
       1  5  10  15  20  25  30  35  40  45  50  55  60  65  70  75  80  90

SEQ ID NO: 493
LENGTH: 49
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 493
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Pro Gly Ala  
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
Gly  
       1  5  10  15  20  25  30  35  40  45
<210> SEQ ID NO 494
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 494

Gln Val Gln Leu Val Glu Ser Gly Gly Gln Gln Val Gln Pro Gln Arg
1      5      10     15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20     25     30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35     40     45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50     55     60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65     70     75     80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85     90     95
 Ala Arg

<210> SEQ ID NO 495
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 495

Gln Val Gln Leu Val Glu Ser Gly Gly Gln Gln Val Gln Pro Gln Arg
1      5      10     15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20     25     30
Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35     40     45
 Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50     55     60
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65     70     75     80
 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85     90     95
 Ala Arg

<210> SEQ ID NO 496
<211> LENGTH: 98
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 496

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1      5      10     15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Tyr
20     25     30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Ile
35     40     45
Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50     55     60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65     70     75     80
 Glu Asp Val Ala Thr Tyr Tyr Cys
<210> SEQ ID NO 497
<211> LENGTH: 90
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 497

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1      5     10     15
Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20     25     30
Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu
35     40     45
Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50     55     60
Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65     70     75     80
Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys
85     90

<210> SEQ ID NO 498
<211> LENGTH: 97
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 498

Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val Ala Leu Gly Gln
1      5     10     15
Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg Ser Tyr Tyr Ala
20     25     30
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr
35     40     45
Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser Gly Ser
50     55     60
Ser Ser Gly Ser Thr Ala Ser Leu Thr Ile Thr Gly Ala Gln Ala Glu
65     70     75     80
Asp Glu Ala Asp Tyr Tyr Cys
85

<210> SEQ ID NO 499
<211> LENGTH: 13
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 499

Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn
1      5     10

<210> SEQ ID NO 500
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 500

Gly Phe Thr Phe Ser Asn Tyr Trp Met Ser
1      5     10

<210> SEQ ID NO 501
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 501

Ser Ile Lys Gln Asp Gln Ser Glu Lys Tyr Tyr Val Asp Ser Val Lys
   1   5   10   15

Gly

<210> SEQ ID NO 502
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 502

Asp Leu Val Leu Met Val Tyr Asp Ile Asp Tyr Tyr Tyr Gly Met
   1   5   10   15

Asp Val

<210> SEQ ID NO 503
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 503

Arg Ser Ser Gln Ser Leu Leu Leu His Ser Asn Gly Tyr Asn Tyr Leu Asp
   1   5   10   15

<210> SEQ ID NO 504
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 504

Leu Gly Ser Asn Arg Ala Ser
   1   5

<210> SEQ ID NO 505
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 505

Met Gln Thr Leu Gln Thr Pro Leu Thr
   1   5

<210> SEQ ID NO 506
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 506

Gln Val Thr Leu Lys Glu Ser Gly Pro Val Leu Val Lys Pro Thr Glu
   1   5   10   15

Thr Leu Thr Leu Thr Cys Thr Val Ser
   20   25

<210> SEQ ID NO 507
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 507

Gly Phe Ser Leu Ser Asn Ala Arg Met Gly Val Ser
<210> SEQ ID NO 508
<211> LENGTH: 12
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 508

Gly Phe Ser Leu Ser Asn Val Arg Met Gly Val Ser
1 5 10

<210> SEQ ID NO 509
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 509

Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala
1 5 10

<210> SEQ ID NO 510
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 510

Glu Val Gln Leu Val Gln Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ala Ser
20 25

<210> SEQ ID NO 511
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 511

Gly Phe Thr Phe Ser Ser Tyr Trp Met Ser
1 5 10

<210> SEQ ID NO 512
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 512

Gly Leu Thr Phe Ser Asn Phe Trp Met Ser
1 5 10

<210> SEQ ID NO 513
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 513

Gly Phe Thr Phe Ser Asn Tyr Trp Met Thr
1 5 10

<210> SEQ ID NO 514
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

400> SEQUENCE: 514
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
1 5 10

SEQ ID NO 515
LENGTH: 25
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 515
Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25

SEQ ID NO 516
LENGTH: 25
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 516
Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser
20 25

SEQ ID NO 517
LENGTH: 10
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 517
Gly Phe Thr Phe Ser Ser Tyr Gly Met His
1 5 10

SEQ ID NO 518
LENGTH: 14
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 518
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala
1 5 10

SEQ ID NO 519
LENGTH: 16
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 519
His Ile Phe Ser Ser Asn Asp Glu Lys Ser Tyr Ser Thr Ser Leu Lys Ser
1 5 10 15

SEQ ID NO 520
LENGTH: 16
TYPE: PRT
ORGANISM: Homo sapiens

SEQUENCE: 520
His Ile Phe Ser Ser Asn Asp Glu Asn Ser Tyr Arg Thr Ser Leu Lys Ser
1 5 10 15

SEQ ID NO 521
LENGTH: 33
TYPE: PRT
ORGANISM: Homo sapiens

SEQ ID NO: 521
LENGTH: 11
TYPE: PRT

ORGANISM: Homo sapiens

SEQ ID NO: 522
LENGTH: 11
TYPE: PRT

ORGANISM: Homo sapiens

SEQ ID NO: 523
LENGTH: 11
TYPE: PRT

ORGANISM: Homo sapiens

SEQ ID NO: 524
LENGTH: 11
TYPE: PRT

ORGANISM: Homo sapiens

SEQ ID NO: 525
LENGTH: 17
TYPE: PRT

ORGANISM: Homo sapiens

SEQ ID NO: 526
LENGTH: 17
TYPE: PRT

ORGANISM: Homo sapiens

SEQ ID NO: 527
Gly

<210> SEQ ID NO 528
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 528

Ser Ile Lys Gln Asp Gly Ser Glu Arg Tyr Tyr Val Asp Ser Val Lys
1  5 10 15
Gly

<210> SEQ ID NO 529
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 529

Arg Phe Thr Ile Ser Arg Asp Aen Ala Lys Aen Ser Leu Tyr Leu Gln
1  5 10 15
Met Aen Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 530
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 530

Arg Phe Thr Ile Ser Arg Asp Aen Ala Arg Aen Ser Leu Tyr Leu Gln
1  5 10 15
Met Aen Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 531
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 531

Arg Phe Ala Ile Ser Arg Asp Aen Ala Lys Aen Ser Leu Phe Leu Gln
1  5 10 15
Met Aen Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 532
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 532

Arg Phe Thr Ile Ser Arg Asp Thr Ala Lys Aen Ser Leu Tyr Leu Gln
1  5 10 15
Met Aen Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 533
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 533
<table>
<thead>
<tr>
<th></th>
<th>Glu</th>
<th>Ser</th>
<th>Asn</th>
<th>Trp</th>
<th>Gly</th>
<th>Phe</th>
<th>Ala</th>
<th>Phe</th>
<th>Asp</th>
<th>Ile</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
</tr>
</tbody>
</table>

SEQ ID NO 534
LENGTH: 16
TYPE: PRT
ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>Pro</th>
<th>Leu</th>
<th>Val</th>
<th>Leu</th>
<th>Met</th>
<th>Val</th>
<th>Tyr</th>
<th>Ala</th>
<th>Leu</th>
<th>His</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Gly</th>
<th>Met</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Amp | Val |

SEQ ID NO 535
LENGTH: 17
TYPE: PRT
ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>Val</th>
<th>Ile</th>
<th>Trp</th>
<th>Tyr</th>
<th>Asp</th>
<th>Gly</th>
<th>Ser</th>
<th>Asn</th>
<th>Lys</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Ala</th>
<th>Asp</th>
<th>Ser</th>
<th>Val</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gly |

SEQ ID NO 536
LENGTH: 17
TYPE: PRT
ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>Val</th>
<th>Ile</th>
<th>Tyr</th>
<th>Tyr</th>
<th>Asp</th>
<th>Gly</th>
<th>Ile</th>
<th>Asn</th>
<th>Lys</th>
<th>His</th>
<th>Tyr</th>
<th>Ala</th>
<th>Asp</th>
<th>Ser</th>
<th>Val</th>
<th>Lys</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gly |

SEQ ID NO 537
LENGTH: 32
TYPE: PRT
ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>Arg</th>
<th>Phe</th>
<th>Thr</th>
<th>Ile</th>
<th>Ser</th>
<th>Arg</th>
<th>Asp</th>
<th>Ser</th>
<th>Lys</th>
<th>Asn</th>
<th>Thr</th>
<th>Leu</th>
<th>Tyr</th>
<th>Leu</th>
<th>Gln</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Met | Asn | Ser | Leu | Arg | Ala | Glu | Asp | Thr | Ala | Val | Tyr | Tyr | Cys | Ala | Arg |
|    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 20 | 25  | 30  |     |     |     |     |     |     |     |     |     |     |     |     |     |

SEQ ID NO 538
LENGTH: 5
TYPE: PRT
ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>Asp</th>
<th>Arg</th>
<th>Gly</th>
<th>Leu</th>
<th>Asp</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td>5</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

SEQ ID NO 539
LENGTH: 11
TYPE: PRT
ORGANISM: Homo sapiens

<table>
<thead>
<tr>
<th></th>
<th>Trp</th>
<th>Gly</th>
<th>Gln</th>
<th>Gly</th>
<th>Thr</th>
<th>Leu</th>
<th>Val</th>
<th>Thr</th>
<th>Val</th>
<th>Ser</th>
<th>Ser</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<210> SEQ ID NO 540
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 540

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1  5  10  15

Glu Pro Ala Ser Ile Ser Cys
20

<210> SEQ ID NO 541
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 541

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr
1  5  10  15

<210> SEQ ID NO 542
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 542

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1  5  10  15

Glu Arg Ala Thr Ile Asn Cys
20

<210> SEQ ID NO 543
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 543

Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Asn Lys Asn Tyr Leu
1  5  10  15

Ala

<210> SEQ ID NO 544
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 544

Lys Ser Ser Gln Ser Val Leu Tyr Ser Ser Asn Ser Lys Asn Tyr Leu
1  5  10  15

Val

<210> SEQ ID NO 545
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 545

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
1  5  10  15

<210> SEQ ID NO 546
<211> LENGTH: 22
<table>
<thead>
<tr>
<th>Sequence</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln</td>
<td>Arg Val Thr Ile Ser Cys</td>
</tr>
<tr>
<td>Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Thr Val Asn</td>
<td></td>
</tr>
<tr>
<td>Ser Gly Ser Ser Ser Asn Ile Gly Ser Lys Thr Val Asn</td>
<td></td>
</tr>
<tr>
<td>Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr</td>
<td></td>
</tr>
<tr>
<td>Trp Tyr Gln Gln Phe Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr</td>
<td></td>
</tr>
<tr>
<td>Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys</td>
<td>Thr Ala Arg Ile Thr Cys</td>
</tr>
<tr>
<td>Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln</td>
<td></td>
</tr>
</tbody>
</table>
Thr Ala Arg Ile Thr Cys

20

<210> SEQ ID NO 553
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 553

Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His

1   5   10

<210> SEQ ID NO 554
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 554

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Ile Tyr

1   5   10   15

<210> SEQ ID NO 555
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 555

Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val Leu Val Val Tyr

1   5   10   15

<210> SEQ ID NO 556
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 556

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr

1   5   10   15

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys

20   25   30

<210> SEQ ID NO 557
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 557

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr His Leu Thr

1   5   10   15

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys

20   25   30

<210> SEQ ID NO 558
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 558

Met Gln Ala Leu Gln Thr Pro Leu Thr

1   5

<210> SEQ ID NO 559
<211> LENGTH: 10
Phe Gly Gly Thr Lys Val Glu Ile Lys
  1      5      10

Trp Ala Ser Thr Arg Glu Ser
  1      5

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
  1      5      10      15
Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys
  20     25     30

Gln Gln Tyr Tyr Ser Thr Pro Trp Thr
  1      5

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
  1      5      10

Ser Asn Arg Gln Arg Pro Ser
  1      5
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 566
Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser
1          5          10         15
Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Ala Asp Tyr Tyr Cys
20         25         30

<210> SEQ ID NO 567
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 567
Ala Ala Trp Asp Arg Ser Leu Asn Trp Val
1          5          10

<210> SEQ ID NO 568
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 568
Ala Thr Trp Asp Arg Leu Asn Trp Val
1          5          10

<210> SEQ ID NO 569
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 569
Phe Gly Ala Gly Thr Lys Leu Thr Val Leu
1          5          10

<210> SEQ ID NO 570
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 570
Tyr Asp Ser Asp Arg Pro Ser
1          5

<210> SEQ ID NO 571
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 571
Asp Asp Ser Asp Arg Pro Ser
1          5

<210> SEQ ID NO 572
<211> LENGTH: 21
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 572
Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn Thr Ala Thr
1          5          10         15
Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Tyr Cys
What is claimed is:

1. An isolated monoclonal antibody that binds to PCSK9, wherein the isolated monoclonal antibody binds an epitope on PCSK9 comprising at least one of residues 237 or 238 of SEQ ID NO: 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.

2. The isolated monoclonal antibody of claim 1, wherein the isolated monoclonal antibody is a neutralizing antibody.

3. The isolated monoclonal antibody of claim 2, wherein the isolated monoclonal antibody was produced by a CHO cell.

4. The isolated monoclonal antibody of claim 3, wherein the isolated monoclonal antibody binds to PCSK9 with a $K_D$ of less than or equal to $5\times10^{-9}$ M.

5. The isolated monoclonal antibody of claim 2, wherein the isolated monoclonal antibody is a human antibody.

6. The isolated monoclonal antibody of claim 5, wherein the isolated monoclonal antibody comprises a light chain region that comprises an amino acid sequence of SEQ ID NO: 157.

7. The isolated monoclonal antibody of claim 2, wherein the epitope is a functional epitope.

8. The isolated monoclonal antibody of claim 2, wherein the epitope is a structural epitope.

9. The isolated monoclonal antibody of claim 2, wherein the epitope is an epitope on a native PCSK9 protein.

10. The isolated monoclonal antibody of claim 2, wherein the epitope comprises at least residue 237 of SEQ ID NO: 3.

11. The isolated monoclonal antibody of claim 2, wherein the epitope comprises at least residue 238 of SEQ ID NO: 3.

12. The isolated monoclonal antibody of claim 2, wherein the isolated monoclonal antibody is a humanized antibody.

13. An isolated monoclonal antibody that binds to human PCSK9 at one or more of amino acid residues 237 or 238 of SEQ ID NO: 3, and wherein the monoclonal antibody blocks binding of PCSK9 to LDLR.

14. The isolated monoclonal antibody of claim 13, wherein the isolated monoclonal antibody is a neutralizing antibody.

15. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody was produced by a CHO cell.

16. The isolated monoclonal antibody of claim 15, wherein the isolated monoclonal antibody binds to PCSK9 with a $K_D$ of less than or equal to $5\times10^{-9}$ M.

17. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody is a human antibody.

18. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody comprises a light chain region that comprises an amino acid sequence of SEQ ID NO: 157.

19. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody further binds at least one of amino acid residues 153, 194, 374, 377, or 379 of SEQ ID NO: 3.

20. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody further binds at least one of amino acid residues 367 or 382 of SEQ ID NO: 3.

21. The isolated monoclonal antibody of claim 17, wherein the isolated monoclonal antibody further binds at least one of amino acid residues 192, 194, or 197 of SEQ ID NO: 3.

22. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody is a humanized antibody.

23. The isolated monoclonal antibody of claim 14, wherein the isolated monoclonal antibody binds at least amino acid residue 237 of SEQ ID NO: 3.
24. The isolated monoclonal antibody of claim 14, wherein
the isolated monoclonal antibody binds at least amino acid
residue 238 of SEQ ID NO: 3.